NO_RELATION	In unanesthetized , spontaneously <e2> hypertensive </e2> rats the decrease in blood pressure and heart rate produced by intravenous <e1> clonidine </e1> , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .
NO_RELATION	In unanesthetized , spontaneously <e2> hypertensive </e2> rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by <e1> nalozone </e1> , 0 . 2 to 2 mg / kg .
CID	The <e2> hypotensive </e2> effect of 100 mg / kg <e1> alpha - methyldopa </e1> was also partially reversed by naloxone .
NO_RELATION	The <e2> hypotensive </e2> effect of 100 mg / kg alpha - methyldopa was also partially reversed by <e1> naloxone </e1> .
NO_RELATION	In brain membranes from spontaneously <e2> hypertensive </e2> rats <e1> clonidine </e1> , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
NO_RELATION	In brain membranes from spontaneously <e2> hypertensive </e2> rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of <e1> [ 3H ] - naloxone </e1> ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
NO_RELATION	In brain membranes from spontaneously <e2> hypertensive </e2> rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and <e1> naloxone </e1> , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
NO_RELATION	In brain membranes from spontaneously <e2> hypertensive </e2> rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence <e1> clonidine </e1> - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
NO_RELATION	In brain membranes from spontaneously <e2> hypertensive </e2> rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of <e1> [ 3H ] - dihydroergocryptine </e1> ( 1 nM ) .
CID	<e1> Lidocaine </e1> - induced <e2> cardiac asystole </e2> .
NO_RELATION	Intravenous administration of a single 50 - mg bolus of <e1> lidocaine </e1> in a 67 - year - old man resulted in profound <e2> depression </e2> of the activity of the sinoatrial and atrioventricular nodal pacemakers .
NO_RELATION	The patient had no apparent associated conditions which might have predisposed him to the development of <e2> bradyarrhythmias </e2> ; and , thus , this probably represented a true idiosyncrasy to <e1> lidocaine </e1> .
CID	<e1> Suxamethonium </e1> infusion rate and observed <e2> fasciculations </e2> .
NO_RELATION	The infusion was discontinued either when there was no muscular response to <e2> tetanic </e2> stimulation of the ulnar nerve or when <e1> Sch </e1> 120 mg was exceeded .
NO_RELATION	<e1> Galanthamine hydrobromide </e1> , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) <e2> overdosage </e2> .
CID	Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of <e1> scopolamine </e1> ( hyoscine ) <e2> overdosage </e2> .
CID	Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( <e1> hyoscine </e1> ) <e2> overdosage </e2> .
CID	Effects of uninephrectomy and high protein feeding on <e1> lithium </e1> - induced <e2> chronic renal failure </e2> in rats .
NO_RELATION	Rats with <e1> lithium </e1> - induced <e2> nephropathy </e2> were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .
NO_RELATION	Rats with <e1> lithium </e1> - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of <e2> renal failure </e2> .
CID	<e1> Lithium </e1> also caused <e2> proteinuria </e2> and systolic hypertension in absence of glomerulosclerosis .
CID	<e1> Lithium </e1> also caused proteinuria and systolic <e2> hypertension </e2> in absence of glomerulosclerosis .
NO_RELATION	<e1> Lithium </e1> also caused proteinuria and systolic hypertension in absence of <e2> glomerulosclerosis </e2> .
NO_RELATION	HP failed to accentuante progression of <e2> renal failure </e2> and in fact tended to increase GFR and decrease plasma <e1> creatinine </e1> levels in lithium pretreated rats .
NO_RELATION	HP failed to accentuante progression of <e2> renal failure </e2> and in fact tended to increase GFR and decrease plasma creatinine levels in <e1> lithium </e1> pretreated rats .
NO_RELATION	The results indicate that <e1> Li </e1> - induced <e2> nephropathy </e2> , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .
CID	The results indicate that <e1> Li </e1> - induced nephropathy , even when the GFR is only modestly reduced , is associated with <e2> proteinuria </e2> and arterial systolic hypertension .
CID	The results indicate that <e1> Li </e1> - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic <e2> hypertension </e2> .
NO_RELATION	Treatment of <e2> Crohn ' s disease </e2> with <e1> fusidic acid </e1> : an antibiotic with immunosuppressive properties similar to cyclosporin .
NO_RELATION	Treatment of <e2> Crohn ' s disease </e2> with fusidic acid : an antibiotic with immunosuppressive properties similar to <e1> cyclosporin </e1> .
NO_RELATION	Because of the need for the development of new treatments for <e2> Crohn ' s disease </e2> , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of <e1> fusidic acid </e1> treatment in chronic active , therapy - resistant patients .
NO_RELATION	The results of this pilot study suggest that <e1> fusidic acid </e1> may be of benefit in selected chronic active <e2> Crohn ' s disease </e2> patients in whom conventional treatment is ineffective .
NO_RELATION	Because there seems to exist a scientific rationale for the use of <e1> fusidic acid </e1> at the cytokine level in <e2> inflammatory bowel disease </e2> , we suggest that the role of this treatment should be further investigated .
NO_RELATION	Electrocardiographic evidence of <e2> myocardial injury </e2> in psychiatrically hospitalized <e1> cocaine </e1> abusers .
NO_RELATION	The electrocardiograms ( ECG ) of 99 <e1> cocaine </e1> - abusing patients were compared with the ECGs of 50 <e2> schizophrenic </e2> controls .
NO_RELATION	Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant <e2> myocardial injury </e2> defined as myocardial infarction , ischemia , and bundle branch block .
CID	Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as <e2> myocardial infarction </e2> , ischemia , and bundle branch block .
NO_RELATION	Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , <e2> ischemia </e2> , and bundle branch block .
CID	Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and <e2> bundle branch block </e2> .
CID	<e1> Sulpiride </e1> - induced <e2> tardive dystonia </e2> .
NO_RELATION	Although initially thought to be free of extrapyramidal side effects , <e1> sulpiride </e1> - induced <e2> tardive dyskinesia </e2> and parkinsonism have been reported occasionally .
NO_RELATION	Although initially thought to be free of extrapyramidal side effects , <e1> sulpiride </e1> - induced tardive dyskinesia and <e2> parkinsonism </e2> have been reported occasionally .
CID	We studied a 37 - year - old man who developed persistent segmental <e2> dystonia </e2> within 2 months after starting <e1> sulpiride </e1> therapy .
CID	We could not find any previous reports of <e1> sulpiride </e1> - induced <e2> tardive dystonia </e2> .
NO_RELATION	<e2> Ocular and auditory toxicity </e2> in hemodialyzed patients receiving <e1> desferrioxamine </e1> .
NO_RELATION	During an 18 - month period of study 41 hemodialyzed patients receiving <e1> desferrioxamine </e1> ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of <e2> audiovisual toxicity </e2> .
NO_RELATION	<e1> Desferrioxamine </e1> withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of <e2> hearing loss </e2> in 3 patients and partial recovery in 3 .
NO_RELATION	This <e2> toxicity </e2> appeared in patients receiving the higher doses of <e1> desferrioxamine </e1> or coincided with the normalization of ferritin or aluminium serum levels .
NO_RELATION	This <e2> toxicity </e2> appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or <e1> aluminium </e1> serum levels .
NO_RELATION	The data indicate that <e2> audiovisual toxicity </e2> is not an infrequent complication in hemodialyzed patients receiving <e1> desferrioxamine </e1> .
CID	<e2> Myasthenia gravis </e2> presenting as weakness after <e1> magnesium </e1> administration .
NO_RELATION	We studied a patient with no prior history of <e2> neuromuscular disease </e2> who became virtually quadriplegic after parenteral <e1> magnesium </e1> administration for preeclampsia .
NO_RELATION	We studied a patient with no prior history of neuromuscular disease who became virtually <e2> quadriplegic </e2> after parenteral <e1> magnesium </e1> administration for preeclampsia .
NO_RELATION	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral <e1> magnesium </e1> administration for <e2> preeclampsia </e2> .
NO_RELATION	Although <e2> paralysis </e2> after <e1> magnesium </e1> administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .
CID	Although paralysis after <e1> magnesium </e1> administration has been described in patients with known <e2> myasthenia gravis </e2> , it has not previously been reported to be the initial or only manifestation of the disease .
NO_RELATION	Patients who are unusually sensitive to the neuromuscular effects of <e1> magnesium </e1> should be suspected of having an underlying <e2> disorder of neuromuscular transmission </e2> .
NO_RELATION	Based on clinical data , indicating that <e1> chloroacetaldehyde </e1> ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Based on clinical data , indicating that chloroacetaldehyde ( <e1> CAA </e1> ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of <e1> CAA </e1> in the development of <e2> hemorrhagic cystitis </e2> .
CID	Twenty common <e2> migraine </e2> patients received a one sided frontotemporal application of <e1> nitroglycerin </e1> ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .
CID	Early onset <e2> migraine </e2> attacks were induced by <e1> nitroglycerin </e1> in seven out of 10 patients versus no patient in the placebo group .
CID	Subsequently 20 <e2> migraine </e2> patients , who developed an early onset attack with frontotemporal <e1> nitroglycerin </e1> , received the drug in a second induction test at other body areas .
CID	Thus the <e2> migraine </e2> - inducing effect of <e1> nitroglycerin </e1> seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
NO_RELATION	Thus the migraine - inducing effect of <e1> nitroglycerin </e1> seems to depend on direct stimulation of the habitual site of <e2> pain </e2> , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
CID	Thus the migraine - inducing effect of <e1> nitroglycerin </e1> seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a <e2> migraine </e2> crisis .
CID	<e1> Clotiazepam </e1> - induced acute <e2> hepatitis </e2> .
CID	We report the case of a patient who developed acute <e2> hepatitis </e2> with extensive hepatocellular necrosis , 7 months after the onset of administration of <e1> clotiazepam </e1> , a thienodiazepine derivative .
NO_RELATION	We report the case of a patient who developed acute hepatitis with <e2> extensive hepatocellular necrosis </e2> , 7 months after the onset of administration of <e1> clotiazepam </e1> , a thienodiazepine derivative .
NO_RELATION	We report the case of a patient who developed acute <e2> hepatitis </e2> with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a <e1> thienodiazepine </e1> derivative .
NO_RELATION	We report the case of a patient who developed acute hepatitis with <e2> extensive hepatocellular necrosis </e2> , 7 months after the onset of administration of clotiazepam , a <e1> thienodiazepine </e1> derivative .
NO_RELATION	The administration of several <e1> benzodiazepines </e1> , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of <e2> hepatitis </e2> .
CID	The administration of several benzodiazepines , chemically related to <e1> clotiazepam </e1> , did not interfere with recovery and did not induce any relapse of <e2> hepatitis </e2> .
CID	This observation shows that <e1> clotiazepam </e1> can induce acute <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .
CID	This observation shows that <e1> clotiazepam </e1> can induce acute hepatitis and suggests that there is no cross <e2> hepatotoxicity </e2> between clotiazepam and several benzodiazepines .
CID	This observation shows that clotiazepam can induce acute <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between <e1> clotiazepam </e1> and several benzodiazepines .
CID	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross <e2> hepatotoxicity </e2> between <e1> clotiazepam </e1> and several benzodiazepines .
NO_RELATION	This observation shows that clotiazepam can induce acute <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several <e1> benzodiazepines </e1> .
NO_RELATION	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross <e2> hepatotoxicity </e2> between clotiazepam and several <e1> benzodiazepines </e1> .
CID	Arterial <e2> hypertension </e2> as a complication of prolonged <e1> ketoconazole </e1> treatment .
NO_RELATION	Two of 14 patients with <e2> Cushing ' s syndrome </e2> treated on a long - term basis with <e1> ketoconazole </e1> developed sustained hypertension .
CID	Two of 14 patients with Cushing ' s syndrome treated on a long - term basis with <e1> ketoconazole </e1> developed sustained <e2> hypertension </e2> .
NO_RELATION	In both cases normal plasma and urinary free <e1> cortisol </e1> levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated <e2> hypertension </e2> 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
CID	In both cases normal plasma and urinary free cortisol levels had been achieved following <e1> ketoconazole </e1> therapy , yet continuous blood pressure monitoring demonstrated <e2> hypertension </e2> 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
CID	Our findings show that long - term treatment with high doses of <e1> ketoconazole </e1> may induce enzyme blockade leading to mineralocorticoid - related <e2> hypertension </e2> .
NO_RELATION	Effects of an inhibitor of <e1> angiotensin </e1> converting enzyme ( Captopril ) on <e2> pulmonary and renal insufficiency </e2> due to intravascular coagulation in the rat .
NO_RELATION	Effects of an inhibitor of <e1> angiotensin </e1> converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to <e2> intravascular coagulation </e2> in the rat .
NO_RELATION	Effects of an inhibitor of angiotensin converting enzyme ( <e1> Captopril </e1> ) on <e2> pulmonary and renal insufficiency </e2> due to intravascular coagulation in the rat .
NO_RELATION	Effects of an inhibitor of angiotensin converting enzyme ( <e1> Captopril </e1> ) on pulmonary and renal insufficiency due to <e2> intravascular coagulation </e2> in the rat .
CID	Induction of <e2> intravascular coagulation </e2> and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> ( AMCA ) in the rat gives rise to <e2> pulmonary and renal insufficiency </e2> resembling that occurring after trauma or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2> trauma </e2> or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2> sepsis </e2> in man .
CID	Induction of <e2> intravascular coagulation </e2> and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1> AMCA </e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1> AMCA </e1> ) in the rat gives rise to <e2> pulmonary and renal insufficiency </e2> resembling that occurring after trauma or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1> AMCA </e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2> trauma </e2> or sepsis in man .
NO_RELATION	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( <e1> AMCA </e1> ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2> sepsis </e2> in man .
NO_RELATION	Injection of <e1> Captopril </e1> ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both <e2> pulmonary and renal insufficiency </e2> in this rat model .
NO_RELATION	Injection of Captopril ( 1 mg / kg ) , an inhibitor of <e1> angiotensin </e1> converting enzyme ( ACE ) , reduced both <e2> pulmonary and renal insufficiency </e2> in this rat model .
NO_RELATION	<e2> Renal damage </e2> as reflected by an increase in serum <e1> urea </e1> and in kidney weight was prevented by Captopril .
NO_RELATION	<e2> Renal damage </e2> as reflected by an increase in serum urea and in kidney weight was prevented by <e1> Captopril </e1> .
NO_RELATION	<e1> Captopril </e1> may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less <e2> kidney damage </e2> will be produced .
CID	A randomized comparison of <e1> labetalol </e1> and nitroprusside for induced <e2> hypotension </e2> .
CID	A randomized comparison of labetalol and <e1> nitroprusside </e1> for induced <e2> hypotension </e2> .
CID	In a randomized study , <e1> labetalol </e1> - induced <e2> hypotension </e2> and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
CID	In a randomized study , <e1> labetalol </e1> - induced hypotension and nitroprusside - induced <e2> hypotension </e2> were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
CID	In a randomized study , labetalol - induced <e2> hypotension </e2> and <e1> nitroprusside </e1> - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
CID	In a randomized study , labetalol - induced hypotension and <e1> nitroprusside </e1> - induced <e2> hypotension </e2> were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
CID	Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) <e2> increase in heart rate and cardiac output </e2> ; rebound hypertension was observed in three patients after discontinuation of <e1> nitroprusside </e1> .
NO_RELATION	Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound <e2> hypertension </e2> was observed in three patients after discontinuation of <e1> nitroprusside </e1> .
NO_RELATION	Chronic <e1> carbamazepine </e1> treatment in the rat : efficacy , <e2> toxicity </e2> , and effect on plasma and tissue folate concentrations .
NO_RELATION	Chronic carbamazepine treatment in the rat : efficacy , <e2> toxicity </e2> , and effect on plasma and tissue <e1> folate </e1> concentrations .
NO_RELATION	In the course of developing this model , a common vehicle , <e1> propylene glycol </e1> , by itself in high doses , was found to exhibit protective properties against induced <e2> seizures </e2> and inhibited weight gain .
NO_RELATION	In the course of developing this model , a common vehicle , <e1> propylene glycol </e1> , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited <e2> weight gain </e2> .
CID	<e2> Seizures </e2> induced by <e1> hexafluorodiethyl ether </e1> ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
CID	Seizures induced by <e1> hexafluorodiethyl ether </e1> ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than <e2> seizures </e2> induced by maximal electroshock ( MES ) .
CID	<e2> Seizures </e2> induced by hexafluorodiethyl ether ( <e1> HFDE </e1> ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
CID	Seizures induced by hexafluorodiethyl ether ( <e1> HFDE </e1> ) were also found to be a more sensitive measure of protection by CBZ than <e2> seizures </e2> induced by maximal electroshock ( MES ) .
NO_RELATION	<e2> Seizures </e2> induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by <e1> CBZ </e1> than seizures induced by maximal electroshock ( MES ) .
NO_RELATION	Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by <e1> CBZ </e1> than <e2> seizures </e2> induced by maximal electroshock ( MES ) .
NO_RELATION	Oral administration of <e1> CBZ </e1> as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced <e2> seizures </e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment .
NO_RELATION	Oral administration of <e1> CBZ </e1> as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by <e2> weight gain </e2> over 8 weeks of treatment .
CID	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against <e1> HFDE </e1> - induced <e2> seizures </e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment .
NO_RELATION	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against <e1> HFDE </e1> - induced seizures and was minimally toxic as measured by <e2> weight gain </e2> over 8 weeks of treatment .
NO_RELATION	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no <e2> tachycardia </e2> and no augmentation of the <e1> norepinephrine </e1> release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .
NO_RELATION	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the <e1> norepinephrine </e1> release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable <e2> hypotension </e2> induced by hydralazine or nitroglycerin .
NO_RELATION	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no <e2> tachycardia </e2> and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by <e1> hydralazine </e1> or nitroglycerin .
CID	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable <e2> hypotension </e2> induced by <e1> hydralazine </e1> or nitroglycerin .
NO_RELATION	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no <e2> tachycardia </e2> and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or <e1> nitroglycerin </e1> .
CID	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable <e2> hypotension </e2> induced by hydralazine or <e1> nitroglycerin </e1> .
CID	<e2> Impotence </e2> was more common among male patients than controls and was found to be associated with co - morbidity and the taking of <e1> methotrexate </e1> .
NO_RELATION	Does <e1> paracetamol </e1> cause <e2> urothelial cancer </e2> or renal papillary necrosis ?
NO_RELATION	Does <e1> paracetamol </e1> cause urothelial cancer or <e2> renal papillary necrosis </e2> ?
CID	The risk of developing <e2> renal papillary necrosis </e2> or cancer of the renal pelvis , ureter or bladder associated with consumption of either <e1> phenacetin </e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
NO_RELATION	The risk of developing renal papillary necrosis or <e2> cancer of the renal pelvis , ureter or bladder </e2> associated with consumption of either <e1> phenacetin </e1> or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
NO_RELATION	The risk of developing <e2> renal papillary necrosis </e2> or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or <e1> paracetamol </e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
NO_RELATION	The risk of developing renal papillary necrosis or <e2> cancer of the renal pelvis , ureter or bladder </e2> associated with consumption of either phenacetin or <e1> paracetamol </e1> was calculated from data acquired by questionnaire from 381 cases and 808 controls .
CID	The risk of <e2> renal papillary necrosis </e2> was increased nearly 20 - fold by consumption of <e1> phenacetin </e1> , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .
NO_RELATION	The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of <e1> phenacetin </e1> , which also increased the risk for <e2> cancer of the renal pelvis and bladder </e2> but not for ureteric cancer .
NO_RELATION	The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of <e1> phenacetin </e1> , which also increased the risk for cancer of the renal pelvis and bladder but not for <e2> ureteric cancer </e2> .
NO_RELATION	By contrast , we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for <e2> renal papillary necrosis </e2> or any of these cancers although there was a suggestion of an association with cancer of the ureter .
NO_RELATION	By contrast , we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for renal papillary necrosis or any of these <e2> cancers </e2> although there was a suggestion of an association with cancer of the ureter .
NO_RELATION	By contrast , we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with <e2> cancer of the ureter </e2> .
CID	<e1> Dapsone </e1> - associated Heinz body <e2> hemolytic anemia </e2> in a Cambodian woman with hemoglobin E trait .
NO_RELATION	A Cambodian woman with hemoglobin E trait ( AE ) and <e2> leprosy </e2> developed a Heinz body hemolytic anemia while taking a dose of <e1> dapsone </e1> ( 50 mg / day ) not usually associated with clinical hemolysis .
CID	A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body <e2> hemolytic anemia </e2> while taking a dose of <e1> dapsone </e1> ( 50 mg / day ) not usually associated with clinical hemolysis .
NO_RELATION	A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of <e1> dapsone </e1> ( 50 mg / day ) not usually associated with clinical <e2> hemolysis </e2> .
CID	Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since <e1> dapsone </e1> does not cause <e2> hemolytic anemia </e2> at this dose in hematologically normal individuals .
NO_RELATION	Therefore , patients belonging to the poor - metabolizer phenotype of <e1> sparteine </e1> / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience <e2> adverse drug reactions </e2> when treated with standard doses of one of these drugs alone .
NO_RELATION	Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / <e1> debrisoquine </e1> polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience <e2> adverse drug reactions </e2> when treated with standard doses of one of these drugs alone .
CID	<e1> Triazolam </e1> - induced brief episodes of secondary <e2> mania </e2> in a depressed patient .
NO_RELATION	<e1> Triazolam </e1> - induced brief episodes of secondary mania in a <e2> depressed </e2> patient .
CID	Large doses of <e1> triazolam </e1> repeatedly induced brief episodes of <e2> mania </e2> in a depressed elderly woman .
NO_RELATION	Large doses of <e1> triazolam </e1> repeatedly induced brief episodes of mania in a <e2> depressed </e2> elderly woman .
CID	<e2> Manic </e2> excitement was coincident with the duration of action of <e1> triazolam </e1> .
CID	On the mechanisms of the development of tolerance to the <e2> muscular rigidity </e2> produced by <e1> morphine </e1> in rats .
CID	The development of tolerance to the <e2> muscular rigidity </e2> produced by <e1> morphine </e1> was studied in rats .
CID	Saline - pretreated controls given a test dose of <e1> morphine </e1> ( 20 mg / kg i . p . ) showed a pronounced <e2> rigidity </e2> recorded as tonic activity in the electromyogram .
CID	Rats treated for 11 days with <e1> morphine </e1> and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a <e2> rigidity </e2> after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .
CID	Rats treated for 11 days with <e1> morphine </e1> and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were <e2> akinetic </e2> ( A group ) .
CID	Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a <e2> rigidity </e2> after the test dose of <e1> morphine </e1> that was not significantly less than in the controls and were akinetic ( A group ) .
CID	Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of <e1> morphine </e1> that was not significantly less than in the controls and were <e2> akinetic </e2> ( A group ) .
CID	In a further series of experiments , <e1> haloperidol </e1> ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the <e2> rigidity </e2> without any dopaminergic interference .
CID	<e1> Haloperidol </e1> enhanced the <e2> rigidity </e2> in the A group .
CID	The results suggest that <e2> rigidity </e2> , which is assumed to be due to an action of <e1> morphine </e1> in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .
NO_RELATION	<e2> Compression neuropathy of the radial nerve </e2> due to <e1> pentazocine </e1> - induced fibrous myopathy .
NO_RELATION	Compression neuropathy of the radial nerve due to <e1> pentazocine </e1> - induced <e2> fibrous myopathy </e2> .
NO_RELATION	<e2> Fibrous myopathy </e2> is a common , well - known side effect of repeated <e1> pentazocine </e1> injection .
CID	However , <e2> compression neuropathy </e2> due to fibrotic muscle affected by <e1> pentazocine </e1> - induced myopathy has not previously been reported .
CID	However , compression neuropathy due to fibrotic muscle affected by <e1> pentazocine </e1> - induced <e2> myopathy </e2> has not previously been reported .
NO_RELATION	In a 37 - year - old woman with documented <e1> pentazocine </e1> - induced <e2> fibrous myopathy </e2> of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .
NO_RELATION	In a 37 - year - old woman with documented <e1> pentazocine </e1> - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the <e2> fibrous myopathy </e2> .
CID	Recurrent reversible <e2> acute renal failure </e2> from <e1> amphotericin </e1> .
NO_RELATION	A patient with cryptogenic <e2> cirrhosis </e2> and disseminated sporotrichosis developed acute renal failure immediately following the administration of <e1> amphotericin B </e1> on four separate occasions .
NO_RELATION	A patient with cryptogenic cirrhosis and disseminated <e2> sporotrichosis </e2> developed acute renal failure immediately following the administration of <e1> amphotericin B </e1> on four separate occasions .
CID	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed <e2> acute renal failure </e2> immediately following the administration of <e1> amphotericin B </e1> on four separate occasions .
CID	We propose that <e1> amphotericin </e1> , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to <e2> acute renal failure </e2> .
NO_RELATION	Pneumonitis with <e2> pleural and pericardial effusion </e2> and neuropathy during <e1> amiodarone </e1> therapy .
NO_RELATION	Pneumonitis with pleural and pericardial effusion and <e2> neuropathy </e2> during <e1> amiodarone </e1> therapy .
NO_RELATION	A patient with <e2> sinuatrial disease </e2> and implanted pacemaker was treated with <e1> amiodarone </e1> ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .
NO_RELATION	A patient with sinuatrial disease and implanted pacemaker was treated with <e1> amiodarone </e1> ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of <e2> supraventricular tachyarrhythmias </e2> .
CID	Review of this and previously reported cases indicates the need for early diagnosis of <e1> amiodarone </e1> <e2> pneumonitis </e2> , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .
CID	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone <e2> pneumonitis </e2> , immediate withdrawal of <e1> amiodarone </e1> , and prompt but continued steroid therapy to ensure full recovery .
NO_RELATION	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone <e2> pneumonitis </e2> , immediate withdrawal of amiodarone , and prompt but continued <e1> steroid </e1> therapy to ensure full recovery .
NO_RELATION	<e1> Indomethacin </e1> - induced <e2> renal insufficiency </e2> : recurrence on rechallenge .
NO_RELATION	We have reported a case of acute oliguric <e2> renal failure </e2> with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after <e1> indomethacin </e1> therapy .
CID	We have reported a case of acute oliguric renal failure with <e2> hyperkalemia </e2> in a patient with cirrhosis , ascites , and cor pulmonale after <e1> indomethacin </e1> therapy .
CID	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with <e2> cirrhosis </e2> , ascites , and cor pulmonale after <e1> indomethacin </e1> therapy .
CID	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , <e2> ascites </e2> , and cor pulmonale after <e1> indomethacin </e1> therapy .
CID	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and <e2> cor pulmonale </e2> after <e1> indomethacin </e1> therapy .
CID	Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of <e1> indomethacin </e1> caused recurrence of acute reversible <e2> oliguria </e2> .
NO_RELATION	Changes in heart size during long - term <e1> timolol </e1> treatment after <e2> myocardial infarction </e2> .
NO_RELATION	The effect of long - term <e1> timolol </e1> treatment on heart size after <e2> myocardial infarction </e2> was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .
NO_RELATION	The effect of long - term timolol treatment on heart size after <e2> myocardial infarction </e2> was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , <e1> timolol </e1> 115 ) .
NO_RELATION	These differences may be caused by <e1> timolol </e1> - induced <e2> bradycardia </e2> and a compensatory increase in end - diastolic volume .
NO_RELATION	After re - <e2> infarction </e2> , heart size increased in the placebo group and remained unchanged in the <e1> timolol </e1> group .
NO_RELATION	<e1> Vitamin D3 </e1> <e2> toxicity </e2> in dairy cows .
CID	Large parenteral doses of <e1> vitamin D3 </e1> ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged <e2> hypercalcemia </e2> , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
CID	Large parenteral doses of <e1> vitamin D3 </e1> ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , <e2> hyperphosphatemia </e2> , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
CID	Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU <e1> vitamin D3 </e1> ) were associated with prolonged <e2> hypercalcemia </e2> , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
CID	Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU <e1> vitamin D3 </e1> ) were associated with prolonged hypercalcemia , <e2> hyperphosphatemia </e2> , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
CID	Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged <e2> hypercalcemia </e2> , hyperphosphatemia , and large increases of <e1> vitamin D3 </e1> and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
CID	Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , <e2> hyperphosphatemia </e2> , and large increases of <e1> vitamin D3 </e1> and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
NO_RELATION	None of the cows treated with <e1> vitamin D3 </e1> showed signs of <e2> milk fever </e2> during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .
NO_RELATION	None of the cows treated with <e1> vitamin D3 </e1> showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of <e2> milk fever </e2> during this period .
NO_RELATION	Signs of <e1> vitamin D3 </e1> <e2> toxicity </e2> were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .
NO_RELATION	Signs of <e1> vitamin D3 </e1> toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 <e2> toxicity </e2> and 10 of 17 cows died .
NO_RELATION	Signs of vitamin D3 <e2> toxicity </e2> were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of <e1> vitamin D3 </e1> toxicity and 10 of 17 cows died .
NO_RELATION	Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of <e1> vitamin D3 </e1> <e2> toxicity </e2> and 10 of 17 cows died .
NO_RELATION	Because of the extreme <e2> toxicity </e2> of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent <e2> milk fever </e2> and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce <e2> milk fever </e2> , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum .
NO_RELATION	Because of the extreme <e2> toxicity </e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent <e2> milk fever </e2> and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent milk fever and doses that induce <e2> milk fever </e2> , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum .
NO_RELATION	Because of the extreme <e2> toxicity </e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that <e1> vitamin D3 </e1> cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent <e2> milk fever </e2> and doses that induce milk fever , we concluded that <e1> vitamin D3 </e1> cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce <e2> milk fever </e2> , we concluded that <e1> vitamin D3 </e1> cannot be used practically to prevent milk fever when injected several weeks prepartum .
NO_RELATION	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that <e1> vitamin D3 </e1> cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum .
CID	<e2> Peripheral neuropathy </e2> due to nutritional deficiency of <e1> thiamine </e1> and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
NO_RELATION	Peripheral neuropathy due to <e2> nutritional deficiency </e2> of <e1> thiamine </e1> and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
CID	Peripheral neuropathy due to nutritional deficiency of <e1> thiamine </e1> and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and <e2> sensori - motor neuropathy </e2> .
CID	<e2> Peripheral neuropathy </e2> due to nutritional deficiency of thiamine and <e1> riboflavin </e1> was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
NO_RELATION	Peripheral neuropathy due to <e2> nutritional deficiency </e2> of thiamine and <e1> riboflavin </e1> was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
CID	Peripheral neuropathy due to nutritional deficiency of thiamine and <e1> riboflavin </e1> was common ( 10 . 1 % ) and presented mainly as sensory and <e2> sensori - motor neuropathy </e2> .
NO_RELATION	<e1> Isoniazid </e1> was the most frequent agent in drug - induced <e2> neuropathy </e2> .
NO_RELATION	A double - blind study of the efficacy and safety of <e1> dothiepin hydrochloride </e1> in the treatment of major <e2> depressive disorder </e2> .
NO_RELATION	In a 6 - week double - blind parallel treatment study , <e1> dothiepin </e1> and amitriptyline were compared to placebo in the treatment of 33 <e2> depressed </e2> outpatients .
NO_RELATION	In a 6 - week double - blind parallel treatment study , dothiepin and <e1> amitriptyline </e1> were compared to placebo in the treatment of 33 <e2> depressed </e2> outpatients .
NO_RELATION	<e1> Dothiepin </e1> and amitriptyline were equally effective in alleviating the symptoms of <e2> depressive illness </e2> , and both were significantly superior to placebo .
NO_RELATION	Dothiepin and <e1> amitriptyline </e1> were equally effective in alleviating the symptoms of <e2> depressive illness </e2> , and both were significantly superior to placebo .
NO_RELATION	The overall incidence of side effects and the frequency and severity of <e2> blurred vision </e2> , dry mouth , and drowsiness were significantly less with <e1> dothiepin </e1> than with amitriptyline .
NO_RELATION	The overall incidence of side effects and the frequency and severity of blurred vision , <e2> dry mouth </e2> , and drowsiness were significantly less with <e1> dothiepin </e1> than with amitriptyline .
CID	The overall incidence of side effects and the frequency and severity of <e2> blurred vision </e2> , dry mouth , and drowsiness were significantly less with dothiepin than with <e1> amitriptyline </e1> .
CID	The overall incidence of side effects and the frequency and severity of blurred vision , <e2> dry mouth </e2> , and drowsiness were significantly less with dothiepin than with <e1> amitriptyline </e1> .
NO_RELATION	<e1> Dothiepin </e1> thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of <e2> depressed </e2> outpatients .
NO_RELATION	Dothiepin thus was found to be an effective <e1> antidepressant </e1> drug associated with fewer side effects than amitriptyline in the treatment of <e2> depressed </e2> outpatients .
NO_RELATION	Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than <e1> amitriptyline </e1> in the treatment of <e2> depressed </e2> outpatients .
NO_RELATION	Behavioral effects of <e1> diazepam </e1> and propranolol in patients with <e2> panic disorder </e2> and agoraphobia .
NO_RELATION	Behavioral effects of <e1> diazepam </e1> and propranolol in patients with panic disorder and <e2> agoraphobia </e2> .
NO_RELATION	Behavioral effects of diazepam and <e1> propranolol </e1> in patients with <e2> panic disorder </e2> and agoraphobia .
NO_RELATION	Behavioral effects of diazepam and <e1> propranolol </e1> in patients with panic disorder and <e2> agoraphobia </e2> .
NO_RELATION	The effects of oral doses of <e1> diazepam </e1> ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with <e2> panic disorders </e2> and agoraphobia were investigated in a double - blind , randomized and crossover design .
NO_RELATION	The effects of oral doses of <e1> diazepam </e1> ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and <e2> agoraphobia </e2> were investigated in a double - blind , randomized and crossover design .
NO_RELATION	The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and <e1> propranolol </e1> ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with <e2> panic disorders </e2> and agoraphobia were investigated in a double - blind , randomized and crossover design .
NO_RELATION	The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and <e1> propranolol </e1> ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and <e2> agoraphobia </e2> were investigated in a double - blind , randomized and crossover design .
CID	Both drugs <e2> impaired immediate free recall </e2> but the decrease was greater for <e1> diazepam </e1> than propranolol .
CID	Both drugs <e2> impaired immediate free recall </e2> but the decrease was greater for diazepam than <e1> propranolol </e1> .
NO_RELATION	The co - administration of <e1> aspirin </e1> with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors .
NO_RELATION	The co - administration of <e1> aspirin </e1> with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2> .
CID	The co - administration of aspirin with <e1> N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide </e1> ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors .
CID	The co - administration of aspirin with <e1> N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide </e1> ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2> .
CID	The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( <e1> FANFT </e1> ) to rats resulted in a reduced incidence of FANFT - induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors .
CID	The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( <e1> FANFT </e1> ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2> .
CID	The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of <e1> FANFT </e1> - induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors .
CID	The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of <e1> FANFT </e1> - induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2> .
NO_RELATION	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in <e1> FANFT </e1> <e2> carcinogenesis </e2> in the bladder and forestomach , and that aspirin ' s effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
NO_RELATION	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT <e2> carcinogenesis </e2> in the bladder and forestomach , and that <e1> aspirin </e1> ' s effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
NO_RELATION	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT <e2> carcinogenesis </e2> in the bladder and forestomach , and that aspirin ' s effect on <e1> FANFT </e1> in the forestomach is not due to an irritant effect associated with increased cell proliferation .
CID	Provocation of postural <e2> hypotension </e2> by <e1> nitroglycerin </e1> in diabetic autonomic neuropathy ?
NO_RELATION	Provocation of postural hypotension by <e1> nitroglycerin </e1> in <e2> diabetic autonomic neuropathy </e2> ?
NO_RELATION	The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 <e2> diabetic </e2> subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .
NO_RELATION	The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without <e2> autonomic neuropathy </e2> , and 5 diabetic subjects with autonomic neuropathy .
NO_RELATION	The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 <e2> diabetic </e2> subjects with autonomic neuropathy .
NO_RELATION	The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with <e2> autonomic neuropathy </e2> .
NO_RELATION	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and <e2> diabetic </e2> subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
NO_RELATION	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without <e2> autonomic neuropathy </e2> , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
NO_RELATION	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the <e2> diabetic </e2> subjects with autonomic neuropathy .
NO_RELATION	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with <e2> autonomic neuropathy </e2> .
NO_RELATION	Characterization of <e1> estrogen </e1> - induced <e2> adenohypophyseal tumors </e2> in the Fischer 344 rat .
CID	<e2> Pituitary tumors </e2> were induced in F344 female rats by chronic treatment with <e1> diethylstilbestrol </e1> ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
CID	<e2> Pituitary tumors </e2> were induced in F344 female rats by chronic treatment with diethylstilbestrol ( <e1> DES </e1> , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
NO_RELATION	The data extend the findings of other investigators , further establishing the <e1> DES </e1> - induced <e2> tumor </e2> as a model for study of PRL cellular control mechanisms .
CID	<e1> Triamterene </e1> <e2> nephrolithiasis </e2> complicating dyazide therapy .
NO_RELATION	Triamterene <e2> nephrolithiasis </e2> complicating <e1> dyazide </e1> therapy .
CID	A case of <e1> triamterene </e1> <e2> nephrolithiasis </e2> is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .
NO_RELATION	A case of <e1> triamterene </e1> nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for <e2> hypertension </e2> .
NO_RELATION	A case of triamterene <e2> nephrolithiasis </e2> is reported in a man after 4 years of <e1> hydrochlorothiazide - triamterene </e1> therapy for hypertension .
NO_RELATION	A case of triamterene nephrolithiasis is reported in a man after 4 years of <e1> hydrochlorothiazide - triamterene </e1> therapy for <e2> hypertension </e2> .
CID	Factors affecting <e1> triamterene </e1> <e2> nephrolithiasis </e2> are discussed and 2 previously reported cases are reviewed .
CID	Metabolic involvement in <e1> adriamycin </e1> <e2> cardiotoxicity </e2> .
CID	The <e2> cardiotoxic </e2> effects of <e1> adriamycin </e1> were studied in mammalian myocardial cells in culture as a model system .
NO_RELATION	Age - dependent sensitivity of the rat to <e2> neurotoxic </e2> effects of <e1> streptomycin </e1> .
CID	<e2> Abnormal movements </e2> and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1> streptomycin </e1> than the site ( vestibular or central ) responsible for the dyskinesias .
CID	Abnormal movements and <e2> deafness </e2> occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1> streptomycin </e1> than the site ( vestibular or central ) responsible for the dyskinesias .
CID	Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to <e1> streptomycin </e1> than the site ( vestibular or central ) responsible for the <e2> dyskinesias </e2> .
CID	Crescentic fibrillary <e2> glomerulonephritis </e2> associated with intermittent <e1> rifampin </e1> therapy for pulmonary tuberculosis .
NO_RELATION	Crescentic fibrillary glomerulonephritis associated with intermittent <e1> rifampin </e1> therapy for <e2> pulmonary tuberculosis </e2> .
CID	This case study reveals an unusual finding of rapidly proliferative crescentic <e2> glomerulonephritis </e2> in a patient treated with <e1> rifampin </e1> who had no other identifiable causes for developing this disease .
NO_RELATION	This patient underwent a 10 - month regimen of <e1> rifampin </e1> and isoniazid for <e2> pulmonary tuberculosis </e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
CID	This patient underwent a 10 - month regimen of <e1> rifampin </e1> and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe <e2> renal failure </e2> five weeks after completion of therapy .
NO_RELATION	This patient underwent a 10 - month regimen of rifampin and <e1> isoniazid </e1> for <e2> pulmonary tuberculosis </e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
NO_RELATION	This patient underwent a 10 - month regimen of rifampin and <e1> isoniazid </e1> for pulmonary tuberculosis and was discovered to have developed signs of severe <e2> renal failure </e2> five weeks after completion of therapy .
CID	This report documents the unusual occurrence of rapidly progressive <e2> glomerulonephritis </e2> with crescents and fibrillar glomerulonephritis in a patient treated with <e1> rifampin </e1> .
CID	This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar <e2> glomerulonephritis </e2> in a patient treated with <e1> rifampin </e1> .
CID	Time course of lipid peroxidation in <e1> puromycin aminonucleoside </e1> - induced <e2> nephropathy </e2> .
NO_RELATION	Reactive <e1> oxygen </e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced <e2> nephropathy </e2> , with antioxidants significantly reducing the proteinuria .
NO_RELATION	Reactive <e1> oxygen </e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the <e2> proteinuria </e2> .
CID	Reactive oxygen species have been implicated in the pathogenesis of acute <e1> puromycin aminonucleoside </e1> ( PAN ) - induced <e2> nephropathy </e2> , with antioxidants significantly reducing the proteinuria .
CID	Reactive oxygen species have been implicated in the pathogenesis of acute <e1> puromycin aminonucleoside </e1> ( PAN ) - induced nephropathy , with antioxidants significantly reducing the <e2> proteinuria </e2> .
CID	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( <e1> PAN </e1> ) - induced <e2> nephropathy </e2> , with antioxidants significantly reducing the proteinuria .
CID	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( <e1> PAN </e1> ) - induced nephropathy , with antioxidants significantly reducing the <e2> proteinuria </e2> .
CID	This study supports the role of lipid peroxidation in mediating the <e2> proteinuric injury </e2> in <e1> PAN </e1> nephropathy .
CID	This study supports the role of lipid peroxidation in mediating the proteinuric injury in <e1> PAN </e1> <e2> nephropathy </e2> .
CID	<e1> Clomipramine </e1> - induced <e2> sleep disturbance </e2> does not impair its prolactin - releasing action .
CID	The present study was undertaken to examine the role of <e2> sleep disturbance </e2> , induced by <e1> clomipramine </e1> administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .
CID	<e2> Angioedema </e2> following the intravenous administration of <e1> metoprolol </e1> .
CID	A history of <e2> angioedema </e2> secondary to <e1> lisinopril </e1> therapy was elicited .
CID	During the first day of hospitalization ( while intubated ) , intravenous <e1> metoprolol </e1> was given , resulting in severe <e2> angioedema </e2> .
NO_RELATION	The <e2> angioedema </e2> resolved after therapy with intravenous <e1> steroids </e1> and diphenhydramine hydrochloride .
NO_RELATION	The <e2> angioedema </e2> resolved after therapy with intravenous steroids and <e1> diphenhydramine </e1> hydrochloride .
CID	However , <e1> coniine </e1> has failed to produce <e2> arthrogryposis </e2> in rats or mice and is only weakly teratogenic in rabbits .
NO_RELATION	The <e2> deformations </e2> caused by both <e1> coniine </e1> and nicotine sulfate were excessive flexion or extension of one or more toes .
NO_RELATION	The deformations caused by both <e1> coniine </e1> and nicotine sulfate were <e2> excessive flexion or extension of one or more toes </e2> .
NO_RELATION	The <e2> deformations </e2> caused by both coniine and <e1> nicotine </e1> sulfate were excessive flexion or extension of one or more toes .
NO_RELATION	The deformations caused by both coniine and <e1> nicotine </e1> sulfate were <e2> excessive flexion or extension of one or more toes </e2> .
CID	No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive <e2> cranial hemorrhage </e2> occurred in all <e1> nicotine </e1> sulfate - treated chicks .
CID	In summary , the chick embryo provides a reliable and simple experimental animal model of <e1> coniine </e1> - induced <e2> arthrogryposis </e2> .
CID	Epidural blood flow during <e1> prostaglandin E1 </e1> or trimethaphan induced <e2> hypotension </e2> .
CID	Epidural blood flow during prostaglandin E1 or <e1> trimethaphan </e1> induced <e2> hypotension </e2> .
CID	To evaluate the effect of <e1> prostaglandin E1 </e1> ( PGE1 ) or trimethaphan ( TMP ) induced <e2> hypotension </e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
CID	To evaluate the effect of prostaglandin E1 ( <e1> PGE1 </e1> ) or trimethaphan ( TMP ) induced <e2> hypotension </e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
CID	To evaluate the effect of prostaglandin E1 ( PGE1 ) or <e1> trimethaphan </e1> ( TMP ) induced <e2> hypotension </e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
CID	To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( <e1> TMP </e1> ) induced <e2> hypotension </e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
NO_RELATION	To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced <e2> hypotension </e2> on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under <e1> isoflurane </e1> anaesthesia .
CID	After starting <e1> PGE1 </e1> or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of <e2> hypotension </e2> due to PGE1 remained constant until 60 min after its discontinuation .
CID	After starting PGE1 or <e1> TMP </e1> , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of <e2> hypotension </e2> due to PGE1 remained constant until 60 min after its discontinuation .
CID	After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of <e2> hypotension </e2> due to <e1> PGE1 </e1> remained constant until 60 min after its discontinuation .
CID	These results suggest that <e1> PGE1 </e1> may be preferable to TMP for <e2> hypotensive </e2> anaesthesia in spinal surgery because TMP decreased EBF .
CID	These results suggest that PGE1 may be preferable to <e1> TMP </e1> for <e2> hypotensive </e2> anaesthesia in spinal surgery because TMP decreased EBF .
CID	These results suggest that PGE1 may be preferable to TMP for <e2> hypotensive </e2> anaesthesia in spinal surgery because <e1> TMP </e1> decreased EBF .
NO_RELATION	Focal <e2> injury in the cortex </e2> was produced by infusion of <e1> lactate </e1> at acid pH or by stab caused by needle insertion .
CID	<e2> Infarcts in substantia nigra pars reticulata </e2> were evoked by prolonged <e1> pilocarpine </e1> - induced status epilepticus .
CID	Infarcts in substantia nigra pars reticulata were evoked by prolonged <e1> pilocarpine </e1> - induced <e2> status epilepticus </e2> .
CID	Increase of <e2> Parkinson disability </e2> after <e1> fluoxetine </e1> medication .
NO_RELATION	We report the increased amount of <e2> motor disability </e2> in four patients with idiopathic Parkinson ' s disease after exposure to the <e1> antidepressant </e1> fluoxetine .
NO_RELATION	We report the increased amount of motor disability in four patients with <e2> idiopathic Parkinson ' s disease </e2> after exposure to the <e1> antidepressant </e1> fluoxetine .
CID	We report the increased amount of <e2> motor disability </e2> in four patients with idiopathic Parkinson ' s disease after exposure to the antidepressant <e1> fluoxetine </e1> .
NO_RELATION	We report the increased amount of motor disability in four patients with <e2> idiopathic Parkinson ' s disease </e2> after exposure to the antidepressant <e1> fluoxetine </e1> .
NO_RELATION	The possibility of a clinically relevant <e1> dopamine </e1> - antagonistic capacity of fluoxetine in <e2> Parkinson ' s disease </e2> patients must be considered .
NO_RELATION	The possibility of a clinically relevant dopamine - antagonistic capacity of <e1> fluoxetine </e1> in <e2> Parkinson ' s disease </e2> patients must be considered .
CID	<e1> Acetaminophen </e1> - induced <e2> hypotension </e2> .
NO_RELATION	The potential for <e1> acetaminophen </e1> to produce <e2> cardiovascular toxicities </e2> is very low .
NO_RELATION	However , <e1> acetaminophen </e1> has been demonstrated to produce symptoms of <e2> anaphylaxis </e2> , including hypotension , in sensitive individuals .
CID	However , <e1> acetaminophen </e1> has been demonstrated to produce symptoms of anaphylaxis , including <e2> hypotension </e2> , in sensitive individuals .
NO_RELATION	This article describes two <e2> critically ill </e2> patients in whom transient episodes of hypotension reproducibly developed after administration of <e1> acetaminophen </e1> .
CID	This article describes two critically ill patients in whom transient episodes of <e2> hypotension </e2> reproducibly developed after administration of <e1> acetaminophen </e1> .
CID	The reports illustrate the need for clinicians to consider <e1> acetaminophen </e1> in patients with <e2> hypotension </e2> of unknown origin .
CID	Acute <e2> hepatitis </e2> , autoimmune hemolytic anemia , and erythroblastocytopenia induced by <e1> ceftriaxone </e1> .
CID	Acute hepatitis , <e2> autoimmune hemolytic anemia </e2> , and erythroblastocytopenia induced by <e1> ceftriaxone </e1> .
NO_RELATION	Acute hepatitis , autoimmune hemolytic anemia , and <e2> erythroblastocytopenia </e2> induced by <e1> ceftriaxone </e1> .
CID	An 80 - yr - old man developed acute <e2> hepatitis </e2> shortly after ingesting oral <e1> ceftriaxone </e1> .
NO_RELATION	Although the transaminases gradually returned to baseline after withholding the <e1> beta lactam </e1> antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an <e2> autoimmune hemolytic anemia </e2> and erythroblastocytopenia .
NO_RELATION	Although the transaminases gradually returned to baseline after withholding the <e1> beta lactam </e1> antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and <e2> erythroblastocytopenia </e2> .
NO_RELATION	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum <e1> bilirubin </e1> and a decrease in hemoglobin concentration caused by an <e2> autoimmune hemolytic anemia </e2> and erythroblastocytopenia .
NO_RELATION	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum <e1> bilirubin </e1> and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and <e2> erythroblastocytopenia </e2> .
NO_RELATION	The newer atypical agents have a lower risk of <e2> EPS </e2> , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1> clozapine </e1> ) , and agranulocytosis ( clozapine only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , <e2> weight gain </e2> , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1> clozapine </e1> ) , and agranulocytosis ( clozapine only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , <e2> sexual dysfunction </e2> , hepatic effects , lowered seizure threshold ( primarily <e1> clozapine </e1> ) , and agranulocytosis ( clozapine only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered <e2> seizure </e2> threshold ( primarily <e1> clozapine </e1> ) , and agranulocytosis ( clozapine only ) .
CID	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily <e1> clozapine </e1> ) , and <e2> agranulocytosis </e2> ( clozapine only ) .
NO_RELATION	The newer atypical agents have a lower risk of <e2> EPS </e2> , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1> clozapine </e1> only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , <e2> weight gain </e2> , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1> clozapine </e1> only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , <e2> sexual dysfunction </e2> , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( <e1> clozapine </e1> only ) .
NO_RELATION	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered <e2> seizure </e2> threshold ( primarily clozapine ) , and agranulocytosis ( <e1> clozapine </e1> only ) .
CID	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and <e2> agranulocytosis </e2> ( <e1> clozapine </e1> only ) .
NO_RELATION	Effects of <e1> tetrandrine </e1> and fangchinoline on experimental <e2> thrombosis </e2> in mice and human platelet aggregation .
NO_RELATION	Effects of <e1> tetrandrine </e1> and fangchinoline on experimental thrombosis in mice and human <e2> platelet aggregation </e2> .
NO_RELATION	Effects of tetrandrine and <e1> fangchinoline </e1> on experimental <e2> thrombosis </e2> in mice and human platelet aggregation .
NO_RELATION	Effects of tetrandrine and <e1> fangchinoline </e1> on experimental thrombosis in mice and human <e2> platelet aggregation </e2> .
NO_RELATION	The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental <e2> thrombosis </e2> induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and <e2> platelet aggregation </e2> and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and <e2> blood coagulation </e2> in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental <e2> thrombosis </e2> induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and <e2> platelet aggregation </e2> and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and <e2> blood coagulation </e2> in vitro .
CID	The present study was undertaken to investigate the effects of TET and FAN on the experimental <e2> thrombosis </e2> induced by collagen plus <e1> epinephrine </e1> ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1> epinephrine </e1> ( EP ) in mice , and <e2> platelet aggregation </e2> and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1> epinephrine </e1> ( EP ) in mice , and platelet aggregation and <e2> blood coagulation </e2> in vitro .
CID	The present study was undertaken to investigate the effects of TET and FAN on the experimental <e2> thrombosis </e2> induced by collagen plus epinephrine ( <e1> EP </e1> ) in mice , and platelet aggregation and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( <e1> EP </e1> ) in mice , and <e2> platelet aggregation </e2> and blood coagulation in vitro .
NO_RELATION	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( <e1> EP </e1> ) in mice , and platelet aggregation and <e2> blood coagulation </e2> in vitro .
NO_RELATION	In the in vivo study , the administration ( 50 mg / kg , i . p . ) of <e1> TET </e1> and FAN in mice showed the inhibition of <e2> thrombosis </e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
NO_RELATION	In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and <e1> FAN </e1> in mice showed the inhibition of <e2> thrombosis </e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
NO_RELATION	In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of <e2> thrombosis </e2> by 55 % and 35 % , respectively , while <e1> acetylsalicylic acid </e1> ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
NO_RELATION	In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of <e2> thrombosis </e2> by 55 % and 35 % , respectively , while acetylsalicylic acid ( <e1> ASA </e1> , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
NO_RELATION	In the vitro human <e2> platelet aggregations </e2> induced by the agonists used in tests , <e1> TET </e1> and FAN showed the inhibitions dose dependently .
NO_RELATION	In the vitro human <e2> platelet aggregations </e2> induced by the agonists used in tests , TET and <e1> FAN </e1> showed the inhibitions dose dependently .
NO_RELATION	<e1> Gemcitabine </e1> plus vinorelbine in <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive cisplatin .
NO_RELATION	Gemcitabine plus <e1> vinorelbine </e1> in <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive cisplatin .
NO_RELATION	Gemcitabine plus vinorelbine in <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive <e1> cisplatin </e1> .
NO_RELATION	Recent reports indicate that single agent therapy with <e1> vinorelbine </e1> ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life .
NO_RELATION	Recent reports indicate that single agent therapy with vinorelbine ( <e1> VNB </e1> ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life .
NO_RELATION	Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or <e1> gemcitabine </e1> ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life .
NO_RELATION	Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( <e1> GEM </e1> ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life .
NO_RELATION	In the current study the efficacy and <e2> toxicity </e2> of the combination of <e1> GEM </e1> and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
NO_RELATION	In the current study the efficacy and toxicity of the combination of <e1> GEM </e1> and VNB in elderly patients with advanced <e2> NSCLC </e2> or those with some contraindication to receiving cisplatin were assessed .
NO_RELATION	In the current study the efficacy and <e2> toxicity </e2> of the combination of GEM and <e1> VNB </e1> in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
NO_RELATION	In the current study the efficacy and toxicity of the combination of GEM and <e1> VNB </e1> in elderly patients with advanced <e2> NSCLC </e2> or those with some contraindication to receiving cisplatin were assessed .
NO_RELATION	In the current study the efficacy and <e2> toxicity </e2> of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving <e1> cisplatin </e1> were assessed .
NO_RELATION	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced <e2> NSCLC </e2> or those with some contraindication to receiving <e1> cisplatin </e1> were assessed .
NO_RELATION	METHODS : Forty - nine patients with advanced <e2> NSCLC </e2> were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving <e1> cisplatin </e1> .
CID	<e1> Warfarin </e1> - induced <e2> artery calcification </e2> is accelerated by growth and vitamin D .
NO_RELATION	Warfarin - induced <e2> artery calcification </e2> is accelerated by growth and <e1> vitamin D </e1> .
NO_RELATION	The present studies demonstrate that growth and <e1> vitamin D </e1> treatment enhance the extent of <e2> artery calcification </e2> in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
NO_RELATION	The present studies demonstrate that growth and <e1> vitamin D </e1> treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
CID	The present studies demonstrate that growth and vitamin D treatment enhance the extent of <e2> artery calcification </e2> in rats given sufficient doses of <e1> Warfarin </e1> to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
NO_RELATION	The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of <e1> Warfarin </e1> to inhibit gamma - carboxylation of matrix Gla protein , a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
CID	The first series of experiments examined the influence of age and growth status on <e2> artery calcification </e2> in <e1> Warfarin </e1> - treated rats .
CID	Treatment for 2 weeks with <e1> Warfarin </e1> caused massive focal <e2> calcification of the artery </e2> media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .
NO_RELATION	Treatment for 2 weeks with <e1> Warfarin </e1> caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal <e2> calcification </e2> in 42 - day - old rats .
CID	In contrast , no <e2> artery calcification </e2> could be detected in 10 - month - old adult rats even after 4 weeks of <e1> Warfarin </e1> treatment .
CID	To directly examine the importance of growth to <e1> Warfarin </e1> - induced <e2> artery calcification </e2> in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .
CID	Concurrent treatment of both dietary groups with <e1> Warfarin </e1> produced massive focal <e2> calcification of the artery </e2> media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .
CID	Concurrent treatment of both dietary groups with <e1> Warfarin </e1> produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable <e2> artery calcification </e2> in the restricted - diet , growth - inhibited group .
NO_RELATION	Although the explanation for the association between <e2> artery calcification </e2> and growth status cannot be determined from the present study , there was a relationship between higher serum <e1> phosphate </e1> and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
NO_RELATION	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum <e1> phosphate </e1> and susceptibility to <e2> artery calcification </e2> , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
NO_RELATION	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum <e1> phosphate </e1> and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced <e2> artery calcification </e2> , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
NO_RELATION	Although the explanation for the association between <e2> artery calcification </e2> and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum <e1> phosphate </e1> in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
NO_RELATION	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to <e2> artery calcification </e2> , with 30 % higher levels of serum <e1> phosphate </e1> in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
NO_RELATION	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum <e1> phosphate </e1> in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced <e2> artery calcification </e2> , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
CID	Although the explanation for the association between <e2> artery calcification </e2> and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1> - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
CID	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to <e2> artery calcification </e2> , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1> - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
CID	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1> - induced <e2> artery calcification </e2> , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
CID	This observation suggests that increased susceptibility to <e1> Warfarin </e1> - induced <e2> artery calcification </e2> could be related to higher serum phosphate levels .
NO_RELATION	This observation suggests that increased susceptibility to Warfarin - induced <e2> artery calcification </e2> could be related to higher serum <e1> phosphate </e1> levels .
NO_RELATION	The second set of experiments examined the possible synergy between <e1> vitamin D </e1> and Warfarin in <e2> artery calcification </e2> .
CID	The second set of experiments examined the possible synergy between vitamin D and <e1> Warfarin </e1> in <e2> artery calcification </e2> .
NO_RELATION	High doses of <e1> vitamin D </e1> are known to cause <e2> calcification of the artery </e2> media in as little as 3 to 4 days .
NO_RELATION	High doses of the <e1> vitamin K </e1> antagonist Warfarin are also known to cause <e2> calcification of the artery </e2> media , but at treatment times of 2 weeks or longer yet not at 1 week .
CID	High doses of the vitamin K antagonist <e1> Warfarin </e1> are also known to cause <e2> calcification of the artery </e2> media , but at treatment times of 2 weeks or longer yet not at 1 week .
NO_RELATION	In the current study , we investigated the synergy between these 2 treatments and found that concurrent <e1> Warfarin </e1> administration dramatically increased the extent of <e2> calcification </e2> in the media of vitamin D - treated rats at 3 and 4 days .
NO_RELATION	In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of <e2> calcification </e2> in the media of <e1> vitamin D </e1> - treated rats at 3 and 4 days .
NO_RELATION	There was a close parallel between the effect of <e1> vitamin D </e1> dose on <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of <e1> vitamin D </e1> dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on <e2> artery calcification </e2> and the effect of <e1> vitamin D </e1> dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of <e1> vitamin D </e1> dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum <e1> calcium </e1> , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum <e1> calcium </e1> , which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that <e1> vitamin D </e1> may induce artery calcification through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that <e1> vitamin D </e1> may induce <e2> artery calcification </e2> through its effect on serum calcium .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum <e1> calcium </e1> .
NO_RELATION	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum <e1> calcium </e1> .
NO_RELATION	Because <e1> Warfarin </e1> treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	Because Warfarin treatment had no effect on the elevation in serum <e1> calcium </e1> produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	Because Warfarin treatment had no effect on the elevation in serum calcium produced by <e1> vitamin D </e1> , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between <e1> Warfarin </e1> and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and <e1> vitamin D </e1> is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that <e1> Warfarin </e1> inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor .
NO_RELATION	High levels of matrix Gla protein are found at sites of <e2> artery calcification </e2> in rats treated with <e1> vitamin D </e1> plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .
CID	High levels of matrix Gla protein are found at sites of <e2> artery calcification </e2> in rats treated with vitamin D plus <e1> Warfarin </e1> , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .
NO_RELATION	High levels of matrix Gla protein are found at sites of <e2> artery calcification </e2> in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not <e1> gamma - carboxylated </e1> .
NO_RELATION	These observations indicate that although the <e1> gamma - carboxyglutamate </e1> residues of matrix Gla protein are apparently required for its function as a <e2> calcification </e2> inhibitor , they are not required for its accumulation at calcification sites .
NO_RELATION	These observations indicate that although the <e1> gamma - carboxyglutamate </e1> residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at <e2> calcification </e2> sites .
CID	<e1> Antidepressant </e1> - induced <e2> mania </e2> in bipolar patients : identification of risk factors .
CID	<e1> Antidepressant </e1> - induced mania in <e2> bipolar </e2> patients : identification of risk factors .
CID	BACKGROUND : Concerns about possible risks of switching to <e2> mania </e2> associated with <e1> antidepressants </e1> continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .
CID	BACKGROUND : Concerns about possible risks of switching to mania associated with <e1> antidepressants </e1> continue to interfere with the establishment of an optimal treatment paradigm for <e2> bipolar depression </e2> .
CID	<e2> bipolar II </e2> ) , number of previous manic episodes , type of <e1> antidepressant </e1> therapy used ( electroconvulsive therapy vs .
CID	bipolar II ) , number of previous <e2> manic </e2> episodes , type of <e1> antidepressant </e1> therapy used ( electroconvulsive therapy vs .
CID	RESULTS : Switches to <e2> hypomania </e2> or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1> SSRIs </e1> [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
CID	RESULTS : Switches to hypomania or <e2> mania </e2> occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1> SSRIs </e1> [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
CID	RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1> SSRIs </e1> [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced <e2> manic </e2> episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
CID	RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with <e1> SSRIs </e1> [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced <e2> hypomanic </e2> episodes .
NO_RELATION	<e1> Caffeine </e1> - induced <e2> cardiac arrhythmia </e2> : an unrecognised danger of healthfood products .
NO_RELATION	We describe a 25 - year - old woman with pre - existing <e2> mitral valve prolapse </e2> who developed intractable ventricular fibrillation after consuming a " natural energy " guarana health drink containing a high concentration of <e1> caffeine </e1> .
CID	We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable <e2> ventricular fibrillation </e2> after consuming a " natural energy " guarana health drink containing a high concentration of <e1> caffeine </e1> .
CID	Bladder <e2> retention of urine </e2> as a result of continuous intravenous infusion of <e1> fentanyl </e1> : 2 case reports .
NO_RELATION	Various reported side effects of <e1> fentanyl </e1> administration include <e2> chest wall rigidity </e2> , hypotension , respiratory depression , and bradycardia .
CID	Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity , <e2> hypotension </e2> , respiratory depression , and bradycardia .
CID	Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity , hypotension , <e2> respiratory depression </e2> , and bradycardia .
CID	Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity , hypotension , respiratory depression , and <e2> bradycardia </e2> .
CID	Here , 2 cases of <e2> urinary bladder retention </e2> leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of <e1> fentanyl </e1> are reported .
NO_RELATION	Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking <e2> hydronephrosis </e2> as a result of continuous infusion of <e1> fentanyl </e1> are reported .
NO_RELATION	Combined antiretroviral therapy causes <e2> cardiomyopathy </e2> and elevates plasma <e1> lactate </e1> in transgenic AIDS mice .
NO_RELATION	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma <e1> lactate </e1> in transgenic <e2> AIDS </e2> mice .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in <e2> cardiomyopathy </e2> ( CM ) and in elevated plasma <e1> lactate </e1> ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( <e2> CM </e2> ) and in elevated plasma <e1> lactate </e1> ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma <e1> lactate </e1> ( LA ) in <e2> AIDS </e2> through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma <e1> lactate </e1> ( LA ) in AIDS through mechanisms of <e2> mitochondrial dysfunction </e2> .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in <e2> cardiomyopathy </e2> ( CM ) and in elevated plasma lactate ( <e1> LA </e1> ) in AIDS through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( <e2> CM </e2> ) and in elevated plasma lactate ( <e1> LA </e1> ) in AIDS through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( <e1> LA </e1> ) in <e2> AIDS </e2> through mechanisms of mitochondrial dysfunction .
NO_RELATION	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( <e1> LA </e1> ) in AIDS through mechanisms of <e2> mitochondrial dysfunction </e2> .
NO_RELATION	To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic <e2> AIDS </e2> mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of <e1> zidovudine </e1> , lamivudine , and indinavir or vehicle control for 10 days or 35 days .
NO_RELATION	To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic <e2> AIDS </e2> mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , <e1> lamivudine </e1> , and indinavir or vehicle control for 10 days or 35 days .
NO_RELATION	To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic <e2> AIDS </e2> mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and <e1> indinavir </e1> or vehicle control for 10 days or 35 days .
NO_RELATION	At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of <e2> CM </e2> ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic <e1> calcium </e1> ATPase [ SERCA2 ] ) , and determination of plasma LA .
NO_RELATION	At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of <e2> CM </e2> ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma <e1> LA </e1> .
NO_RELATION	Results show that cumulative HAART caused mitochondrial <e2> CM </e2> with elevated <e1> LA </e1> in AIDS transgenic mice .
NO_RELATION	Results show that cumulative HAART caused mitochondrial CM with elevated <e1> LA </e1> in <e2> AIDS </e2> transgenic mice .
CID	<e1> Oral contraceptives </e1> and the risk of <e2> myocardial infarction </e2> .
CID	BACKGROUND : An association between the use of <e1> oral contraceptives </e1> and the risk of <e2> myocardial infarction </e2> has been found in some , but not all , studies .
NO_RELATION	We investigated this association , according to the type of <e1> progestagen </e1> included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of <e1> progestagen </e1> included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , <e1> desogestrel </e1> or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , <e1> desogestrel </e1> or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or <e1> gestodene </e1> ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or <e1> gestodene </e1> ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , <e1> levonorgestrel </e1> ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , <e1> levonorgestrel </e1> ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
CID	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) <e1> oral contraceptives </e1> , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
CID	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) <e1> oral contraceptives </e1> , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of <e1> estrogen </e1> , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
NO_RELATION	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of <e1> estrogen </e1> , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age , calendar year of the index event , and area of residence .
CID	An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for <e2> myocardial infarction </e2> among women who used any type of combined <e1> oral contraceptive </e1> , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .
CID	Among women who used <e1> oral contraceptives </e1> , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of <e2> myocardial infarction </e2> was increased among women who used second - generation oral contraceptives .
CID	Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of <e2> myocardial infarction </e2> was increased among women who used second - generation <e1> oral contraceptives </e1> .
CID	The risk of <e2> myocardial infarction </e2> was similar among women who used <e1> oral contraceptives </e1> whether or not they had a prothrombotic mutation .
CID	Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the <e1> cocaine </e1> - induced <e2> locomotor hyperactivity </e2> in rats .
CID	The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the <e2> locomotor hyperactivity </e2> induced by <e1> cocaine </e1> in rats .
NO_RELATION	<e1> GR 55562 </e1> ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced <e2> locomotor hyperactivity </e2> .
CID	GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to <e1> cocaine </e1> , dose - dependently attenuated the psychostimulant - induced <e2> locomotor hyperactivity </e2> .
CID	Our findings indicate that <e1> cocaine </e1> induced <e2> hyperlocomotion </e2> is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .
NO_RELATION	Our findings indicate that cocaine induced <e2> hyperlocomotion </e2> is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( <e1> GR 55562 </e1> ) and agonist ( CP 93129 ) , respectively .
CID	Our findings indicate that cocaine induced <e2> hyperlocomotion </e2> is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( <e1> CP 93129 </e1> ) , respectively .
NO_RELATION	<e1> Ticlopidine </e1> - induced <e2> cholestatic hepatitis </e2> .
NO_RELATION	OBJECTIVE : To report 2 cases of <e1> ticlopidine </e1> - induced <e2> cholestatic hepatitis </e2> , investigate its mechanism , and compare the observed main characteristics with those of the published cases .
NO_RELATION	CASE SUMMARIES : Two patients developed prolonged <e2> cholestatic hepatitis </e2> after receiving <e1> ticlopidine </e1> following percutaneous coronary angioplasty , with complete remission during the follow - up period .
NO_RELATION	DISCUSSION : <e2> Cholestatic hepatitis </e2> is a rare complication of the antiplatelet agent <e1> ticlopidine </e1> ; several cases have been reported but few in the English literature .
CID	Our patients developed <e2> jaundice </e2> following treatment with <e1> ticlopidine </e1> and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .
NO_RELATION	Our patients developed jaundice following treatment with <e1> ticlopidine </e1> and showed the clinical and laboratory characteristics of <e2> cholestatic hepatitis </e2> , which resolved after discontinuation of the drug .
CID	The mechanisms of this <e1> ticlopidine </e1> - induced <e2> cholestasis </e2> are unclear .
NO_RELATION	CONCLUSIONS : <e2> Cholestatic hepatitis </e2> is a rare adverse effect of <e1> ticlopidine </e1> that may be immune mediated .
NO_RELATION	Epithelial <e1> sodium </e1> channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced <e2> nephrotic syndrome </e2> .
CID	Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with <e1> puromycin aminonucleoside </e1> - induced <e2> nephrotic syndrome </e2> .
NO_RELATION	In experimental <e2> nephrotic syndrome </e2> , urinary <e1> sodium </e1> excretion is decreased during the early phase of the disease .
CID	We examined the abundance of ENaC subunit mRNAs and proteins in <e1> puromycin aminonucleoside </e1> ( PAN ) - induced <e2> nephrotic syndrome </e2> .
CID	We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( <e1> PAN </e1> ) - induced <e2> nephrotic syndrome </e2> .
NO_RELATION	The time courses of urinary <e1> sodium </e1> excretion , plasma aldosterone concentration and <e2> proteinuria </e2> were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .
NO_RELATION	The time courses of urinary sodium excretion , plasma <e1> aldosterone </e1> concentration and <e2> proteinuria </e2> were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .
CID	The time courses of urinary sodium excretion , plasma aldosterone concentration and <e2> proteinuria </e2> were studied in male Sprague - Dawley rats treated with a single dose of either <e1> PAN </e1> or vehicle .
NO_RELATION	The kinetics of urinary <e1> sodium </e1> excretion and the appearance of <e2> proteinuria </e2> were comparable with those reported previously .
CID	In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of <e1> PAN </e1> - induced <e2> nephrotic syndrome </e2> in rats , but appears to escape from the regulation by aldosterone after day 3 .
NO_RELATION	In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced <e2> nephrotic syndrome </e2> in rats , but appears to escape from the regulation by <e1> aldosterone </e1> after day 3 .
NO_RELATION	<e1> NO </e1> - induced <e2> migraine </e2> attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .
NO_RELATION	NO - induced <e2> migraine </e2> attack : strong increase in plasma <e1> calcitonin gene - related peptide </e1> ( CGRP ) concentration and negative correlation with platelet serotonin release .
NO_RELATION	NO - induced <e2> migraine </e2> attack : strong increase in plasma calcitonin gene - related peptide ( <e1> CGRP </e1> ) concentration and negative correlation with platelet serotonin release .
NO_RELATION	NO - induced <e2> migraine </e2> attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet <e1> serotonin </e1> release .
NO_RELATION	The aim of the present study was to investigate changes in the plasma <e1> calcitonin gene - related peptide </e1> ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma <e1> calcitonin gene - related peptide </e1> ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( <e1> CGRP </e1> ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( <e1> CGRP </e1> ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet <e1> serotonin </e1> ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet <e1> serotonin </e1> ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( <e1> 5 - hydroxytriptamine </e1> , 5 - HT ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( <e1> 5 - hydroxytriptamine </e1> , 5 - HT ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , <e1> 5 - HT </e1> ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , <e1> 5 - HT </e1> ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by <e1> nitroglycerin </e1> .
NO_RELATION	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by <e1> nitroglycerin </e1> .
NO_RELATION	Blood was collected from the antecubital vein four times : 60 min before and after the <e1> nitroglycerin </e1> application , and 60 and 120 min after the beginning of the <e2> migraine </e2> attack ( mean 344 and 404 min ; 12 subjects ) .
NO_RELATION	Plasma <e1> CGRP </e1> concentration increased significantly ( P < 0 . 01 ) during the <e2> migraine </e2> attack and returned to baseline after the cessation of the migraine .
NO_RELATION	Plasma <e1> CGRP </e1> concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the <e2> migraine </e2> .
NO_RELATION	However , plasma <e1> CGRP </e1> concentrations failed to change during immediate <e2> headache </e2> and in the subjects with no migraine attack .
NO_RELATION	However , plasma <e1> CGRP </e1> concentrations failed to change during immediate headache and in the subjects with no <e2> migraine </e2> attack .
NO_RELATION	Basal <e1> CGRP </e1> concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a <e2> migraine </e2> attack .
NO_RELATION	Basal CGRP concentration was significantly higher and platelet <e1> 5 - HT </e1> content tended to be lower in subjects who experienced a <e2> migraine </e2> attack .
NO_RELATION	Platelet <e1> serotonin </e1> content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no <e2> migraine </e2> attack but no consistent change was observed in patients with migraine attack .
NO_RELATION	Platelet <e1> serotonin </e1> content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with <e2> migraine </e2> attack .
NO_RELATION	Platelet serotonin content decreased significantly ( P < 0 . 01 ) after <e1> nitroglycerin </e1> in subjects with no <e2> migraine </e2> attack but no consistent change was observed in patients with migraine attack .
NO_RELATION	Platelet serotonin content decreased significantly ( P < 0 . 01 ) after <e1> nitroglycerin </e1> in subjects with no migraine attack but no consistent change was observed in patients with <e2> migraine </e2> attack .
NO_RELATION	In conclusion , the fact that plasma <e1> CGRP </e1> concentration correlates with the timing and severity of a <e2> migraine </e2> headache suggests a direct relationship between CGRP and migraine .
NO_RELATION	In conclusion , the fact that plasma <e1> CGRP </e1> concentration correlates with the timing and severity of a migraine <e2> headache </e2> suggests a direct relationship between CGRP and migraine .
NO_RELATION	In conclusion , the fact that plasma <e1> CGRP </e1> concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and <e2> migraine </e2> .
NO_RELATION	In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a <e2> migraine </e2> headache suggests a direct relationship between <e1> CGRP </e1> and migraine .
NO_RELATION	In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine <e2> headache </e2> suggests a direct relationship between <e1> CGRP </e1> and migraine .
NO_RELATION	In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between <e1> CGRP </e1> and <e2> migraine </e2> .
NO_RELATION	In contrast , <e1> serotonin </e1> release from platelets does not provoke <e2> migraine </e2> , it may even counteract the headache and the concomitant CGRP release in this model .
NO_RELATION	In contrast , <e1> serotonin </e1> release from platelets does not provoke migraine , it may even counteract the <e2> headache </e2> and the concomitant CGRP release in this model .
NO_RELATION	In contrast , serotonin release from platelets does not provoke <e2> migraine </e2> , it may even counteract the headache and the concomitant <e1> CGRP </e1> release in this model .
NO_RELATION	In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the <e2> headache </e2> and the concomitant <e1> CGRP </e1> release in this model .
CID	<e2> Coronary aneurysm </e2> after implantation of a <e1> paclitaxel </e1> - eluting stent .
CID	We present a 43 - year - old man who developed a <e2> coronary aneurysm </e2> in the right coronary artery 6 months after receiving a <e1> paclitaxel </e1> - eluting stent .
NO_RELATION	Intracerebroventricular ( i . c . v . ) injection of <e1> U - II </e1> causes <e2> hypertension </e2> and bradycardia and stimulates prolactin and thyrotropin secretion .
NO_RELATION	Intracerebroventricular ( i . c . v . ) injection of <e1> U - II </e1> causes hypertension and <e2> bradycardia </e2> and stimulates prolactin and thyrotropin secretion .
NO_RELATION	Whatever was the dose , the central administration of <e1> U - II </e1> had no effect on body temperature , nociception , apomorphine - induced <e2> penile erection </e2> and climbing behavior , and stress - induced plasma corticosterone level .
CID	Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , <e1> apomorphine </e1> - induced <e2> penile erection </e2> and climbing behavior , and stress - induced plasma corticosterone level .
NO_RELATION	Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced <e2> penile erection </e2> and climbing behavior , and stress - induced plasma <e1> corticosterone </e1> level .
NO_RELATION	These data suggest that <e1> U - II </e1> may be involved in some aspects of <e2> psychiatric disorders </e2> .
CID	Recurrent <e2> dysphonia </e2> and <e1> acitretin </e1> .
CID	We report the case of a woman complaining of <e2> dysphonia </e2> while she was treated by <e1> acitretin </e1> .
CID	To our knowledge , this is the first case of <e1> acitretin </e1> - induced <e2> dysphonia </e2> .
NO_RELATION	The aim of this study was to assess the effects of <e1> gabapentin </e1> , a drug effective in <e2> neuropathic pain </e2> patients , on brain processing of nociceptive information in normal and central sensitization states .
NO_RELATION	Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the <e1> gabapentin </e1> - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced <e2> secondary hyperalgesia </e2> .
CID	Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and <e1> capsaicin </e1> - induced <e2> secondary hyperalgesia </e2> .
CID	<e1> MDMA </e1> polydrug users show process - specific central executive impairments coupled with <e2> impaired social and emotional judgement processes </e2> .
NO_RELATION	In recent years working <e2> memory deficits </e2> have been reported in users of <e1> MDMA </e1> ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .
NO_RELATION	In recent years working <e2> memory deficits </e2> have been reported in users of MDMA ( <e1> 3 , 4 - methylenedioxymethamphetamine </e1> , ecstasy ) .
NO_RELATION	In recent years working <e2> memory deficits </e2> have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , <e1> ecstasy </e1> ) .
NO_RELATION	Severe <e1> citrate </e1> <e2> toxicity </e2> complicating volunteer apheresis platelet donation .
NO_RELATION	We report a case of severe <e1> citrate </e1> <e2> toxicity </e2> during volunteer donor apheresis platelet collection .
NO_RELATION	Empirical treatment with intravenous <e1> calcium gluconate </e1> was initiated , and <e2> muscle contractions </e2> slowly subsided over approximately 10 to 15 minutes .
NO_RELATION	The events are consistent with a severe reaction to <e1> calcium </e1> chelation by sodium citrate anticoagulant resulting in symptomatic systemic <e2> hypocalcemia </e2> .
CID	The events are consistent with a severe reaction to calcium chelation by <e1> sodium citrate </e1> anticoagulant resulting in symptomatic systemic <e2> hypocalcemia </e2> .
NO_RELATION	Upon additional retrospective analysis , it was noted that <e1> bumetanide </e1> is a loop diuretic that may cause significant <e2> hypocalcemia </e2> .
NO_RELATION	Upon additional retrospective analysis , it was noted that bumetanide is a <e1> loop diuretic </e1> that may cause significant <e2> hypocalcemia </e2> .
CID	We conclude that careful screening for medications and underlying conditions predisposing to <e2> hypocalcemia </e2> is recommended to help prevent severe reactions due to <e1> citrate </e1> toxicity .
NO_RELATION	We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to <e1> citrate </e1> <e2> toxicity </e2> .
CID	<e2> Proteinuria </e2> after conversion to <e1> sirolimus </e1> in renal transplant recipients .
CID	More recently , <e2> proteinuria </e2> has been reported as a consequence of <e1> sirolimus </e1> therapy , although the mechanism has remained unclear .
CID	We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased <e2> proteinuria </e2> after <e1> SRL </e1> conversion .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to <e2> chronic allograft nephropathy </e2> ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( <e2> CAN </e2> ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) <e2> neoplasia </e2> ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; <e2> Kaposi ' s sarcoma </e2> , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four <e2> skin cancers </e2> , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One <e2> intestinal tumors </e2> , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One <e2> renal cell carsinom </e2> ) or BK virus nephropathy ( n = 2 ) .
NO_RELATION	The patient cohort ( 14 men , 11 women ) was treated with <e1> SRL </e1> as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus <e2> nephropathy </e2> ( n = 2 ) .
CID	Heavy <e2> proteinuria </e2> was common after the use of <e1> SRL </e1> as rescue therapy for renal transplantation .
CID	In vitro characterization of parasympathetic and sympathetic responses in <e1> cyclophosphamide </e1> - induced <e2> cystitis </e2> in the rat .
CID	In <e1> cyclophosphamide </e1> - induced <e2> cystitis </e2> in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .
CID	However , use of <e1> BZDs </e1> / RDs was associated with <e2> dizziness </e2> , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
CID	However , use of <e1> BZDs </e1> / RDs was associated with dizziness , <e2> inability to sleep </e2> after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
CID	However , use of <e1> BZDs </e1> / RDs was associated with dizziness , inability to sleep after awaking at night and <e2> tiredness </e2> in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
CID	However , use of <e1> BZDs </e1> / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger <e2> depressive symptoms </e2> measured at the beginning of the hospital stay .
CID	Acute <e2> vocal fold palsy </e2> after acute <e1> disulfiram </e1> intoxication .
CID	Acute <e2> peripheral neuropathy </e2> caused by a <e1> disulfiram </e1> overdose is very rare and there is no report of it leading to vocal fold palsy .
NO_RELATION	Acute peripheral neuropathy caused by a <e1> disulfiram </e1> <e2> overdose </e2> is very rare and there is no report of it leading to vocal fold palsy .
CID	Acute peripheral neuropathy caused by a <e1> disulfiram </e1> overdose is very rare and there is no report of it leading to <e2> vocal fold palsy </e2> .
NO_RELATION	This was a case of acute <e2> palsy </e2> of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose <e1> disulfiram </e1> intoxication .
NO_RELATION	This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal <e2> polyneuropathy </e2> caused by high - dose <e1> disulfiram </e1> intoxication .
CID	Higher optical density of an antigen assay predicts <e2> thrombosis </e2> in patients with <e1> heparin </e1> - induced thrombocytopenia .
CID	Higher optical density of an antigen assay predicts thrombosis in patients with <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step <e1> heparin </e1> - induced thrombocytopenia ( <e2> HIT </e2> ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step <e1> heparin </e1> - induced thrombocytopenia ( HIT ) antigen assay with <e2> thrombosis </e2> ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced <e2> thrombocytopenia </e2> ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> concentration .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( <e2> HIT </e2> ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> concentration .
CID	OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with <e2> thrombosis </e2> ; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> concentration .
CID	PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or <e2> thrombocytopenia </e2> ( < 150 x 10 ( 9 ) / L ) after exposure to <e1> heparin </e1> , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .
CID	PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or <e2> thrombocytopenia </e2> ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of <e1> heparin </e1> ] were included in the study .
CID	Central <e2> retinal vein occlusion </e2> associated with <e1> clomiphene </e1> - induced ovulation .
CID	OBJECTIVE : To report a case of central <e2> retinal vein occlusion </e2> associated with <e1> clomiphene citrate </e1> ( CC ) .
CID	OBJECTIVE : To report a case of central <e2> retinal vein occlusion </e2> associated with clomiphene citrate ( <e1> CC </e1> ) .
CID	MAIN OUTCOME MEASURE ( S ) : Central <e2> retinal vein occlusion </e2> after ovulation induction with <e1> CC </e1> .
CID	RESULT ( S ) : A 36 - year - old Chinese woman developed central <e2> retinal vein occlusion </e2> after eight courses of <e1> CC </e1> .
NO_RELATION	A search of the literature on the <e2> thromboembolic </e2> complications of <e1> CC </e1> does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .
CID	A search of the literature on the thromboembolic complications of <e1> CC </e1> does not include this severe ophthalmic complication , although mild <e2> visual disturbance </e2> after CC intake is not uncommon .
NO_RELATION	A search of the literature on the <e2> thromboembolic </e2> complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after <e1> CC </e1> intake is not uncommon .
CID	A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild <e2> visual disturbance </e2> after <e1> CC </e1> intake is not uncommon .
CID	CONCLUSION ( S ) : This is the first reported case of central <e2> retinal vein occlusion </e2> after treatment with <e1> CC </e1> .
NO_RELATION	Extra caution is warranted in treating <e2> infertility </e2> patients with <e1> CC </e1> , and patients should be well informed of this side effect before commencement of therapy .
CID	<e1> Nicotine </e1> - induced <e2> nystagmus </e2> correlates with midpontine activation .
CID	The pathomechanism of <e1> nicotine </e1> - induced <e2> nystagmus </e2> ( NIN ) is unknown .
CID	The pathomechanism of <e1> nicotine </e1> - induced nystagmus ( <e2> NIN </e2> ) is unknown .
NO_RELATION	<e2> NIN </e2> correlated with blood <e1> oxygen </e1> level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .
NO_RELATION	Protective effect of <e1> verapamil </e1> on <e2> gastric hemorrhagic </e2> ulcers in severe atherosclerotic rats .
NO_RELATION	Protective effect of <e1> verapamil </e1> on gastric hemorrhagic <e2> ulcers </e2> in severe atherosclerotic rats .
NO_RELATION	Protective effect of <e1> verapamil </e1> on gastric hemorrhagic ulcers in severe <e2> atherosclerotic </e2> rats .
NO_RELATION	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell <e1> histamine </e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
NO_RELATION	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell <e1> histamine </e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
NO_RELATION	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell <e1> histamine </e1> release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2> atherosclerosis </e2> induced by coadministration of vitamin D2 and cholesterol .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of <e1> vitamin D2 </e1> and cholesterol .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of <e1> vitamin D2 </e1> and cholesterol .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2> atherosclerosis </e2> induced by coadministration of <e1> vitamin D2 </e1> and cholesterol .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1> cholesterol </e1> .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1> cholesterol </e1> .
CID	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2> atherosclerosis </e2> induced by coadministration of vitamin D2 and <e1> cholesterol </e1> .
NO_RELATION	Additionally , the protective effect of <e1> verapamil </e1> on this <e2> ulcer </e2> model was evaluated .
CID	Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing <e1> vitamin D2 </e1> and cholesterol to induce <e2> atherosclerosis </e2> .
CID	Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and <e1> cholesterol </e1> to induce <e2> atherosclerosis </e2> .
NO_RELATION	Gastric acid back - diffusion , mucosal LPO generation , <e1> histamine </e1> concentration , microvascular permeability , luminal hemoglobin content and <e2> ulcer </e2> areas were determined .
NO_RELATION	Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , <e1> luminal </e1> hemoglobin content and <e2> ulcer </e2> areas were determined .
NO_RELATION	Elevated <e2> atherosclerotic </e2> parameters , such as serum <e1> calcium </e1> , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .
NO_RELATION	Elevated atherosclerotic parameters , such as serum <e1> calcium </e1> , total cholesterol and low - density lipoprotein concentration were obtained in <e2> atherosclerotic </e2> rats .
CID	Elevated <e2> atherosclerotic </e2> parameters , such as serum calcium , total <e1> cholesterol </e1> and low - density lipoprotein concentration were obtained in atherosclerotic rats .
CID	Elevated atherosclerotic parameters , such as serum calcium , total <e1> cholesterol </e1> and low - density lipoprotein concentration were obtained in <e2> atherosclerotic </e2> rats .
NO_RELATION	Severe gastric <e2> ulcers </e2> accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , <e1> histamine </e1> release , LPO generation and luminal hemoglobin content were also observed in these rats .
NO_RELATION	Severe gastric <e2> ulcers </e2> accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and <e1> luminal </e1> hemoglobin content were also observed in these rats .
NO_RELATION	Moreover , a positive correlation of <e1> histamine </e1> to <e2> gastric hemorrhage </e2> and to ulcer was found in those atherosclerotic rats .
NO_RELATION	Moreover , a positive correlation of <e1> histamine </e1> to gastric hemorrhage and to <e2> ulcer </e2> was found in those atherosclerotic rats .
NO_RELATION	Moreover , a positive correlation of <e1> histamine </e1> to gastric hemorrhage and to ulcer was found in those <e2> atherosclerotic </e2> rats .
NO_RELATION	This <e2> hemorrhagic </e2> ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric <e1> verapamil </e1> .
NO_RELATION	This hemorrhagic <e2> ulcer </e2> and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric <e1> verapamil </e1> .
NO_RELATION	<e2> Atherosclerosis </e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , <e1> histamine </e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
NO_RELATION	Atherosclerosis could produce <e2> gastric hemorrhagic </e2> ulcer via aggravation of gastric acid back - diffusion , LPO generation , <e1> histamine </e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
NO_RELATION	Atherosclerosis could produce gastric hemorrhagic <e2> ulcer </e2> via aggravation of gastric acid back - diffusion , LPO generation , <e1> histamine </e1> release and microvascular permeability that could be ameliorated by verapamil in rats .
NO_RELATION	<e2> Atherosclerosis </e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1> verapamil </e1> in rats .
NO_RELATION	Atherosclerosis could produce <e2> gastric hemorrhagic </e2> ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1> verapamil </e1> in rats .
NO_RELATION	Atherosclerosis could produce gastric hemorrhagic <e2> ulcer </e2> via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by <e1> verapamil </e1> in rats .
NO_RELATION	<e1> Adriamycin </e1> - induced autophagic cardiomyocyte <e2> death </e2> plays a pathogenic role in a rat model of heart failure .
CID	<e1> Adriamycin </e1> - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of <e2> heart failure </e2> .
CID	BACKGROUND : The mechanisms underlying <e2> heart failure </e2> induced by <e1> adriamycin </e1> are very complicated and still unclear .
CID	The aim of this study was to investigate whether autophagy was involved in the progression of <e2> heart failure </e2> induced by <e1> adriamycin </e1> , so that we can develop a novel treatment strategy for heart failure .
CID	The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by <e1> adriamycin </e1> , so that we can develop a novel treatment strategy for <e2> heart failure </e2> .
NO_RELATION	METHODS : <e1> 3 - methyladenine </e1> ( 3MA ) , a specific inhibitor on autophagy was used in a <e2> heart failure </e2> model of rats induced by adriamycin .
NO_RELATION	METHODS : 3 - methyladenine ( <e1> 3MA </e1> ) , a specific inhibitor on autophagy was used in a <e2> heart failure </e2> model of rats induced by adriamycin .
CID	METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a <e2> heart failure </e2> model of rats induced by <e1> adriamycin </e1> .
NO_RELATION	CONCLUSION : Autophagic cardiomyocyte <e2> death </e2> plays an important role in the pathogenesis of heart failure in rats induced by <e1> adriamycin </e1> .
CID	CONCLUSION : Autophagic cardiomyocyte death plays an important role in the pathogenesis of <e2> heart failure </e2> in rats induced by <e1> adriamycin </e1> .
CID	Mitochondrial injury may be involved in the progression of <e2> heart failure </e2> caused by <e1> adriamycin </e1> via the autophagy pathway .
CID	<e2> Confusion </e2> , a rather serious adverse drug reaction with <e1> valproic acid </e1> : a review of the French Pharmacovigilance database .
CID	INTRODUCTION : <e2> Confusion </e2> is an adverse drug reaction frequently observed with <e1> valproic acid </e1> .
CID	METHODS : Using the French Pharmacovigilance database , we selected the cases of <e2> confusion </e2> reported since 1985 with <e1> valproic acid </e1> .
CID	RESULTS : 272 cases of <e2> confusion </e2> were reported with <e1> valproic acid </e1> : 153 women and 119 men .
CID	<e2> Confusion </e2> mostly occurred during the two first weeks following <e1> valproic acid </e1> exposure ( 39 . 7 % ) .
CID	CONCLUSION : This work shows that <e2> confusion </e2> with <e1> valproic acid </e1> is a serious , rather frequent but reversible adverse drug reaction .
NO_RELATION	<e2> Learning and memory deficits </e2> in <e1> ecstasy </e1> users and their neural correlates during a face - learning task .
NO_RELATION	It has been consistently shown that <e1> ecstasy </e1> users display <e2> impairments in learning and memory </e2> performance .
NO_RELATION	<e2> Deficits in learning and memory </e2> : parahippocampal hyperactivity and frontocortical hypoactivity in <e1> cannabis </e1> users .
NO_RELATION	Deficits in learning and memory : parahippocampal <e2> hyperactivity </e2> and frontocortical hypoactivity in <e1> cannabis </e1> users .
NO_RELATION	A conjunction analysis of the encode and recall phases of the task revealed <e1> ecstasy </e1> - specific <e2> hyperactivity </e2> in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .
NO_RELATION	These <e1> ecstasy </e1> - specific effects may be related to the vulnerability of isocortical and allocortical regions to the <e2> neurotoxic </e2> effects of ecstasy .
NO_RELATION	These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the <e2> neurotoxic </e2> effects of <e1> ecstasy </e1> .
NO_RELATION	Prolonged elevation of plasma <e1> argatroban </e1> in a cardiac transplant patient with a suspected history of heparin - induced <e2> thrombocytopenia </e2> with thrombosis .
NO_RELATION	Prolonged elevation of plasma <e1> argatroban </e1> in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with <e2> thrombosis </e2> .
NO_RELATION	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> with thrombosis .
NO_RELATION	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1> heparin </e1> - induced thrombocytopenia with <e2> thrombosis </e2> .
NO_RELATION	BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
NO_RELATION	BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1> - induced thrombocytopenia ( <e2> HIT </e2> ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
NO_RELATION	BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1> - induced thrombocytopenia ( HIT ) or <e2> HIT </e2> with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
NO_RELATION	BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1> - induced thrombocytopenia ( HIT ) or HIT with <e2> thrombosis </e2> ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
NO_RELATION	BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1> - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( <e2> HITT </e2> ) undergoing cardiopulmonary bypass ( CPB ) .
NO_RELATION	In the following report , a 65 - year - old <e2> critically ill </e2> patient with a suspected history of HITT was administered <e1> argatroban </e1> for anticoagulation on bypass during heart transplantation .
NO_RELATION	In the following report , a 65 - year - old critically ill patient with a suspected history of <e2> HITT </e2> was administered <e1> argatroban </e1> for anticoagulation on bypass during heart transplantation .
NO_RELATION	RESULTS : Unexpectedly high concentrations of <e1> argatroban </e1> were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with <e2> hepatic impairment </e2> ] ) .
NO_RELATION	RESULTS : Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma <e1> argatroban </e1> half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with <e2> hepatic impairment </e2> ] ) .
NO_RELATION	CONCLUSIONS : Correlation of plasma <e1> argatroban </e1> concentration versus the patient ' s coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient ' s extended <e2> coagulopathy </e2> .
NO_RELATION	CONCLUSIONS : Correlation of plasma argatroban concentration versus the patient ' s coagulation variables and clinical course suggest that prolonged elevated levels of plasma <e1> argatroban </e1> may have contributed to the patient ' s extended <e2> coagulopathy </e2> .
NO_RELATION	This is the first report to measure plasma <e1> argatroban </e1> concentration in the context of CPB and extended <e2> coagulopathy </e2> .
CID	<e1> Antituberculosis </e1> therapy - induced <e2> acute liver failure </e2> : magnitude , profile , prognosis , and predictors of outcome .
CID	<e1> Antituberculosis </e1> therapy ( ATT ) - associated <e2> acute liver failure </e2> ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .
CID	<e1> Antituberculosis </e1> therapy ( ATT ) - associated acute liver failure ( ATT - <e2> ALF </e2> ) is the commonest drug - induced ALF in South Asia .
CID	<e1> Antituberculosis </e1> therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced <e2> ALF </e2> in South Asia .
NO_RELATION	In multivariate analysis , three factors independently predicted mortality : serum <e1> bilirubin </e1> ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV <e2> encephalopathy </e2> at presentation .
NO_RELATION	CNS complications included posterior reversible <e2> leukoencephalopathy </e2> syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose <e1> methotrexate </e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
NO_RELATION	CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , <e2> stroke </e2> ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose <e1> methotrexate </e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
NO_RELATION	CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , <e2> temporal lobe epilepsy </e2> ( n = 2 ) , high - dose <e1> methotrexate </e1> toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
NO_RELATION	CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose <e1> methotrexate </e1> <e2> toxicity </e2> ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
NO_RELATION	CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose <e1> methotrexate </e1> toxicity ( n = 2 ) , syndrome of <e2> inappropriate antidiuretic hormone secretion </e2> ( n = 1 ) , and other unclassified events ( n = 7 ) .
NO_RELATION	IMPORTANCE OF THE FIELD : <e1> Fluoropyrimidines </e1> , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid <e2> tumors </e2> , including colorectal , breast and head and neck cancers , for > 40 years .
NO_RELATION	IMPORTANCE OF THE FIELD : <e1> Fluoropyrimidines </e1> , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including <e2> colorectal , breast and head and neck cancers </e2> , for > 40 years .
NO_RELATION	IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1> 5 - fluorouracil </e1> ( 5 - FU ) , have been the mainstay of treatment for several solid <e2> tumors </e2> , including colorectal , breast and head and neck cancers , for > 40 years .
NO_RELATION	IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular <e1> 5 - fluorouracil </e1> ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including <e2> colorectal , breast and head and neck cancers </e2> , for > 40 years .
NO_RELATION	IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( <e1> 5 - FU </e1> ) , have been the mainstay of treatment for several solid <e2> tumors </e2> , including colorectal , breast and head and neck cancers , for > 40 years .
NO_RELATION	IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( <e1> 5 - FU </e1> ) , have been the mainstay of treatment for several solid tumors , including <e2> colorectal , breast and head and neck cancers </e2> , for > 40 years .
NO_RELATION	WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of <e1> capecitabine </e1> in special populations such as patients with advanced age , <e2> renal and kidney disease </e2> .
CID	The most commonly reported toxic effects of <e1> capecitabine </e1> are <e2> diarrhea </e2> , nausea , vomiting , stomatitis and hand - foot syndrome .
CID	The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea , <e2> nausea </e2> , vomiting , stomatitis and hand - foot syndrome .
CID	The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea , nausea , <e2> vomiting </e2> , stomatitis and hand - foot syndrome .
CID	The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea , nausea , vomiting , <e2> stomatitis </e2> and hand - foot syndrome .
CID	The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea , nausea , vomiting , stomatitis and <e2> hand - foot syndrome </e2> .
NO_RELATION	<e1> Capecitabine </e1> has a well - established safety profile and can be given safely to patients with advanced age , <e2> hepatic and renal dysfunctions </e2> .
NO_RELATION	Effects of pallidal <e1> neurotensin </e1> on haloperidol - induced <e2> parkinsonian catalepsy </e2> : behavioral and electrophysiological studies .
CID	Effects of pallidal neurotensin on <e1> haloperidol </e1> - induced <e2> parkinsonian catalepsy </e2> : behavioral and electrophysiological studies .
NO_RELATION	The present study aimed to investigate the effects of pallidal <e1> neurotensin </e1> on haloperidol - induced <e2> parkinsonian symptoms </e2> .
NO_RELATION	The present study aimed to investigate the effects of pallidal neurotensin on <e1> haloperidol </e1> - induced <e2> parkinsonian symptoms </e2> .
NO_RELATION	RESULTS : Bilateral infusions of <e1> neurotensin </e1> into the globus pallidus reversed haloperidol - induced <e2> parkinsonian catalepsy </e2> in rats .
CID	RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed <e1> haloperidol </e1> - induced <e2> parkinsonian catalepsy </e2> in rats .
CID	This was accounted for by a significant number of <e2> depressions </e2> occurring in <e1> methyl dopa </e1> treated patients with psychiatric histories .
NO_RELATION	This was accounted for by a significant number of depressions occurring in <e1> methyl dopa </e1> treated patients with <e2> psychiatric </e2> histories .
CID	Pulmonary shunt and cardiovascular responses to CPAP during <e1> nitroprusside </e1> - induced <e2> hypotension </e2> .
NO_RELATION	Ten cm <e1> H2O </e1> CPAP before nitroprusside infusion produced a further <e2> decrease in arterial blood pressure </e2> and significantly increased heart rate and decreased cardiac output and QS / QT .
NO_RELATION	Ten cm <e1> H2O </e1> CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and <e2> decreased cardiac output </e2> and QS / QT .
CID	Ten cm H2O CPAP before <e1> nitroprusside </e1> infusion produced a further <e2> decrease in arterial blood pressure </e2> and significantly increased heart rate and decreased cardiac output and QS / QT .
NO_RELATION	Ten cm H2O CPAP before <e1> nitroprusside </e1> infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and <e2> decreased cardiac output </e2> and QS / QT .
CID	<e1> Nitroprusside </e1> caused significant <e2> decreases in arterial blood pressure </e2> and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .
NO_RELATION	During <e1> nitroprusside </e1> infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked <e2> decreases in arterial blood pressure and cardiac output </e2> .
NO_RELATION	During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm <e1> H2O </e1> ) , while decreasing QS / QT , produce marked <e2> decreases in arterial blood pressure and cardiac output </e2> .
NO_RELATION	Mediation of enhanced reflex vagal <e2> bradycardia </e2> by <e1> L - dopa </e1> via central dopamine formation in dogs .
NO_RELATION	Mediation of enhanced reflex vagal <e2> bradycardia </e2> by L - dopa via central <e1> dopamine </e1> formation in dogs .
CID	In addition , reflex <e2> bradycardia </e2> caused by injected <e1> norepinephrine </e1> was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
NO_RELATION	In addition , reflex <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by <e1> L - dopa </e1> , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
NO_RELATION	In addition , reflex <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L - dopa , <e1> DL - Threo - dihydroxyphenylserine </e1> had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
CID	In addition , reflex <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to <e1> norepinephrine </e1> .
NO_RELATION	<e1> FLA - 63 </e1> , a dopamine - beta - oxidase inhibitor , did not have any effect on the <e2> hypotension </e2> , bradycardia or reflex - enhancing effect of L - dopa .
NO_RELATION	<e1> FLA - 63 </e1> , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , <e2> bradycardia </e2> or reflex - enhancing effect of L - dopa .
NO_RELATION	FLA - 63 , a <e1> dopamine </e1> - beta - oxidase inhibitor , did not have any effect on the <e2> hypotension </e2> , bradycardia or reflex - enhancing effect of L - dopa .
NO_RELATION	FLA - 63 , a <e1> dopamine </e1> - beta - oxidase inhibitor , did not have any effect on the hypotension , <e2> bradycardia </e2> or reflex - enhancing effect of L - dopa .
NO_RELATION	FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the <e2> hypotension </e2> , bradycardia or reflex - enhancing effect of <e1> L - dopa </e1> .
NO_RELATION	FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , <e2> bradycardia </e2> or reflex - enhancing effect of <e1> L - dopa </e1> .
NO_RELATION	However , <e1> L - dopa </e1> restored the <e2> bradycardia </e2> caused by norepinephrine in addition to decreasing blood pressure and heart rate .
CID	However , L - dopa restored the <e2> bradycardia </e2> caused by <e1> norepinephrine </e1> in addition to decreasing blood pressure and heart rate .
NO_RELATION	<e1> 5 - HTP </e1> ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex <e2> bradycardia </e2> to norepinephrine .
CID	5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex <e2> bradycardia </e2> to <e1> norepinephrine </e1> .
NO_RELATION	It is concluded that <e1> L - dopa </e1> enhances reflex <e2> bradycardia </e2> through central alpha - receptor stimulation .
CID	<e1> Cocaine </e1> - induced <e2> myocardial infarction </e2> : clinical observations and pathogenetic considerations .
CID	Clinical and experimental data published to date suggest several possible mechanisms by which <e1> cocaine </e1> may result in <e2> acute myocardial infarction </e2> .
NO_RELATION	In individuals with preexisting , high - grade coronary arterial narrowing , <e2> acute myocardial infarction </e2> may result from an increase in myocardial <e1> oxygen </e1> demand associated with cocaine - induced increase in rate - pressure product .
CID	In individuals with preexisting , high - grade coronary arterial narrowing , <e2> acute myocardial infarction </e2> may result from an increase in myocardial oxygen demand associated with <e1> cocaine </e1> - induced increase in rate - pressure product .
NO_RELATION	With regard to <e2> spasm </e2> , the clinical findings are largely circumstantial , and the locus of <e1> cocaine </e1> - induced vasoconstriction remains speculative .
NO_RELATION	Finally , the contribution of a primary , <e2> thrombotic </e2> effect of <e1> cocaine </e1> has not been excluded .
NO_RELATION	<e2> Rabbit syndrome </e2> , <e1> antidepressant </e1> use , and cerebral perfusion SPECT scan findings .
NO_RELATION	Acute bronchodilating effects of <e1> ipratropium bromide </e1> and theophylline in <e2> chronic obstructive pulmonary disease </e2> .
NO_RELATION	Acute bronchodilating effects of ipratropium bromide and <e1> theophylline </e1> in <e2> chronic obstructive pulmonary disease </e2> .
NO_RELATION	The bronchodilator effects of a single dose of <e1> ipratropium bromide </e1> aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , <e2> chronic obstructive pulmonary disease </e2> .
NO_RELATION	The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting <e1> theophylline </e1> tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , <e2> chronic obstructive pulmonary disease </e2> .
NO_RELATION	While side effects were rare , those experienced after <e1> theophylline </e1> use did involve the <e2> cardiovascular and gastrointestinal systems </e2> .
NO_RELATION	These results show that <e1> ipratropium </e1> is a more potent bronchodilator than oral theophylline in patients with <e2> chronic airflow obstruction </e2> .
NO_RELATION	These results show that ipratropium is a more potent bronchodilator than oral <e1> theophylline </e1> in patients with <e2> chronic airflow obstruction </e2> .
CID	<e2> Renal papillary necrosis </e2> ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with <e1> aspirin </e1> and paracetamol in female Fischer 344 rats .
CID	Renal papillary necrosis ( <e2> RPN </e2> ) and a decreased urinary concentrating ability developed during continuous long - term treatment with <e1> aspirin </e1> and paracetamol in female Fischer 344 rats .
CID	<e2> Renal papillary necrosis </e2> ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and <e1> paracetamol </e1> in female Fischer 344 rats .
CID	Renal papillary necrosis ( <e2> RPN </e2> ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and <e1> paracetamol </e1> in female Fischer 344 rats .
CID	<e1> Lithium </e1> - induced <e2> polyuria </e2> seems to be related to extrarenal as well as to renal effects .
NO_RELATION	Effect of <e1> adriamycin </e1> combined with whole body <e2> hyperthermia </e2> on tumor and normal tissues .
NO_RELATION	Effect of <e1> adriamycin </e1> combined with whole body hyperthermia on <e2> tumor </e2> and normal tissues .
NO_RELATION	Thermal enhancement of <e1> Adriamycin </e1> - mediated antitumor activity and normal tissue <e2> toxicities </e2> by whole body hyperthermia were compared using a F344 rat model .
NO_RELATION	Thermal enhancement of <e1> Adriamycin </e1> - mediated antitumor activity and normal tissue toxicities by whole body <e2> hyperthermia </e2> were compared using a F344 rat model .
NO_RELATION	Whole body <e2> hyperthermia </e2> ( 120 min at 41 . 5 degrees C ) enhanced both <e1> Adriamycin </e1> - mediated antitumor activity and toxic side effects .
NO_RELATION	Thus , while whole body <e2> hyperthermia </e2> enhances <e1> Adriamycin </e1> - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
NO_RELATION	Thus , while whole body hyperthermia enhances <e1> Adriamycin </e1> - mediated antitumor effect , normal tissue <e2> toxicity </e2> is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
CID	<e1> Prazosin </e1> - induced <e2> stress incontinence </e2> .
CID	A case of genuine <e2> stress incontinence </e2> due to <e1> prazosin </e1> , a common antihypertensive drug , is presented .
CID	Patients who present with <e2> stress incontinence </e2> while taking <e1> prazosin </e1> should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .
NO_RELATION	Patients who present with stress incontinence while taking <e1> prazosin </e1> should change their antihypertensive medication before considering surgery , because their <e2> incontinence </e2> may resolve spontaneously with a change in drug therapy .
CID	<e2> Myocardial infarction </e2> following sublingual administration of <e1> isosorbide dinitrate </e1> .
NO_RELATION	A 78 - year - old with healed septal <e2> necrosis </e2> suffered a recurrent myocardial infarction of the anterior wall following the administration of <e1> isosorbide dinitrate </e1> 5 mg sublingually .
CID	A 78 - year - old with healed septal necrosis suffered a recurrent <e2> myocardial infarction </e2> of the anterior wall following the administration of <e1> isosorbide dinitrate </e1> 5 mg sublingually .
CID	<e1> Fluoxetine </e1> - induced <e2> akathisia </e2> : clinical and theoretical implications .
NO_RELATION	Five patients receiving <e1> fluoxetine </e1> for the treatment of <e2> obsessive compulsive disorder </e2> or major depression developed akathisia .
NO_RELATION	Five patients receiving <e1> fluoxetine </e1> for the treatment of obsessive compulsive disorder or <e2> major depression </e2> developed akathisia .
CID	Five patients receiving <e1> fluoxetine </e1> for the treatment of obsessive compulsive disorder or major depression developed <e2> akathisia </e2> .
NO_RELATION	The typical <e1> fluoxetine </e1> - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked <e2> anxiety </e2> were indistinguishable from those of neuroleptic - induced akathisia .
CID	The typical <e1> fluoxetine </e1> - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced <e2> akathisia </e2> .
CID	Three patients who had experienced neuroleptic - induced <e2> akathisia </e2> in the past reported that the symptoms of <e1> fluoxetine </e1> - induced akathisia were identical , although somewhat milder .
CID	Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of <e1> fluoxetine </e1> - induced <e2> akathisia </e2> were identical , although somewhat milder .
CID	<e2> Akathisia </e2> appeared to be a common side effect of <e1> fluoxetine </e1> and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .
NO_RELATION	<e2> Akathisia </e2> appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist <e1> propranolol </e1> , dose reduction , or both .
CID	The authors suggest that <e1> fluoxetine </e1> - induced <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical .
CID	The authors suggest that <e1> fluoxetine </e1> - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced <e2> akathisia </e2> and tricyclic antidepressant - induced " jitteriness " may be identical .
CID	The authors suggest that fluoxetine - induced <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1> fluoxetine </e1> - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical .
CID	The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1> fluoxetine </e1> - induced <e2> akathisia </e2> and tricyclic antidepressant - induced " jitteriness " may be identical .
NO_RELATION	The authors suggest that fluoxetine - induced <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic <e1> antidepressant </e1> - induced " jitteriness " may be identical .
NO_RELATION	The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced <e2> akathisia </e2> and tricyclic <e1> antidepressant </e1> - induced " jitteriness " may be identical .
NO_RELATION	<e2> Chronic active hepatitis </e2> associated with <e1> diclofenac sodium </e1> therapy .
CID	Although generally well - tolerated , asymptomatic <e2> abnormalities of liver function </e2> have been recorded and , less commonly , severe hepatitis induced by <e1> diclofenac </e1> .
CID	Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe <e2> hepatitis </e2> induced by <e1> diclofenac </e1> .
NO_RELATION	The patient described developed <e2> chronic active hepatitis </e2> after six months therapy with <e1> diclofenac sodium </e1> which progressed despite the withdrawal of the drug , a finding not previously reported .
NO_RELATION	<e2> Stroke </e2> associated with <e1> cocaine </e1> use .
NO_RELATION	We describe eight patients in whom <e1> cocaine </e1> use was related to <e2> stroke </e2> and review 39 cases from the literature .
NO_RELATION	<e2> Stroke </e2> followed <e1> cocaine </e1> use by inhalation , intranasal , intravenous , and intramuscular routes .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of <e2> stroke </e2> related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated <e2> stroke </e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) <e2> stroke </e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2> ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated <e2> stroke </e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction .
CID	These data indicate that ( 1 ) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2> .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of <e2> stroke </e2> related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated <e2> stroke </e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) <e2> stroke </e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2> ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated <e2> stroke </e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction .
CID	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) <e1> cocaine </e1> - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2> .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of <e2> stroke </e2> related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated <e2> stroke </e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) <e2> stroke </e2> may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2> ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated <e2> stroke </e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction .
CID	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of <e1> cocaine </e1> administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2> .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of <e2> stroke </e2> related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated <e2> stroke </e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) <e2> stroke </e2> may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2> stroke </e2> after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2> ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated <e2> stroke </e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction .
CID	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2> .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of <e2> stroke </e2> related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated <e2> stroke </e2> occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) <e2> stroke </e2> may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2> ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated <e2> stroke </e2> , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
NO_RELATION	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction .
CID	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in <e1> cocaine </e1> - associated stroke , the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2> .
CID	<e1> Glyburide </e1> - induced <e2> hepatitis </e2> .
NO_RELATION	Drug - induced <e2> hepatotoxicity </e2> , although common , has been reported only infrequently with <e1> sulfonylureas </e1> .
CID	For <e1> glyburide </e1> , a second - generation sulfonylurea , only two brief reports of <e2> hepatotoxicity </e2> exist .
NO_RELATION	For glyburide , a second - generation <e1> sulfonylurea </e1> , only two brief reports of <e2> hepatotoxicity </e2> exist .
NO_RELATION	Two patients with <e2> type II diabetes mellitus </e2> developed an acute hepatitis - like syndrome soon after initiation of <e1> glyburide </e1> therapy .
CID	Two patients with type II diabetes mellitus developed an <e2> acute hepatitis - like syndrome </e2> soon after initiation of <e1> glyburide </e1> therapy .
CID	<e1> Glyburide </e1> can produce an <e2> acute hepatitis - like illness </e2> in some persons .
NO_RELATION	Systolic pressure variation is greater during <e2> hemorrhage </e2> than during <e1> sodium nitroprusside </e1> - induced hypotension in ventilated dogs .
CID	Systolic pressure variation is greater during hemorrhage than during <e1> sodium nitroprusside </e1> - induced <e2> hypotension </e2> in ventilated dogs .
NO_RELATION	Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by <e2> hemorrhage </e2> ( HEM , n = 7 ) or by continuous infusion of <e1> sodium nitroprusside </e1> ( SNP , n = 7 ) .
NO_RELATION	Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( <e2> HEM </e2> , n = 7 ) or by continuous infusion of <e1> sodium nitroprusside </e1> ( SNP , n = 7 ) .
NO_RELATION	Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by <e2> hemorrhage </e2> ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( <e1> SNP </e1> , n = 7 ) .
NO_RELATION	Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( <e2> HEM </e2> , n = 7 ) or by continuous infusion of sodium nitroprusside ( <e1> SNP </e1> , n = 7 ) .
NO_RELATION	During <e2> HEM </e2> - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1> SNP </e1> group .
CID	During HEM - induced <e2> hypotension </e2> the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1> SNP </e1> group .
CID	The SPV during <e2> hypotension </e2> was 15 . 7 + / - 6 . 7 mm Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm Hg in the <e1> SNP </e1> group ( P less than 0 . 02 ) .
NO_RELATION	The SPV during hypotension was 15 . 7 + / - 6 . 7 mm Hg in the <e2> HEM </e2> group , compared with 9 . 1 + / - 2 . 0 mm Hg in the <e1> SNP </e1> group ( P less than 0 . 02 ) .
NO_RELATION	The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / - 3 . 8 mm Hg in the <e2> HEM </e2> and <e1> SNP </e1> groups , respectively , during hypotension ( P less than 0 . 02 ) .
CID	The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / - 3 . 8 mm Hg in the HEM and <e1> SNP </e1> groups , respectively , during <e2> hypotension </e2> ( P less than 0 . 02 ) .
NO_RELATION	Drug - induced arterial <e2> spasm </e2> relieved by <e1> lidocaine </e1> .
NO_RELATION	Following major intracranial surgery in a 35 - year - old man , <e1> sodium pentothal </e1> was intravenously infused to minimize <e2> cerebral ischaemia </e2> .
NO_RELATION	Since the cranial condition precluded use of more usual methods , <e1> lidocaine </e1> was given intra - arterially , with careful cardiovascular monitoring , to counteract the <e2> vasospasm </e2> .
CID	Cerebral blood flow and metabolism during <e1> isoflurane </e1> - induced <e2> hypotension </e2> in patients subjected to surgery for cerebral aneurysms .
NO_RELATION	Cerebral blood flow and metabolism during <e1> isoflurane </e1> - induced hypotension in patients subjected to surgery for <e2> cerebral aneurysms </e2> .
NO_RELATION	Cerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> were measured during isoflurane - induced <e2> hypotension </e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
NO_RELATION	Cerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2> cerebral aneurysm </e2> .
CID	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1> - induced <e2> hypotension </e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
NO_RELATION	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1> - induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2> cerebral aneurysm </e2> .
NO_RELATION	Flow and metabolism were measured 5 - 13 days after the <e2> subarachnoid haemorrhage </e2> by a modification of the classical Kety - Schmidt technique using <e1> xenon </e1> - 133 i . v .
NO_RELATION	Controlled <e2> hypotension </e2> to an average MAP of 50 - 55 mm <e1> Hg </e1> was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .
CID	Controlled <e2> hypotension </e2> to an average MAP of 50 - 55 mm Hg was induced by increasing the dose of <e1> isoflurane </e1> , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .
NO_RELATION	After the clipping of the <e2> aneurysm </e2> the <e1> isoflurane </e1> concentration was reduced to 0 . 75 % .
NO_RELATION	<e2> Allergic reaction </e2> to <e1> 5 - fluorouracil </e1> infusion .
NO_RELATION	An <e2> allergic reaction </e2> consisting of angioneurotic edema secondary to continuous infusion <e1> 5 - fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .
CID	An allergic reaction consisting of <e2> angioneurotic edema </e2> secondary to continuous infusion <e1> 5 - fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5 - fluorouracil </e1> occurred in a patient with recurrent <e2> carcinoma of the oral cavity </e2> , cirrhosis , and cisplatin - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5 - fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity , <e2> cirrhosis </e2> , and cisplatin - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5 - fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced <e2> impaired renal function </e2> .
NO_RELATION	An <e2> allergic reaction </e2> consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1> cisplatin </e1> - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of <e2> angioneurotic edema </e2> secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1> cisplatin </e1> - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent <e2> carcinoma of the oral cavity </e2> , cirrhosis , and <e1> cisplatin </e1> - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , <e2> cirrhosis </e2> , and <e1> cisplatin </e1> - induced impaired renal function .
NO_RELATION	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and <e1> cisplatin </e1> - induced <e2> impaired renal function </e2> .
NO_RELATION	Oral <e1> diphenhydramine </e1> and prednisone were ineffective in preventing the recurrence of the <e2> allergic reaction </e2> .
NO_RELATION	Oral diphenhydramine and <e1> prednisone </e1> were ineffective in preventing the recurrence of the <e2> allergic reaction </e2> .
CID	<e1> Amiodarone </e1> - induced <e2> sinoatrial block </e2> .
CID	We observed <e2> sinoatrial block </e2> due to chronic <e1> amiodarone </e1> administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .
NO_RELATION	We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5 - year - old boy with <e2> primary cardiomyopathy </e2> , Wolff - Parkinson - White syndrome and supraventricular tachycardia .
NO_RELATION	We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5 - year - old boy with primary cardiomyopathy , <e2> Wolff - Parkinson - White syndrome </e2> and supraventricular tachycardia .
NO_RELATION	We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and <e2> supraventricular tachycardia </e2> .
CID	Reduction in the dosage of <e1> amiodarone </e1> resulted in the disappearance of the <e2> sinoatrial block </e2> and the persistence of asymptomatic sinus bradycardia .
NO_RELATION	Reduction in the dosage of <e1> amiodarone </e1> resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic <e2> sinus bradycardia </e2> .
NO_RELATION	Three infants , born of two mothers with <e2> inflammatory bowel disease </e2> who received treatment with <e1> sulphasalazine </e1> throughout pregnancy , were found to have major congenital anomalies .
NO_RELATION	Three infants , born of two mothers with inflammatory bowel disease who received treatment with <e1> sulphasalazine </e1> throughout pregnancy , were found to have major <e2> congenital anomalies </e2> .
CID	<e2> Veno - occlusive liver disease </e2> after <e1> dacarbazine </e1> therapy ( DTIC ) for melanoma .
NO_RELATION	Veno - occlusive liver disease after <e1> dacarbazine </e1> therapy ( DTIC ) for <e2> melanoma </e2> .
CID	<e2> Veno - occlusive liver disease </e2> after dacarbazine therapy ( <e1> DTIC </e1> ) for melanoma .
NO_RELATION	Veno - occlusive liver disease after dacarbazine therapy ( <e1> DTIC </e1> ) for <e2> melanoma </e2> .
CID	A case of <e2> veno - occlusive disease of the liver </e2> with fatal outcome after <e1> dacarbazine </e1> ( DTIC ) therapy for melanoma is reported .
NO_RELATION	A case of veno - occlusive disease of the liver with fatal outcome after <e1> dacarbazine </e1> ( DTIC ) therapy for <e2> melanoma </e2> is reported .
CID	A case of <e2> veno - occlusive disease of the liver </e2> with fatal outcome after dacarbazine ( <e1> DTIC </e1> ) therapy for melanoma is reported .
NO_RELATION	A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( <e1> DTIC </e1> ) therapy for <e2> melanoma </e2> is reported .
CID	A case of <e2> tardive dyskinesia </e2> caused by <e1> metoclopramide </e1> .
CID	<e2> Abnormal involuntary movements </e2> appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took <e1> metoclopramide </e1> for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .
NO_RELATION	Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took <e1> metoclopramide </e1> for <e2> gastrointestinal disorder </e2> in a regimen of 30 mg per day for a total of about 260 days .
CID	When the <e1> metoclopramide </e1> administration was discontinued , the <e2> abnormal movements </e2> gradually improved to a considerable extent .
CID	A case is presented of a reversible <e2> intra - Hisian block </e2> occurring under <e1> amiodarone </e1> treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .
NO_RELATION	A case is presented of a reversible intra - Hisian block occurring under <e1> amiodarone </e1> treatment for <e2> atrial tachycardia </e2> in a patient without clear intraventricular conduction abnormalities .
NO_RELATION	A case is presented of a reversible intra - Hisian block occurring under <e1> amiodarone </e1> treatment for atrial tachycardia in a patient without clear <e2> intraventricular conduction abnormalities </e2> .
NO_RELATION	Thirty days after <e1> amiodarone </e1> discontinuation , His bundle electrograms showed <e2> atrial flutter </e2> without intra - Hisian or infra - Hisian delay .
NO_RELATION	<e1> Busulfan </e1> - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	A case of a <e1> busulfan </e1> - induced <e2> hemorrhage cystitis </e2> is reported .
CID	The similarity between the histologic appearances of <e1> busulfan </e1> <e2> cystitis </e2> and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .
CID	The similarity between the histologic appearances of <e1> busulfan </e1> cystitis and both radiation and cyclophosphamide - induced <e2> cystitis </e2> is discussed and the world literature reviewed .
NO_RELATION	The similarity between the histologic appearances of busulfan <e2> cystitis </e2> and both radiation and <e1> cyclophosphamide </e1> - induced cystitis is discussed and the world literature reviewed .
NO_RELATION	The similarity between the histologic appearances of busulfan cystitis and both radiation and <e1> cyclophosphamide </e1> - induced <e2> cystitis </e2> is discussed and the world literature reviewed .
NO_RELATION	In view of the known tendency of <e1> busulfan </e1> to induce cellular atypia and <e2> carcinoma </e2> in other sites , periodic urinary cytology is suggested in patients on long - term therapy .
NO_RELATION	Rebound <e2> hypertensive </e2> after <e1> sodium nitroprusside </e1> prevented by saralasin in rats .
NO_RELATION	Rebound <e2> hypertensive </e2> after sodium nitroprusside prevented by <e1> saralasin </e1> in rats .
NO_RELATION	The role of the renin - - <e1> angiotensin </e1> system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced <e2> hypotension </e2> was evaluated .
CID	The role of the renin - - angiotensin system in the maintenance of blood pressure during <e1> halothane </e1> anesthesia and sodium nitroprusside ( SNP ) - induced <e2> hypotension </e2> was evaluated .
CID	The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and <e1> sodium nitroprusside </e1> ( SNP ) - induced <e2> hypotension </e2> was evaluated .
CID	The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( <e1> SNP </e1> ) - induced <e2> hypotension </e2> was evaluated .
NO_RELATION	During the <e1> SNP </e1> infusion the control animals demonstrated a progressive <e2> increase in blood pressure </e2> to 61 torr , whereas the saralasin - treated animals showed no change .
NO_RELATION	During the SNP infusion the control animals demonstrated a progressive <e2> increase in blood pressure </e2> to 61 torr , whereas the <e1> saralasin </e1> - treated animals showed no change .
NO_RELATION	This demonstrates the participation of the renin - - <e1> angiotensin </e1> system in antagonizing the combined <e2> hypotensive </e2> effects of halothane and SNP .
CID	This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined <e2> hypotensive </e2> effects of <e1> halothane </e1> and SNP .
CID	This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined <e2> hypotensive </e2> effects of halothane and <e1> SNP </e1> .
CID	<e2> Toxic hepatitis </e2> induced by antithyroid drugs : four cases including one with cross - reactivity between <e1> carbimazole </e1> and benzylthiouracil .
NO_RELATION	<e2> Toxic hepatitis </e2> induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and <e1> benzylthiouracil </e1> .
NO_RELATION	Two patients had a <e2> cholestatic hepatitis </e2> induced by <e1> carbimazole </e1> ( N omercazole ) .
NO_RELATION	Two patients had a <e2> cholestatic hepatitis </e2> induced by carbimazole ( <e1> N omercazole </e1> ) .
CID	Two others had a mixed ( <e2> cholestatic </e2> and cytolytic ) hepatitis following <e1> carbimazole </e1> .
CID	Two others had a mixed ( cholestatic and cytolytic ) <e2> hepatitis </e2> following <e1> carbimazole </e1> .
NO_RELATION	One of the latter two patients further experienced a cytolytic <e2> hepatitis </e2> which appeared after <e1> Benzylthiouracil </e1> ( Basd ne ) had replaced carbimazole .
NO_RELATION	One of the latter two patients further experienced a cytolytic <e2> hepatitis </e2> which appeared after Benzylthiouracil ( <e1> Basd ne </e1> ) had replaced carbimazole .
CID	One of the latter two patients further experienced a cytolytic <e2> hepatitis </e2> which appeared after Benzylthiouracil ( Basd ne ) had replaced <e1> carbimazole </e1> .
NO_RELATION	Study of the role of <e1> vitamin B12 </e1> and folinic acid supplementation in preventing hematologic <e2> toxicity </e2> of zidovudine .
NO_RELATION	Study of the role of vitamin B12 and <e1> folinic acid </e1> supplementation in preventing hematologic <e2> toxicity </e2> of zidovudine .
NO_RELATION	Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic <e2> toxicity </e2> of <e1> zidovudine </e1> .
NO_RELATION	A prospective , randomized study was conducted to evaluate the role of <e1> vitamin B12 </e1> and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced <e2> bone marrow suppression </e2> .
NO_RELATION	A prospective , randomized study was conducted to evaluate the role of vitamin B12 and <e1> folinic acid </e1> supplementation in preventing zidovudine ( ZDV ) - induced <e2> bone marrow suppression </e2> .
CID	A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing <e1> zidovudine </e1> ( ZDV ) - induced <e2> bone marrow suppression </e2> .
CID	A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( <e1> ZDV </e1> ) - induced <e2> bone marrow suppression </e2> .
NO_RELATION	Seventy - five <e2> human immunodeficiency virus ( HIV ) - infected </e2> patients with CD4 + cell counts < 500 / mm3 were randomized to receive either <e1> ZDV </e1> ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
NO_RELATION	Seventy - five <e2> human immunodeficiency virus ( HIV ) - infected </e2> patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with <e1> folinic acid </e1> ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
NO_RELATION	Seventy - five <e2> human immunodeficiency virus ( HIV ) - infected </e2> patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular <e1> vitamin B12 </e1> ( 1000 micrograms monthly ) ( group II , n = 37 ) .
NO_RELATION	There was no correlation between <e1> vitamin B12 </e1> or folate levels and development of <e2> myelosuppression </e2> .
NO_RELATION	There was no correlation between vitamin B12 or <e1> folate </e1> levels and development of <e2> myelosuppression </e2> .
NO_RELATION	<e1> Vitamin B12 </e1> and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced <e2> myelotoxicity </e2> in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .
NO_RELATION	Vitamin B12 and <e1> folinic acid </e1> supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced <e2> myelotoxicity </e2> in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .
CID	Vitamin B12 and folinic acid supplementation of <e1> ZDV </e1> therapy does not seem useful in preventing or reducing ZDV - induced <e2> myelotoxicity </e2> in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .
CID	Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing <e1> ZDV </e1> - induced <e2> myelotoxicity </e2> in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .
CID	Acute <e2> confusion </e2> induced by a high - dose infusion of <e1> 5 - fluorouracil </e1> and folinic acid .
CID	Acute <e2> confusion </e2> induced by a high - dose infusion of 5 - fluorouracil and <e1> folinic acid </e1> .
NO_RELATION	A 61 - year - old man was treated with combination chemotherapy incorporating <e1> cisplatinum </e1> , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2> .
NO_RELATION	A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , <e1> etoposide </e1> , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2> .
NO_RELATION	A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose <e1> 5 - fluorouracil </e1> ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2> .
NO_RELATION	A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and <e1> folinic acid </e1> for an inoperable <e2> gastric adenocarcinoma </e2> .
CID	He developed acute neurologic symptoms of mental <e2> confusion </e2> , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1> 5 - fluorouracil </e1> and folinic acid infusion .
CID	He developed acute neurologic symptoms of mental confusion , <e2> disorientation </e2> and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1> 5 - fluorouracil </e1> and folinic acid infusion .
NO_RELATION	He developed acute neurologic symptoms of mental confusion , disorientation and <e2> irritability </e2> , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1> 5 - fluorouracil </e1> and folinic acid infusion .
CID	He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep <e2> coma </e2> , lasting for approximately 40 hours during the first dose ( day 2 ) of <e1> 5 - fluorouracil </e1> and folinic acid infusion .
CID	He developed acute neurologic symptoms of mental <e2> confusion </e2> , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and <e1> folinic acid </e1> infusion .
CID	He developed acute neurologic symptoms of mental confusion , <e2> disorientation </e2> and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and <e1> folinic acid </e1> infusion .
NO_RELATION	He developed acute neurologic symptoms of mental confusion , disorientation and <e2> irritability </e2> , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and <e1> folinic acid </e1> infusion .
CID	He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep <e2> coma </e2> , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and <e1> folinic acid </e1> infusion .
NO_RELATION	Because <e1> folinic acid </e1> was unlikely to be associated with this condition , <e2> neurotoxicity </e2> due to high - dose 5 - fluorouracil was highly suspected .
NO_RELATION	Because folinic acid was unlikely to be associated with this condition , <e2> neurotoxicity </e2> due to high - dose <e1> 5 - fluorouracil </e1> was highly suspected .
NO_RELATION	The pathogenesis of <e1> 5 - fluorouracil </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
NO_RELATION	The pathogenesis of 5 - fluorouracil <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by <e1> fluoroacetate </e1> and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
NO_RELATION	The pathogenesis of 5 - fluorouracil <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and <e1> fluorocitrate </e1> , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
NO_RELATION	The pathogenesis of 5 - fluorouracil <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , <e1> thiamine </e1> deficiency , or dihydrouracil dehydrogenase deficiency .
NO_RELATION	The pathogenesis of 5 - fluorouracil <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or <e1> dihydrouracil </e1> dehydrogenase deficiency .
NO_RELATION	High - dose <e1> 5 - fluorouracil </e1> / folinic acid infusion therapy has recently become a popular regimen for various <e2> cancers </e2> .
NO_RELATION	High - dose 5 - fluorouracil / <e1> folinic acid </e1> infusion therapy has recently become a popular regimen for various <e2> cancers </e2> .
NO_RELATION	<e1> Carbamazepine </e1> was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
NO_RELATION	<e1> Carbamazepine </e1> was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol , chlorpromazine or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue <e1> oxcarbazepine </e1> among six difficult - to - treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue <e1> oxcarbazepine </e1> among six difficult - to - treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol , chlorpromazine or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly <e1> haloperidol </e1> , chlorpromazine or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly <e1> haloperidol </e1> , chlorpromazine or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol , <e1> chlorpromazine </e1> or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol , <e1> chlorpromazine </e1> or clozapine .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol , chlorpromazine or <e1> clozapine </e1> .
NO_RELATION	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol , chlorpromazine or <e1> clozapine </e1> .
CID	<e2> Erythema multiforme </e2> and hypersensitivity myocarditis caused by <e1> ampicillin </e1> .
CID	Erythema multiforme and <e2> hypersensitivity myocarditis </e2> caused by <e1> ampicillin </e1> .
CID	OBJECTIVE : To report a case of <e2> erythema multiforme </e2> and hypersensitivity myocarditis caused by <e1> ampicillin </e1> .
CID	OBJECTIVE : To report a case of erythema multiforme and <e2> hypersensitivity myocarditis </e2> caused by <e1> ampicillin </e1> .
NO_RELATION	CASE SUMMARY : A 13 - year - old boy was treated with <e1> ampicillin </e1> and gentamicin because of suspected <e2> septicemia </e2> .
NO_RELATION	CASE SUMMARY : A 13 - year - old boy was treated with ampicillin and <e1> gentamicin </e1> because of suspected <e2> septicemia </e2> .
NO_RELATION	CONCLUSIONS : <e2> Hypersensitivity myocarditis </e2> is a rare and dangerous manifestation of allergy to <e1> penicillins </e1> .
NO_RELATION	CONCLUSIONS : Hypersensitivity myocarditis is a rare and dangerous manifestation of <e2> allergy </e2> to <e1> penicillins </e1> .
CID	Immediate <e2> allergic reactions </e2> to <e1> amoxicillin </e1> .
NO_RELATION	A large group of patients with suspected <e2> allergic reactions </e2> to <e1> beta - lactam </e1> antibiotics was evaluated .
NO_RELATION	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2> allergic </e2> to <e1> beta - lactam </e1> antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .
NO_RELATION	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to <e1> beta - lactam </e1> antibiotics had selective immediate <e2> allergic </e2> responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .
CID	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2> allergic </e2> to beta - lactam antibiotics had selective immediate allergic responses to <e1> amoxicillin </e1> ( AX ) or were cross - reacting with other penicillin derivatives .
CID	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate <e2> allergic </e2> responses to <e1> amoxicillin </e1> ( AX ) or were cross - reacting with other penicillin derivatives .
CID	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2> allergic </e2> to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( <e1> AX </e1> ) or were cross - reacting with other penicillin derivatives .
CID	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate <e2> allergic </e2> responses to amoxicillin ( <e1> AX </e1> ) or were cross - reacting with other penicillin derivatives .
NO_RELATION	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients <e2> allergic </e2> to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other <e1> penicillin </e1> derivatives .
NO_RELATION	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate <e2> allergic </e2> responses to amoxicillin ( AX ) or were cross - reacting with other <e1> penicillin </e1> derivatives .
NO_RELATION	A total of 177 patients were diagnosed as <e2> allergic </e2> to <e1> beta - lactam </e1> antibiotics .
CID	We selected the 54 ( 30 . 5 % ) cases of immediate <e1> AX </e1> <e2> allergy </e2> with good tolerance of PG .
NO_RELATION	We selected the 54 ( 30 . 5 % ) cases of immediate AX <e2> allergy </e2> with good tolerance of <e1> PG </e1> .
NO_RELATION	All the patients were skin test negative to <e1> BPO </e1> ; 49 of 51 ( 96 % ) were also negative to <e2> MDM </e2> , and 44 of 46 ( 96 % ) to PG .
NO_RELATION	All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to <e2> MDM </e2> , and 44 of 46 ( 96 % ) to <e1> PG </e1> .
CID	Challenge tests with <e1> AX </e1> were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2> allergic reaction </e2> to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
CID	Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2> allergic reaction </e2> to <e1> AX </e1> , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
CID	Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate <e2> allergic reaction </e2> to AX , and in 15 cases ( 28 % ) both skin test and RAST for <e1> AX </e1> were negative .
CID	We describe the largest group of <e1> AX </e1> - <e2> allergic </e2> patients who have tolerated PG reported so far .
NO_RELATION	We describe the largest group of AX - <e2> allergic </e2> patients who have tolerated <e1> PG </e1> reported so far .
CID	Persistent <e2> paralysis </e2> after prolonged use of <e1> atracurium </e1> in the absence of corticosteroids .
CID	Reports of persistent <e2> paralysis </e2> after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as <e1> vecuronium bromide </e1> , especially when used in conjunction with corticosteroids .
CID	<e1> Atracurium besylate </e1> , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent <e2> paralysis </e2> , but only when used with corticosteroids .
NO_RELATION	Atracurium besylate , a short - acting <e1> benzylisoquinolinium </e1> NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent <e2> paralysis </e2> , but only when used with corticosteroids .
CID	We report a case of <e1> atracurium </e1> - related <e2> paralysis </e2> persisting for approximately 50 hours in a patient who was not treated with corticosteroids .
NO_RELATION	Habitual use of <e1> acetaminophen </e1> as a risk factor for <e2> chronic renal failure </e2> : a comparison with phenacetin .
CID	Habitual use of acetaminophen as a risk factor for <e2> chronic renal failure </e2> : a comparison with <e1> phenacetin </e1> .
CID	Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of <e2> chronic renal failure </e2> and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .
CID	Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of chronic renal failure and <e2> end - stage renal disease </e2> ( ESRD ) , with a relative risk in the range of 4 to 19 .
CID	Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of chronic renal failure and end - stage renal disease ( <e2> ESRD </e2> ) , with a relative risk in the range of 4 to 19 .
NO_RELATION	However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of <e1> acetaminophen </e1> is also associated with <e2> chronic renal failure </e2> and ESRD , with a relative risk in the range of 2 to 4 .
NO_RELATION	However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of <e1> acetaminophen </e1> is also associated with chronic renal failure and <e2> ESRD </e2> , with a relative risk in the range of 2 to 4 .
CID	These studies suggest that both <e1> phenacetin </e1> and acetaminophen may contribute to the burden of <e2> ESRD </e2> , with the risk of the latter being somewhat less than that of the former .
NO_RELATION	These studies suggest that both phenacetin and <e1> acetaminophen </e1> may contribute to the burden of <e2> ESRD </e2> , with the risk of the latter being somewhat less than that of the former .
NO_RELATION	The possibility that habitual use of <e1> acetaminophen </e1> alone increases the risk of <e2> ESRD </e2> has not been clearly demonstrated , but cannot be dismissed .
NO_RELATION	Reduction of <e1> heparan sulphate </e1> - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced <e2> diabetic nephropathy </e2> .
CID	Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with <e1> streptozotocin </e1> - induced <e2> diabetic nephropathy </e2> .
NO_RELATION	<e1> Heparan sulphate </e1> - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2> diabetes </e2> by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .
NO_RELATION	Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2> diabetes </e2> by <e1> streptozotocin </e1> and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .
NO_RELATION	Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2> diabetes </e2> by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye <e1> cuprolinic blue </e1> .
NO_RELATION	We conclude that in <e1> streptozotocin </e1> - <e2> diabetic </e2> rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .
NO_RELATION	We conclude that in streptozotocin - <e2> diabetic </e2> rats with an increased urinary albumin excretion , a reduced <e1> heparan sulphate </e1> charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as <e1> nitrogranulogen </e1> ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( <e1> NG </e1> ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , <e1> methotrexate </e1> ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( <e1> MTX </e1> ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , <e1> 5 - fluorouracil </e1> ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( <e1> 5 - FU </e1> ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and <e1> cyclophosphamide </e1> ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( <e1> CY </e1> ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ <e1> MTX </e1> + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + <e1> 5 - FU </e1> + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	The <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + <e1> CY </e1> ( CMF ) ] was evaluated in experiments on Wistar rats .
NO_RELATION	<e1> CY </e1> caused <e2> hemorrhagic cystitis </e2> in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .
NO_RELATION	CY caused <e2> hemorrhagic cystitis </e2> in 40 % of rats , but it did not cause this complication when combined with <e1> 5 - FU </e1> and MTX .
NO_RELATION	CY caused <e2> hemorrhagic cystitis </e2> in 40 % of rats , but it did not cause this complication when combined with 5 - FU and <e1> MTX </e1> .
NO_RELATION	Our studies indicate that <e2> nephrotoxicity </e2> of <e1> MTX </e1> + 5 - FU + CY administered jointly is lower than in monotherapy .
NO_RELATION	Our studies indicate that <e2> nephrotoxicity </e2> of MTX + <e1> 5 - FU </e1> + CY administered jointly is lower than in monotherapy .
NO_RELATION	Our studies indicate that <e2> nephrotoxicity </e2> of MTX + 5 - FU + <e1> CY </e1> administered jointly is lower than in monotherapy .
CID	<e1> Lithium </e1> - associated <e2> cognitive and functional deficits </e2> reduced by a switch to divalproex sodium : a case series .
NO_RELATION	Lithium - associated <e2> cognitive and functional deficits </e2> reduced by a switch to <e1> divalproex sodium </e1> : a case series .
NO_RELATION	BACKGROUND : <e1> Lithium </e1> remains a first - line treatment for the acute and maintenance treatment of <e2> bipolar disorder </e2> .
NO_RELATION	Although much has been written about the management of the more common adverse effects of <e1> lithium </e1> , such as <e2> polyuria </e2> and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
NO_RELATION	Although much has been written about the management of the more common adverse effects of <e1> lithium </e1> , such as polyuria and <e2> tremor </e2> , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of <e1> lithium </e1> , such as polyuria and tremor , more subtle lithium side effects such as <e2> cognitive deficits </e2> , loss of creativity , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of <e1> lithium </e1> , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , <e2> loss of creativity </e2> , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of <e1> lithium </e1> , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and <e2> functional impairments </e2> remain understudied .
NO_RELATION	Although much has been written about the management of the more common adverse effects of lithium , such as <e2> polyuria </e2> and tremor , more subtle <e1> lithium </e1> side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
NO_RELATION	Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and <e2> tremor </e2> , more subtle <e1> lithium </e1> side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1> lithium </e1> side effects such as <e2> cognitive deficits </e2> , loss of creativity , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1> lithium </e1> side effects such as cognitive deficits , <e2> loss of creativity </e2> , and functional impairments remain understudied .
CID	Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle <e1> lithium </e1> side effects such as cognitive deficits , loss of creativity , and <e2> functional impairments </e2> remain understudied .
NO_RELATION	This report summarizes our experience in switching <e2> bipolar </e2> patients from <e1> lithium </e1> to divalproex sodium to alleviate such cognitive and functional impairments .
CID	This report summarizes our experience in switching bipolar patients from <e1> lithium </e1> to divalproex sodium to alleviate such <e2> cognitive and functional impairments </e2> .
NO_RELATION	This report summarizes our experience in switching <e2> bipolar </e2> patients from lithium to <e1> divalproex sodium </e1> to alleviate such cognitive and functional impairments .
NO_RELATION	This report summarizes our experience in switching bipolar patients from lithium to <e1> divalproex sodium </e1> to alleviate such <e2> cognitive and functional impairments </e2> .
CID	RESULTS : We report seven cases where substitution of <e1> lithium </e1> , either fully or partially , with divalproex sodium was extremely helpful in reducing the <e2> cognitive , motivational , or creative deficits </e2> attributed to lithium in our bipolar patients .
NO_RELATION	RESULTS : We report seven cases where substitution of <e1> lithium </e1> , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our <e2> bipolar </e2> patients .
NO_RELATION	RESULTS : We report seven cases where substitution of lithium , either fully or partially , with <e1> divalproex sodium </e1> was extremely helpful in reducing the <e2> cognitive , motivational , or creative deficits </e2> attributed to lithium in our bipolar patients .
NO_RELATION	RESULTS : We report seven cases where substitution of lithium , either fully or partially , with <e1> divalproex sodium </e1> was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our <e2> bipolar </e2> patients .
CID	RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the <e2> cognitive , motivational , or creative deficits </e2> attributed to <e1> lithium </e1> in our bipolar patients .
NO_RELATION	RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to <e1> lithium </e1> in our <e2> bipolar </e2> patients .
NO_RELATION	CONCLUSION : In this preliminary report , <e1> divalproex sodium </e1> was a superior alternative to lithium in <e2> bipolar </e2> patients experiencing cognitive deficits , loss of creativity , and functional impairments .
NO_RELATION	CONCLUSION : In this preliminary report , <e1> divalproex sodium </e1> was a superior alternative to lithium in bipolar patients experiencing <e2> cognitive deficits </e2> , loss of creativity , and functional impairments .
NO_RELATION	CONCLUSION : In this preliminary report , <e1> divalproex sodium </e1> was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , <e2> loss of creativity </e2> , and functional impairments .
NO_RELATION	CONCLUSION : In this preliminary report , <e1> divalproex sodium </e1> was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and <e2> functional impairments </e2> .
NO_RELATION	CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1> lithium </e1> in <e2> bipolar </e2> patients experiencing cognitive deficits , loss of creativity , and functional impairments .
CID	CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1> lithium </e1> in bipolar patients experiencing <e2> cognitive deficits </e2> , loss of creativity , and functional impairments .
CID	CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1> lithium </e1> in bipolar patients experiencing cognitive deficits , <e2> loss of creativity </e2> , and functional impairments .
CID	CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to <e1> lithium </e1> in bipolar patients experiencing cognitive deficits , loss of creativity , and <e2> functional impairments </e2> .
NO_RELATION	Treatment of previously treated metastatic <e2> breast cancer </e2> by <e1> mitoxantrone </e1> and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .
NO_RELATION	Treatment of previously treated metastatic breast cancer by <e1> mitoxantrone </e1> and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related <e2> toxicity </e2> .
NO_RELATION	Treatment of previously treated metastatic <e2> breast cancer </e2> by mitoxantrone and 48 - hour continuous infusion of high - dose <e1> 5 - FU </e1> and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .
NO_RELATION	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose <e1> 5 - FU </e1> and leucovorin ( MFL ) : low palliative benefit and high treatment - related <e2> toxicity </e2> .
NO_RELATION	Treatment of previously treated metastatic <e2> breast cancer </e2> by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and <e1> leucovorin </e1> ( MFL ) : low palliative benefit and high treatment - related toxicity .
NO_RELATION	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and <e1> leucovorin </e1> ( MFL ) : low palliative benefit and high treatment - related <e2> toxicity </e2> .
NO_RELATION	Treatment of previously treated metastatic <e2> breast cancer </e2> by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( <e1> MFL </e1> ) : low palliative benefit and high treatment - related toxicity .
NO_RELATION	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( <e1> MFL </e1> ) : low palliative benefit and high treatment - related <e2> toxicity </e2> .
NO_RELATION	From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic <e2> breast cancer </e2> by <e1> mitoxantrone </e1> , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .
NO_RELATION	From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic <e2> breast cancer </e2> by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of <e1> 5 - FU </e1> , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .
NO_RELATION	From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic <e2> breast cancer </e2> by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with <e1> leucovorin </e1> , 300 mg / m2 , for 48 h from day 1 to 2 .
NO_RELATION	The <e1> MFL regimen </e1> achieves little palliative benefit and induces severe <e2> toxicity </e2> at a fairly high rate .
NO_RELATION	Upregulation of the expression of <e1> vasopressin </e1> gene in the paraventricular and supraoptic nuclei of the lithium - induced <e2> diabetes insipidus </e2> rat .
NO_RELATION	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the <e1> lithium </e1> - induced <e2> diabetes insipidus </e2> rat .
NO_RELATION	The expression of <e1> arginine vasopressin </e1> ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced <e2> polyuria </e2> , using in situ hybridization histochemistry and radioimmunoassay .
NO_RELATION	The expression of arginine vasopressin ( <e1> AVP </e1> ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced <e2> polyuria </e2> , using in situ hybridization histochemistry and radioimmunoassay .
NO_RELATION	The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with <e1> lithium </e1> ( Li ) - induced <e2> polyuria </e2> , using in situ hybridization histochemistry and radioimmunoassay .
NO_RELATION	The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( <e1> Li </e1> ) - induced <e2> polyuria </e2> , using in situ hybridization histochemistry and radioimmunoassay .
CID	The male Wistar rats consuming a diet that contained <e1> LiCl </e1> ( 60 mmol / kg ) for 4 weeks developed marked <e2> polyuria </e2> .
NO_RELATION	These results suggest that <e2> dehydration </e2> and / or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1> AVP </e1> and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .
NO_RELATION	These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1> AVP </e1> and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced <e2> diabetes insipidus </e2> rat .
NO_RELATION	These results suggest that <e2> dehydration </e2> and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1> AVP </e1> gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .
NO_RELATION	These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1> AVP </e1> gene expression in the PVN and the SON of the Li - induced <e2> diabetes insipidus </e2> rat .
NO_RELATION	These results suggest that <e2> dehydration </e2> and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1> Li </e1> - induced diabetes insipidus rat .
NO_RELATION	These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1> Li </e1> - induced <e2> diabetes insipidus </e2> rat .
CID	<e1> Suxamethonium </e1> - induced <e2> cardiac arrest </e2> and death following 5 days of immobilization .
NO_RELATION	<e1> Suxamethonium </e1> - induced cardiac arrest and <e2> death </e2> following 5 days of immobilization .
CID	The present report describes a case of <e2> cardiac arrest </e2> and subsequent death as a result of hyperkalaemia following the use of <e1> suxamethonium </e1> in a 23 - year - old Malawian woman .
NO_RELATION	The present report describes a case of cardiac arrest and subsequent <e2> death </e2> as a result of hyperkalaemia following the use of <e1> suxamethonium </e1> in a 23 - year - old Malawian woman .
CID	The present report describes a case of cardiac arrest and subsequent death as a result of <e2> hyperkalaemia </e2> following the use of <e1> suxamethonium </e1> in a 23 - year - old Malawian woman .
CID	Forty seconds after injection of <e1> suxamethonium </e1> , <e2> bradycardia </e2> and cardiac arrest occurred .
CID	Forty seconds after injection of <e1> suxamethonium </e1> , bradycardia and <e2> cardiac arrest </e2> occurred .
CID	Apart from the reduction in the patient ' s level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for <e2> hyperkalaemia </e2> following the administration of <e1> suxamethonium </e1> .
NO_RELATION	It is postulated that her <e2> death </e2> was caused by hypersensitivity to <e1> suxamethonium </e1> , associated with her 5 - day immobilization .
CID	It is postulated that her death was caused by <e2> hypersensitivity </e2> to <e1> suxamethonium </e1> , associated with her 5 - day immobilization .
CID	An <e2> increase in blood pressure </e2> , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .
CID	An increase in blood pressure , accompanied by <e2> atrial fibrillation </e2> , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , <e2> agitation </e2> , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , <e2> incomprehensible shouts </e2> and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and <e2> loss of consciousness </e2> , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0 . 225 mg , for correction of <e2> Dupuytren ' s contracture </e2> .
CID	An <e2> increase in blood pressure </e2> , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of Dupuytren ' s contracture .
CID	An increase in blood pressure , accompanied by <e2> atrial fibrillation </e2> , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , <e2> agitation </e2> , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , <e2> incomprehensible shouts </e2> and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and <e2> loss of consciousness </e2> , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of Dupuytren ' s contracture .
NO_RELATION	An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0 . 225 mg , for correction of <e2> Dupuytren ' s contracture </e2> .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent <e2> IgA nephropathy </e2> ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic <e1> FK506 </e1> nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic <e1> FK506 </e1> <e2> nephropathy </e2> ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic <e1> FK506 </e1> nephropathy ( n = 9 ) , and mild - type FK506 <e2> nephropathy </e2> ( n = 11 ) .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent <e2> IgA nephropathy </e2> ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type <e1> FK506 </e1> nephropathy ( n = 11 ) .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 <e2> nephropathy </e2> ( n = 9 ) , and mild - type <e1> FK506 </e1> nephropathy ( n = 11 ) .
NO_RELATION	RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type <e1> FK506 </e1> <e2> nephropathy </e2> ( n = 11 ) .
NO_RELATION	Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic <e1> FK506 </e1> <e2> nephropathy </e2> , respectively .
NO_RELATION	Chronic <e1> FK506 </e1> <e2> nephropathy </e2> consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
CID	Chronic <e1> FK506 </e1> nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , <e2> focal segmental glomerulosclerosis </e2> ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
NO_RELATION	Chronic <e1> FK506 </e1> nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of <e2> interstitial fibrosis </e2> ( 11 biopsies ) .
NO_RELATION	The serum <e1> creatinine </e1> levels of patients in the mild - type chronic FK506 <e2> nephropathy </e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .
NO_RELATION	The serum <e1> creatinine </e1> levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - <e2> nephropathy </e2> group ( P < 0 . 001 ) .
NO_RELATION	The serum creatinine levels of patients in the mild - type chronic <e1> FK506 </e1> <e2> nephropathy </e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .
NO_RELATION	The serum creatinine levels of patients in the mild - type chronic <e1> FK506 </e1> nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - <e2> nephropathy </e2> group ( P < 0 . 001 ) .
NO_RELATION	The serum creatinine levels of patients in the mild - type chronic FK506 <e2> nephropathy </e2> group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic <e1> FK506 </e1> - nephropathy group ( P < 0 . 001 ) .
NO_RELATION	The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic <e1> FK506 </e1> - <e2> nephropathy </e2> group ( P < 0 . 001 ) .
NO_RELATION	CONCLUSIONS : This study demonstrates that chronic <e1> FK506 </e1> <e2> nephropathy </e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .
NO_RELATION	CONCLUSIONS : This study demonstrates that chronic <e1> FK506 </e1> nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 <e2> nephropathy </e2> is a condition which may lead to deterioration of renal allograft function .
NO_RELATION	CONCLUSIONS : This study demonstrates that chronic FK506 <e2> nephropathy </e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic <e1> FK506 </e1> nephropathy is a condition which may lead to deterioration of renal allograft function .
NO_RELATION	CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic <e1> FK506 </e1> <e2> nephropathy </e2> is a condition which may lead to deterioration of renal allograft function .
NO_RELATION	In the mouse passive - avoidance test , <e1> PG - 9 </e1> ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented <e2> amnesia </e2> induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .
CID	In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented <e2> amnesia </e2> induced by both the non selective antimuscarinic drug <e1> scopolamine </e1> and the M1 - selective antagonist S - ( - ) - ET - 126 .
CID	In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented <e2> amnesia </e2> induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist <e1> S - ( - ) - ET - 126 </e1> .
NO_RELATION	In the same experimental conditions , <e1> PG - 9 </e1> ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced <e2> amnesia </e2> , demonstrating a central localization of the activity .
CID	<e2> Angioedema </e2> due to <e1> ACE inhibitors </e1> : common and inadequately diagnosed .
CID	The estimated incidence of <e2> angioedema </e2> during <e1> angiotensin - converting enzyme ( ACE ) inhibitor </e1> treatment is between 1 and 7 per thousand patients .
CID	Recurrent use of newer <e1> oral contraceptives </e1> and the risk of <e2> venous thromboembolism </e2> .
CID	The epidemiological studies that assessed the risk of <e2> venous thromboembolism </e2> ( VTE ) associated with newer <e1> oral contraceptives </e1> ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
CID	The epidemiological studies that assessed the risk of venous thromboembolism ( <e2> VTE </e2> ) associated with newer <e1> oral contraceptives </e1> ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
CID	The epidemiological studies that assessed the risk of <e2> venous thromboembolism </e2> ( VTE ) associated with newer oral contraceptives ( <e1> OC </e1> ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
CID	The epidemiological studies that assessed the risk of venous thromboembolism ( <e2> VTE </e2> ) associated with newer oral contraceptives ( <e1> OC </e1> ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
CID	The epidemiological studies that assessed the risk of <e2> venous thromboembolism </e2> ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of <e1> OC </e1> use , namely first - time users , repeaters and switchers .
CID	The epidemiological studies that assessed the risk of venous thromboembolism ( <e2> VTE </e2> ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of <e1> OC </e1> use , namely first - time users , repeaters and switchers .
CID	The adjusted rate ratio of <e2> VTE </e2> for repeat users of third generation <e1> OC </e1> was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .
CID	Development of <e1> apomorphine </e1> - induced <e2> aggressive behavior </e2> : comparison of adult male and female Wistar rats .
CID	In male animals , repeated <e1> apomorphine </e1> treatment induced a gradual development of <e2> aggressive behavior </e2> as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .
CID	In male animals , repeated <e1> apomorphine </e1> treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of <e2> aggressiveness </e2> and shortened latency before the first attack toward the opponent .
CID	In conclusion , the present study demonstrates gender differences in the development of the <e1> apomorphine </e1> - induced <e2> aggressive behavior </e2> and indicates that the female rats do not fill the validation criteria for use in this method .
CID	<e1> Serotonergic antidepressants </e1> and <e2> urinary incontinence </e2> .
CID	This concerns 2 male patients who experienced <e2> incontinence </e2> while taking <e1> venlafaxine </e1> .
NO_RELATION	In the present paper the authors describe 2 female patients who developed <e2> incontinence </e2> secondary to the selective <e1> serotonin </e1> reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .
CID	In the present paper the authors describe 2 female patients who developed <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors <e1> paroxetine </e1> and sertraline , as well as a third who developed this side effect on venlafaxine .
CID	In the present paper the authors describe 2 female patients who developed <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and <e1> sertraline </e1> , as well as a third who developed this side effect on venlafaxine .
CID	In the present paper the authors describe 2 female patients who developed <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on <e1> venlafaxine </e1> .
CID	In 2 of the 3 cases the patients were also taking <e1> lithium carbonate </e1> and beta - blockers , both of which could have contributed to the <e2> incontinence </e2> .
CID	Animal studies suggest that <e2> incontinence </e2> secondary to <e1> serotonergic antidepressants </e1> could be mediated by the 5HT4 receptors found on the bladder .
CID	<e2> Hypotension </e2> following the initiation of <e1> tizanidine </e1> in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .
NO_RELATION	Hypotension following the initiation of <e1> tizanidine </e1> in a patient treated with an angiotensin converting enzyme inhibitor for chronic <e2> hypertension </e2> .
NO_RELATION	<e2> Hypotension </e2> following the initiation of tizanidine in a patient treated with an <e1> angiotensin </e1> converting enzyme inhibitor for chronic hypertension .
NO_RELATION	Hypotension following the initiation of tizanidine in a patient treated with an <e1> angiotensin </e1> converting enzyme inhibitor for chronic <e2> hypertension </e2> .
NO_RELATION	Adults chronically treated with <e1> angiotensin </e1> converting enzyme inhibitors may have a limited ability to respond to <e2> hypotension </e2> when the sympathetic response is simultaneously blocked .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with <e1> lisinopril </e1> , an angiotensin converting enzyme inhibitor , to control <e2> hypertension </e2> who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
CID	The authors present a 10 - year - old boy chronically treated with <e1> lisinopril </e1> , an angiotensin converting enzyme inhibitor , to control hypertension who developed <e2> hypotension </e2> following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with <e1> lisinopril </e1> , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of <e2> spasticity </e2> .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with lisinopril , an <e1> angiotensin </e1> converting enzyme inhibitor , to control <e2> hypertension </e2> who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with lisinopril , an <e1> angiotensin </e1> converting enzyme inhibitor , to control hypertension who developed <e2> hypotension </e2> following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with lisinopril , an <e1> angiotensin </e1> converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of <e2> spasticity </e2> .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control <e2> hypertension </e2> who developed hypotension following the addition of <e1> tizanidine </e1> , an alpha - 2 agonist , for the treatment of spasticity .
CID	The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed <e2> hypotension </e2> following the addition of <e1> tizanidine </e1> , an alpha - 2 agonist , for the treatment of spasticity .
NO_RELATION	The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of <e1> tizanidine </e1> , an alpha - 2 agonist , for the treatment of <e2> spasticity </e2> .
NO_RELATION	The possible interaction of <e1> tizanidine </e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either <e2> hypertension </e2> or spasticity in such patients .
NO_RELATION	The possible interaction of <e1> tizanidine </e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or <e2> spasticity </e2> in such patients .
NO_RELATION	These 13 included cases of <e2> malignant hypertension </e2> , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and <e1> cocaine </e1> - related acute renal failure .
NO_RELATION	These 13 included cases of malignant hypertension , <e2> thrombotic microangiopathy </e2> , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and <e1> cocaine </e1> - related acute renal failure .
NO_RELATION	These 13 included cases of malignant hypertension , thrombotic microangiopathy , <e2> lupus nephritis </e2> , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and <e1> cocaine </e1> - related acute renal failure .
NO_RELATION	These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , <e2> Henoch - Schonlein nephritis </e2> , crescentic glomerulonephritis , and <e1> cocaine </e1> - related acute renal failure .
NO_RELATION	These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic <e2> glomerulonephritis </e2> , and <e1> cocaine </e1> - related acute renal failure .
CID	These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and <e1> cocaine </e1> - related <e2> acute renal failure </e2> .
NO_RELATION	In behavioral studies , pre - treatment of mice with <e1> BD1018 </e1> , BD1063 , or LR132 significantly attenuated cocaine - induced <e2> convulsions </e2> and lethality .
NO_RELATION	In behavioral studies , pre - treatment of mice with BD1018 , <e1> BD1063 </e1> , or LR132 significantly attenuated cocaine - induced <e2> convulsions </e2> and lethality .
NO_RELATION	In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or <e1> LR132 </e1> significantly attenuated cocaine - induced <e2> convulsions </e2> and lethality .
CID	In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated <e1> cocaine </e1> - induced <e2> convulsions </e2> and lethality .
NO_RELATION	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist <e1> di - o - tolylguanidine </e1> ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral <e2> toxicity </e2> of cocaine .
NO_RELATION	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( <e1> DTG </e1> ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral <e2> toxicity </e2> of cocaine .
NO_RELATION	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist <e1> BD1031 </e1> ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral <e2> toxicity </e2> of cocaine .
NO_RELATION	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( <e1> 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane </e1> ) each worsened the behavioral <e2> toxicity </e2> of cocaine .
NO_RELATION	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral <e2> toxicity </e2> of <e1> cocaine </e1> .
CID	To further validate the hypothesis that the anti - <e1> cocaine </e1> effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the <e2> convulsive </e2> and locomotor stimulatory effects of cocaine .
NO_RELATION	To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense <e1> oligodeoxynucleotide </e1> against sigma1 receptors was also shown to significantly attenuate the <e2> convulsive </e2> and locomotor stimulatory effects of cocaine .
CID	To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the <e2> convulsive </e2> and locomotor stimulatory effects of <e1> cocaine </e1> .
CID	Four compounds known to increase QT interval and cause <e2> TDP </e2> were investigated : <e1> terfenadine </e1> , terodiline , cisapride and E4031 .
CID	Four compounds known to increase QT interval and cause <e2> TDP </e2> were investigated : terfenadine , <e1> terodiline </e1> , cisapride and E4031 .
CID	Four compounds known to increase QT interval and cause <e2> TDP </e2> were investigated : terfenadine , terodiline , <e1> cisapride </e1> and E4031 .
NO_RELATION	Four compounds known to increase QT interval and cause <e2> TDP </e2> were investigated : terfenadine , terodiline , cisapride and <e1> E4031 </e1> .
CID	For compounds that have shown <e2> TDP </e2> in the clinic ( <e1> terfenadine </e1> , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .
CID	For compounds that have shown <e2> TDP </e2> in the clinic ( terfenadine , <e1> terodiline </e1> , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .
CID	For compounds that have shown <e2> TDP </e2> in the clinic ( terfenadine , terodiline , <e1> cisapride </e1> ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .
NO_RELATION	Fatal <e2> myeloencephalopathy </e2> due to accidental intrathecal <e1> vincristin </e1> administration : a report of two cases .
NO_RELATION	We report on two fatal cases of accidental intrathecal <e1> vincristine </e1> instillation in a 5 - year old girl with recurrent <e2> acute lymphoblastic leucemia </e2> and a 57 - year old man with lymphoblastic lymphoma .
NO_RELATION	We report on two fatal cases of accidental intrathecal <e1> vincristine </e1> instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with <e2> lymphoblastic lymphoma </e2> .
NO_RELATION	Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed <e2> degeneration of myelin and axons </e2> as well as pseudocystic transformation in areas exposed to <e1> vincristine </e1> , accompanied by secondary changes with numerous prominent macrophages .
NO_RELATION	Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as <e2> pseudocystic transformation </e2> in areas exposed to <e1> vincristine </e1> , accompanied by secondary changes with numerous prominent macrophages .
CID	Intravenous administration of <e1> prochlorperazine </e1> by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of <e2> akathisia </e2> : a prospective , randomized , controlled trial .
CID	STUDY OBJECTIVE : We sought to compare the rate of <e2> akathisia </e2> after administration of intravenous <e1> prochlorperazine </e1> as a 2 - minute bolus or 15 - minute infusion .
NO_RELATION	Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for <e2> headache </e2> , nausea , or vomiting were eligible for inclusion .
NO_RELATION	Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for headache , <e2> nausea </e2> , or vomiting were eligible for inclusion .
NO_RELATION	Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for headache , nausea , or <e2> vomiting </e2> were eligible for inclusion .
CID	CONCLUSION : A 50 % reduction in the incidence of <e2> akathisia </e2> when <e1> prochlorperazine </e1> was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .
NO_RELATION	The efficacy of <e1> prochlorperazine </e1> in the treatment of <e2> headache </e2> and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
NO_RELATION	The efficacy of <e1> prochlorperazine </e1> in the treatment of headache and <e2> nausea </e2> likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
NO_RELATION	<e1> Antithymocyte globulin </e1> in the treatment of D - penicillamine - induced <e2> aplastic anemia </e2> .
CID	Antithymocyte globulin in the treatment of <e1> D - penicillamine </e1> - induced <e2> aplastic anemia </e2> .
NO_RELATION	A patient who received <e1> antithymocyte globulin </e1> therapy for <e2> aplastic anemia </e2> due to D - penicillamine therapy is described .
CID	A patient who received antithymocyte globulin therapy for <e2> aplastic anemia </e2> due to <e1> D - penicillamine </e1> therapy is described .
NO_RELATION	Use of <e1> antithymocyte globulin </e1> may be the optimal treatment of D - penicillamine - induced <e2> aplastic anemia </e2> .
CID	Use of antithymocyte globulin may be the optimal treatment of <e1> D - penicillamine </e1> - induced <e2> aplastic anemia </e2> .
NO_RELATION	The relationship between hippocampal <e1> acetylcholine </e1> release and cholinergic convulsant sensitivity in withdrawal <e2> seizure </e2> - prone and withdrawal seizure - resistant selected mouse lines .
NO_RELATION	The relationship between hippocampal <e1> acetylcholine </e1> release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal <e2> seizure </e2> - resistant selected mouse lines .
NO_RELATION	METHODS : Cholinergic convulsant sensitivity was examined in <e1> alcohol </e1> - na ve Withdrawal <e2> Seizure </e2> - Prone ( WSP ) and - Resistant ( WSR ) mice .
NO_RELATION	Animals were administered <e1> nicotine </e1> , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose .
NO_RELATION	Animals were administered nicotine , <e1> carbachol </e1> , or neostigmine via timed tail vein infusion , and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose .
NO_RELATION	Animals were administered nicotine , carbachol , or <e1> neostigmine </e1> via timed tail vein infusion , and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose .
NO_RELATION	Hippocampal <e1> ACh </e1> also was measured during testing for handling - induced <e2> convulsions </e2> .
CID	RESULTS : Sensitivity to several <e2> convulsion </e2> endpoints induced by <e1> nicotine </e1> , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .
CID	RESULTS : Sensitivity to several <e2> convulsion </e2> endpoints induced by nicotine , <e1> carbachol </e1> , and neostigmine were significantly greater in WSR versus WSP mice .
CID	RESULTS : Sensitivity to several <e2> convulsion </e2> endpoints induced by nicotine , carbachol , and <e1> neostigmine </e1> were significantly greater in WSR versus WSP mice .
NO_RELATION	When hippocampal <e1> ACh </e1> was measured during testing for handling - induced <e2> convulsions </e2> , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
NO_RELATION	When hippocampal ACh was measured during testing for handling - induced <e2> convulsions </e2> , extracellular <e1> ACh </e1> was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
NO_RELATION	CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic <e2> convulsants </e2> may be associated with <e1> ethanol </e1> withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .
NO_RELATION	CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic <e2> convulsants </e2> may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in <e1> alcohol </e1> withdrawal .
CID	Prenatal <e1> dexamethasone </e1> programs <e2> hypertension </e2> and renal injury in the rat .
CID	Prenatal <e1> dexamethasone </e1> programs hypertension and <e2> renal injury </e2> in the rat .
CID	The purpose of the present study was to determine if prenatal <e1> dexamethasone </e1> programmed a progressive <e2> increase in blood pressure </e2> and renal injury in rats .
CID	The purpose of the present study was to determine if prenatal <e1> dexamethasone </e1> programmed a progressive increase in blood pressure and <e2> renal injury </e2> in rats .
CID	Offspring of rats administered <e1> dexamethasone </e1> on days 15 and 16 gestation had a 20 % <e2> reduction in glomerular number </e2> compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .
CID	Male rats that received prenatal <e1> dexamethasone </e1> on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had <e2> elevated blood pressures </e2> at 6 months of age ; the latter group did not have a reduction in glomerular number .
CID	Male rats that received prenatal <e1> dexamethasone </e1> on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a <e2> reduction in glomerular number </e2> .
NO_RELATION	Adult rats given <e1> dexamethasone </e1> on days 15 and 16 of gestation had more glomeruli with <e2> glomerulosclerosis </e2> than control rats .
CID	This study shows that prenatal <e1> dexamethasone </e1> in rats results in a <e2> reduction in glomerular number </e2> , glomerulosclerosis , and hypertension when administered at specific points during gestation .
NO_RELATION	This study shows that prenatal <e1> dexamethasone </e1> in rats results in a reduction in glomerular number , <e2> glomerulosclerosis </e2> , and hypertension when administered at specific points during gestation .
CID	This study shows that prenatal <e1> dexamethasone </e1> in rats results in a reduction in glomerular number , glomerulosclerosis , and <e2> hypertension </e2> when administered at specific points during gestation .
CID	The risk of <e2> venous thromboembolism </e2> in women prescribed <e1> cyproterone acetate </e1> in combination with ethinyl estradiol : a nested cohort analysis and case - control study .
CID	The risk of <e2> venous thromboembolism </e2> in women prescribed cyproterone acetate in combination with <e1> ethinyl estradiol </e1> : a nested cohort analysis and case - control study .
NO_RELATION	BACKGROUND : <e1> Cyproterone acetate </e1> combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : <e1> Cyproterone acetate </e1> combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : <e1> Cyproterone acetate </e1> combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> ( PCOS ) .
NO_RELATION	BACKGROUND : <e1> Cyproterone acetate </e1> combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2> PCOS </e2> ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with <e1> ethinyl estradiol </e1> ( CPA / EE ) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with <e1> ethinyl estradiol </e1> ( CPA / EE ) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with <e1> ethinyl estradiol </e1> ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with <e1> ethinyl estradiol </e1> ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2> PCOS </e2> ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1> CPA </e1> / EE ) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1> CPA </e1> / EE ) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1> CPA </e1> / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( <e1> CPA </e1> / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2> PCOS </e2> ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / <e1> EE </e1> ) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / <e1> EE </e1> ) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / <e1> EE </e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> ( PCOS ) .
NO_RELATION	BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / <e1> EE </e1> ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( <e2> PCOS </e2> ) .
CID	Previous studies have demonstrated an increased risk of <e2> venous thromboembolism </e2> ( VTE ) associated with <e1> CPA </e1> / EE compared with conventional combined oral contraceptives ( COCs ) .
CID	Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2> VTE </e2> ) associated with <e1> CPA </e1> / EE compared with conventional combined oral contraceptives ( COCs ) .
CID	Previous studies have demonstrated an increased risk of <e2> venous thromboembolism </e2> ( VTE ) associated with CPA / <e1> EE </e1> compared with conventional combined oral contraceptives ( COCs ) .
CID	Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2> VTE </e2> ) associated with CPA / <e1> EE </e1> compared with conventional combined oral contraceptives ( COCs ) .
NO_RELATION	Previous studies have demonstrated an increased risk of <e2> venous thromboembolism </e2> ( VTE ) associated with CPA / EE compared with conventional combined <e1> oral contraceptives </e1> ( COCs ) .
NO_RELATION	Previous studies have demonstrated an increased risk of venous thromboembolism ( <e2> VTE </e2> ) associated with CPA / EE compared with conventional combined <e1> oral contraceptives </e1> ( COCs ) .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with <e2> acne </e2> , hirsutism or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> / EE .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , <e2> hirsutism </e2> or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> / EE .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or <e2> PCOS </e2> to estimate the risk of VTE associated with <e1> CPA </e1> / EE .
CID	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of <e2> VTE </e2> associated with <e1> CPA </e1> / EE .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with <e2> acne </e2> , hirsutism or PCOS to estimate the risk of VTE associated with CPA / <e1> EE </e1> .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , <e2> hirsutism </e2> or PCOS to estimate the risk of VTE associated with CPA / <e1> EE </e1> .
NO_RELATION	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or <e2> PCOS </e2> to estimate the risk of VTE associated with CPA / <e1> EE </e1> .
CID	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of <e2> VTE </e2> associated with CPA / <e1> EE </e1> .
CID	CONCLUSIONS : We have demonstrated an increased risk of <e2> VTE </e2> associated with the use of <e1> CPA </e1> / EE in women with acne , hirsutism or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1> / EE in women with <e2> acne </e2> , hirsutism or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1> / EE in women with acne , <e2> hirsutism </e2> or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1> / EE in women with acne , hirsutism or <e2> PCOS </e2> although residual confounding by indication cannot be excluded .
CID	CONCLUSIONS : We have demonstrated an increased risk of <e2> VTE </e2> associated with the use of CPA / <e1> EE </e1> in women with acne , hirsutism or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / <e1> EE </e1> in women with <e2> acne </e2> , hirsutism or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / <e1> EE </e1> in women with acne , <e2> hirsutism </e2> or PCOS although residual confounding by indication cannot be excluded .
NO_RELATION	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / <e1> EE </e1> in women with acne , hirsutism or <e2> PCOS </e2> although residual confounding by indication cannot be excluded .
NO_RELATION	<e2> Pseudoacromegaly </e2> induced by the long - term use of <e1> minoxidil </e1> .
NO_RELATION	We present a patient with <e2> pseudoacromegaly </e2> that resulted from the long - term use of <e1> minoxidil </e1> at an unusually high dose .
NO_RELATION	This is the first case report of <e2> pseudoacromegaly </e2> as a side effect of <e1> minoxidil </e1> use .
CID	All patients received CAB [ <e1> leuprolide acetate </e1> ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .
CID	All patients received CAB [ leuprolide acetate ( <e1> LHRH - A </e1> ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .
CID	All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg <e1> flutamide </e1> , tid , per Os ] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .
CID	Reversible <e2> dilated cardiomyopathy </e2> related to <e1> amphotericin B </e1> therapy .
CID	We describe a patient who developed <e2> dilated cardiomyopathy </e2> and clinical congestive heart failure after 2 months of therapy with <e1> amphotericin B </e1> ( AmB ) for disseminated coccidioidomycosis .
CID	We describe a patient who developed dilated cardiomyopathy and clinical congestive <e2> heart failure </e2> after 2 months of therapy with <e1> amphotericin B </e1> ( AmB ) for disseminated coccidioidomycosis .
NO_RELATION	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with <e1> amphotericin B </e1> ( AmB ) for disseminated <e2> coccidioidomycosis </e2> .
CID	We describe a patient who developed <e2> dilated cardiomyopathy </e2> and clinical congestive heart failure after 2 months of therapy with amphotericin B ( <e1> AmB </e1> ) for disseminated coccidioidomycosis .
CID	We describe a patient who developed dilated cardiomyopathy and clinical congestive <e2> heart failure </e2> after 2 months of therapy with amphotericin B ( <e1> AmB </e1> ) for disseminated coccidioidomycosis .
NO_RELATION	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( <e1> AmB </e1> ) for disseminated <e2> coccidioidomycosis </e2> .
NO_RELATION	His echocardiographic abnormalities and <e2> heart failure </e2> resolved after <e1> posaconazole </e1> was substituted for AmB .
CID	His echocardiographic abnormalities and <e2> heart failure </e2> resolved after posaconazole was substituted for <e1> AmB </e1> .
NO_RELATION	It is important to recognize the rare and potentially reversible <e2> toxicity </e2> of <e1> AmB </e1> .
NO_RELATION	Although the United States Food and Drug Administration banned its use for <e2> nocturnal leg cramps </e2> due to lack of safety and efficacy , <e1> quinine </e1> is widely available in beverages including tonic water and bitter lemon .
NO_RELATION	Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce <e2> neurological complications </e2> , including confusion , altered mental status , seizures , and coma , particularly in older women .
CID	Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications , including <e2> confusion </e2> , altered mental status , seizures , and coma , particularly in older women .
CID	Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications , including confusion , altered mental status , <e2> seizures </e2> , and coma , particularly in older women .
CID	Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications , including confusion , altered mental status , seizures , and <e2> coma </e2> , particularly in older women .
NO_RELATION	<e1> Organophosphate </e1> - induced <e2> convulsions </e2> and prevention of neuropathological damages .
NO_RELATION	<e1> Organophosphate </e1> - induced convulsions and prevention of <e2> neuropathological damages </e2> .
NO_RELATION	The acute <e2> toxicity </e2> of <e1> OPs </e1> is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .
NO_RELATION	The acute <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates <e1> acetylcholine </e1> ( ACh ) levels .
NO_RELATION	The acute <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( <e1> ACh </e1> ) levels .
NO_RELATION	The rats treated with <e1> DFP </e1> - atropine showed severe typical OP - induced <e2> toxicity </e2> signs .
NO_RELATION	The rats treated with DFP - <e1> atropine </e1> showed severe typical OP - induced <e2> toxicity </e2> signs .
NO_RELATION	The rats treated with DFP - atropine showed severe typical <e1> OP </e1> - induced <e2> toxicity </e2> signs .
NO_RELATION	When <e1> CPA </e1> , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2> poisoning </e2> .
NO_RELATION	When CPA , <e1> diazepam </e1> or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2> poisoning </e2> .
NO_RELATION	When CPA , diazepam or <e1> 2PAM </e1> was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2> poisoning </e2> .
NO_RELATION	When CPA , diazepam or 2PAM was given immediately after <e1> DFP </e1> - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2> poisoning </e2> .
NO_RELATION	When CPA , diazepam or 2PAM was given immediately after DFP - <e1> atropine </e1> , these treatments prevented , delayed or shortened the occurrence of serious signs of <e2> poisoning </e2> .
NO_RELATION	<e1> Atropine </e1> - MK801 did not offer any additional protection against DFP <e2> toxicity </e2> .
NO_RELATION	Atropine - <e1> MK801 </e1> did not offer any additional protection against DFP <e2> toxicity </e2> .
NO_RELATION	Atropine - MK801 did not offer any additional protection against <e1> DFP </e1> <e2> toxicity </e2> .
NO_RELATION	In conclusion , <e1> CPA </e1> , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat .
NO_RELATION	In conclusion , <e1> CPA </e1> , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat .
NO_RELATION	In conclusion , CPA , <e1> diazepam </e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat .
NO_RELATION	In conclusion , CPA , <e1> diazepam </e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat .
NO_RELATION	In conclusion , CPA , diazepam and <e1> 2PAM </e1> in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat .
NO_RELATION	In conclusion , CPA , diazepam and <e1> 2PAM </e1> in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat .
NO_RELATION	In conclusion , CPA , diazepam and 2PAM in combination with <e1> atropine </e1> prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat .
NO_RELATION	In conclusion , CPA , diazepam and 2PAM in combination with <e1> atropine </e1> prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat .
NO_RELATION	In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of <e1> DFP </e1> in rat .
NO_RELATION	In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of <e1> DFP </e1> in rat .
NO_RELATION	Differential modulation by <e1> estrogen </e1> of alpha2 - adrenergic and I1 - imidazoline receptor - mediated <e2> hypotension </e2> in female rats .
NO_RELATION	Differential modulation by estrogen of alpha2 - adrenergic and I1 - <e1> imidazoline </e1> receptor - mediated <e2> hypotension </e2> in female rats .
NO_RELATION	We have recently shown that <e1> estrogen </e1> negatively modulates the <e2> hypotensive </e2> effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
NO_RELATION	We have recently shown that estrogen negatively modulates the <e2> hypotensive </e2> effect of <e1> clonidine </e1> ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
CID	In sham - operated rats , <e1> rilmenidine </e1> or alpha - methyldopa elicited similar <e2> hypotension </e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
CID	In sham - operated rats , rilmenidine or <e1> alpha - methyldopa </e1> elicited similar <e2> hypotension </e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
CID	Ovx significantly enhanced the <e2> hypotensive </e2> response to <e1> alpha - methyldopa </e1> , in contrast to no effect on rilmenidine hypotension .
CID	Ovx significantly enhanced the hypotensive response to <e1> alpha - methyldopa </e1> , in contrast to no effect on rilmenidine <e2> hypotension </e2> .
CID	Ovx significantly enhanced the <e2> hypotensive </e2> response to alpha - methyldopa , in contrast to no effect on <e1> rilmenidine </e1> hypotension .
CID	Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on <e1> rilmenidine </e1> <e2> hypotension </e2> .
CID	The enhanced <e1> alpha - methyldopa </e1> <e2> hypotension </e2> in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .
NO_RELATION	The enhanced <e1> alpha - methyldopa </e1> hypotension in Ovx rats was paralleled with further reduction in SDRR and <e2> a reduced locomotor activity </e2> .
NO_RELATION	These findings suggest that <e1> estrogen </e1> downregulates alpha2 - but not I1 - receptor - mediated <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .
CID	These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in <e1> alpha - methyldopa </e1> - estrogen interaction .
NO_RELATION	These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in alpha - methyldopa - <e1> estrogen </e1> interaction .
NO_RELATION	Cardioprotective effect of <e1> tincture of Crataegus </e1> on isoproterenol - induced <e2> myocardial infarction </e2> in rats .
CID	Cardioprotective effect of tincture of Crataegus on <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	The present study was done to investigate the protective effect of <e1> TCR </e1> on experimentally induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	METHODS : The Multiple Outcomes of <e1> Raloxifene </e1> Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with <e2> osteoporosis </e2> .
CID	RESULTS : During a mean follow - up of 3 . 3 years , <e1> raloxifene </e1> was associated with an increased risk for <e2> venous thromboembolism </e2> ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .
NO_RELATION	<e1> Raloxifene </e1> did not increase risk for <e2> cataracts </e2> ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
NO_RELATION	<e1> Raloxifene </e1> did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , <e2> gallbladder disease </e2> ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
NO_RELATION	<e1> Raloxifene </e1> did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , <e2> endometrial hyperplasia </e2> ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
NO_RELATION	<e1> Raloxifene </e1> did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or <e2> endometrial cancer </e2> ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
CID	CONCLUSION : <e1> Raloxifene </e1> was associated with an increased risk for <e2> venous thromboembolism </e2> , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
NO_RELATION	CONCLUSION : <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for <e2> cataracts </e2> , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
NO_RELATION	CONCLUSION : <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , <e2> gallbladder disease </e2> , endometrial hyperplasia , or endometrial cancer .
NO_RELATION	CONCLUSION : <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , <e2> endometrial hyperplasia </e2> , or endometrial cancer .
NO_RELATION	CONCLUSION : <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or <e2> endometrial cancer </e2> .
CID	<e1> Ceftriaxone </e1> - associated <e2> biliary pseudolithiasis </e2> in paediatric surgical patients .
CID	It is well known that <e1> ceftriaxone </e1> leads to <e2> pseudolithiasis </e2> in some patients .
CID	In this study , we prospectively evaluated the incidence and clinical importance of <e2> pseudolithiasis </e2> in paediatric surgical patients receiving <e1> ceftriaxone </e1> treatment , who often had to fast in the post - operative period .
NO_RELATION	Evaluation of the anticocaine monoclonal antibody <e1> GNC92H2 </e1> as an immunotherapy for <e2> cocaine overdose </e2> .
NO_RELATION	The illicit use of <e1> cocaine </e1> continues in epidemic proportions and treatment for <e2> cocaine overdose </e2> remains elusive .
NO_RELATION	The therapeutic potential of the anticocaine antibody <e1> GNC92H2 </e1> was examined using a model of <e2> cocaine overdose </e2> .
NO_RELATION	Significant blockade of <e1> cocaine </e1> <e2> toxicity </e2> was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
CID	Significant blockade of <e1> cocaine </e1> toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , <e2> seizures </e2> up to 77 % and death by 72 % .
NO_RELATION	Significant blockade of <e1> cocaine </e1> toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and <e2> death </e2> by 72 % .
NO_RELATION	Significant blockade of cocaine <e2> toxicity </e2> was observed with the higher dose of <e1> GNC92H2 </e1> ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
NO_RELATION	Significant blockade of cocaine toxicity was observed with the higher dose of <e1> GNC92H2 </e1> ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , <e2> seizures </e2> up to 77 % and death by 72 % .
NO_RELATION	Significant blockade of cocaine toxicity was observed with the higher dose of <e1> GNC92H2 </e1> ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and <e2> death </e2> by 72 % .
NO_RELATION	Importantly , <e1> GNC92H2 </e1> prevented <e2> death </e2> even post - cocaine injection .
NO_RELATION	Importantly , GNC92H2 prevented <e2> death </e2> even post - <e1> cocaine </e1> injection .
NO_RELATION	The results support the important potential of <e1> GNC92H2 </e1> as a therapeutic tool against <e2> cocaine overdose </e2> .
CID	CONCLUSION : We suggest that the increased risk of <e2> venous thromboembolism </e2> due to <e1> raloxifene </e1> treatment may be related to increased tPA levels , but not TAFI levels .
CID	<e1> Ketoconazole </e1> induced <e2> torsades de pointes </e2> without concomitant use of QT interval - prolonging drug .
NO_RELATION	We report a woman with <e2> coronary artery disease </e2> who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking <e1> ketoconazole </e1> for treatment of fungal infection .
CID	We report a woman with coronary artery disease who developed a markedly <e2> prolonged QT interval </e2> and torsades de pointes ( TdP ) after taking <e1> ketoconazole </e1> for treatment of fungal infection .
CID	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and <e2> torsades de pointes </e2> ( TdP ) after taking <e1> ketoconazole </e1> for treatment of fungal infection .
CID	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( <e2> TdP </e2> ) after taking <e1> ketoconazole </e1> for treatment of fungal infection .
NO_RELATION	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking <e1> ketoconazole </e1> for treatment of <e2> fungal infection </e2> .
CID	We postulate that by virtue of its direct blocking action on IKr , <e1> ketoconazole </e1> alone may prolong QT interval and induce <e2> TdP </e2> .
CID	This calls for attention when <e1> ketoconazole </e1> is administered to patients with risk factors for acquired <e2> long QT syndrome </e2> .
CID	<e1> Diazepam </e1> - , scopolamine - and ageing - induced <e2> amnesia </e2> served as the interoceptive behavioral models .
CID	Diazepam - , <e1> scopolamine </e1> - and ageing - induced <e2> amnesia </e2> served as the interoceptive behavioral models .
NO_RELATION	Furthermore , <e1> DCE </e1> reversed the <e2> amnesia </e2> induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .
CID	Furthermore , DCE reversed the <e2> amnesia </e2> induced by <e1> scopolamine </e1> ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .
CID	Furthermore , DCE reversed the <e2> amnesia </e2> induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and <e1> diazepam </e1> ( 1 mg / kg , i . p . ) .
NO_RELATION	Therefore , <e1> DCE </e1> may prove to be a useful remedy for the management of <e2> cognitive dysfunctions </e2> on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .
NO_RELATION	Therefore , DCE may prove to be a useful remedy for the management of <e2> cognitive dysfunctions </e2> on account of its multifarious beneficial effects such as , memory improving property , <e1> cholesterol </e1> lowering property and anticholinesterase activity .
NO_RELATION	<e2> Cauda equina syndrome </e2> after epidural <e1> steroid </e1> injection : a case report .
NO_RELATION	OBJECTIVE : Conventional treatment methods of lumbusacral <e2> radiculopathy </e2> are physical therapy , epidural <e1> steroid </e1> injections , oral medications , and spinal manipulative therapy .
NO_RELATION	The following case is a report of <e2> cauda equina syndrome </e2> possibly caused by epidural injection of <e1> triamcinolone </e1> and bupivacaine .
CID	The following case is a report of <e2> cauda equina syndrome </e2> possibly caused by epidural injection of triamcinolone and <e1> bupivacaine </e1> .
NO_RELATION	CLINICAL FEATURES : A 50 - year - old woman with <e2> low back and right leg pain </e2> was scheduled for epidural <e1> steroid </e1> injection .
NO_RELATION	Clinical examination and continued vigilance for <e2> neurologic deterioration </e2> after epidural <e1> steroid </e1> injections is important .
CID	High - dose <e1> testosterone </e1> is associated with <e2> atherosclerosis </e2> in postmenopausal women .
NO_RELATION	METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose <e1> estrogen </e1> - testosterone therapy ( estradiol - and testosterone esters ) and aortic <e2> atherosclerosis </e2> .
CID	METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - <e1> testosterone </e1> therapy ( estradiol - and testosterone esters ) and aortic <e2> atherosclerosis </e2> .
NO_RELATION	METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( <e1> estradiol - and testosterone esters </e1> ) and aortic <e2> atherosclerosis </e2> .
NO_RELATION	The association remained after additional adjustment for <e2> diabetes </e2> , <e1> cholesterol </e1> level , systolic blood pressure , or alcohol use .
NO_RELATION	The association remained after additional adjustment for <e2> diabetes </e2> , cholesterol level , systolic blood pressure , or <e1> alcohol </e1> use .
CID	CONCLUSION : Our results suggest that high - dose <e1> testosterone </e1> therapy may adversely affect <e2> atherosclerosis </e2> in postmenopausal women and indicate that androgen replacement in these women may not be harmless .
CID	<e1> Sirolimus </e1> - associated <e2> proteinuria </e2> and renal dysfunction .
CID	<e1> Sirolimus </e1> - associated proteinuria and <e2> renal dysfunction </e2> .
CID	<e1> Sirolimus </e1> represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft <e2> nephropathy </e2> .
CID	Because <e1> sirolimus </e1> does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - <e2> nephrotoxic </e2> drug ' .
CID	However , clinical reports suggest that , under some circumstances , <e1> sirolimus </e1> is associated with <e2> proteinuria </e2> and acute renal dysfunction .
NO_RELATION	However , clinical reports suggest that , under some circumstances , <e1> sirolimus </e1> is associated with proteinuria and <e2> acute renal dysfunction </e2> .
CID	The mechanisms of <e1> sirolimus </e1> - associated <e2> proteinuria </e2> are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .
NO_RELATION	The <e2> acute renal dysfunction </e2> associated with <e1> sirolimus </e1> ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .
CID	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of <e1> sirolimus </e1> on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2> proteinuria </e2> and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
CID	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of <e1> sirolimus </e1> on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed .
CID	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of <e1> sirolimus </e1> in appropriate patient populations , close monitoring of <e2> proteinuria </e2> and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
CID	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of <e1> sirolimus </e1> in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed .
NO_RELATION	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2> proteinuria </e2> and renal function , use of <e1> angiotensin </e1> - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
NO_RELATION	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of <e1> angiotensin </e1> - converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed .
NO_RELATION	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of <e2> proteinuria </e2> and renal function , use of angiotensin - converting enzyme inhibitors or <e1> angiotensin II </e1> receptor blockers if proteinuria occurs and withdrawal if needed .
NO_RELATION	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or <e1> angiotensin II </e1> receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed .
CID	Progressive <e2> myopathy </e2> with up - regulation of MHC - I associated with <e1> statin </e1> therapy .
CID	<e1> Statins </e1> can cause a necrotizing <e2> myopathy </e2> and hyperCKaemia which is reversible on cessation of the drug .
NO_RELATION	<e1> Statins </e1> can cause a necrotizing myopathy and <e2> hyperCKaemia </e2> which is reversible on cessation of the drug .
CID	What is less well known is a phenomenon whereby <e1> statins </e1> may induce a <e2> myopathy </e2> , which persists or may progress after stopping the drug .
CID	These observations suggest that <e1> statins </e1> may initiate an immune - mediated <e2> myopathy </e2> that persists after withdrawal of the drug and responds to immunosuppressive therapy .
CID	The mechanism of this <e2> myopathy </e2> is uncertain but may involve the induction by <e1> statins </e1> of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .
CID	<e1> Clonidine </e1> - induced <e2> bradycardia </e2> in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .
CID	The influence of <e1> smoking </e1> during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with <e2> hearing loss </e2> in adults .
CID	The influence of smoking during pregnancy on the developing cochlea has not been estimated , although <e1> smoking </e1> has been positively associated with <e2> hearing loss </e2> in adults .
NO_RELATION	<e2> Neuroinflammation </e2> and behavioral abnormalities after neonatal <e1> terbutaline </e1> treatment in rats : implications for autism .
NO_RELATION	Neuroinflammation and <e2> behavioral abnormalities </e2> after neonatal <e1> terbutaline </e1> treatment in rats : implications for autism .
CID	Neuroinflammation and behavioral abnormalities after neonatal <e1> terbutaline </e1> treatment in rats : implications for <e2> autism </e2> .
NO_RELATION	<e1> Terbutaline </e1> , a beta2 - adrenoceptor agonist used to arrest <e2> preterm labor </e2> , has been associated with increased concordance for autism in dizygotic twins .
CID	<e1> Terbutaline </e1> , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for <e2> autism </e2> in dizygotic twins .
CID	Acute <e2> myocarditis </e2> associated with <e1> clozapine </e1> .
CID	OBJECTIVE : A case of acute <e2> myocarditis </e2> associated with the commencement of <e1> clozapine </e1> is described , highlighting the onset , course and possible contributing factors .
NO_RELATION	RESULTS : A 20 - year - old male with <e2> schizophrenia </e2> developed a sudden onset of myocarditis after commencement of <e1> clozapine </e1> .
CID	RESULTS : A 20 - year - old male with schizophrenia developed a sudden onset of <e2> myocarditis </e2> after commencement of <e1> clozapine </e1> .
CID	CONCLUSIONS : <e2> Myocarditis </e2> is an increasingly recognized complication associated with the use of <e1> clozapine </e1> .
NO_RELATION	Considering that <e1> clozapine </e1> remains the gold standard in treatment of resistant <e2> psychosis </e2> , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .
CID	<e2> Encephalopathy </e2> induced by <e1> levetiracetam </e1> added to valproate .
CID	<e2> Encephalopathy </e2> induced by levetiracetam added to <e1> valproate </e1> .
CID	BACKGROUND : We report on the manifestation of a <e1> levetiracetam </e1> ( LEV ) - induced <e2> encephalopathy </e2> .
CID	BACKGROUND : We report on the manifestation of a levetiracetam ( <e1> LEV </e1> ) - induced <e2> encephalopathy </e2> .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from <e2> idiopathic epilepsy </e2> with generalized seizures was treated with <e1> LEV </e1> ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized <e2> seizures </e2> was treated with <e1> LEV </e1> ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from <e2> idiopathic epilepsy </e2> with generalized seizures was treated with LEV ( 3000 mg ) added to <e1> valproate </e1> ( VPA ) ( 2000 mg ) .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized <e2> seizures </e2> was treated with LEV ( 3000 mg ) added to <e1> valproate </e1> ( VPA ) ( 2000 mg ) .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from <e2> idiopathic epilepsy </e2> with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( <e1> VPA </e1> ) ( 2000 mg ) .
NO_RELATION	FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized <e2> seizures </e2> was treated with LEV ( 3000 mg ) added to valproate ( <e1> VPA </e1> ) ( 2000 mg ) .
NO_RELATION	OUTCOME : Following discontinuation of <e1> LEV </e1> , EEG and neuropsychological findings improved and <e2> seizure </e2> frequency decreased .
NO_RELATION	<e1> Norepinephrine </e1> signaling through beta - adrenergic receptors is critical for expression of cocaine - induced <e2> anxiety </e2> .
CID	Norepinephrine signaling through beta - adrenergic receptors is critical for expression of <e1> cocaine </e1> - induced <e2> anxiety </e2> .
CID	While the mechanisms underlying <e1> cocaine </e1> ' s rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as <e2> anxiety </e2> .
CID	While the mechanisms underlying cocaine ' s rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by <e1> cocaine </e1> , such as <e2> anxiety </e2> .
NO_RELATION	METHODS : In this study , we evaluated the performance of <e1> dopamine </e1> beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced <e2> anxiety </e2> .
NO_RELATION	METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack <e1> norepinephrine </e1> ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced <e2> anxiety </e2> .
NO_RELATION	METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( <e1> NE </e1> ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced <e2> anxiety </e2> .
CID	METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to <e1> cocaine </e1> - induced <e2> anxiety </e2> .
CID	RESULTS : We found that <e1> cocaine </e1> dose - dependently increased <e2> anxiety </e2> - like behavior in control ( Dbh + / - ) mice , as measured by a decrease in open arm exploration .
CID	<e1> Cocaine </e1> - induced <e2> anxiety </e2> was also attenuated in Dbh + / - mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .
NO_RELATION	Cocaine - induced <e2> anxiety </e2> was also attenuated in Dbh + / - mice following administration of <e1> disulfiram </e1> , a dopamine beta - hydroxylase ( DBH ) inhibitor .
NO_RELATION	Cocaine - induced <e2> anxiety </e2> was also attenuated in Dbh + / - mice following administration of disulfiram , a <e1> dopamine </e1> beta - hydroxylase ( DBH ) inhibitor .
NO_RELATION	In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist <e1> propranolol </e1> blocked cocaine - induced <e2> anxiety </e2> - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .
CID	In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked <e1> cocaine </e1> - induced <e2> anxiety </e2> - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .
NO_RELATION	In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced <e2> anxiety </e2> - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist <e1> prazosin </e1> and the alpha ( 2 ) antagonist yohimbine had no effect .
NO_RELATION	In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced <e2> anxiety </e2> - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist <e1> yohimbine </e1> had no effect .
CID	CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for <e1> cocaine </e1> - induced <e2> anxiety </e2> in mice .
NO_RELATION	<e1> Clonidine </e1> for <e2> attention - deficit / hyperactivity disorder </e2> : II .
NO_RELATION	OBJECTIVE : To examine the safety and tolerability of <e1> clonidine </e1> used alone or with methylphenidate in children with <e2> attention - deficit / hyperactivity disorder </e2> ( ADHD ) .
NO_RELATION	OBJECTIVE : To examine the safety and tolerability of <e1> clonidine </e1> used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( <e2> ADHD </e2> ) .
NO_RELATION	OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with <e1> methylphenidate </e1> in children with <e2> attention - deficit / hyperactivity disorder </e2> ( ADHD ) .
NO_RELATION	OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with <e1> methylphenidate </e1> in children with attention - deficit / hyperactivity disorder ( <e2> ADHD </e2> ) .
NO_RELATION	METHOD : In a 16 - week multicenter , double - blind trial , 122 children with <e2> ADHD </e2> were randomly assigned to <e1> clonidine </e1> ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
NO_RELATION	METHOD : In a 16 - week multicenter , double - blind trial , 122 children with <e2> ADHD </e2> were randomly assigned to clonidine ( n = 31 ) , <e1> methylphenidate </e1> ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
NO_RELATION	METHOD : In a 16 - week multicenter , double - blind trial , 122 children with <e2> ADHD </e2> were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , <e1> clonidine </e1> and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
NO_RELATION	METHOD : In a 16 - week multicenter , double - blind trial , 122 children with <e2> ADHD </e2> were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and <e1> methylphenidate </e1> ( n = 32 ) , or placebo ( n = 30 ) .
CID	RESULTS : There were more incidents of <e2> bradycardia </e2> in subjects treated with <e1> clonidine </e1> compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
CID	RESULTS : There were more incidents of <e2> bradycardia </e2> in subjects treated with clonidine compared with those not treated with <e1> clonidine </e1> ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
NO_RELATION	<e2> Drowsiness </e2> was common on <e1> clonidine </e1> , but generally resolved by 6 to 8 weeks .
NO_RELATION	CONCLUSIONS : <e1> Clonidine </e1> , used alone or with methylphenidate , appears safe and well tolerated in childhood <e2> ADHD </e2> .
NO_RELATION	CONCLUSIONS : Clonidine , used alone or with <e1> methylphenidate </e1> , appears safe and well tolerated in childhood <e2> ADHD </e2> .
CID	Physicians prescribing <e1> clonidine </e1> should monitor for <e2> bradycardia </e2> and advise patients about the high likelihood of initial drowsiness .
NO_RELATION	Physicians prescribing <e1> clonidine </e1> should monitor for bradycardia and advise patients about the high likelihood of initial <e2> drowsiness </e2> .
NO_RELATION	<e1> Thalidomide </e1> has limited single - agent activity in relapsed or refractory indolent <e2> non - Hodgkin lymphomas </e2> : a phase II trial of the Cancer and Leukemia Group B .
NO_RELATION	<e1> Thalidomide </e1> has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the <e2> Cancer </e2> and Leukemia Group B .
NO_RELATION	<e1> Thalidomide </e1> has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and <e2> Leukemia </e2> Group B .
NO_RELATION	<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in <e2> multiple myeloma </e2> , mantle cell lymphoma and lymphoplasmacytic lymphoma .
NO_RELATION	<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma , <e2> mantle cell lymphoma </e2> and lymphoplasmacytic lymphoma .
NO_RELATION	<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and <e2> lymphoplasmacytic lymphoma </e2> .
NO_RELATION	Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent <e2> lymphomas </e2> received <e1> thalidomide </e1> 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .
NO_RELATION	Our results failed to demonstrate an important response rate to single agent <e1> thalidomide </e1> in indolent <e2> lymphomas </e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .
NO_RELATION	Our results failed to demonstrate an important response rate to single agent thalidomide in indolent <e2> lymphomas </e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent , <e1> lenalidomide </e1> .
NO_RELATION	Intracavernous <e1> epinephrine </e1> : a minimally invasive treatment for <e2> priapism </e2> in the emergency department .
CID	A 45 - year - old man , an admitted frequent <e1> cocaine </e1> user , presented to the Emergency Department ( ED ) on two separate occasions with a history of <e2> priapism </e2> after cocaine use .
CID	A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of <e2> priapism </e2> after <e1> cocaine </e1> use .
NO_RELATION	Effect of <e1> green tea </e1> and vitamin E combination in isoproterenol induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	Effect of green tea and <e1> vitamin E </e1> combination in isoproterenol induced <e2> myocardial infarction </e2> in rats .
CID	Effect of green tea and vitamin E combination in <e1> isoproterenol </e1> induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	The present study was aimed to investigate the combined effects of <e1> green tea </e1> and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	The present study was aimed to investigate the combined effects of green tea and <e1> vitamin E </e1> on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced <e2> myocardial infarction </e2> in rats .
CID	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in <e1> isoproterenol </e1> ( ISO ) - induced <e2> myocardial infarction </e2> in rats .
CID	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( <e1> ISO </e1> ) - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	These findings indicate the synergistic protective effect of <e1> green tea </e1> and vitamin E during ISO induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	These findings indicate the synergistic protective effect of green tea and <e1> vitamin E </e1> during ISO induced <e2> myocardial infarction </e2> in rats .
CID	These findings indicate the synergistic protective effect of green tea and vitamin E during <e1> ISO </e1> induced <e2> myocardial infarction </e2> in rats .
CID	Development of <e2> ocular myasthenia </e2> during <e1> pegylated interferon </e1> and ribavirin treatment for chronic hepatitis C .
NO_RELATION	Development of ocular myasthenia during <e1> pegylated interferon </e1> and ribavirin treatment for <e2> chronic hepatitis C </e2> .
CID	Development of <e2> ocular myasthenia </e2> during pegylated interferon and <e1> ribavirin </e1> treatment for chronic hepatitis C .
NO_RELATION	Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> treatment for <e2> chronic hepatitis C </e2> .
NO_RELATION	A 63 - year - old male experienced sudden <e2> diplopia </e2> after 9 weeks of administration of <e1> pegylated interferon ( IFN ) alpha - 2b </e1> and ribavirin for chronic hepatitis C ( CHC ) .
NO_RELATION	A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon ( IFN ) alpha - 2b </e1> and ribavirin for <e2> chronic hepatitis C </e2> ( CHC ) .
NO_RELATION	A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon ( IFN ) alpha - 2b </e1> and ribavirin for chronic hepatitis C ( <e2> CHC </e2> ) .
NO_RELATION	A 63 - year - old male experienced sudden <e2> diplopia </e2> after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and <e1> ribavirin </e1> for chronic hepatitis C ( CHC ) .
NO_RELATION	A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and <e1> ribavirin </e1> for <e2> chronic hepatitis C </e2> ( CHC ) .
NO_RELATION	A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and <e1> ribavirin </e1> for chronic hepatitis C ( <e2> CHC </e2> ) .
CID	The <e2> ocular myasthenia </e2> associated with combination therapy of <e1> pegylated IFN alpha - 2b </e1> and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
NO_RELATION	The ocular myasthenia associated with combination therapy of <e1> pegylated IFN alpha - 2b </e1> and ribavirin for <e2> CHC </e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
CID	The <e2> ocular myasthenia </e2> associated with combination therapy of pegylated IFN alpha - 2b and <e1> ribavirin </e1> for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
NO_RELATION	The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and <e1> ribavirin </e1> for <e2> CHC </e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
CID	The <e2> ocular myasthenia </e2> associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of <e1> IFN </e1> therapy .
NO_RELATION	The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for <e2> CHC </e2> is very rarely reported ; therefore , we present this case with a review of the various eye complications of <e1> IFN </e1> therapy .
NO_RELATION	<e2> Schizophrenia </e2> has been initially associated with dysfunction in <e1> dopamine </e1> neurotransmission .
NO_RELATION	However , the observation that antagonists of the <e1> glutamate </e1> N - methyl - D - aspartate ( NMDA ) receptor produce <e2> schizophrenic </e2> - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
NO_RELATION	However , the observation that antagonists of the glutamate <e1> N - methyl - D - aspartate </e1> ( NMDA ) receptor produce <e2> schizophrenic </e2> - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
NO_RELATION	However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( <e1> NMDA </e1> ) receptor produce <e2> schizophrenic </e2> - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
NO_RELATION	However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce <e2> schizophrenic </e2> - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1> NMDA </e1> receptor .
NO_RELATION	This study aimed at investigating the potential antipsychotic - like properties of <e1> SSR103800 </e1> , with a particular focus on models of <e2> hyperactivity </e2> , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .
CID	This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of <e2> hyperactivity </e2> , involving either drug challenge ( ie , <e1> amphetamine </e1> and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .
CID	This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of <e2> hyperactivity </e2> , involving either drug challenge ( ie , amphetamine and <e1> MK - 801 </e1> ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .
NO_RELATION	This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of <e2> hyperactivity </e2> , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , <e1> NMDA </e1> Nr1 ( neo - / - ) and DAT ( - / - ) ) .
NO_RELATION	Results showed that <e1> SSR103800 </e1> ( 10 - 30 mg / kg p . o . ) blocked <e2> hyperactivity </e2> induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .
NO_RELATION	Results showed that <e1> SSR103800 </e1> ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous <e2> hyperactivity </e2> of NMDA Nr1 ( neo - / - ) mice .
NO_RELATION	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked <e2> hyperactivity </e2> induced by the non - competitive <e1> NMDA </e1> receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .
NO_RELATION	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive <e1> NMDA </e1> receptor antagonist , MK - 801 and partially reversed spontaneous <e2> hyperactivity </e2> of NMDA Nr1 ( neo - / - ) mice .
CID	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked <e2> hyperactivity </e2> induced by the non - competitive NMDA receptor antagonist , <e1> MK - 801 </e1> and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .
CID	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , <e1> MK - 801 </e1> and partially reversed spontaneous <e2> hyperactivity </e2> of NMDA Nr1 ( neo - / - ) mice .
NO_RELATION	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked <e2> hyperactivity </e2> induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of <e1> NMDA </e1> Nr1 ( neo - / - ) mice .
NO_RELATION	Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous <e2> hyperactivity </e2> of <e1> NMDA </e1> Nr1 ( neo - / - ) mice .
NO_RELATION	In contrast , <e1> SSR103800 </e1> failed to affect <e2> hyperactivity </e2> induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .
CID	In contrast , SSR103800 failed to affect <e2> hyperactivity </e2> induced by <e1> amphetamine </e1> or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .
NO_RELATION	In contrast , SSR103800 failed to affect <e2> hyperactivity </e2> induced by amphetamine or naturally observed in <e1> dopamine </e1> transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .
NO_RELATION	Importantly , both classical ( <e1> haloperidol </e1> ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of <e2> hyperactivity </e2> .
NO_RELATION	Importantly , both classical ( haloperidol ) and atypical ( <e1> olanzapine </e1> , clozapine and aripiprazole ) antipsychotics were effective in all these models of <e2> hyperactivity </e2> .
NO_RELATION	Importantly , both classical ( haloperidol ) and atypical ( olanzapine , <e1> clozapine </e1> and aripiprazole ) antipsychotics were effective in all these models of <e2> hyperactivity </e2> .
NO_RELATION	Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and <e1> aripiprazole </e1> ) antipsychotics were effective in all these models of <e2> hyperactivity </e2> .
NO_RELATION	However , unlike these latter , <e1> SSR103800 </e1> did not produce <e2> catalepsy </e2> ( retention on the bar test ) up to 30 mg / kg p . o .
CID	<e1> Phenylephrine </e1> but not ephedrine <e2> reduces frontal lobe oxygenation </e2> following anesthesia - induced hypotension .
NO_RELATION	<e1> Phenylephrine </e1> but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced <e2> hypotension </e2> .
NO_RELATION	Phenylephrine but not <e1> ephedrine </e1> <e2> reduces frontal lobe oxygenation </e2> following anesthesia - induced hypotension .
NO_RELATION	Phenylephrine but not <e1> ephedrine </e1> reduces frontal lobe oxygenation following anesthesia - induced <e2> hypotension </e2> .
NO_RELATION	We describe the effect of <e1> phenylephrine </e1> and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced <e2> hypotension </e2> .
NO_RELATION	We describe the effect of phenylephrine and <e1> ephedrine </e1> on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced <e2> hypotension </e2> .
NO_RELATION	CONCLUSIONS : The utilization of <e1> phenylephrine </e1> to correct <e2> hypotension </e2> induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .
NO_RELATION	CONCLUSIONS : The utilization of phenylephrine to correct <e2> hypotension </e2> induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while <e1> ephedrine </e1> maintains frontal lobe oxygenation potentially related to an increase in CO .
CID	RESULTS : <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced <e2> anxiety </e2> ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .
NO_RELATION	RESULTS : <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , <e2> behavioral inflexibility </e2> ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .
CID	RESULTS : <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working <e2> memory impairment </e2> ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .
CID	RESULTS : <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , <e2> hoarding </e2> , and corticostriatal dysfunction .
NO_RELATION	RESULTS : <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and <e2> corticostriatal dysfunction </e2> .
CID	A case is reported of the <e2> hemolytic uremic syndrome </e2> ( HUS ) in a woman taking <e1> oral contraceptives </e1> .
CID	A case is reported of the hemolytic uremic syndrome ( <e2> HUS </e2> ) in a woman taking <e1> oral contraceptives </e1> .
NO_RELATION	She was treated with <e1> heparin </e1> , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of <e2> anuria </e2> , dialysis treatment was stopped .
NO_RELATION	She was treated with heparin , <e1> dipyridamole </e1> and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of <e2> anuria </e2> , dialysis treatment was stopped .
NO_RELATION	Effects of <e1> acetylsalicylic acid </e1> , dipyridamole , and hydrocortisone on epinephrine - induced <e2> myocardial injury </e2> in dogs .
NO_RELATION	Effects of acetylsalicylic acid , <e1> dipyridamole </e1> , and hydrocortisone on epinephrine - induced <e2> myocardial injury </e2> in dogs .
NO_RELATION	Effects of acetylsalicylic acid , dipyridamole , and <e1> hydrocortisone </e1> on epinephrine - induced <e2> myocardial injury </e2> in dogs .
CID	Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on <e1> epinephrine </e1> - induced <e2> myocardial injury </e2> in dogs .
CID	A reproducible model for producing diffuse <e2> myocardial injury </e2> ( <e1> epinephrine </e1> infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .
NO_RELATION	A reproducible model for producing diffuse myocardial injury ( <e1> epinephrine </e1> infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute <e2> myocardial infarction </e2> .
NO_RELATION	Eight <e2> glaucomatous </e2> patients chronically treated with <e1> timolol </e1> 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .
CID	Eight glaucomatous patients chronically treated with <e1> timolol </e1> 0 . 5 % / 12h , suffering from <e2> depression </e2> diagnosed through DMS - III - R criteria , were included in the study .
CID	In a double blind cross - over study with control group , the patients under <e1> timolol </e1> treatment presented higher <e2> depression </e2> values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .
NO_RELATION	These results suggest that <e1> betaxolol </e1> could be less of a <e2> depression </e2> - inducer than timolol in predisposed patients .
CID	These results suggest that betaxolol could be less of a <e2> depression </e2> - inducer than <e1> timolol </e1> in predisposed patients .
CID	Long - term follow - up of <e1> ifosfamide </e1> <e2> renal toxicity </e2> in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .
NO_RELATION	Long - term follow - up of <e1> ifosfamide </e1> renal toxicity in children treated for <e2> malignant mesenchymal tumors </e2> : an International Society of Pediatric Oncology report .
NO_RELATION	The renal function of 74 children with <e2> malignant mesenchymal tumors </e2> in complete remission and who have received the same <e1> ifosfamide </e1> chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
NO_RELATION	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same <e1> ifosfamide </e1> chemotherapy protocol ( International Society of Pediatric Oncology <e2> Malignant Mesenchymal Tumor </e2> Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , <e2> glucosuria </e2> , proteinuria , aminoaciduria , urinary pH , osmolarity , <e1> creatinine </e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , <e2> proteinuria </e2> , aminoaciduria , urinary pH , osmolarity , <e1> creatinine </e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , <e2> aminoaciduria </e2> , urinary pH , osmolarity , <e1> creatinine </e1> clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , <e2> glucosuria </e2> , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , <e1> phosphate </e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , <e2> proteinuria </e2> , aminoaciduria , urinary pH , osmolarity , creatinine clearance , <e1> phosphate </e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , <e2> aminoaciduria </e2> , urinary pH , osmolarity , creatinine clearance , <e1> phosphate </e1> tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
NO_RELATION	Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major <e2> toxicity </e2> resulting in Fanconi ' s syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1> phosphate </e1> reabsorption .
NO_RELATION	Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in <e2> Fanconi ' s syndrome </e2> ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1> phosphate </e1> reabsorption .
NO_RELATION	Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi ' s syndrome ( <e2> TDFS </e2> ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low <e1> phosphate </e1> reabsorption .
NO_RELATION	Severe <e2> toxicity </e2> was correlated with the higher cumulative dose of 60 g / m2 of <e1> ifosfamide </e1> , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .
NO_RELATION	Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of <e1> ifosfamide </e1> , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic <e2> tumor </e2> involvement .
NO_RELATION	This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of <e1> ifosfamide </e1> in the treatment of <e2> mesenchymal tumors </e2> in children .
NO_RELATION	Evidence for an involvement of D1 and D2 <e1> dopamine </e1> receptors in mediating nicotine - induced <e2> hyperactivity </e2> in rats .
CID	Evidence for an involvement of D1 and D2 dopamine receptors in mediating <e1> nicotine </e1> - induced <e2> hyperactivity </e2> in rats .
CID	<e1> Nicotine </e1> ( 1 . 0 mg / kg ) caused a significant <e2> increase in locomotor activity </e2> in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .
CID	<e1> Nicotine </e1> - induced <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .
NO_RELATION	Nicotine - induced <e2> hyperactivity </e2> was blocked by the selective D1 antagonist <e1> SCH 23390 </e1> , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .
NO_RELATION	Nicotine - induced <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist <e1> raclopride </e1> and the D1 / D2 antagonist fluphenazine .
NO_RELATION	Nicotine - induced <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist <e1> fluphenazine </e1> .
NO_RELATION	Pretreatment with the D2 agonist <e1> PHNO </e1> enhanced nicotine - induced <e2> hyperactivity </e2> , whereas the D1 agonist SKF 38393 had no effect .
CID	Pretreatment with the D2 agonist PHNO enhanced <e1> nicotine </e1> - induced <e2> hyperactivity </e2> , whereas the D1 agonist SKF 38393 had no effect .
NO_RELATION	Pretreatment with the D2 agonist PHNO enhanced nicotine - induced <e2> hyperactivity </e2> , whereas the D1 agonist <e1> SKF 38393 </e1> had no effect .
CID	The results indicate that acute <e1> nicotine </e1> injection induces a pronounced <e2> hyperactivity </e2> in rats habituated to the test environment .
NO_RELATION	Therefore , certain limitations for <e2> malaria </e2> prophylaxis and treatment with <e1> mefloquine </e1> are recommended .
CID	Reduction in injection <e2> pain </e2> using buffered <e1> lidocaine </e1> as a local anesthetic before cardiac catheterization .
CID	Previous reports have suggested that <e2> pain </e2> associated with the injection of <e1> lidocaine </e1> is related to the acidic pH of the solution .
CID	To determine if the addition of a buffering solution to adjust the pH of <e1> lidocaine </e1> into the physiologic range would reduce <e2> pain </e2> during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .
CID	Twenty patients were asked to quantify the severity of <e2> pain </e2> after receiving standard <e1> lidocaine </e1> in one femoral area and buffered lidocaine in the opposite femoral area .
CID	Twenty patients were asked to quantify the severity of <e2> pain </e2> after receiving standard lidocaine in one femoral area and buffered <e1> lidocaine </e1> in the opposite femoral area .
CID	The mean <e2> pain </e2> score for buffered <e1> lidocaine </e1> was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs .
CID	The mean <e2> pain </e2> score for buffered lidocaine was significantly lower than the mean score for standard <e1> lidocaine </e1> ( 2 . 7 + / - 1 . 9 vs .
CID	The pH adjustment of standard <e1> lidocaine </e1> can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the <e2> pain </e2> occurring during the infiltration of tissues .
NO_RELATION	Randomized , double - blind trial of <e1> mazindol </e1> in <e2> Duchenne dystrophy </e2> .
NO_RELATION	We conducted a 12 - month controlled trial of <e1> mazindol </e1> , a putative growth hormone secretion inhibitor , in 83 boys with <e2> Duchenne dystrophy </e2> .
CID	Side effects attributable to <e1> mazindol </e1> included <e2> decreased appetite </e2> ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
CID	Side effects attributable to <e1> mazindol </e1> included decreased appetite ( 36 % ) , <e2> dry mouth </e2> ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
CID	Side effects attributable to <e1> mazindol </e1> included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and <e2> gastrointestinal symptoms </e2> ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
CID	Side effects attributable to mazindol included <e2> decreased appetite </e2> ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; <e1> mazindol </e1> dosage was reduced in 43 % of patients .
CID	Side effects attributable to mazindol included decreased appetite ( 36 % ) , <e2> dry mouth </e2> ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; <e1> mazindol </e1> dosage was reduced in 43 % of patients .
CID	Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and <e2> gastrointestinal symptoms </e2> ( 18 % ) ; <e1> mazindol </e1> dosage was reduced in 43 % of patients .
NO_RELATION	<e1> Mazindol </e1> doses not slow the progression of <e2> weakness </e2> in Duchenne dystrophy .
NO_RELATION	<e1> Mazindol </e1> doses not slow the progression of weakness in <e2> Duchenne dystrophy </e2> .
NO_RELATION	<e1> Pentoxifylline </e1> ( Trental ) does not inhibit dipyridamole - induced coronary <e2> hyperemia </e2> : implications for dipyridamole - thallium - 201 myocardial imaging .
NO_RELATION	Pentoxifylline ( <e1> Trental </e1> ) does not inhibit dipyridamole - induced coronary <e2> hyperemia </e2> : implications for dipyridamole - thallium - 201 myocardial imaging .
CID	Pentoxifylline ( Trental ) does not inhibit <e1> dipyridamole </e1> - induced coronary <e2> hyperemia </e2> : implications for dipyridamole - thallium - 201 myocardial imaging .
CID	Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary <e2> hyperemia </e2> : implications for <e1> dipyridamole </e1> - thallium - 201 myocardial imaging .
NO_RELATION	Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary <e2> hyperemia </e2> : implications for dipyridamole - <e1> thallium </e1> - 201 myocardial imaging .
NO_RELATION	<e1> Dipyridamole </e1> - thallium - 201 imaging is often performed in patients unable to exercise because of <e2> peripheral vascular disease </e2> .
NO_RELATION	Dipyridamole - <e1> thallium </e1> - 201 imaging is often performed in patients unable to exercise because of <e2> peripheral vascular disease </e2> .
CID	Many of these patients are taking <e1> pentoxifylline </e1> ( Trental ) , a methylxanthine derivative which may improve <e2> intermittent claudication </e2> .
CID	Many of these patients are taking pentoxifylline ( <e1> Trental </e1> ) , a methylxanthine derivative which may improve <e2> intermittent claudication </e2> .
NO_RELATION	Many of these patients are taking pentoxifylline ( Trental ) , a <e1> methylxanthine </e1> derivative which may improve <e2> intermittent claudication </e2> .
NO_RELATION	Whether <e1> pentoxifylline </e1> inhibits dipyridamole - induced coronary <e2> hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
CID	Whether pentoxifylline inhibits <e1> dipyridamole </e1> - induced coronary <e2> hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
NO_RELATION	Whether pentoxifylline inhibits dipyridamole - induced coronary <e2> hyperemia </e2> like other <e1> methylxanthines </e1> such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
NO_RELATION	Whether pentoxifylline inhibits dipyridamole - induced coronary <e2> hyperemia </e2> like other methylxanthines such as <e1> theophylline </e1> and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
CID	Whether pentoxifylline inhibits dipyridamole - induced coronary <e2> hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to <e1> dipyridamole </e1> - thallium - 201 imaging is unknown .
NO_RELATION	Whether pentoxifylline inhibits dipyridamole - induced coronary <e2> hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - <e1> thallium </e1> - 201 imaging is unknown .
NO_RELATION	Neither dose of <e1> pentoxifylline </e1> significantly decreased the dipyridamole - induced <e2> hyperemia </e2> , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .
CID	Neither dose of pentoxifylline significantly decreased the <e1> dipyridamole </e1> - induced <e2> hyperemia </e2> , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .
NO_RELATION	Neither dose of pentoxifylline significantly decreased the dipyridamole - induced <e2> hyperemia </e2> , while peak coronary blood flow was significantly lower after <e1> theophylline </e1> ( p less than 0 . 01 ) .
NO_RELATION	We conclude that <e1> pentoxyifylline </e1> does not inhibit dipyridamole - induced coronary <e2> hyperemia </e2> even at high doses .
CID	We conclude that pentoxyifylline does not inhibit <e1> dipyridamole </e1> - induced coronary <e2> hyperemia </e2> even at high doses .
NO_RELATION	The low incidence of <e2> cerebral haemorrhage </e2> as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of <e2> death </e2> in patients with Parkinson ' s disease may reflect the hypotensive effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with <e2> Parkinson ' s disease </e2> may reflect the hypotensive effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
CID	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the <e2> hypotensive </e2> effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
CID	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of <e1> levodopa </e1> and a <e2> hypotensive </e2> mechanism due to reduced noradrenaline levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the <e2> parkinsonian </e2> brain .
NO_RELATION	The low incidence of <e2> cerebral haemorrhage </e2> as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of <e2> death </e2> in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with <e2> Parkinson ' s disease </e2> may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the <e2> hypotensive </e2> effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a <e2> hypotensive </e2> mechanism due to reduced <e1> noradrenaline </e1> levels in the parkinsonian brain .
NO_RELATION	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the <e2> parkinsonian </e2> brain .
NO_RELATION	Tolerance and antiviral effect of <e1> ribavirin </e1> in patients with <e2> Argentine hemorrhagic fever </e2> .
NO_RELATION	Tolerance and antiviral effect of <e1> ribavirin </e1> was studied in 6 patients with <e2> Argentine hemorrhagic fever </e2> ( AHF ) of more than 8 days of evolution .
NO_RELATION	Tolerance and antiviral effect of <e1> ribavirin </e1> was studied in 6 patients with Argentine hemorrhagic fever ( <e2> AHF </e2> ) of more than 8 days of evolution .
NO_RELATION	Administration of <e1> ribavirin </e1> resulted in a neutralization of <e2> viremia </e2> and a drop of endogenous interferon titers .
NO_RELATION	From these results , we conclude that <e1> ribavirin </e1> has an antiviral effect in advanced cases of <e2> AHF </e2> , and that anemia , the only secondary reaction observed , can be easily managed .
CID	From these results , we conclude that <e1> ribavirin </e1> has an antiviral effect in advanced cases of AHF , and that <e2> anemia </e2> , the only secondary reaction observed , can be easily managed .
NO_RELATION	The possible beneficial effect of <e1> ribavirin </e1> during the initial days of <e2> AHF </e2> is discussed .
NO_RELATION	<e1> Dipyridamole </e1> - induced <e2> myocardial ischemia </e2> .
CID	<e2> Angina </e2> and ischemic electrocardiographic changes occurred after administration of oral <e1> dipyridamole </e1> in four patients awaiting urgent myocardial revascularization procedures .
NO_RELATION	To our knowledge , this has not previously been reported as a side effect of preoperative <e1> dipyridamole </e1> therapy , although dipyridamole - induced <e2> myocardial ischemia </e2> has been demonstrated to occur in animals and humans with coronary artery disease .
NO_RELATION	To our knowledge , this has not previously been reported as a side effect of preoperative <e1> dipyridamole </e1> therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with <e2> coronary artery disease </e2> .
NO_RELATION	To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although <e1> dipyridamole </e1> - induced <e2> myocardial ischemia </e2> has been demonstrated to occur in animals and humans with coronary artery disease .
NO_RELATION	To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although <e1> dipyridamole </e1> - induced myocardial ischemia has been demonstrated to occur in animals and humans with <e2> coronary artery disease </e2> .
NO_RELATION	Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary " steal " phenomenon may be the mechanism of the <e1> dipyridamole </e1> - induced <e2> ischemia </e2> observed .
CID	<e1> Nitroprusside </e1> - induced <e2> hypotension </e2> evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .
CID	Suppression of irCRF secretion in response to <e1> nitroprusside </e1> - induced <e2> hypotension </e2> is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .
NO_RELATION	Suppression of irCRF secretion in response to nitroprusside - induced <e2> hypotension </e2> is observed and occurs at a plasma <e1> corticosterone </e1> level between 8 - 12 micrograms / dl .
CID	Noradrenergic involvement in <e2> catalepsy </e2> induced by <e1> delta 9 - tetrahydrocannabinol </e1> .
CID	These results indicate that noradrenergic neurons have an important role in the manifestation of <e2> catalepsy </e2> induced by <e1> THC </e1> , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .
CID	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by <e1> THC </e1> , whereas dopaminergic neurons are important in <e2> catalepsy </e2> induced by haloperidol .
CID	These results indicate that noradrenergic neurons have an important role in the manifestation of <e2> catalepsy </e2> induced by THC , whereas dopaminergic neurons are important in catalepsy induced by <e1> haloperidol </e1> .
CID	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in <e2> catalepsy </e2> induced by <e1> haloperidol </e1> .
CID	Intracranial pressure increases during <e1> alfentanil </e1> - induced <e2> rigidity </e2> .
CID	Intracranial pressure ( ICP ) was measured during <e1> alfentanil </e1> - induced <e2> rigidity </e2> in rats .
NO_RELATION	These variables returned to baseline when <e2> rigidity </e2> was abolished with <e1> metocurine </e1> .
CID	These observations suggest that <e2> rigidity </e2> should be prevented when <e1> alfentanil </e1> , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .
CID	It is concluded that patients on <e1> 5 - FU </e1> treatment should be under close supervision and that the treatment should be discontinued if <e2> chest pain </e2> or tachyarrhythmia is observed .
NO_RELATION	It is concluded that patients on <e1> 5 - FU </e1> treatment should be under close supervision and that the treatment should be discontinued if chest pain or <e2> tachyarrhythmia </e2> is observed .
CID	<e1> Verapamil </e1> - induced carbamazepine <e2> neurotoxicity </e2> .
CID	Verapamil - induced <e1> carbamazepine </e1> <e2> neurotoxicity </e2> .
CID	Two patients with signs of <e1> carbamazepine </e1> <e2> neurotoxicity </e2> after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .
CID	Two patients with signs of carbamazepine <e2> neurotoxicity </e2> after combined treatment with <e1> verapamil </e1> showed complete recovery after discontinuation of the calcium entry blocker .
NO_RELATION	Two patients with signs of carbamazepine <e2> neurotoxicity </e2> after combined treatment with verapamil showed complete recovery after discontinuation of the <e1> calcium </e1> entry blocker .
NO_RELATION	Serial studies of <e2> auditory neurotoxicity </e2> in patients receiving <e1> deferoxamine </e1> therapy .
NO_RELATION	<e2> Visual and auditory neurotoxicity </e2> was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving <e1> iron </e1> chelation therapy with daily subcutaneous deferoxamine .
NO_RELATION	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent <e2> anemia </e2> who were receiving <e1> iron </e1> chelation therapy with daily subcutaneous deferoxamine .
NO_RELATION	<e2> Visual and auditory neurotoxicity </e2> was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous <e1> deferoxamine </e1> .
NO_RELATION	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent <e2> anemia </e2> who were receiving iron chelation therapy with daily subcutaneous <e1> deferoxamine </e1> .
NO_RELATION	Since 18 of the 22 patients were initially receiving <e1> deferoxamine </e1> doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of <e2> auditory abnormality </e2> , and with the exception of two cases no further toxicity was demonstrated .
NO_RELATION	Since 18 of the 22 patients were initially receiving <e1> deferoxamine </e1> doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further <e2> toxicity </e2> was demonstrated .
NO_RELATION	Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving <e1> deferoxamine </e1> , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and <e2> ototoxicity </e2> .
NO_RELATION	Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between <e1> deferoxamine </e1> administration and <e2> ototoxicity </e2> .
NO_RELATION	<e1> Flurbiprofen </e1> in the treatment of <e2> juvenile rheumatoid arthritis </e2> .
NO_RELATION	Thirty - four patients with <e2> juvenile rheumatoid arthritis </e2> , who were treated with <e1> flurbiprofen </e1> at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .
NO_RELATION	Thirty - four patients with juvenile rheumatoid arthritis , who were treated with <e1> flurbiprofen </e1> at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 <e2> arthritis </e2> indices after 12 weeks of treatment .
NO_RELATION	The correlation between <e2> neurotoxic </e2> esterase inhibition and <e1> mipafox </e1> - induced neuropathic damage in rats .
NO_RELATION	The correlation between neurotoxic esterase inhibition and <e1> mipafox </e1> - induced <e2> neuropathic damage </e2> in rats .
NO_RELATION	The correlation between <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1> Mipafox </e1> ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of <e2> neurotoxic </e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1> Mipafox </e1> ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2> neuropathy </e2> target enzyme ( NTE ) was examined in rats acutely exposed to <e1> Mipafox </e1> ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to <e1> Mipafox </e1> ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a <e2> neurotoxic </e2> organophosphate .
NO_RELATION	The correlation between <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1> N , N ' - diisopropylphosphorodiamidofluoridate </e1> ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of <e2> neurotoxic </e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1> N , N ' - diisopropylphosphorodiamidofluoridate </e1> ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2> neuropathy </e2> target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1> N , N ' - diisopropylphosphorodiamidofluoridate </e1> ) , a neurotoxic organophosphate .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( <e1> N , N ' - diisopropylphosphorodiamidofluoridate </e1> ) , a <e2> neurotoxic </e2> organophosphate .
NO_RELATION	The correlation between <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1> organophosphate </e1> .
NO_RELATION	The correlation between neuropathic damage and inhibition of <e2> neurotoxic </e2> esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1> organophosphate </e1> .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or <e2> neuropathy </e2> target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic <e1> organophosphate </e1> .
NO_RELATION	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a <e2> neurotoxic </e2> <e1> organophosphate </e1> .
CID	In contrast , dosages of <e1> Mipafox </e1> ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of <e2> cord damage </e2> in only 9 % of the animals .
NO_RELATION	These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after <e1> Mipafox </e1> exposure can predict <e2> neuropathic damage </e2> in rats several weeks later .
CID	<e2> Cerebral infarction </e2> with a single oral dose of <e1> phenylpropanolamine </e1> .
CID	We report the case of a young woman who suffered a <e2> cerebral infarction </e2> after taking a single oral dose of <e1> PPA </e1> .
NO_RELATION	Treatment of <e2> psoriasis </e2> with <e1> azathioprine </e1> .
NO_RELATION	<e1> Azathioprine </e1> treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe <e2> psoriasis </e2> .
NO_RELATION	Liver biopsies should be undertaken at regular intervals if <e1> azathioprine </e1> therapy is continued so that structural <e2> liver damage </e2> may be detected at an early and reversible stage .
CID	Maternal <e1> lithium </e1> and neonatal <e2> Ebstein ' s anomaly </e2> : evaluation with cross - sectional echocardiography .
NO_RELATION	Cross - sectional echocardiographic screening of newborns exposed to <e1> lithium </e1> during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced <e2> cardiac malformations </e2> .
NO_RELATION	Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of <e1> lithium </e1> - induced <e2> cardiac malformations </e2> .
CID	The effects of exercise on the severity of <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .
NO_RELATION	Effect of <e1> polyethylene glycol 400 </e1> on adriamycin <e2> toxicity </e2> in mice .
NO_RELATION	Effect of polyethylene glycol 400 on <e1> adriamycin </e1> <e2> toxicity </e2> in mice .
CID	Light microscopic analysis showed a significant protection against <e1> ADR </e1> - induced <e2> cardiac morphological alterations </e2> .
NO_RELATION	Such treatment did not diminish the <e1> ADR </e1> antitumor activity in <e2> L1210 leukemia </e2> and in Ehrlich ascites tumor .
NO_RELATION	Such treatment did not diminish the <e1> ADR </e1> antitumor activity in L1210 leukemia and in <e2> Ehrlich ascites tumor </e2> .
NO_RELATION	Intra - arterial <e1> BCNU </e1> chemotherapy for treatment of <e2> malignant gliomas </e2> of the central nervous system .
NO_RELATION	Because of the rapid systemic clearance of <e1> BCNU </e1> ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2> malignant gliomas </e2> .
NO_RELATION	Because of the rapid systemic clearance of BCNU ( <e1> 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea </e1> ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2> malignant gliomas </e2> .
NO_RELATION	Twenty - four patients with recurrent Grade I to IV <e2> astrocytomas </e2> , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial <e1> BCNU </e1> therapy .
NO_RELATION	The frequency of <e2> visual loss </e2> decreased after the concentration of the <e1> ethanol </e1> diluent was lowered .
CID	Intrarenal infusion of <e1> noradrenaline </e1> caused <e2> hypertension </e2> at doses which did not do so when infused intravenously .
CID	These results suggest that <e2> hypertension </e2> after chronic intrarenal <e1> noradrenaline </e1> infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .
CID	These results suggest that <e2> hypertension </e2> after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating <e1> noradrenaline </e1> and by triggering of an additional intrarenal pressor mechanism .
CID	There was only one case of <e2> dementia </e2> possibly due to <e1> cimetidine </e1> ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .
NO_RELATION	There was only one case of dementia possibly due to <e1> cimetidine </e1> ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without <e2> liver or kidney disease </e2> who had cimetidine levels above 1 . 25 microgram / ml .
CID	There was only one case of <e2> dementia </e2> possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had <e1> cimetidine </e1> levels above 1 . 25 microgram / ml .
NO_RELATION	There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without <e2> liver or kidney disease </e2> who had <e1> cimetidine </e1> levels above 1 . 25 microgram / ml .
CID	Thus , high <e1> cimetidine </e1> levels alone do not always induce <e2> dementia </e2> .
CID	Development of <e2> clear cell adenocarcinoma </e2> in <e1> DES </e1> - exposed offspring under observation .
NO_RELATION	Two cases of <e2> clear cell adenocarcinoma of the vagina </e2> detected at follow - up in young women exposed in utero to <e1> diethylstilbestrol </e1> are reported .
CID	<e1> Phenobarbitone </e1> - induced <e2> enlargement of the liver </e2> in the rat : its relationship to carbon tetrachloride - induced cirrhosis .
NO_RELATION	<e1> Phenobarbitone </e1> - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced <e2> cirrhosis </e2> .
NO_RELATION	Phenobarbitone - induced <e2> enlargement of the liver </e2> in the rat : its relationship to <e1> carbon tetrachloride </e1> - induced cirrhosis .
NO_RELATION	Phenobarbitone - induced enlargement of the liver in the rat : its relationship to <e1> carbon tetrachloride </e1> - induced <e2> cirrhosis </e2> .
CID	The yield of severe <e2> cirrhosis of the liver </e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1> carbon tetrachloride </e1> given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2> ascites </e2> greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1> carbon tetrachloride </e1> given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , <e2> splenomegaly </e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1> carbon tetrachloride </e1> given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular <e2> atrophy </e2> approximately half normal weight ) after 12 doses of <e1> carbon tetrachloride </e1> given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of <e1> carbon tetrachloride </e1> given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced <e2> enlargement of the liver </e2> .
CID	The yield of severe <e2> cirrhosis of the liver </e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2> ascites </e2> greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , <e2> splenomegaly </e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular <e2> atrophy </e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
CID	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the phenobarbitone - induced <e2> enlargement of the liver </e2> .
CID	The yield of severe <e2> cirrhosis of the liver </e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1> carbon tetrachloride </e1> at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2> ascites </e2> greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1> carbon tetrachloride </e1> at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , <e2> splenomegaly </e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1> carbon tetrachloride </e1> at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular <e2> atrophy </e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1> carbon tetrachloride </e1> at the peak of the phenobarbitone - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of <e1> carbon tetrachloride </e1> at the peak of the phenobarbitone - induced <e2> enlargement of the liver </e2> .
CID	The yield of severe <e2> cirrhosis of the liver </e2> ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , <e2> ascites </e2> greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , <e2> splenomegaly </e2> 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> - induced enlargement of the liver .
NO_RELATION	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular <e2> atrophy </e2> approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> - induced enlargement of the liver .
CID	The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial " calibrating " dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> - induced <e2> enlargement of the liver </e2> .
CID	Attenuation of the <e1> lithium </e1> - induced <e2> diabetes - insipidus - like syndrome </e2> by amiloride in rats .
NO_RELATION	Attenuation of the lithium - induced <e2> diabetes - insipidus - like syndrome </e2> by <e1> amiloride </e1> in rats .
NO_RELATION	The effect of <e1> amiloride </e1> on lithium - induced <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of <e1> amiloride </e1> on lithium - induced polydipsia and <e2> polyuria </e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of amiloride on <e1> lithium </e1> - induced <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of amiloride on <e1> lithium </e1> - induced polydipsia and <e2> polyuria </e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of amiloride on lithium - induced <e2> polydipsia </e2> and polyuria and on the <e1> lithium </e1> concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of amiloride on lithium - induced polydipsia and <e2> polyuria </e2> and on the <e1> lithium </e1> concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
NO_RELATION	The effect of amiloride on lithium - induced <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with <e1> LiCl </e1> .
NO_RELATION	The effect of amiloride on lithium - induced polydipsia and <e2> polyuria </e2> and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with <e1> LiCl </e1> .
CID	In all the experiments , the attenuation of the <e1> lithium </e1> - induced <e2> diabetes - insipidus - like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
NO_RELATION	In all the experiments , the attenuation of the lithium - induced <e2> diabetes - insipidus - like syndrome </e2> by <e1> amiloride </e1> was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
CID	In all the experiments , the attenuation of the lithium - induced <e2> diabetes - insipidus - like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the <e1> lithium </e1> concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
NO_RELATION	In all the experiments , the attenuation of the lithium - induced <e2> diabetes - insipidus - like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma <e1> potassium </e1> level .
NO_RELATION	It is concluded that acute <e1> amiloride </e1> administration to lithium - treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute <e1> amiloride </e1> administration to lithium - treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to <e1> lithium </e1> - treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to <e1> lithium </e1> - treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to lithium - treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged <e1> amiloride </e1> supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged <e1> amiloride </e1> supplementation would result in elevated lithium levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to lithium - treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated <e1> lithium </e1> levels and might be hazardous .
NO_RELATION	It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated <e1> lithium </e1> levels and might be hazardous .
NO_RELATION	The efficacy of <e1> alprazolam </e1> and placebo in <e2> panic disorder </e2> with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .
NO_RELATION	The efficacy of <e1> alprazolam </e1> and placebo in panic disorder with <e2> agoraphobia </e2> , and the side - effect and adverse effect profiles of both drug groups were measured .
NO_RELATION	METHOD : In London and Toronto 154 patients who met DSM - III criteria for <e2> panic disorder </e2> with agoraphobia were randomised to <e1> alprazolam </e1> or placebo .
NO_RELATION	METHOD : In London and Toronto 154 patients who met DSM - III criteria for panic disorder with <e2> agoraphobia </e2> were randomised to <e1> alprazolam </e1> or placebo .
NO_RELATION	<e1> Dup 753 </e1> prevents the development of puromycin aminonucleoside - induced <e2> nephrosis </e2> .
NO_RELATION	Dup 753 prevents the development of <e1> puromycin aminonucleoside </e1> - induced <e2> nephrosis </e2> .
NO_RELATION	The appearance of <e2> nephrotic syndromes </e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in <e1> blood nitrogen urea </e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as <e2> proteinuria </e2> , hypoalbuminemia , hypercholesterolemia and increase in <e1> blood nitrogen urea </e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , <e2> hypoalbuminemia </e2> , hypercholesterolemia and increase in <e1> blood nitrogen urea </e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2> hypercholesterolemia </e2> and increase in <e1> blood nitrogen urea </e1> , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
CID	The appearance of <e2> nephrotic syndromes </e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1> puromycin aminonucleoside </e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
CID	The appearance of nephrotic syndromes such as <e2> proteinuria </e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1> puromycin aminonucleoside </e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
CID	The appearance of nephrotic syndromes such as proteinuria , <e2> hypoalbuminemia </e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of <e1> puromycin aminonucleoside </e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
CID	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea , induced in rats by injection of <e1> puromycin aminonucleoside </e1> was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of <e2> nephrotic syndromes </e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as <e2> proteinuria </e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , <e2> hypoalbuminemia </e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of <e2> nephrotic syndromes </e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1> losartan </e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as <e2> proteinuria </e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1> losartan </e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , <e2> hypoalbuminemia </e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1> losartan </e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( <e1> losartan </e1> ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of <e2> nephrotic syndromes </e2> such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1> angiotensin II </e1> receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as <e2> proteinuria </e2> , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1> angiotensin II </e1> receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , <e2> hypoalbuminemia </e2> , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1> angiotensin II </e1> receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel <e1> angiotensin II </e1> receptor antagonist , at a dose of 1 or 2 mg / kg per day .
NO_RELATION	The results suggest a possible involvement of the renin - <e1> angiotensin </e1> system in the development of puromycin aminonucleoside - induced <e2> nephrosis </e2> .
NO_RELATION	The results suggest a possible involvement of the renin - angiotensin system in the development of <e1> puromycin aminonucleoside </e1> - induced <e2> nephrosis </e2> .
NO_RELATION	<e1> Sodium bicarbonate </e1> alleviates <e2> penile pain </e2> induced by intracavernous injections for erectile dysfunction .
NO_RELATION	<e1> Sodium bicarbonate </e1> alleviates penile pain induced by intracavernous injections for <e2> erectile dysfunction </e2> .
NO_RELATION	In an attempt to determine whether <e2> penile pain </e2> associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of <e1> sodium bicarbonate </e1> to the intracorporeal medications .
NO_RELATION	In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of <e2> penile pain </e2> following intracorporeal injections with or without the addition of <e1> sodium bicarbonate </e1> to the intracorporeal medications .
NO_RELATION	Of the 19 patients without <e1> sodium bicarbonate </e1> added to the medication 11 ( 58 % ) complained of <e2> penile pain </e2> due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .
NO_RELATION	Of the 19 patients without <e1> sodium bicarbonate </e1> added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of <e2> penile pain </e2> .
NO_RELATION	Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of <e2> penile pain </e2> due to the medication , while only 1 of the 19 men ( 5 % ) who received <e1> sodium bicarbonate </e1> complained of penile pain .
NO_RELATION	Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received <e1> sodium bicarbonate </e1> complained of <e2> penile pain </e2> .
CID	Prospective study of the long - term effects of somatostatin analog ( <e1> octreotide </e1> ) on gallbladder function and <e2> gallstone </e2> formation in Chinese acromegalic patients .
NO_RELATION	Prospective study of the long - term effects of somatostatin analog ( <e1> octreotide </e1> ) on gallbladder function and gallstone formation in Chinese <e2> acromegalic </e2> patients .
NO_RELATION	This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active <e2> acromegaly </e2> treated with sc injection of the somatostatin analog <e1> octreotide </e1> in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .
CID	During treatment with <e1> octreotide </e1> , 17 patients developed sludge , 10 had <e2> gallstones </e2> , and 1 developed acute cholecystitis requiring surgery .
CID	During treatment with <e1> octreotide </e1> , 17 patients developed sludge , 10 had gallstones , and 1 developed <e2> acute cholecystitis </e2> requiring surgery .
CID	After withdrawal of <e1> octreotide </e1> in 10 patients without <e2> gallstones </e2> , 8 patients assessed had return of normal gallbladder contractility within 1 month .
CID	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , <e2> gallstones </e2> , and cholecystitis during <e1> octreotide </e1> therapy in Chinese acromegalic patients .
NO_RELATION	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and <e2> cholecystitis </e2> during <e1> octreotide </e1> therapy in Chinese acromegalic patients .
NO_RELATION	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during <e1> octreotide </e1> therapy in Chinese <e2> acromegalic </e2> patients .
NO_RELATION	It is therefore very important to follow the changes of gallbladder function during long - term <e1> octreotide </e1> therapy of <e2> acromegalic </e2> patients .
CID	Improvement of <e1> levodopa </e1> - induced <e2> dyskinesia </e2> by propranolol in Parkinson ' s disease .
NO_RELATION	Improvement of <e1> levodopa </e1> - induced dyskinesia by propranolol in <e2> Parkinson ' s disease </e2> .
NO_RELATION	Improvement of levodopa - induced <e2> dyskinesia </e2> by <e1> propranolol </e1> in Parkinson ' s disease .
NO_RELATION	Improvement of levodopa - induced dyskinesia by <e1> propranolol </e1> in <e2> Parkinson ' s disease </e2> .
NO_RELATION	Seven patients suffering from <e2> Parkinson ' s disease </e2> ( PD ) with severely disabling dyskinesia received low - dose <e1> propranolol </e1> as an adjunct to the currently used medical treatment .
NO_RELATION	Seven patients suffering from Parkinson ' s disease ( <e2> PD </e2> ) with severely disabling dyskinesia received low - dose <e1> propranolol </e1> as an adjunct to the currently used medical treatment .
NO_RELATION	Seven patients suffering from Parkinson ' s disease ( PD ) with severely disabling <e2> dyskinesia </e2> received low - dose <e1> propranolol </e1> as an adjunct to the currently used medical treatment .
CID	This study suggests that administration of low doses of beta - blockers may improve <e1> levodopa </e1> - induced ballistic and choreic <e2> dyskinesia </e2> in PD .
NO_RELATION	This study suggests that administration of low doses of beta - blockers may improve <e1> levodopa </e1> - induced ballistic and choreic dyskinesia in <e2> PD </e2> .
CID	Morphological features of <e2> encephalopathy </e2> after chronic administration of the antiepileptic drug <e1> valproate </e1> to rats .
NO_RELATION	once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed <e2> neurological disorders </e2> indicating cerebellum damage ( " <e1> valproate </e1> encephalopathy " ) .
NO_RELATION	once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating <e2> cerebellum damage </e2> ( " <e1> valproate </e1> encephalopathy " ) .
CID	once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( " <e1> valproate </e1> <e2> encephalopathy </e2> " ) .
NO_RELATION	The possible influence of the <e2> hepatic damage </e2> , mainly hyperammonemia , upon the development of <e1> valproate </e1> encephalopathy is discussed .
NO_RELATION	The possible influence of the hepatic damage , mainly <e2> hyperammonemia </e2> , upon the development of <e1> valproate </e1> encephalopathy is discussed .
CID	The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of <e1> valproate </e1> <e2> encephalopathy </e2> is discussed .
NO_RELATION	Macula <e2> toxicity </e2> after intravitreal <e1> amikacin </e1> .
NO_RELATION	BACKGROUND : Although intravitreal <e1> aminoglycosides </e1> have substantially improved visual prognosis in <e2> endophthalmitis </e2> , macular infarction may impair full visual recovery .
NO_RELATION	BACKGROUND : Although intravitreal <e1> aminoglycosides </e1> have substantially improved visual prognosis in endophthalmitis , macular <e2> infarction </e2> may impair full visual recovery .
CID	METHODS : We present a case of presumed <e1> amikacin </e1> <e2> retinal toxicity </e2> following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .
NO_RELATION	METHODS : We present a case of presumed <e1> amikacin </e1> retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic <e2> streptococcal endophthalmitis </e2> .
CID	METHODS : We present a case of presumed amikacin <e2> retinal toxicity </e2> following treatment with <e1> amikacin </e1> and vancomycin for alpha - haemolytic streptococcal endophthalmitis .
NO_RELATION	METHODS : We present a case of presumed amikacin retinal toxicity following treatment with <e1> amikacin </e1> and vancomycin for alpha - haemolytic <e2> streptococcal endophthalmitis </e2> .
NO_RELATION	METHODS : We present a case of presumed amikacin <e2> retinal toxicity </e2> following treatment with amikacin and <e1> vancomycin </e1> for alpha - haemolytic streptococcal endophthalmitis .
NO_RELATION	METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and <e1> vancomycin </e1> for alpha - haemolytic <e2> streptococcal endophthalmitis </e2> .
NO_RELATION	Fundus <e1> fluorescein </e1> angiography confirmed macular capillary closure and <e2> telangiectasis </e2> .
CID	Iatrogenically induced intractable <e2> atrioventricular reentrant tachycardia </e2> after <e1> verapamil </e1> and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .
NO_RELATION	Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1> verapamil </e1> and catheter ablation in a patient with <e2> Wolff - Parkinson - White syndrome </e2> and idiopathic dilated cardiomyopathy .
NO_RELATION	Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1> verapamil </e1> and catheter ablation in a patient with Wolff - Parkinson - White syndrome and <e2> idiopathic dilated cardiomyopathy </e2> .
CID	QRS without preexcitation , caused by junctional escape beats after <e1> verapamil </e1> or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent <e2> AVRT </e2> attack .
NO_RELATION	Epidemic of <e2> liver disease </e2> caused by <e1> hydrochlorofluorocarbons </e1> used as ozone - sparing substitutes of chlorofluorocarbons .
NO_RELATION	Epidemic of <e2> liver disease </e2> caused by hydrochlorofluorocarbons used as <e1> ozone </e1> - sparing substitutes of chlorofluorocarbons .
NO_RELATION	Epidemic of <e2> liver disease </e2> caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of <e1> chlorofluorocarbons </e1> .
CID	We investigated an epidemic of <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of <e1> 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane </e1> ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .
CID	We investigated an epidemic of <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( <e1> HCFC 123 </e1> ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .
CID	We investigated an epidemic of <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and <e1> 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane </e1> ( HCFC 124 ) .
CID	We investigated an epidemic of <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( <e1> HCFC 124 </e1> ) .
NO_RELATION	Both compounds are metabolised in the same way as <e1> 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane </e1> ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2> hepatotoxicity </e2> of halothane .
NO_RELATION	Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( <e1> halothane </e1> ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2> hepatotoxicity </e2> of halothane .
NO_RELATION	Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive <e1> trifluoroacetyl </e1> halide intermediates , which have been implicated in the <e2> hepatotoxicity </e2> of halothane .
NO_RELATION	Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the <e2> hepatotoxicity </e2> of <e1> halothane </e1> .
NO_RELATION	We aimed to test whether <e1> HCFCs 123 and 124 </e1> can result in serious <e2> liver disease </e2> .
NO_RELATION	INTERPRETATION : Repeated exposure of human beings to <e1> HCFCs 123 and 124 </e1> can result in serious <e2> liver injury </e2> in a large proportion of the exposed population .
NO_RELATION	Although the exact mechanism of <e2> hepatotoxicity </e2> of these agents is not known , the results suggest that <e1> trifluoroacetyl </e1> - altered liver proteins are involved .
CID	Patients given <e1> prilocaine </e1> were more likely to develop <e2> hearing loss </e2> ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .
CID	Patients given prilocaine were more likely to develop <e2> hearing loss </e2> ( 10 out of 22 ) than those given <e1> bupivacaine </e1> ( 4 out of 22 ) ( P < 0 . 05 ) .
CID	The average <e2> hearing loss </e2> for speech frequencies was about 10 dB after <e1> prilocaine </e1> and 15 dB after bupivacaine .
CID	The average <e2> hearing loss </e2> for speech frequencies was about 10 dB after prilocaine and 15 dB after <e1> bupivacaine </e1> .
NO_RELATION	A transient <e2> neurological deficit </e2> following intrathecal injection of 1 % hyperbaric <e1> bupivacaine </e1> for unilateral spinal anaesthesia .
NO_RELATION	We describe a case of transient <e2> neurological deficit </e2> that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric <e1> bupivacaine </e1> slowly injected through a 25 - gauge pencil - point spinal needle .
CID	<e1> Pethidine </e1> - associated <e2> seizure </e2> in a healthy adolescent receiving pethidine for postoperative pain control .
NO_RELATION	<e1> Pethidine </e1> - associated seizure in a healthy adolescent receiving pethidine for <e2> postoperative pain </e2> control .
CID	Pethidine - associated <e2> seizure </e2> in a healthy adolescent receiving <e1> pethidine </e1> for postoperative pain control .
NO_RELATION	Pethidine - associated seizure in a healthy adolescent receiving <e1> pethidine </e1> for <e2> postoperative pain </e2> control .
NO_RELATION	A healthy 17 - year - old male received standard intermittent doses of <e1> pethidine </e1> via a patient - controlled analgesia ( PCA ) pump for management of <e2> postoperative pain </e2> control .
NO_RELATION	A previously healthy child who developed acute , severe , rapidly progressive <e2> vanishing bile duct syndrome </e2> shortly after Stevens - Johnson syndrome is described ; this was temporally associated with <e1> ibuprofen </e1> use .
CID	A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after <e2> Stevens - Johnson syndrome </e2> is described ; this was temporally associated with <e1> ibuprofen </e1> use .
NO_RELATION	Despite therapy with <e1> ursodeoxycholic acid </e1> , prednisone , and then tacrolimus , her <e2> cholestatic disease </e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
NO_RELATION	Despite therapy with <e1> ursodeoxycholic acid </e1> , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation .
NO_RELATION	Despite therapy with ursodeoxycholic acid , <e1> prednisone </e1> , and then tacrolimus , her <e2> cholestatic disease </e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
NO_RELATION	Despite therapy with ursodeoxycholic acid , <e1> prednisone </e1> , and then tacrolimus , her cholestatic disease was unrelenting , with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation .
NO_RELATION	Despite therapy with ursodeoxycholic acid , prednisone , and then <e1> tacrolimus </e1> , her <e2> cholestatic disease </e2> was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
NO_RELATION	Despite therapy with ursodeoxycholic acid , prednisone , and then <e1> tacrolimus </e1> , her cholestatic disease was unrelenting , with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation .
CID	High incidence of <e2> primary pulmonary hypertension </e2> associated with <e1> appetite suppressants </e1> in Belgium .
CID	<e2> Primary pulmonary hypertension </e2> is a rare , progressive and incurable disease , which has been associated with the intake of <e1> appetite suppressant </e1> drugs .
CID	In 8 patients the diagnosis of <e2> primary pulmonary hypertension </e2> was uncertain , 5 of them had taken <e1> appetite suppressants </e1> .
CID	A policy of unrestricted prescription of <e1> appetite suppressants </e1> may lead to a high incidence of associated <e2> primary pulmonary hypertension </e2> .
CID	<e2> Choreoathetoid movements </e2> associated with rapid adjustment to <e1> methadone </e1> .
NO_RELATION	<e2> Choreatiform hyperkinesias </e2> are known to be occasional movement abnormalities during intoxications with <e1> cocaine </e1> but not opiates .
NO_RELATION	Choreatiform hyperkinesias are known to be occasional <e2> movement abnormalities </e2> during intoxications with <e1> cocaine </e1> but not opiates .
CID	This is a case report of euphoria and <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist <e1> methadone </e1> in an inpatient previously abusing heroine and cocaine .
NO_RELATION	This is a case report of euphoria and <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing <e1> heroine </e1> and cocaine .
CID	This is a case report of euphoria and <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and <e1> cocaine </e1> .
CID	<e1> Cocaine </e1> - induced <e2> mood disorder </e2> : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .
NO_RELATION	<e1> Cocaine </e1> - induced mood disorder : prevalence rates and <e2> psychiatric </e2> symptoms in an outpatient cocaine - dependent sample .
CID	Cocaine - induced <e2> mood disorder </e2> : prevalence rates and psychiatric symptoms in an outpatient <e1> cocaine </e1> - dependent sample .
NO_RELATION	Cocaine - induced mood disorder : prevalence rates and <e2> psychiatric </e2> symptoms in an outpatient <e1> cocaine </e1> - dependent sample .
CID	243 <e1> cocaine </e1> - dependent outpatients with cocaine - induced <e2> mood disorder </e2> ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
NO_RELATION	243 <e1> cocaine </e1> - dependent outpatients with cocaine - induced mood disorder ( <e2> CIMD </e2> ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
CID	243 <e1> cocaine </e1> - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other <e2> mood disorders </e2> , or no mood disorder were compared on measures of psychiatric symptoms .
CID	243 <e1> cocaine </e1> - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no <e2> mood disorder </e2> were compared on measures of psychiatric symptoms .
NO_RELATION	243 <e1> cocaine </e1> - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of <e2> psychiatric </e2> symptoms .
CID	243 cocaine - dependent outpatients with <e1> cocaine </e1> - induced <e2> mood disorder </e2> ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
NO_RELATION	243 cocaine - dependent outpatients with <e1> cocaine </e1> - induced mood disorder ( <e2> CIMD </e2> ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
CID	243 cocaine - dependent outpatients with <e1> cocaine </e1> - induced mood disorder ( CIMD ) , other <e2> mood disorders </e2> , or no mood disorder were compared on measures of psychiatric symptoms .
CID	243 cocaine - dependent outpatients with <e1> cocaine </e1> - induced mood disorder ( CIMD ) , other mood disorders , or no <e2> mood disorder </e2> were compared on measures of psychiatric symptoms .
NO_RELATION	243 cocaine - dependent outpatients with <e1> cocaine </e1> - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of <e2> psychiatric </e2> symptoms .
CID	<e2> Hemolysis </e2> of human erythrocytes induced by <e1> tamoxifen </e1> is related to disruption of membrane structure .
NO_RELATION	<e1> Tamoxifen </e1> ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of <e2> breast cancer </e2> , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
CID	<e1> Tamoxifen </e1> ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and <e2> hemolytic anemia </e2> .
NO_RELATION	Tamoxifen ( <e1> TAM </e1> ) , the antiestrogenic drug most widely prescribed in the chemotherapy of <e2> breast cancer </e2> , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
CID	Tamoxifen ( <e1> TAM </e1> ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and <e2> hemolytic anemia </e2> .
CID	This work evaluates the effects of <e1> TAM </e1> on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced <e2> hemolytic anemia </e2> and the involvement of biomembranes in its cytostatic action mechanisms .
CID	This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on <e1> TAM </e1> - induced <e2> hemolytic anemia </e2> and the involvement of biomembranes in its cytostatic action mechanisms .
CID	<e1> TAM </e1> induces <e2> hemolysis </e2> of erythrocytes as a function of concentration .
CID	The extension of <e2> hemolysis </e2> is variable with erythrocyte samples , but 12 . 5 microM <e1> TAM </e1> induces total hemolysis of all tested suspensions .
CID	The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM <e1> TAM </e1> induces total <e2> hemolysis </e2> of all tested suspensions .
CID	The <e2> hemolytic </e2> effect of <e1> TAM </e1> is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
CID	The hemolytic effect of <e1> TAM </e1> is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of <e1> alpha - tocopherol </e1> ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
NO_RELATION	The hemolytic effect of TAM is prevented by low concentrations of <e1> alpha - tocopherol </e1> ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of alpha - tocopherol ( <e1> alpha - T </e1> ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
NO_RELATION	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( <e1> alpha - T </e1> ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and <e1> alpha - tocopherol acetate </e1> ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
NO_RELATION	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and <e1> alpha - tocopherol acetate </e1> ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( <e1> alpha - TAc </e1> ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
NO_RELATION	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( <e1> alpha - TAc </e1> ) ( inactivated functional hydroxyl ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional <e1> hydroxyl </e1> ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
NO_RELATION	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional <e1> hydroxyl </e1> ) indicating that TAM - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
CID	The <e2> hemolytic </e2> effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that <e1> TAM </e1> - induced hemolysis is not related to oxidative membrane damage .
CID	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that <e1> TAM </e1> - induced <e2> hemolysis </e2> is not related to oxidative membrane damage .
NO_RELATION	This was further evidenced by absence of <e1> oxygen </e1> consumption and hemoglobin oxidation both determined in parallel with TAM - induced <e2> hemolysis </e2> .
CID	This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with <e1> TAM </e1> - induced <e2> hemolysis </e2> .
CID	<e2> Hemolysis </e2> caused by <e1> TAM </e1> was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
CID	Hemolysis caused by <e1> TAM </e1> was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of <e2> hemolysis </e2> , according to the effects on osmotic fragility curves .
NO_RELATION	<e2> Hemolysis </e2> caused by TAM was not preceded by the leakage of <e1> K </e1> ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
NO_RELATION	Hemolysis caused by TAM was not preceded by the leakage of <e1> K </e1> ( + ) from the cells , also excluding a colloid - osmotic type mechanism of <e2> hemolysis </e2> , according to the effects on osmotic fragility curves .
NO_RELATION	These effects suggest that the protection from <e2> hemolysis </e2> by <e1> tocopherols </e1> is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
CID	These effects suggest that the protection from <e2> hemolysis </e2> by tocopherols is related to a decreased <e1> TAM </e1> incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
CID	Therefore , <e1> TAM </e1> - induced <e2> hemolysis </e2> results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .
CID	These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by <e1> TAM </e1> , resulting in <e2> hemolytic anemia </e2> .
NO_RELATION	Changes of <e1> sodium </e1> and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient <e2> hypertension </e2> .
NO_RELATION	Changes of sodium and <e1> ATP </e1> affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient <e2> hypertension </e2> .
NO_RELATION	Changes of sodium and ATP affinities of the cardiac ( <e1> Na </e1> , K ) - ATPase during and after nitric oxide deficient <e2> hypertension </e2> .
NO_RELATION	Changes of sodium and ATP affinities of the cardiac ( Na , <e1> K </e1> ) - ATPase during and after nitric oxide deficient <e2> hypertension </e2> .
CID	Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after <e1> nitric oxide </e1> deficient <e2> hypertension </e2> .
CID	Inhibition of <e1> NO </e1> synthesis induces sustained <e2> hypertension </e2> .
NO_RELATION	In several models of <e2> hypertension </e2> , elevation of intracellular <e1> sodium </e1> level was documented in cardiac tissue .
NO_RELATION	To assess the molecular basis of disturbances in transmembraneous transport of <e1> Na </e1> + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
NO_RELATION	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( <e1> Na </e1> , K ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
NO_RELATION	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , <e1> K </e1> ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
CID	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to <e1> NO </e1> - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
CID	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by <e1> NO </e1> - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
NO_RELATION	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day <e1> N ( G ) - nitro - L - arginine methyl ester </e1> ( L - NAME ) for 4 four weeks .
NO_RELATION	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient <e2> hypertension </e2> induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( <e1> L - NAME </e1> ) for 4 four weeks .
NO_RELATION	After recovery from <e2> hypertension </e2> , the activity of ( <e1> Na </e1> , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .
NO_RELATION	After recovery from <e2> hypertension </e2> , the activity of ( Na , <e1> K </e1> ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .
NO_RELATION	After recovery from <e2> hypertension </e2> , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the <e1> ATP </e1> - binding site , as revealed from the lowered Km value for ATP .
NO_RELATION	After recovery from <e2> hypertension </e2> , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for <e1> ATP </e1> .
CID	Inhibition of <e1> NO </e1> - synthase induced a reversible <e2> hypertension </e2> accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of <e1> NO </e1> - synthase induced a reversible hypertension accompanied by <e2> depressed </e2> Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible <e2> hypertension </e2> accompanied by depressed <e1> Na </e1> + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible hypertension accompanied by <e2> depressed </e2> <e1> Na </e1> + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible <e2> hypertension </e2> accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated <e1> Na </e1> + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible hypertension accompanied by <e2> depressed </e2> Na + - extrusion from cardiac cells as a consequence of deteriorated <e1> Na </e1> + - binding properties of the ( Na , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible <e2> hypertension </e2> accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( <e1> Na </e1> , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible hypertension accompanied by <e2> depressed </e2> Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( <e1> Na </e1> , K ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible <e2> hypertension </e2> accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , <e1> K </e1> ) - ATPase .
NO_RELATION	Inhibition of NO - synthase induced a reversible hypertension accompanied by <e2> depressed </e2> Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , <e1> K </e1> ) - ATPase .
NO_RELATION	Effects of long - term pretreatment with <e1> isoproterenol </e1> on bromocriptine - induced <e2> tachycardia </e2> in conscious rats .
CID	Effects of long - term pretreatment with isoproterenol on <e1> bromocriptine </e1> - induced <e2> tachycardia </e2> in conscious rats .
CID	It has been shown that <e1> bromocriptine </e1> - induced <e2> tachycardia </e2> , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
NO_RELATION	It has been shown that bromocriptine - induced <e2> tachycardia </e2> , which persisted after adrenalectomy , is ( i ) mediated by central <e1> dopamine </e1> D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
NO_RELATION	It has been shown that bromocriptine - induced <e2> tachycardia </e2> , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day <e1> isoproterenol </e1> pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
NO_RELATION	This study was conducted to examine whether prolonged pretreatment with <e1> isoproterenol </e1> could abolish bromocriptine - induced <e2> tachycardia </e2> in conscious rats .
CID	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish <e1> bromocriptine </e1> - induced <e2> tachycardia </e2> in conscious rats .
CID	<e1> Isoproterenol </e1> pretreatment for 15 days caused <e2> cardiac hypertrophy </e2> without affecting baseline blood pressure and heart rate .
CID	In control rats , intravenous <e1> bromocriptine </e1> ( 150 microg / kg ) induced significant <e2> hypotension </e2> and tachycardia .
CID	In control rats , intravenous <e1> bromocriptine </e1> ( 150 microg / kg ) induced significant hypotension and <e2> tachycardia </e2> .
CID	<e1> Bromocriptine </e1> - induced <e2> hypotension </e2> was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .
CID	<e1> Bromocriptine </e1> - induced hypotension was unaffected by isoproterenol pretreatment , while <e2> tachycardia </e2> was reversed to significant bradycardia , an effect that was partly reduced by i . v .
NO_RELATION	<e1> Bromocriptine </e1> - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant <e2> bradycardia </e2> , an effect that was partly reduced by i . v .
NO_RELATION	Bromocriptine - induced <e2> hypotension </e2> was unaffected by <e1> isoproterenol </e1> pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .
NO_RELATION	Bromocriptine - induced hypotension was unaffected by <e1> isoproterenol </e1> pretreatment , while <e2> tachycardia </e2> was reversed to significant bradycardia , an effect that was partly reduced by i . v .
CID	Bromocriptine - induced hypotension was unaffected by <e1> isoproterenol </e1> pretreatment , while tachycardia was reversed to significant <e2> bradycardia </e2> , an effect that was partly reduced by i . v .
NO_RELATION	These results show that 15 - day <e1> isoproterenol </e1> pretreatment not only abolished but reversed bromocriptine - induced <e2> tachycardia </e2> to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
CID	These results show that 15 - day <e1> isoproterenol </e1> pretreatment not only abolished but reversed bromocriptine - induced tachycardia to <e2> bradycardia </e2> , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
CID	These results show that 15 - day isoproterenol pretreatment not only abolished but reversed <e1> bromocriptine </e1> - induced <e2> tachycardia </e2> to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
NO_RELATION	These results show that 15 - day isoproterenol pretreatment not only abolished but reversed <e1> bromocriptine </e1> - induced tachycardia to <e2> bradycardia </e2> , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
CID	They suggest that , in normal conscious rats , the central <e2> tachycardia </e2> of <e1> bromocriptine </e1> appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .
NO_RELATION	They suggest that , in normal conscious rats , the central tachycardia of <e1> bromocriptine </e1> appears to predominate and to mask the <e2> bradycardia </e2> of this agonist at peripheral dopamine D2 receptors .
NO_RELATION	They suggest that , in normal conscious rats , the central <e2> tachycardia </e2> of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral <e1> dopamine </e1> D2 receptors .
NO_RELATION	They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the <e2> bradycardia </e2> of this agonist at peripheral <e1> dopamine </e1> D2 receptors .
CID	Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that <e1> clonidine </e1> induces sympathetic withdrawal and <e2> bradycardia </e2> , we hypothesized that clonidine ' s developmental effects on cardiac rate and ultrasound production would mirror each other .
CID	Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and <e2> bradycardia </e2> , we hypothesized that <e1> clonidine </e1> ' s developmental effects on cardiac rate and ultrasound production would mirror each other .
CID	Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and <e1> clonidine </e1> - induced <e2> bradycardia </e2> .
NO_RELATION	Differential effects of systemically administered <e1> ketamine </e1> and lidocaine on dynamic and static <e2> hyperalgesia </e2> induced by intradermal capsaicin in humans .
NO_RELATION	Differential effects of systemically administered ketamine and <e1> lidocaine </e1> on dynamic and static <e2> hyperalgesia </e2> induced by intradermal capsaicin in humans .
CID	Differential effects of systemically administered ketamine and lidocaine on dynamic and static <e2> hyperalgesia </e2> induced by intradermal <e1> capsaicin </e1> in humans .
NO_RELATION	We have examined the effect of systemic administration of <e1> ketamine </e1> and lidocaine on brush - evoked ( dynamic ) <e2> pain </e2> and punctate - evoked ( static ) hyperalgesia induced by capsaicin .
NO_RELATION	We have examined the effect of systemic administration of <e1> ketamine </e1> and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) <e2> hyperalgesia </e2> induced by capsaicin .
NO_RELATION	We have examined the effect of systemic administration of ketamine and <e1> lidocaine </e1> on brush - evoked ( dynamic ) <e2> pain </e2> and punctate - evoked ( static ) hyperalgesia induced by capsaicin .
NO_RELATION	We have examined the effect of systemic administration of ketamine and <e1> lidocaine </e1> on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) <e2> hyperalgesia </e2> induced by capsaicin .
CID	We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) <e2> pain </e2> and punctate - evoked ( static ) hyperalgesia induced by <e1> capsaicin </e1> .
CID	We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) <e2> hyperalgesia </e2> induced by <e1> capsaicin </e1> .
NO_RELATION	<e1> Ketamine </e1> reduced both the area of brush - evoked and punctate - evoked <e2> hyperalgesia </e2> significantly and it tended to reduce brush - evoked pain .
NO_RELATION	<e1> Ketamine </e1> reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked <e2> pain </e2> .
NO_RELATION	<e1> Lidocaine </e1> reduced the area of punctate - evoked <e2> hyperalgesia </e2> significantly .
NO_RELATION	The differential effects of <e1> ketamine </e1> and lidocaine on static and dynamic <e2> hyperalgesia </e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
NO_RELATION	The differential effects of <e1> ketamine </e1> and lidocaine on static and dynamic hyperalgesia suggest that the two types of <e2> hyperalgesia </e2> are mediated by separate mechanisms and have a distinct pharmacology .
NO_RELATION	The differential effects of ketamine and <e1> lidocaine </e1> on static and dynamic <e2> hyperalgesia </e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
NO_RELATION	The differential effects of ketamine and <e1> lidocaine </e1> on static and dynamic hyperalgesia suggest that the two types of <e2> hyperalgesia </e2> are mediated by separate mechanisms and have a distinct pharmacology .
CID	<e1> Cyclosporine </e1> and tacrolimus - associated <e2> thrombotic microangiopathy </e2> .
CID	Cyclosporine and <e1> tacrolimus </e1> - associated <e2> thrombotic microangiopathy </e2> .
CID	The development of <e2> thrombotic microangiopathy </e2> ( TMA ) associated with the use of <e1> cyclosporine </e1> has been well documented .
CID	The development of thrombotic microangiopathy ( <e2> TMA </e2> ) associated with the use of <e1> cyclosporine </e1> has been well documented .
CID	As a result , switching to <e1> tacrolimus </e1> has been reported to be a viable therapeutic option in the setting of cyclosporine - induced <e2> TMA </e2> .
CID	As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of <e1> cyclosporine </e1> - induced <e2> TMA </e2> .
CID	With the more widespread application of <e1> tacrolimus </e1> in organ transplantation , tacrolimus - associated <e2> TMA </e2> has also been recognized .
CID	With the more widespread application of tacrolimus in organ transplantation , <e1> tacrolimus </e1> - associated <e2> TMA </e2> has also been recognized .
CID	However , literature regarding the incidence of the recurrence of <e2> TMA </e2> in patients exposed sequentially to <e1> cyclosporine </e1> and tacrolimus is limited .
CID	However , literature regarding the incidence of the recurrence of <e2> TMA </e2> in patients exposed sequentially to cyclosporine and <e1> tacrolimus </e1> is limited .
CID	We report a case of a living donor renal transplant recipient who developed <e1> cyclosporine </e1> - induced <e2> TMA </e2> that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
CID	We report a case of a living donor renal transplant recipient who developed cyclosporine - induced <e2> TMA </e2> that responded to the withdrawal of <e1> cyclosporine </e1> in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
CID	Introduction of <e1> tacrolimus </e1> as an alternative immunosuppressive agent resulted in the recurrence of <e2> TMA </e2> and the subsequent loss of the renal allograft .
CID	Patients who are switched from <e1> cyclosporine </e1> to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent <e2> TMA </e2> .
CID	Patients who are switched from cyclosporine to <e1> tacrolimus </e1> or vice versa should be closely monitored for the signs and symptoms of recurrent <e2> TMA </e2> .
CID	Repeated transient <e2> anuria </e2> following <e1> losartan </e1> administration in a patient with a solitary kidney .
NO_RELATION	We report the case of a 70 - year - old <e2> hypertensive </e2> man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after <e1> losartan </e1> administration .
NO_RELATION	We report the case of a 70 - year - old hypertensive man with a solitary kidney and <e2> chronic renal insufficiency </e2> who developed two episodes of transient anuria after <e1> losartan </e1> administration .
CID	We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient <e2> anuria </e2> after <e1> losartan </e1> administration .
NO_RELATION	Due to severe <e2> systolic dysfunction </e2> <e1> losartan </e1> was prescribed .
CID	Surprisingly , the first dose of 50 mg of <e1> losartan </e1> resulted in a sudden <e2> anuria </e2> , which lasted eight hours despite high - dose furosemide and amine infusion .
NO_RELATION	Surprisingly , the first dose of 50 mg of losartan resulted in a sudden <e2> anuria </e2> , which lasted eight hours despite high - dose <e1> furosemide </e1> and amine infusion .
NO_RELATION	Surprisingly , the first dose of 50 mg of losartan resulted in a sudden <e2> anuria </e2> , which lasted eight hours despite high - dose furosemide and <e1> amine </e1> infusion .
CID	One week later , by mistake , <e1> losartan </e1> was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient <e2> anuria </e2> lasting 10 hours .
NO_RELATION	In this patient , <e2> renal artery stenosis </e2> combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - <e1> angiotensin </e1> system ( RAS ) .
NO_RELATION	In this patient , renal artery stenosis combined with <e2> heart failure </e2> and diuretic therapy certainly resulted in a strong activation of the renin - <e1> angiotensin </e1> system ( RAS ) .
NO_RELATION	This case report highlights the fact that the <e1> angiotensin II </e1> receptor antagonist losartan can cause serious unexpected complications in patients with <e2> renovascular disease </e2> and should be used with extreme caution in this setting .
NO_RELATION	This case report highlights the fact that the angiotensin II receptor antagonist <e1> losartan </e1> can cause serious unexpected complications in patients with <e2> renovascular disease </e2> and should be used with extreme caution in this setting .
CID	In vivo protection of dna damage associated apoptotic and <e2> necrotic </e2> cell deaths during <e1> acetaminophen </e1> - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
CID	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1> - induced <e2> nephrotoxicity </e2> , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1> - induced nephrotoxicity , amiodarone - induced <e2> lung toxicity </e2> and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1> - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract .
CID	In vivo protection of dna damage associated apoptotic and <e2> necrotic </e2> cell deaths during acetaminophen - induced nephrotoxicity , <e1> amiodarone </e1> - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced <e2> nephrotoxicity </e2> , <e1> amiodarone </e1> - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
CID	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , <e1> amiodarone </e1> - induced <e2> lung toxicity </e2> and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , <e1> amiodarone </e1> - induced lung toxicity and doxorubicin - induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract .
CID	In vivo protection of dna damage associated apoptotic and <e2> necrotic </e2> cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and <e1> doxorubicin </e1> - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced <e2> nephrotoxicity </e2> , amiodarone - induced lung toxicity and <e1> doxorubicin </e1> - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced <e2> lung toxicity </e2> and <e1> doxorubicin </e1> - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
CID	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract .
NO_RELATION	In vivo protection of dna damage associated apoptotic and <e2> necrotic </e2> cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced <e2> nephrotoxicity </e2> , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced <e2> lung toxicity </e2> and doxorubicin - induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> .
NO_RELATION	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced <e2> cardiotoxicity </e2> by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> .
NO_RELATION	This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> ( GSPE ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1> GSPE </e1> ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1> GSPE </e1> ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( <e1> GSPE </e1> ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1> acetaminophen </e1> ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1> acetaminophen </e1> ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent <e1> acetaminophen </e1> ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( <e1> AAP </e1> ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( <e1> AAP </e1> ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( <e1> AAP </e1> ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , <e1> amiodarone </e1> ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , <e1> amiodarone </e1> ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , <e1> amiodarone </e1> ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( <e1> AMI </e1> ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( <e1> AMI </e1> ) - induced <e2> lung toxicity </e2> , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( <e1> AMI </e1> ) - induced lung toxicity , and doxorubicin ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and <e1> doxorubicin </e1> ( DOX ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and <e1> doxorubicin </e1> ( DOX ) - induced cardiotoxicity in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and <e1> doxorubicin </e1> ( DOX ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced <e2> nephrotoxicity </e2> , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( <e1> DOX </e1> ) - induced cardiotoxicity in mice .
NO_RELATION	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced <e2> lung toxicity </e2> , and doxorubicin ( <e1> DOX </e1> ) - induced cardiotoxicity in mice .
CID	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( <e1> DOX </e1> ) - induced <e2> cardiotoxicity </e2> in mice .
NO_RELATION	Histopathological examination of kidney , heart and lung sections revealed moderate to massive <e2> tissue damage </e2> with a variety of morphological aberrations by all the three drugs in the absence of <e1> GSPE </e1> preexposure than in its presence .
CID	Interestingly , all the drugs , such as , <e1> AAP </e1> , AMI and DOX induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE .
CID	Interestingly , all the drugs , such as , AAP , <e1> AMI </e1> and DOX induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE .
CID	Interestingly , all the drugs , such as , AAP , AMI and <e1> DOX </e1> induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE .
NO_RELATION	Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by <e1> GSPE </e1> .
CID	<e2> Palpebral twitching </e2> in a depressed adolescent on <e1> citalopram </e1> .
NO_RELATION	Palpebral twitching in a <e2> depressed </e2> adolescent on <e1> citalopram </e1> .
NO_RELATION	We report a favorable response to treatment with <e1> citalopram </e1> by a 15 - year - old boy with <e2> major depression </e2> who exhibited palpebral twitching during his first 2 weeks of treatment .
CID	We report a favorable response to treatment with <e1> citalopram </e1> by a 15 - year - old boy with major depression who exhibited <e2> palpebral twitching </e2> during his first 2 weeks of treatment .
NO_RELATION	<e1> Metamizol </e1> potentiates morphine antinociception but not <e2> constipation </e2> after chronic treatment .
CID	Metamizol potentiates <e1> morphine </e1> antinociception but not <e2> constipation </e2> after chronic treatment .
NO_RELATION	On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , <e2> pain </e2> - induced functional impairment model , and the <e1> charcoal </e1> meal test was used to evaluate the intestinal transit .
CID	In independent groups , <e1> morphine </e1> inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the <e2> constipating </e2> effects .
CID	The combination inhibited intestinal transit similar to that produced by <e1> morphine </e1> regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced <e2> constipation </e2> .
NO_RELATION	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that <e1> metamizol </e1> did not potentiate morphine - induced <e2> constipation </e2> .
CID	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate <e1> morphine </e1> - induced <e2> constipation </e2> .
NO_RELATION	These findings show a significant interaction between <e1> morphine </e1> and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of <e2> chronic pain </e2> .
NO_RELATION	These findings show a significant interaction between morphine and <e1> metamizol </e1> in chronically treated rats , suggesting that this combination could be useful for the treatment of <e2> chronic pain </e2> .
CID	<e1> Ifosfamide </e1> <e2> encephalopathy </e2> presenting with asterixis .
NO_RELATION	<e1> Ifosfamide </e1> encephalopathy presenting with <e2> asterixis </e2> .
CID	We report a case of a 51 - year - old man who developed severe , disabling negative <e2> myoclonus </e2> of the upper and lower extremities after the infusion of <e1> ifosfamide </e1> for plasmacytoma .
NO_RELATION	We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of <e1> ifosfamide </e1> for <e2> plasmacytoma </e2> .
NO_RELATION	The administration of <e1> ifosfamide </e1> was discontinued and within 12 h the <e2> asterixis </e2> resolved completely .
NO_RELATION	In the patient described , the presence of <e2> asterixis </e2> during infusion of <e1> ifosfamide </e1> , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .
CID	In the patient described , the presence of asterixis during infusion of <e1> ifosfamide </e1> , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative <e2> myoclonus </e2> is associated with the use of IFX .
NO_RELATION	In the patient described , the presence of <e2> asterixis </e2> during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of <e1> IFX </e1> .
CID	In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative <e2> myoclonus </e2> is associated with the use of <e1> IFX </e1> .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating <e2> substance abuse </e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose <e1> GVG </e1> on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
CID	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2> visual field defects </e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose <e1> GVG </e1> on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
CID	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2> VFD </e2> ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose <e1> GVG </e1> on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating <e2> substance abuse </e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on <e1> cocaine </e1> - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2> visual field defects </e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on <e1> cocaine </e1> - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2> VFD </e2> ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on <e1> cocaine </e1> - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating <e2> substance abuse </e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) <e1> dopamine </e1> ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2> visual field defects </e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) <e1> dopamine </e1> ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2> VFD </e2> ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) <e1> dopamine </e1> ( DA ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating <e2> substance abuse </e2> and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1> DA </e1> ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of <e2> visual field defects </e2> ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1> DA </e1> ) .
NO_RELATION	OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( <e2> VFD </e2> ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( <e1> DA </e1> ) .
NO_RELATION	In <e2> ICH </e2> induction using 0 . 014 - unit collagenase , <e1> heparin </e1> enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .
CID	In ICH induction using 0 . 014 - unit collagenase , <e1> heparin </e1> enhanced the <e2> hematoma </e2> volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .
NO_RELATION	In ICH induction using 0 . 014 - unit collagenase , <e1> heparin </e1> enhanced the hematoma volume 3 . 4 - fold over that seen in control <e2> ICH </e2> animals and the bleeding 7 . 6 - fold .
NO_RELATION	In ICH induction using 0 . 014 - unit collagenase , <e1> heparin </e1> enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the <e2> bleeding </e2> 7 . 6 - fold .
NO_RELATION	<e1> Estradiol </e1> reduces <e2> seizure </e2> - induced hippocampal injury in ovariectomized female but not in male rats .
NO_RELATION	<e1> Estradiol </e1> reduces seizure - induced <e2> hippocampal injury </e2> in ovariectomized female but not in male rats .
NO_RELATION	Estrogens protect ovariectomized rats from <e2> hippocampal injury </e2> induced by <e1> kainic acid </e1> - induced status epilepticus ( SE ) .
NO_RELATION	Estrogens protect ovariectomized rats from hippocampal injury induced by <e1> kainic acid </e1> - induced <e2> status epilepticus </e2> ( SE ) .
NO_RELATION	Estrogens protect ovariectomized rats from hippocampal injury induced by <e1> kainic acid </e1> - induced status epilepticus ( <e2> SE </e2> ) .
NO_RELATION	We compared the effects of <e1> 17beta - estradiol </e1> in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced <e2> SE </e2> .
CID	We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to <e1> lithium </e1> - pilocarpine - induced <e2> SE </e2> .
CID	We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - <e1> pilocarpine </e1> - induced <e2> SE </e2> .
NO_RELATION	The extent of <e1> silver </e1> - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after <e2> SE </e2> .
NO_RELATION	These findings suggest that the effects of <e1> estradiol </e1> on <e2> seizure </e2> threshold and damage may be altered by sex - related differences in the hormonal environment .
CID	<e2> Delirium </e2> during <e1> clozapine </e1> treatment : incidence and associated risk factors .
CID	BACKGROUND : Incidence and risk factors for <e2> delirium </e2> during <e1> clozapine </e1> treatment require further clarification .
NO_RELATION	METHODS : We used computerized pharmacy records to identify all adult <e2> psychiatric </e2> inpatients treated with <e1> clozapine </e1> ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .
CID	METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with <e1> clozapine </e1> ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of <e2> delirium </e2> , and tested associations with potential risk factors .
CID	CONCLUSIONS : <e2> Delirium </e2> was found in 10 % of <e1> clozapine </e1> - treated inpatients , particularly in older patients exposed to other central anticholinergics .
NO_RELATION	<e1> Ketoconazole </e1> - induced <e2> neurologic sequelae </e2> .
CID	A 77 - y - old patient developed <e2> weakness of extremities </e2> , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> for the first time in his life .
CID	A 77 - y - old patient developed weakness of extremities , <e2> legs paralysis </e2> , dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> for the first time in his life .
CID	A 77 - y - old patient developed weakness of extremities , legs paralysis , <e2> dysarthria </e2> and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> for the first time in his life .
CID	A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and <e2> tremor </e2> 1 h after ingestion of 200 mg <e1> ketoconazole </e1> for the first time in his life .
CID	<e1> Capsaicin </e1> ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced <e2> increases in dural and cortical blood flow </e2> and provoked lacrimation .
NO_RELATION	The evoked <e2> increases in dural blood flow </e2> were also abolished by topical pre - administration of <e1> atropine </e1> ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .
CID	Similar to rats , systemic <e1> pilocarpine </e1> injection causes <e2> status epilepticus </e2> ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
CID	Similar to rats , systemic <e1> pilocarpine </e1> injection causes status epilepticus ( <e2> SE </e2> ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
CID	Similar to rats , systemic <e1> pilocarpine </e1> injection causes status epilepticus ( SE ) and the eventual development of spontaneous <e2> seizures </e2> and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
NO_RELATION	In <e1> Mg </e1> ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience <e2> SE </e2> .
NO_RELATION	In Mg ( 2 + ) - free bathing medium containing <e1> bicuculline </e1> , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience <e2> SE </e2> .
CID	In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and <e1> pilocarpine </e1> - treated mice that did not experience <e2> SE </e2> .
NO_RELATION	In <e2> SE </e2> survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic <e1> glutamate </e1> receptor antagonists .
NO_RELATION	Focal <e1> glutamate </e1> photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from <e2> SE </e2> survivors but not other groups .
NO_RELATION	The alpha3 and beta4 nicotinic <e1> acetylcholine </e1> receptor subunits are necessary for nicotine - induced <e2> seizures </e2> and hypolocomotion in mice .
NO_RELATION	The alpha3 and beta4 nicotinic <e1> acetylcholine </e1> receptor subunits are necessary for nicotine - induced seizures and <e2> hypolocomotion </e2> in mice .
CID	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1> nicotine </e1> - induced <e2> seizures </e2> and hypolocomotion in mice .
NO_RELATION	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1> nicotine </e1> - induced seizures and <e2> hypolocomotion </e2> in mice .
NO_RELATION	Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and <e2> tremors </e2> , to seizures and death .
CID	Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to <e2> seizures </e2> and death .
NO_RELATION	Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and <e2> death </e2> .
NO_RELATION	Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and <e2> tremors </e2> , to seizures and death .
NO_RELATION	Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to <e2> seizures </e2> and death .
NO_RELATION	Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and <e2> death </e2> .
CID	We examined the role of the beta4 subunits in <e1> nicotine </e1> - induced <e2> seizures </e2> and hypolocomotion in beta4 homozygous null ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .
NO_RELATION	We examined the role of the beta4 subunits in <e1> nicotine </e1> - induced seizures and <e2> hypolocomotion </e2> in beta4 homozygous null ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .
CID	beta4 - / - mice were less sensitive to the effects of <e1> nicotine </e1> both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced <e2> seizures </e2> .
CID	beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to <e1> nicotine </e1> - induced <e2> seizures </e2> .
CID	alpha3 + / - mice were partially resistant to <e1> nicotine </e1> - induced <e2> seizures </e2> when compared to wild - type littermates .
CID	Together , these results suggest that the beta4 and the alpha3 subunits are mediators of <e1> nicotine </e1> - induced <e2> seizures </e2> and hypolocomotion .
NO_RELATION	Together , these results suggest that the beta4 and the alpha3 subunits are mediators of <e1> nicotine </e1> - induced seizures and <e2> hypolocomotion </e2> .
CID	Recurrent acute <e2> interstitial nephritis </e2> induced by <e1> azithromycin </e1> .
CID	A 14 - year - old girl is reported with recurrent , <e1> azithromycin </e1> - induced , acute <e2> interstitial nephritis </e2> .
CID	<e1> Valproate </e1> - induced <e2> encephalopathy </e2> .
CID	<e1> Valproate </e1> - induced <e2> encephalopathy </e2> is a rare syndrome that may manifest in otherwise normal epileptic individuals .
NO_RELATION	<e1> Valproate </e1> - induced encephalopathy is a rare syndrome that may manifest in otherwise normal <e2> epileptic </e2> individuals .
CID	A case of <e1> valproate </e1> - induced <e2> encephalopathy </e2> is presented .
NO_RELATION	<e1> Nitro - L - arginine methyl ester </e1> : a potential protector against gentamicin <e2> ototoxicity </e2> .
NO_RELATION	Nitro - L - arginine methyl ester : a potential protector against <e1> gentamicin </e1> <e2> ototoxicity </e2> .
NO_RELATION	The <e1> nitric oxide </e1> ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	The nitric oxide ( <e1> NO </e1> ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	The nitric oxide ( NO ) inhibitor <e1> nitro - L - arginine methyl ester </e1> ( L - NAME ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( <e1> L - NAME </e1> ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by <e1> gentamicin </e1> , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against <e2> high - frequency hearing loss </e2> caused by gentamicin , but further studies are needed to confirm this . <e1> Aminoglycoside </e1> antibiotics are still widely used by virtue of their efficacy and low cost .
NO_RELATION	Their <e2> ototoxicity </e2> is a serious health problem and , as their ototoxic mechanism involves the production of <e1> NO </e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their <e2> ototoxic </e2> mechanism involves the production of <e1> NO </e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of <e1> NO </e1> , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced <e2> sensorineural hearing loss </e2> .
NO_RELATION	Their <e2> ototoxicity </e2> is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of <e1> NO </e1> inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their <e2> ototoxic </e2> mechanism involves the production of NO , we need to assess the use of <e1> NO </e1> inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of <e1> NO </e1> inhibitors for the prevention of aminoglycoside - induced <e2> sensorineural hearing loss </e2> .
NO_RELATION	Their <e2> ototoxicity </e2> is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1> - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their <e2> ototoxic </e2> mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1> - induced sensorineural hearing loss .
NO_RELATION	Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1> - induced <e2> sensorineural hearing loss </e2> .
NO_RELATION	<e1> L - NAME </e1> reduced gentamicin - induced <e2> hearing loss </e2> in the high - frequency range , but gave no protection in the middle or low frequencies .
CID	L - NAME reduced <e1> gentamicin </e1> - induced <e2> hearing loss </e2> in the high - frequency range , but gave no protection in the middle or low frequencies .
CID	<e2> Cerebral vasculitis </e2> following oral <e1> methylphenidate </e1> intake in an adult : a case report .
CID	<e2> Cerebral vasculitis </e2> associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after <e1> methylphenidate </e1> intake in children .
NO_RELATION	Cerebral vasculitis associated with <e2> amphetamine abuse </e2> is well documented , and in rare cases ischaemic stroke has been reported after <e1> methylphenidate </e1> intake in children .
NO_RELATION	Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases <e2> ischaemic stroke </e2> has been reported after <e1> methylphenidate </e1> intake in children .
NO_RELATION	We report the case of a 63 - year - old female who was treated with <e1> methylphenidate </e1> due to <e2> hyperactivity </e2> and suffered from multiple ischaemic strokes .
NO_RELATION	We report the case of a 63 - year - old female who was treated with <e1> methylphenidate </e1> due to hyperactivity and suffered from multiple <e2> ischaemic strokes </e2> .
NO_RELATION	We conclude that <e1> methylphenidate </e1> mediated <e2> vasculitis </e2> should be considered in patients with neurological symptoms and a history of methylphenidate therapy .
NO_RELATION	We conclude that methylphenidate mediated <e2> vasculitis </e2> should be considered in patients with neurological symptoms and a history of <e1> methylphenidate </e1> therapy .
CID	<e2> Cerebral haemorrhage </e2> induced by <e1> warfarin </e1> - the influence of drug - drug interactions .
CID	PURPOSE : To evaluate the frequency , severity and preventability of <e1> warfarin </e1> - induced <e2> cerebral haemorrhages </e2> due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .
CID	PURPOSE : To evaluate the frequency , severity and preventability of warfarin - induced <e2> cerebral haemorrhages </e2> due to <e1> warfarin </e1> and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .
CID	PURPOSE : To evaluate the frequency , severity and preventability of warfarin - induced <e2> cerebral haemorrhages </e2> due to warfarin and <e1> warfarin </e1> - drug interactions in patients living in the county of Osterg tland , Sweden .
CID	Medical records were studied retrospectively to evaluate whether <e1> warfarin </e1> and warfarin - drug interactions could have caused the <e2> cerebral haemorrhage </e2> .
CID	Medical records were studied retrospectively to evaluate whether warfarin and <e1> warfarin </e1> - drug interactions could have caused the <e2> cerebral haemorrhage </e2> .
CID	RESULTS : Among 593 patients with <e2> cerebral haemorrhage </e2> , 59 ( 10 % ) were assessed as related to <e1> warfarin </e1> treatment .
NO_RELATION	A <e1> warfarin </e1> - drug interaction could have contributed to the <e2> haemorrhage </e2> in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
NO_RELATION	A <e1> warfarin </e1> - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the <e2> bleeding </e2> complication was considered being possible to avoid .
NO_RELATION	A warfarin - drug interaction could have contributed to the <e2> haemorrhage </e2> in 24 ( 41 % ) of the <e1> warfarin </e1> patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
NO_RELATION	A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the <e1> warfarin </e1> patients and in 7 of these ( 12 % ) the <e2> bleeding </e2> complication was considered being possible to avoid .
CID	CONCLUSIONS : <e1> Warfarin </e1> - induced <e2> cerebral haemorrhages </e2> are a major clinical problem with a high fatality rate .
CID	A significant proportion of <e1> warfarin </e1> - related <e2> cerebral haemorrhages </e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .
CID	A significant proportion of warfarin - related <e2> cerebral haemorrhages </e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with <e1> warfarin </e1> .
NO_RELATION	PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of <e1> methylprednisolone </e1> and gentamicin into the posterior sub - Tenon ' s space at the end of routine <e2> cataract </e2> surgery .
NO_RELATION	PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and <e1> gentamicin </e1> into the posterior sub - Tenon ' s space at the end of routine <e2> cataract </e2> surgery .
CID	CONCLUSIONS : The administration of <e1> methylprednisolone </e1> and gentamicin in the posterior sub - Tenon ' s space was related to a high incidence of side effects including <e2> nausea , vomiting </e2> , and headache .
CID	CONCLUSIONS : The administration of <e1> methylprednisolone </e1> and gentamicin in the posterior sub - Tenon ' s space was related to a high incidence of side effects including nausea , vomiting , and <e2> headache </e2> .
CID	CONCLUSIONS : The administration of methylprednisolone and <e1> gentamicin </e1> in the posterior sub - Tenon ' s space was related to a high incidence of side effects including <e2> nausea , vomiting </e2> , and headache .
CID	CONCLUSIONS : The administration of methylprednisolone and <e1> gentamicin </e1> in the posterior sub - Tenon ' s space was related to a high incidence of side effects including nausea , vomiting , and <e2> headache </e2> .
NO_RELATION	METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of <e1> iopamidol </e1> and iodixanol in patients with <e2> chronic kidney disease </e2> ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .
NO_RELATION	METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of iopamidol and <e1> iodixanol </e1> in patients with <e2> chronic kidney disease </e2> ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .
NO_RELATION	In 414 patients , contrast volume , presence of <e2> diabetes mellitus </e2> , use of <e1> N - acetylcysteine </e1> , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .
NO_RELATION	In patients with <e2> diabetes </e2> , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with <e1> iopamidol </e1> and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .
NO_RELATION	In patients with <e2> diabetes </e2> , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with <e1> iodixanol </e1> ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .
NO_RELATION	Mean post - SCr increases were significantly less with <e1> iopamidol </e1> ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with <e2> diabetes </e2> : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .
CID	CONCLUSIONS : The rate of contrast - induced <e2> nephropathy </e2> , defined by multiple end points , is not statistically different after the intraarterial administration of <e1> iopamidol </e1> or iodixanol to high - risk patients , with or without diabetes mellitus .
NO_RELATION	CONCLUSIONS : The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of <e1> iopamidol </e1> or iodixanol to high - risk patients , with or without <e2> diabetes mellitus </e2> .
CID	CONCLUSIONS : The rate of contrast - induced <e2> nephropathy </e2> , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or <e1> iodixanol </e1> to high - risk patients , with or without diabetes mellitus .
NO_RELATION	CONCLUSIONS : The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or <e1> iodixanol </e1> to high - risk patients , with or without <e2> diabetes mellitus </e2> .
NO_RELATION	A novel compound , <e1> maltolyl p - coumarate </e1> , attenuates <e2> cognitive deficits </e2> and shows neuroprotective effects in vitro and in vivo dementia models .
NO_RELATION	A novel compound , <e1> maltolyl p - coumarate </e1> , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo <e2> dementia </e2> models .
NO_RELATION	In the present study , we investigated whether <e1> maltolyl p - coumarate </e1> could improve <e2> cognitive decline </e2> in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .
CID	In the present study , we investigated whether maltolyl p - coumarate could improve <e2> cognitive decline </e2> in <e1> scopolamine </e1> - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .
NO_RELATION	In the present study , we investigated whether maltolyl p - coumarate could improve <e2> cognitive decline </e2> in scopolamine - injected rats and in <e1> amyloid beta peptide ( 1 - 42 ) </e1> - infused rats .
NO_RELATION	<e1> Maltolyl p - coumarate </e1> was found to attenuate <e2> cognitive deficits </e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .
NO_RELATION	Maltolyl p - coumarate was found to attenuate <e2> cognitive deficits </e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <e1> amyloid beta peptide ( 1 - 42 ) </e1> - infused rats .
NO_RELATION	Taking these in vitro and in vivo results together , our study suggests that <e1> maltolyl p - coumarate </e1> is a potentially effective candidate against <e2> Alzheimer ' s disease </e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function .
NO_RELATION	Taking these in vitro and in vivo results together , our study suggests that <e1> maltolyl p - coumarate </e1> is a potentially effective candidate against Alzheimer ' s disease that is characterized by wide spread <e2> neuronal death </e2> and progressive decline of cognitive function .
NO_RELATION	Taking these in vitro and in vivo results together , our study suggests that <e1> maltolyl p - coumarate </e1> is a potentially effective candidate against Alzheimer ' s disease that is characterized by wide spread neuronal death and progressive <e2> decline of cognitive function </e2> .
CID	We report 3 cases of serious <e2> bleeding </e2> complications that appear to be the result of the interaction between <e1> warfarin </e1> and levofloxacin .
CID	We report 3 cases of serious <e2> bleeding </e2> complications that appear to be the result of the interaction between warfarin and <e1> levofloxacin </e1> .
NO_RELATION	Mutations associated with <e1> lamivudine </e1> - resistance in therapy - na ve <e2> hepatitis B virus ( HBV ) infected </e2> patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
NO_RELATION	Mutations associated with <e1> lamivudine </e1> - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without <e2> HIV co - infection </e2> : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
NO_RELATION	Mutations associated with <e1> lamivudine </e1> - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in <e2> HBV and HIV co - infected </e2> South African patients .
NO_RELATION	Mutations associated with lamivudine - resistance in therapy - <e1> na </e1> ve <e2> hepatitis B virus ( HBV ) infected </e2> patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
NO_RELATION	Mutations associated with lamivudine - resistance in therapy - <e1> na </e1> ve hepatitis B virus ( HBV ) infected patients with and without <e2> HIV co - infection </e2> : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
NO_RELATION	Mutations associated with lamivudine - resistance in therapy - <e1> na </e1> ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in <e2> HBV and HIV co - infected </e2> South African patients .
NO_RELATION	This was an exploratory study to investigate <e1> lamivudine </e1> - resistant <e2> hepatitis B </e2> virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .
NO_RELATION	This was an exploratory study to investigate <e1> lamivudine </e1> - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without <e2> human immunodeficiency virus ( HIV ) co - infection </e2> in South African patients .
NO_RELATION	This was an exploratory study to investigate lamivudine - resistant <e2> hepatitis B </e2> virus ( HBV ) strains in selected <e1> lamivudine </e1> - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .
NO_RELATION	This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected <e1> lamivudine </e1> - na ve HBV carriers with and without <e2> human immunodeficiency virus ( HIV ) co - infection </e2> in South African patients .
NO_RELATION	This was an exploratory study to investigate lamivudine - resistant <e2> hepatitis B </e2> virus ( HBV ) strains in selected lamivudine - <e1> na </e1> ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .
NO_RELATION	This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - <e1> na </e1> ve HBV carriers with and without <e2> human immunodeficiency virus ( HIV ) co - infection </e2> in South African patients .
NO_RELATION	Thirty - five <e1> lamivudine </e1> - na ve <e2> HBV infected </e2> patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five <e1> lamivudine </e1> - na ve HBV infected patients with or without <e2> HIV co - infection </e2> were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five <e1> lamivudine </e1> - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic <e2> HBV mono - infected </e2> patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five <e1> lamivudine </e1> - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	Thirty - five lamivudine - <e1> na </e1> ve <e2> HBV infected </e2> patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five lamivudine - <e1> na </e1> ve HBV infected patients with or without <e2> HIV co - infection </e2> were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five lamivudine - <e1> na </e1> ve HBV infected patients with or without HIV co - infection were studied : 15 chronic <e2> HBV mono - infected </e2> patients and 20 HBV - HIV co - infected patients .
NO_RELATION	Thirty - five lamivudine - <e1> na </e1> ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	HBV <e1> lamivudine </e1> - resistant strains were detected in 3 of 15 mono - infected chronic <e2> hepatitis B </e2> patients and 10 of 20 HBV - HIV co - infected patients .
NO_RELATION	HBV <e1> lamivudine </e1> - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	To the best of our knowledge , this constitutes the first report of HBV <e1> lamivudine </e1> - resistant strains in therapy - na ve <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - <e1> na </e1> ve <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when <e1> lamivudine </e1> - containing highly active antiretroviral ( ARV ) treatment ( HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of <e2> HBV - HIV co - infected </e2> patients .
NO_RELATION	Sex differences in <e1> NMDA </e1> antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent <e2> pain </e2> : comparisons to two models of acute pain .
NO_RELATION	Sex differences in <e1> NMDA </e1> antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of <e2> acute pain </e2> .
NO_RELATION	Sex differences in NMDA antagonist enhancement of <e1> morphine </e1> antihyperalgesia in a capsaicin model of persistent <e2> pain </e2> : comparisons to two models of acute pain .
NO_RELATION	Sex differences in NMDA antagonist enhancement of <e1> morphine </e1> antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of <e2> acute pain </e2> .
NO_RELATION	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1> capsaicin </e1> model of persistent <e2> pain </e2> : comparisons to two models of acute pain .
NO_RELATION	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1> capsaicin </e1> model of persistent pain : comparisons to two models of <e2> acute pain </e2> .
NO_RELATION	In <e2> acute pain </e2> models , <e1> N - methyl - D - aspartate </e1> ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
NO_RELATION	In <e2> acute pain </e2> models , N - methyl - D - aspartate ( <e1> NMDA </e1> ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
NO_RELATION	In <e2> acute pain </e2> models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of <e1> morphine </e1> to a greater extent in males than females .
CID	To this end , persistent <e2> hyperalgesia </e2> was induced by administration of <e1> capsaicin </e1> in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .
NO_RELATION	Enhancement of <e1> morphine </e1> antinociception by dextromethorphan was seen in both males and females in the <e2> acute pain </e2> models , with the magnitude of this effect being greater in males .
NO_RELATION	Enhancement of morphine antinociception by <e1> dextromethorphan </e1> was seen in both males and females in the <e2> acute pain </e2> models , with the magnitude of this effect being greater in males .
NO_RELATION	These findings demonstrate a sexually - dimorphic interaction between <e1> NMDA </e1> antagonists and morphine in a persistent <e2> pain </e2> model that can be distinguished from those observed in acute pain models .
NO_RELATION	These findings demonstrate a sexually - dimorphic interaction between <e1> NMDA </e1> antagonists and morphine in a persistent pain model that can be distinguished from those observed in <e2> acute pain </e2> models .
NO_RELATION	These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and <e1> morphine </e1> in a persistent <e2> pain </e2> model that can be distinguished from those observed in acute pain models .
NO_RELATION	These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and <e1> morphine </e1> in a persistent pain model that can be distinguished from those observed in <e2> acute pain </e2> models .
CID	Development of <e2> proteinuria </e2> after switch to <e1> sirolimus </e1> - based immunosuppression in long - term cardiac transplant patients .
NO_RELATION	The novel immunosuppressive ( IS ) drug <e1> sirolmus </e1> ( Srl ) lacks <e2> nephrotoxic </e2> effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
CID	The novel immunosuppressive ( IS ) drug <e1> sirolmus </e1> ( Srl ) lacks nephrotoxic effects ; however , <e2> proteinuria </e2> associated with Srl has been reported following renal transplantation .
NO_RELATION	The novel immunosuppressive ( IS ) drug sirolmus ( <e1> Srl </e1> ) lacks <e2> nephrotoxic </e2> effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
CID	The novel immunosuppressive ( IS ) drug sirolmus ( <e1> Srl </e1> ) lacks nephrotoxic effects ; however , <e2> proteinuria </e2> associated with Srl has been reported following renal transplantation .
NO_RELATION	The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks <e2> nephrotoxic </e2> effects ; however , proteinuria associated with <e1> Srl </e1> has been reported following renal transplantation .
CID	The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , <e2> proteinuria </e2> associated with <e1> Srl </e1> has been reported following renal transplantation .
CID	In cardiac transplantation , the incidence of <e2> proteinuria </e2> associated with <e1> Srl </e1> is unknown .
NO_RELATION	<e1> ACE inhibitor </e1> and angiotensin - releasing blocker ( ARB ) therapy reduced <e2> proteinuria </e2> development .
NO_RELATION	ACE inhibitor and <e1> angiotensin - releasing blocker </e1> ( ARB ) therapy reduced <e2> proteinuria </e2> development .
NO_RELATION	ACE inhibitor and angiotensin - releasing blocker ( <e1> ARB </e1> ) therapy reduced <e2> proteinuria </e2> development .
CID	Thus , <e2> proteinuria </e2> may develop in cardiac transplant patients after switch to <e1> Srl </e1> , which may have an adverse effect on renal function in these patients .
CID	<e1> Srl </e1> should be used with ACEi / ARB therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction .
NO_RELATION	<e1> Srl </e1> should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2> .
NO_RELATION	Srl should be used with <e1> ACEi </e1> / ARB therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction .
NO_RELATION	Srl should be used with <e1> ACEi </e1> / ARB therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2> .
NO_RELATION	Srl should be used with ACEi / <e1> ARB </e1> therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction .
NO_RELATION	Srl should be used with ACEi / <e1> ARB </e1> therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2> .
CID	SAR studies led to compound 14 with excellent potency ( K ( i ) = 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg p . o . ) in the rat <e1> haloperidol </e1> - induced <e2> catalepsy </e2> model for Parkinson ' s disease .
NO_RELATION	SAR studies led to compound 14 with excellent potency ( K ( i ) = 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg p . o . ) in the rat <e1> haloperidol </e1> - induced catalepsy model for <e2> Parkinson ' s disease </e2> .
NO_RELATION	<e1> Methamphetamine </e1> - induced <e2> neurotoxicity </e2> and microglial activation are not mediated by fractalkine receptor signaling .
CID	9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of <e1> MPTP </e1> - induced <e2> neurodegeneration </e2> of DA neurons .
NO_RELATION	9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced <e2> neurodegeneration </e2> of <e1> DA </e1> neurons .
CID	Because the <e2> CNS damage </e2> caused by <e1> METH </e1> and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by <e1> METH </e1> and MPTP is highly selective for the DA neuronal system in mouse models of <e2> neurotoxicity </e2> , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by <e1> METH </e1> and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced <e2> neurotoxicity </e2> and microglial activation .
CID	Because the <e2> CNS damage </e2> caused by METH and <e1> MPTP </e1> is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and <e1> MPTP </e1> is highly selective for the DA neuronal system in mouse models of <e2> neurotoxicity </e2> , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and <e1> MPTP </e1> is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced <e2> neurotoxicity </e2> and microglial activation .
NO_RELATION	Because the <e2> CNS damage </e2> caused by METH and MPTP is highly selective for the <e1> DA </e1> neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and MPTP is highly selective for the <e1> DA </e1> neuronal system in mouse models of <e2> neurotoxicity </e2> , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and MPTP is highly selective for the <e1> DA </e1> neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced <e2> neurotoxicity </e2> and microglial activation .
CID	Because the <e2> CNS damage </e2> caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in <e1> METH </e1> - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of <e2> neurotoxicity </e2> , we hypothesized that the CX3CR1 plays a role in <e1> METH </e1> - induced neurotoxicity and microglial activation .
NO_RELATION	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in <e1> METH </e1> - induced <e2> neurotoxicity </e2> and microglial activation .
NO_RELATION	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with <e1> METH </e1> and examined for striatal <e2> neurotoxicity </e2> .
NO_RELATION	We conclude from these studies that CX3CR1 signaling does not modulate <e1> METH </e1> <e2> neurotoxicity </e2> or microglial activation .
CID	Recovery of <e1> tacrolimus </e1> - associated <e2> brachial neuritis </e2> after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .
NO_RELATION	Recovery of tacrolimus - associated <e2> brachial neuritis </e2> after conversion to <e1> everolimus </e1> in a pediatric renal transplant recipient - - case report and review of the literature .
NO_RELATION	<e2> Valvular heart disease </e2> in patients with Parkinson ' s disease treated with <e1> pergolide </e1> .
NO_RELATION	Valvular heart disease in patients with <e2> Parkinson ' s disease </e2> treated with <e1> pergolide </e1> .
NO_RELATION	<e2> Valvular heart abnormalities </e2> have been reported in patients with Parkinson ' s disease ( PD ) treated with <e1> pergolide </e1> .
NO_RELATION	Valvular heart abnormalities have been reported in patients with <e2> Parkinson ' s disease </e2> ( PD ) treated with <e1> pergolide </e1> .
NO_RELATION	Valvular heart abnormalities have been reported in patients with Parkinson ' s disease ( <e2> PD </e2> ) treated with <e1> pergolide </e1> .
NO_RELATION	METHODS : All <e2> PD </e2> patients in the Amiens area treated with <e1> pergolide </e1> were invited to attend a cardiologic assessment including transthoracic echocardiography .
NO_RELATION	A restrictive pattern of <e2> valvular regurgitation </e2> , suggestive of the role of <e1> pergolide </e1> , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .
NO_RELATION	A restrictive pattern of valvular regurgitation , suggestive of the role of <e1> pergolide </e1> , was observed in 12 / 30 ( 40 % ) patients including two with <e2> heart failure </e2> .
NO_RELATION	<e1> Pergolide </e1> was discontinued in 10 patients with <e2> valvular heart disease </e2> , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .
NO_RELATION	<e1> Pergolide </e1> was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with <e2> heart failure </e2> returned to nearly normal clinical examination .
NO_RELATION	This study supports the high frequency of restrictive <e2> valve regurgitation </e2> in PD patients treated with <e1> pergolide </e1> and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .
NO_RELATION	This study supports the high frequency of restrictive valve regurgitation in <e2> PD </e2> patients treated with <e1> pergolide </e1> and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .
NO_RELATION	This study supports the high frequency of restrictive <e2> valve regurgitation </e2> in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot <e1> dopamine </e1> agonists .
NO_RELATION	This study supports the high frequency of restrictive valve regurgitation in <e2> PD </e2> patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot <e1> dopamine </e1> agonists .
NO_RELATION	BACKGROUND : <e1> Papaverine hydrochloride </e1> is a direct - acting vasodilator used to manage <e2> vasospasm </e2> during various neurosurgical operations .
NO_RELATION	Transient <e2> cranial nerve dysfunction </e2> has been described in a few cases with topical <e1> papaverine </e1> .
NO_RELATION	METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical <e1> papaverine </e1> for <e2> vasospasm </e2> .
NO_RELATION	Topical <e1> papaverine </e1> was used as a direct therapeutic action to manage <e2> vasospasm </e2> in a total of 11 patients .
NO_RELATION	CONCLUSIONS : Topical <e1> papaverine </e1> for the treatment of <e2> vasospasm </e2> was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .
NO_RELATION	Recommendations to avoid potential <e2> cranial nerve deficits </e2> from <e1> papaverine </e1> are provided .
NO_RELATION	Massive <e2> proteinuria </e2> and acute renal failure after oral <e1> bisphosphonate </e1> ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
NO_RELATION	Massive proteinuria and <e2> acute renal failure </e2> after oral <e1> bisphosphonate </e1> ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
NO_RELATION	Massive proteinuria and acute renal failure after oral <e1> bisphosphonate </e1> ( alendronate ) administration in a patient with <e2> focal segmental glomerulosclerosis </e2> .
CID	Massive <e2> proteinuria </e2> and acute renal failure after oral bisphosphonate ( <e1> alendronate </e1> ) administration in a patient with focal segmental glomerulosclerosis .
CID	Massive proteinuria and <e2> acute renal failure </e2> after oral bisphosphonate ( <e1> alendronate </e1> ) administration in a patient with focal segmental glomerulosclerosis .
NO_RELATION	Massive proteinuria and acute renal failure after oral bisphosphonate ( <e1> alendronate </e1> ) administration in a patient with <e2> focal segmental glomerulosclerosis </e2> .
NO_RELATION	A 61 - year - old Japanese man with <e2> nephrotic syndrome </e2> due to focal segmental glomerulosclerosis was initially responding well to <e1> steroid </e1> therapy .
NO_RELATION	A 61 - year - old Japanese man with nephrotic syndrome due to <e2> focal segmental glomerulosclerosis </e2> was initially responding well to <e1> steroid </e1> therapy .
NO_RELATION	Within 14 days of the oral <e1> bisphosphonate </e1> ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with <e2> acute renal failure </e2> .
CID	Within 14 days of the oral bisphosphonate ( <e1> alendronate sodium </e1> ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with <e2> acute renal failure </e2> .
NO_RELATION	This report demonstrates that not only intravenous , but also oral <e1> bisphosphonates </e1> can aggravate <e2> proteinuria </e2> and acute renal failure .
NO_RELATION	This report demonstrates that not only intravenous , but also oral <e1> bisphosphonates </e1> can aggravate proteinuria and <e2> acute renal failure </e2> .
CID	Serum - and glucocorticoid - inducible kinase 1 in <e1> doxorubicin </e1> - induced <e2> nephrotic syndrome </e2> .
NO_RELATION	<e1> Doxorubicin </e1> - induced <e2> nephropathy </e2> leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .
NO_RELATION	<e1> Doxorubicin </e1> - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent <e2> volume retention </e2> and renal fibrosis .
NO_RELATION	<e1> Doxorubicin </e1> - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal <e2> fibrosis </e2> .
NO_RELATION	Doxorubicin - induced <e2> nephropathy </e2> leads to epithelial <e1> sodium </e1> channel ( ENaC ) - dependent volume retention and renal fibrosis .
NO_RELATION	Doxorubicin - induced nephropathy leads to epithelial <e1> sodium </e1> channel ( ENaC ) - dependent <e2> volume retention </e2> and renal fibrosis .
NO_RELATION	Doxorubicin - induced nephropathy leads to epithelial <e1> sodium </e1> channel ( ENaC ) - dependent volume retention and renal <e2> fibrosis </e2> .
NO_RELATION	The <e1> aldosterone </e1> - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal <e2> fibrosis </e2> following mineralocorticoid and salt excess .
CID	<e1> Doxorubicin </e1> treatment resulted in heavy <e2> proteinuria </e2> ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .
CID	<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe <e2> nephrotic syndrome </e2> with ascites , lipidemia , and hypoalbuminemia in both genotypes .
CID	<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with <e2> ascites </e2> , lipidemia , and hypoalbuminemia in both genotypes .
CID	<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , <e2> lipidemia </e2> , and hypoalbuminemia in both genotypes .
CID	<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and <e2> hypoalbuminemia </e2> in both genotypes .
NO_RELATION	Plasma <e1> aldosterone </e1> levels increased in <e2> nephrotic </e2> mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .
NO_RELATION	Urinary <e1> sodium </e1> excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body <e2> weight gain </e2> in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs .
NO_RELATION	During the course of <e2> nephrotic syndrome </e2> , serum <e1> urea </e1> concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + ) mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs .
NO_RELATION	During the course of nephrotic syndrome , serum <e1> urea </e1> concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + ) mice leading to <e2> uremia </e2> and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs .
NO_RELATION	Severe and long lasting <e2> cholestasis </e2> after high - dose <e1> co - trimoxazole </e1> treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .
NO_RELATION	Severe and long lasting cholestasis after high - dose <e1> co - trimoxazole </e1> treatment for <e2> Pneumocystis pneumonia </e2> in HIV - infected patients - - a report of two cases .
NO_RELATION	Severe and long lasting cholestasis after high - dose <e1> co - trimoxazole </e1> treatment for Pneumocystis pneumonia in <e2> HIV - infected </e2> patients - - a report of two cases .
NO_RELATION	<e2> Pneumocystis pneumonia </e2> ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of <e1> co - trimoxazole </e1> .
NO_RELATION	Pneumocystis pneumonia ( <e2> PCP </e2> ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of <e1> co - trimoxazole </e1> .
NO_RELATION	Pneumocystis pneumonia ( PCP ) , a common <e2> opportunistic infection </e2> in HIV - infected individuals , is generally treated with high doses of <e1> co - trimoxazole </e1> .
NO_RELATION	Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in <e2> HIV - infected </e2> individuals , is generally treated with high doses of <e1> co - trimoxazole </e1> .
NO_RELATION	Here , we report two cases of severely immunocompromised <e2> HIV - infected </e2> patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1> co - trimoxazole </e1> treatment for PCP .
CID	Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe <e2> intrahepatic cholestasis </e2> , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1> co - trimoxazole </e1> treatment for PCP .
NO_RELATION	Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking <e2> liver abscess </e2> formation on radiologic exams , during <e1> co - trimoxazole </e1> treatment for PCP .
NO_RELATION	Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during <e1> co - trimoxazole </e1> treatment for <e2> PCP </e2> .
CID	Clinically significant <e2> proteinuria </e2> following the administration of <e1> sirolimus </e1> to renal transplant recipients .
NO_RELATION	BACKGROUND : <e1> Sirolimus </e1> is the latest immunosuppressive agent used to prevent rejection , and may have less <e2> nephrotoxicity </e2> than calcineurin inhibitor ( CNI ) - based regimens .
CID	To date there has been little documentation of clinically significant <e2> proteinuria </e2> linked with the use of <e1> sirolimus </e1> .
CID	We have encountered several patients who developed substantial <e2> proteinuria </e2> associated with <e1> sirolimus </e1> use .
CID	In each patient , the close temporal association between the commencement of <e1> sirolimus </e1> therapy and <e2> proteinuria </e2> implicated sirolimus as the most likely etiology of the proteinuria .
CID	In each patient , the close temporal association between the commencement of <e1> sirolimus </e1> therapy and proteinuria implicated sirolimus as the most likely etiology of the <e2> proteinuria </e2> .
CID	In each patient , the close temporal association between the commencement of sirolimus therapy and <e2> proteinuria </e2> implicated <e1> sirolimus </e1> as the most likely etiology of the proteinuria .
CID	In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated <e1> sirolimus </e1> as the most likely etiology of the <e2> proteinuria </e2> .
NO_RELATION	In these patients , the magnitude of <e2> proteinuria </e2> was assessed on morning urine samples by turbidometric measurement or random urine protein : <e1> creatinine </e1> ratios , an estimate of grams of proteinuria / day .
NO_RELATION	In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : <e1> creatinine </e1> ratios , an estimate of grams of <e2> proteinuria </e2> / day .
NO_RELATION	In 7 of the 28 patients there was a striking temporal association between the initiation of <e1> sirolimus </e1> and the development of <e2> nephrotic </e2> - range proteinuria .
CID	In 7 of the 28 patients there was a striking temporal association between the initiation of <e1> sirolimus </e1> and the development of nephrotic - range <e2> proteinuria </e2> .
CID	<e2> Proteinuria </e2> correlated most strongly with <e1> sirolimus </e1> therapy when compared to other demographic and clinical variables .
CID	In most patients , discontinuation of <e1> sirolimus </e1> resulted in a decrease , but not resolution , of <e2> proteinuria </e2> .
CID	CONCLUSIONS : <e1> Sirolimus </e1> induces or aggravates pre - existing <e2> proteinuria </e2> in an unpredictable subset of renal allograft recipients .
CID	<e2> Proteinuria </e2> may improve , but does not resolve , when <e1> sirolimus </e1> is withdrawn .
NO_RELATION	This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release <e1> oxycodone </e1> in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily <e2> pain </e2> .
NO_RELATION	This study suggests that for healthy older adults who are not suffering from <e2> chronic pain </e2> , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release <e1> oxycodone </e1> are similar to those observed for middle - aged adults .
NO_RELATION	OBJECTIVE : The purpose of the present study was to determine the effect of morning - dosed <e1> modafinil </e1> on sleep and <e2> daytime sleepiness </e2> in chronic cocaine users .
CID	OBJECTIVE : The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and <e2> daytime sleepiness </e2> in chronic <e1> cocaine </e1> users .
NO_RELATION	<e1> Modafinil </e1> was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective <e2> daytime sleepiness </e2> .
NO_RELATION	CONCLUSIONS : Morning - dosed <e1> modafinil </e1> promotes nocturnal sleep , normalizes sleep architecture , and decreases <e2> daytime sleepiness </e2> in abstinent cocaine users .
CID	CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases <e2> daytime sleepiness </e2> in abstinent <e1> cocaine </e1> users .
NO_RELATION	Efficacy and safety of <e1> asenapine </e1> in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of <e2> schizophrenia </e2> .
NO_RELATION	Efficacy and safety of asenapine in a placebo - and <e1> haloperidol </e1> - controlled trial in patients with acute exacerbation of <e2> schizophrenia </e2> .
NO_RELATION	<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of <e2> schizophrenia </e2> or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .
NO_RELATION	<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of <e2> manic </e2> or mixed episodes associated with bipolar I disorder with or without psychotic features .
NO_RELATION	<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with <e2> bipolar I disorder </e2> with or without psychotic features .
NO_RELATION	<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without <e2> psychotic </e2> features .
NO_RELATION	In a double - blind 6 - week trial , 458 patients with acute <e2> schizophrenia </e2> were randomly assigned to fixed - dose treatment with <e1> asenapine </e1> at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
NO_RELATION	In a double - blind 6 - week trial , 458 patients with acute <e2> schizophrenia </e2> were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , <e1> asenapine </e1> at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
NO_RELATION	In a double - blind 6 - week trial , 458 patients with acute <e2> schizophrenia </e2> were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or <e1> haloperidol </e1> at 4 mg BID ( to verify assay sensitivity ) .
CID	<e2> Extrapyramidal symptoms </e2> reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the <e1> asenapine </e1> at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
CID	<e2> Extrapyramidal symptoms </e2> reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , <e1> haloperidol </e1> , and placebo groups , respectively .
CID	Post hoc analyses indicated that efficacy was similar with <e1> asenapine </e1> and haloperidol ; greater contrasts were seen in AEs , especially <e2> extrapyramidal symptoms </e2> .
CID	Post hoc analyses indicated that efficacy was similar with asenapine and <e1> haloperidol </e1> ; greater contrasts were seen in AEs , especially <e2> extrapyramidal symptoms </e2> .
CID	Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> .
CID	Using <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .
NO_RELATION	Twin preterm neonates with <e2> cardiac toxicity </e2> related to <e1> lopinavir / ritonavir </e1> therapy .
CID	One of the twins developed complete <e2> heart block </e2> and dilated cardiomyopathy related to <e1> lopinavir / ritonavir </e1> therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .
CID	One of the twins developed complete heart block and <e2> dilated cardiomyopathy </e2> related to <e1> lopinavir / ritonavir </e1> therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .
CID	One of the twins developed complete heart block and dilated cardiomyopathy related to <e1> lopinavir / ritonavir </e1> therapy , a boosted protease - inhibitor agent , while the other twin developed mild <e2> bradycardia </e2> .
CID	Learning of rats under <e2> amnesia </e2> caused by <e1> pentobarbital </e1> .
CID	Dissociated learning of rats in the normal state and the state of <e2> amnesia </e2> produced by <e1> pentobarbital </e1> ( 15 mg / kg , ip ) was carried out .
NO_RELATION	<e2> Angiosarcoma of the liver </e2> associated with <e1> diethylstilbestrol </e1> .
NO_RELATION	<e2> Angiosarcoma of the liver </e2> occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with <e1> diethylstilbestrol </e1> for 13 years .
NO_RELATION	Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated <e2> adenocarcinoma of the liver </e2> with <e1> diethylstilbestrol </e1> for 13 years .
NO_RELATION	Role of <e1> xanthine </e1> oxidase in dexamethasone - induced <e2> hypertension </e2> in rats .
CID	Role of xanthine oxidase in <e1> dexamethasone </e1> - induced <e2> hypertension </e2> in rats .
NO_RELATION	Glucocorticoid - induced <e2> hypertension </e2> ( GC - HT ) in the rat is associated with <e1> nitric oxide </e1> - redox imbalance .
NO_RELATION	Glucocorticoid - induced hypertension ( GC - <e2> HT </e2> ) in the rat is associated with <e1> nitric oxide </e1> - redox imbalance .
NO_RELATION	We studied the role of <e1> xanthine </e1> oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced <e2> hypertension </e2> ( dex - HT ) .
NO_RELATION	We studied the role of <e1> xanthine </e1> oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - <e2> HT </e2> ) .
CID	We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in <e1> dexamethasone </e1> - induced <e2> hypertension </e2> ( dex - HT ) .
CID	We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in <e1> dexamethasone </e1> - induced hypertension ( dex - <e2> HT </e2> ) .
CID	We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced <e2> hypertension </e2> ( <e1> dex </e1> - HT ) .
CID	We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( <e1> dex </e1> - <e2> HT </e2> ) .
CID	<e1> Dex </e1> <e2> increased SBP </e2> ( 110 + / - 2 - 126 + / - 3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P " < 0 . 01 ) .
CID	<e1> Dex </e1> increased SBP ( 110 + / - 2 - 126 + / - 3 mmHg ; P < 0 . 001 ) and <e2> decreased thymus ( P < 0 . 001 ) and bodyweights </e2> ( P " < 0 . 01 ) .
NO_RELATION	<e1> Allopurinol </e1> did not prevent dex - <e2> HT </e2> .
CID	Allopurinol did not prevent <e1> dex </e1> - <e2> HT </e2> .
NO_RELATION	This , together with our previous findings that <e1> allopurinol </e1> failed to prevent adrenocorticotrophic hormone induced <e2> hypertension </e2> , suggests that XO activity is not a major determinant of GC - HT in the rat .
NO_RELATION	This , together with our previous findings that <e1> allopurinol </e1> failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - <e2> HT </e2> in the rat .
NO_RELATION	Previous clinical studies have proposed that <e1> risperidone </e1> ' s pharmacologic profile may produce improved efficacy for negative <e2> psychotic symptoms </e2> and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .
CID	<e2> Drug - induced parkinsonism </e2> was observed in subjects treated with <e1> risperidone </e1> ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .
CID	<e2> Drug - induced parkinsonism </e2> was observed in subjects treated with risperidone ( 42 % ) and <e1> haloperidol </e1> ( 29 % ) and was observed at occupancy levels above 60 % .
NO_RELATION	<e1> Simvastatin - ezetimibe </e1> - induced <e2> hepatic failure </e2> necessitating liver transplantation .
NO_RELATION	However , <e2> hepatotoxic </e2> events have not been widely published with <e1> ezetimibe </e1> or the combination agent simvastatin - ezetimibe .
CID	However , <e2> hepatotoxic </e2> events have not been widely published with ezetimibe or the combination agent <e1> simvastatin - ezetimibe </e1> .
NO_RELATION	We describe a 70 - year - old Hispanic woman who developed <e2> fulminant hepatic failure </e2> necessitating liver transplantation 10 weeks after conversion from <e1> simvastatin </e1> 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .
CID	We describe a 70 - year - old Hispanic woman who developed <e2> fulminant hepatic failure </e2> necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to <e1> simvastatin 10 mg - ezetimibe 40 mg </e1> / day .
NO_RELATION	The patient ' s lipid panel had been maintained with <e1> simvastatin </e1> for 18 months before the conversion without evidence of <e2> hepatotoxicity </e2> .
NO_RELATION	<e1> Simvastatinezetimibe </e1> and escitalopram ( which she was taking for <e2> depression </e2> ) were discontinued , and other potential causes of hepatotoxicity were excluded .
CID	<e1> Simvastatinezetimibe </e1> and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of <e2> hepatotoxicity </e2> were excluded .
NO_RELATION	Simvastatinezetimibe and <e1> escitalopram </e1> ( which she was taking for <e2> depression </e2> ) were discontinued , and other potential causes of hepatotoxicity were excluded .
NO_RELATION	Simvastatinezetimibe and <e1> escitalopram </e1> ( which she was taking for depression ) were discontinued , and other potential causes of <e2> hepatotoxicity </e2> were excluded .
NO_RELATION	<e1> Ezetimibe </e1> undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2> .
NO_RELATION	Ezetimibe undergoes extensive glucuronidation by <e1> uridine diphosphate </e1> glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2> .
NO_RELATION	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of <e1> simvastatin hydroxy acid </e1> , resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2> .
NO_RELATION	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased <e1> simvastatin </e1> exposure and subsequent <e2> hepatotoxicity </e2> .
NO_RELATION	To our knowledge , this is the first case report of <e1> simvastatin - ezetimibe </e1> - induced <e2> liver failure </e2> that resulted in liver transplantation .
CID	We postulate that the mechanism of the <e1> simvastatinezetimibe </e1> - induced <e2> hepatotoxicity </e2> is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .
NO_RELATION	We postulate that the mechanism of the simvastatinezetimibe - induced <e2> hepatotoxicity </e2> is the increased <e1> simvastatin </e1> exposure by ezetimibe inhibition of UGT enzymes .
NO_RELATION	We postulate that the mechanism of the simvastatinezetimibe - induced <e2> hepatotoxicity </e2> is the increased simvastatin exposure by <e1> ezetimibe </e1> inhibition of UGT enzymes .
CID	Clinicians should be aware of potential <e2> hepatotoxicity </e2> with <e1> simvastatin - ezetimibe </e1> especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .
NO_RELATION	BACKGROUND : <e1> Methamphetamine </e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as <e2> cardiac dysrhythmias </e2> , hypertension , hallucinations , and violent behavior .
NO_RELATION	BACKGROUND : <e1> Methamphetamine </e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , <e2> hypertension </e2> , hallucinations , and violent behavior .
NO_RELATION	BACKGROUND : <e1> Methamphetamine </e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , <e2> hallucinations </e2> , and violent behavior .
NO_RELATION	BACKGROUND : <e1> Methamphetamine </e1> is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and <e2> violent behavior </e2> .
NO_RELATION	Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene , <e2> xerostomia </e2> , rampant caries ( " meth mouth " ) , and excessive tooth wear .
CID	Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene , xerostomia , rampant <e2> caries </e2> ( " meth mouth " ) , and excessive tooth wear .
NO_RELATION	Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene , xerostomia , rampant caries ( " <e2> meth mouth </e2> " ) , and excessive tooth wear .
NO_RELATION	Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene , xerostomia , rampant caries ( " meth mouth " ) , and excessive <e2> tooth wear </e2> .
CID	She reported her use of <e1> methamphetamine </e1> for five years and had not experienced any major <e2> carious episodes </e2> before she started using the drug .
NO_RELATION	CLINICAL SIGNIFICANCE : This clinical case showing oral manifestations of <e2> meth mouth </e2> was presented to help dental practitioners recognize and manage patients who may be abusing <e1> methamphetamines </e1> .
CID	<e1> Thyroxine </e1> abuse : an unusual case of <e2> thyrotoxicosis </e2> in pregnancy .
NO_RELATION	In particular it illustrates the derangements of thyroid function seen in pregnant women with <e2> eating disorders </e2> and reminds us that when a cause for thyrotoxicosis remains obscure , <e1> thyroxine </e1> abuse should be considered and explored .
CID	In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for <e2> thyrotoxicosis </e2> remains obscure , <e1> thyroxine </e1> abuse should be considered and explored .
NO_RELATION	Attenuation of <e1> methamphetamine </e1> - induced nigrostriatal dopaminergic <e2> neurotoxicity </e2> in mice by lipopolysaccharide pretreatment .
NO_RELATION	Attenuation of methamphetamine - induced nigrostriatal dopaminergic <e2> neurotoxicity </e2> in mice by <e1> lipopolysaccharide </e1> pretreatment .
NO_RELATION	Immunological activation has been proposed to play a role in <e1> methamphetamine </e1> - induced <e2> dopaminergic terminal damage </e2> .
NO_RELATION	In this study , we examined the roles of <e1> lipopolysaccharide </e1> , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine <e2> neurotoxicity </e2> .
NO_RELATION	In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the <e1> methamphetamine </e1> - induced nigrostriatal dopamine <e2> neurotoxicity </e2> .
NO_RELATION	In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal <e1> dopamine </e1> <e2> neurotoxicity </e2> .
NO_RELATION	<e1> Lipopolysaccharide </e1> pretreatment did not affect the basal body temperature or methamphetamine - elicited <e2> hyperthermia </e2> three days later .
CID	Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1> methamphetamine </e1> - elicited <e2> hyperthermia </e2> three days later .
NO_RELATION	We concluded a critical time window for systemic <e1> lipopolysaccharide </e1> pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine <e2> neurotoxicity </e2> .
NO_RELATION	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against <e1> methamphetamine </e1> - induced nigrostriatal dopamine <e2> neurotoxicity </e2> .
NO_RELATION	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal <e1> dopamine </e1> <e2> neurotoxicity </e2> .
NO_RELATION	Effect of converting enzyme inhibition on the course of <e1> adriamycin </e1> - induced <e2> nephropathy </e2> .
NO_RELATION	The effect of the converting enzyme inhibitor ( CEI ) <e1> enalapril </e1> was assessed in Munich - Wistar rats with established adriamycin <e2> nephrosis </e2> .
CID	The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established <e1> adriamycin </e1> <e2> nephrosis </e2> .
CID	Rats were given a single dose of <e1> adriamycin </e1> and one month later divided into four groups matched for <e2> albuminuria </e2> , blood pressure , and plasma albumin concentration .
NO_RELATION	Groups 3 and 4 were studied at four and at six months to assess the effect of <e1> enalapril </e1> on progression of <e2> renal injury </e2> in adriamycin nephrosis .
NO_RELATION	Groups 3 and 4 were studied at four and at six months to assess the effect of <e1> enalapril </e1> on progression of renal injury in adriamycin <e2> nephrosis </e2> .
NO_RELATION	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of <e2> renal injury </e2> in <e1> adriamycin </e1> nephrosis .
CID	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in <e1> adriamycin </e1> <e2> nephrosis </e2> .
NO_RELATION	Chronic <e1> enalapril </e1> treatment reduced blood pressure without reducing <e2> albuminuria </e2> in group 4 .
CID	Butyrylcholinesterase gene mutations in patients with prolonged <e2> apnea </e2> after <e1> succinylcholine </e1> for electroconvulsive therapy .
CID	CONCLUSION : eleven of 13 patients with a prolonged duration of action of <e1> succinylcholine </e1> had mutations in BCHE , indicating that this is the possible reason for a prolonged period of <e2> apnea </e2> .
NO_RELATION	<e1> Ketamine </e1> sedation for the reduction of children ' s <e2> fractures </e2> in the emergency department .
NO_RELATION	The purpose of the present study was to examine the safety and efficacy of <e1> ketamine </e1> for sedation in the treatment of children ' s <e2> fractures </e2> in the emergency department .
NO_RELATION	RESULTS : The average time from intravenous administration of <e1> ketamine </e1> to manipulation of the <e2> fracture </e2> or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .
NO_RELATION	RESULTS : The average time from intravenous administration of <e1> ketamine </e1> to manipulation of the fracture or <e2> dislocation </e2> was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .
NO_RELATION	CONCLUSIONS : <e1> Ketamine </e1> reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children ' s <e2> fractures </e2> in the emergency department at our institution .
NO_RELATION	Prophylactic use of <e1> lamivudine </e1> with chronic immunosuppressive therapy for <e2> rheumatologic disorders </e2> .
NO_RELATION	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of <e1> lamivudine </e1> in hepatitis B virus surface antigen ( HBs Ag ) positive patients with <e2> rheumatologic disease </e2> .
NO_RELATION	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in <e1> hepatitis B virus surface antigen </e1> ( HBs Ag ) positive patients with <e2> rheumatologic disease </e2> .
NO_RELATION	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( <e1> HBs Ag </e1> ) positive patients with <e2> rheumatologic disease </e2> .
NO_RELATION	From June 2004 to October 2006 , 11 <e1> HBs Ag </e1> positive patients with <e2> rheumatologic diseases </e2> , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .
NO_RELATION	From June 2004 to October 2006 , 11 HBs Ag positive patients with <e2> rheumatologic diseases </e2> , who were on both immunosuppressive and prophylactic <e1> lamivudine </e1> therapies , were retrospectively assessed .
NO_RELATION	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , <e2> stroke </e2> , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the <e1> MZ </e1> dose .
NO_RELATION	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , <e2> myocardiopathy </e2> ( MP ) , duration of the test , mitral regurgitation ( MR ) and the <e1> MZ </e1> dose .
NO_RELATION	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( <e2> MP </e2> ) , duration of the test , mitral regurgitation ( MR ) and the <e1> MZ </e1> dose .
NO_RELATION	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , <e2> mitral regurgitation </e2> ( MR ) and the <e1> MZ </e1> dose .
NO_RELATION	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( <e2> MR </e2> ) and the <e1> MZ </e1> dose .
CID	Mild <e2> hypoxia </e2> ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by <e1> MZ </e1> use .
CID	Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient <e2> hypoxia </e2> due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by <e1> MZ </e1> use .
NO_RELATION	Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper <e2> airway obstruction </e2> by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by <e1> MZ </e1> use .
CID	Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to <e2> hypoxia </e2> caused by <e1> MZ </e1> use .
NO_RELATION	The multivariate analysis showed that severe <e2> MR </e2> , MP ( EF < 45 % ) and high doses of <e1> MZ </e1> ( > 5mg ) were associated with events ( p < 0 . 001 ) .
NO_RELATION	The multivariate analysis showed that severe MR , <e2> MP </e2> ( EF < 45 % ) and high doses of <e1> MZ </e1> ( > 5mg ) were associated with events ( p < 0 . 001 ) .
NO_RELATION	Effects of <e1> calcium </e1> channel blockers on bupivacaine - induced <e2> toxicity </e2> .
NO_RELATION	Effects of calcium channel blockers on <e1> bupivacaine </e1> - induced <e2> toxicity </e2> .
NO_RELATION	The purpose of this study was to investigate the influence of <e1> calcium </e1> channel blockers on bupivacaine - induced acute <e2> toxicity </e2> .
NO_RELATION	The purpose of this study was to investigate the influence of calcium channel blockers on <e1> bupivacaine </e1> - induced acute <e2> toxicity </e2> .
CID	The convulsant activity of <e1> bupivacaine </e1> was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced <e2> convulsions </e2> ; this effect was less pronounced with bepridil .
NO_RELATION	The convulsant activity of bupivacaine was not significantly modified but <e1> calcium </e1> channel blockers decreased the time of latency to obtain bupivacaine - induced <e2> convulsions </e2> ; this effect was less pronounced with bepridil .
CID	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain <e1> bupivacaine </e1> - induced <e2> convulsions </e2> ; this effect was less pronounced with bepridil .
NO_RELATION	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced <e2> convulsions </e2> ; this effect was less pronounced with <e1> bepridil </e1> .
CID	<e1> Selegiline </e1> - induced <e2> postural hypotension </e2> in Parkinson ' s disease : a longitudinal study on the effects of drug withdrawal .
NO_RELATION	<e1> Selegiline </e1> - induced postural hypotension in <e2> Parkinson ' s disease </e2> : a longitudinal study on the effects of drug withdrawal .
NO_RELATION	OBJECTIVES : The United Kingdom <e2> Parkinson ' s Disease </e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( PD ) randomized to receive 10 mg <e1> selegiline </e1> per day and L - dopa compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2> Parkinson ' s disease </e2> ( PD ) randomized to receive 10 mg <e1> selegiline </e1> per day and L - dopa compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( <e2> PD </e2> ) randomized to receive 10 mg <e1> selegiline </e1> per day and L - dopa compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom <e2> Parkinson ' s Disease </e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( PD ) randomized to receive 10 mg selegiline per day and <e1> L - dopa </e1> compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2> Parkinson ' s disease </e2> ( PD ) randomized to receive 10 mg selegiline per day and <e1> L - dopa </e1> compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( <e2> PD </e2> ) randomized to receive 10 mg selegiline per day and <e1> L - dopa </e1> compared with those taking L - dopa alone .
NO_RELATION	OBJECTIVES : The United Kingdom <e2> Parkinson ' s Disease </e2> Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking <e1> L - dopa </e1> alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with <e2> Parkinson ' s disease </e2> ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking <e1> L - dopa </e1> alone .
NO_RELATION	OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( <e2> PD </e2> ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking <e1> L - dopa </e1> alone .
CID	Recently , we found that therapy with <e1> selegiline </e1> and L - dopa was associated with selective <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of selegiline .
NO_RELATION	Recently , we found that therapy with selegiline and <e1> L - dopa </e1> was associated with selective <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of selegiline .
CID	Recently , we found that therapy with selegiline and L - dopa was associated with selective <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of <e1> selegiline </e1> .
CID	The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping <e1> selegiline </e1> in the expectation that this might shed light on the mechanisms by which the drug causes <e2> orthostatic hypotension </e2> .
NO_RELATION	METHODS : The cardiovascular responses to standing and head - up tilt were studied repeatedly in <e2> PD </e2> patients receiving <e1> selegiline </e1> and as the drug was withdrawn .
CID	RESULTS : Head - up tilt caused <e2> systolic orthostatic hypotension </e2> which was marked in six of 20 PD patients on <e1> selegiline </e1> , one of whom lost consciousness with unrecordable blood pressures .
NO_RELATION	RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 <e2> PD </e2> patients on <e1> selegiline </e1> , one of whom lost consciousness with unrecordable blood pressures .
CID	<e2> Orthostatic hypotension </e2> was ameliorated 4 days after withdrawal of <e1> selegiline </e1> and totally abolished 7 days after discontinuation of the drug .
CID	Stopping <e1> selegiline </e1> also significantly <e2> reduced the supine systolic and diastolic blood pressures </e2> consistent with a previously undescribed supine pressor action .
CID	CONCLUSION : This study confirms our previous finding that <e1> selegiline </e1> in combination with L - dopa is associated with selective <e2> orthostatic hypotension </e2> .
NO_RELATION	CONCLUSION : This study confirms our previous finding that selegiline in combination with <e1> L - dopa </e1> is associated with selective <e2> orthostatic hypotension </e2> .
CID	Explicit episodic memory for sensory - discriminative components of <e1> capsaicin </e1> - induced <e2> pain </e2> : immediate and delayed ratings .
CID	In order to address long - term <e2> pain </e2> memory , nine healthy male volunteers received intradermal injections of three doses of <e1> capsaicin </e1> ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .
CID	Subjects were able to reliably discriminate <e2> pain </e2> magnitude and duration across <e1> capsaicin </e1> doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .
NO_RELATION	Reversibility of <e1> captopril </e1> - induced <e2> renal insufficiency </e2> after prolonged use in an unusual case of renovascular hypertension .
NO_RELATION	Reversibility of <e1> captopril </e1> - induced renal insufficiency after prolonged use in an unusual case of <e2> renovascular hypertension </e2> .
NO_RELATION	We report a case of severe <e2> hypertension </e2> with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with <e1> captopril </e1> .
CID	We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed <e2> sudden deterioration of renal function </e2> following treatment with <e1> captopril </e1> .
NO_RELATION	This indicates reversibility in <e1> captopril </e1> - induced <e2> renal failure </e2> even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .
NO_RELATION	<e2> Liver disease </e2> caused by <e1> propylthiouracil </e1> .
CID	This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with <e2> chronic active ( aggressive ) hepatitis </e2> caused by the administration of <e1> propylthiouracil </e1> .
NO_RELATION	<e1> Capsaicin </e1> - induced <e2> muscle pain </e2> alters the excitability of the human jaw - stretch reflex .
CID	<e1> Capsaicin </e1> ( 10 micro g ) was injected into the masseter muscle to induce <e2> pain </e2> in 11 healthy volunteers .
CID	Repetitive transcranial magnetic stimulation for <e1> levodopa </e1> - induced <e2> dyskinesias </e2> in Parkinson ' s disease .
NO_RELATION	Repetitive transcranial magnetic stimulation for <e1> levodopa </e1> - induced dyskinesias in <e2> Parkinson ' s disease </e2> .
CID	In less than 1 hour after the ingestion of <e1> alcohol </e1> , he developed malaise with <e2> flushing of the face </e2> , tachycardia , and dyspnea .
CID	In less than 1 hour after the ingestion of <e1> alcohol </e1> , he developed malaise with flushing of the face , <e2> tachycardia </e2> , and dyspnea .
CID	In less than 1 hour after the ingestion of <e1> alcohol </e1> , he developed malaise with flushing of the face , tachycardia , and <e2> dyspnea </e2> .
NO_RELATION	Five hours after exposure , he developed <e1> disulfiram </e1> - like syndrome with <e2> flushing </e2> , tachycardia , and arterial hypotension after consuming three glasses of wine .
NO_RELATION	Five hours after exposure , he developed <e1> disulfiram </e1> - like syndrome with flushing , <e2> tachycardia </e2> , and arterial hypotension after consuming three glasses of wine .
NO_RELATION	Five hours after exposure , he developed <e1> disulfiram </e1> - like syndrome with flushing , tachycardia , and <e2> arterial hypotension </e2> after consuming three glasses of wine .
NO_RELATION	In the acute experiment <e1> TRI </e1> ( given i . p . ) does not antagonize the reserpine <e2> hypothermia </e2> in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .
CID	In the acute experiment TRI ( given i . p . ) does not antagonize the <e1> reserpine </e1> <e2> hypothermia </e2> in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .
NO_RELATION	In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine <e2> hypothermia </e2> in mice and does not potentiate the <e1> 5 - hydroxytryptophan </e1> head twitches in rats .
CID	<e1> TRI </e1> given repeatedly to rats increases the locomotor <e2> hyperactivity </e2> induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
CID	TRI given repeatedly to rats increases the locomotor <e2> hyperactivity </e2> induced by <e1> d - amphetamine </e1> , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
CID	TRI given repeatedly to rats increases the locomotor <e2> hyperactivity </e2> induced by d - amphetamine , <e1> quinpirole </e1> and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
NO_RELATION	TRI given repeatedly to rats increases the locomotor <e2> hyperactivity </e2> induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( <e1> dopamine </e1> D2 and D3 effects ) .
NO_RELATION	It increases the behaviour stimulation evoked by <e1> phenylephrine </e1> ( given intraventricularly ) in rats , evaluated in the open field test as well as the <e2> aggressiveness </e2> evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .
NO_RELATION	It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the <e2> aggressiveness </e2> evoked by <e1> clonidine </e1> in mice , both these effects being mediated by an alpha1 - adrenergic receptor .
CID	<e1> Ranitidine </e1> - induced acute <e2> interstitial nephritis </e2> in a cadaveric renal allograft .
CID	We report a case of <e1> ranitidine </e1> - induced acute <e2> interstitial nephritis </e2> in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .
NO_RELATION	Late , late <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> .
NO_RELATION	<e2> Cardiac toxicity </e2> is a major complication which limits the use of <e1> adriamycin </e1> as a chemotherapeutic agent .
NO_RELATION	<e1> Acetazolamide </e1> - induced <e2> nephrolithiasis </e2> : implications for treatment of neuromuscular disorders .
NO_RELATION	<e1> Acetazolamide </e1> - induced nephrolithiasis : implications for treatment of <e2> neuromuscular disorders </e2> .
CID	Three patients on <e1> acetazolamide </e1> ( 15 % ) developed <e2> renal calculi </e2> .
NO_RELATION	<e2> Nephrolithiasis </e2> is a complication of <e1> acetazolamide </e1> but does not preclude its use .
NO_RELATION	Treatment for <e2> scabies </e2> is usually initiated by general practitioners ; most consider <e1> lindane </e1> ( gamma benzene hexachloride ) the treatment of choice .
NO_RELATION	Treatment for <e2> scabies </e2> is usually initiated by general practitioners ; most consider lindane ( <e1> gamma benzene hexachloride </e1> ) the treatment of choice .
CID	Evidence is accumulating that <e1> lindane </e1> can be <e2> toxic to the central nervous system </e2> and may be associated with aplastic anaemia .
CID	Evidence is accumulating that <e1> lindane </e1> can be toxic to the central nervous system and may be associated with <e2> aplastic anaemia </e2> .
NO_RELATION	We report an undiagnosed case of <e2> myotonia congenita </e2> in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous <e1> suxamethonium </e1> for induction of anaesthesia .
CID	We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening <e2> masseter spasm </e2> following a standard dose of intravenous <e1> suxamethonium </e1> for induction of anaesthesia .
NO_RELATION	<e2> Toxicity </e2> in rhesus monkeys following administration of the <e1> 8 - aminoquinoline </e1> 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .
NO_RELATION	<e2> Toxicity </e2> in rhesus monkeys following administration of the 8 - aminoquinoline <e1> 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline </e1> ( WR242511 ) .
NO_RELATION	<e2> Toxicity </e2> in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( <e1> WR242511 </e1> ) .
NO_RELATION	RESULTS : The selected doses of <e1> WR242511 </e1> , which produced significant <e2> methemoglobinemia </e2> in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .
CID	Furthermore , transient <e2> hemoglobinuria </e2> was noted approximately 60 minutes postinjection of <e1> WR242511 </e1> ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .
NO_RELATION	It is concluded that <e1> WR242511 </e1> should not be pursued as a pretreatment for CN <e2> poisoning </e2> unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .
NO_RELATION	It is concluded that <e1> WR242511 </e1> should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable <e2> toxicity </e2> .
CID	<e2> Atypical sensations </e2> following the use of subcutaneous <e1> sumatriptan </e1> are common , but of uncertain origin .
CID	<e2> Tremor </e2> side effects of <e1> salbutamol </e1> , quantified by a laser pointer technique .
CID	OBJECTIVE : To study <e2> tremor </e2> side effects of <e1> salbutamol </e1> an easily applicable , quick and low - priced method is needed .
CID	To determine sensitivity we assessed <e2> tremor </e2> in 44 patients with obstructive lung disease after administration of cumulative doses of <e1> salbutamol </e1> .
NO_RELATION	To determine sensitivity we assessed tremor in 44 patients with <e2> obstructive lung disease </e2> after administration of cumulative doses of <e1> salbutamol </e1> .
CID	RESULTS : <e1> Salbutamol </e1> significantly increased <e2> tremor </e2> severity in patients in a dose - dependent way .
CID	Increased frequency of <e2> venous thromboembolism </e2> with the combination of <e1> docetaxel </e1> and thalidomide in patients with metastatic androgen - independent prostate cancer .
NO_RELATION	Increased frequency of venous thromboembolism with the combination of <e1> docetaxel </e1> and thalidomide in patients with metastatic androgen - independent <e2> prostate cancer </e2> .
CID	Increased frequency of <e2> venous thromboembolism </e2> with the combination of docetaxel and <e1> thalidomide </e1> in patients with metastatic androgen - independent prostate cancer .
NO_RELATION	Increased frequency of venous thromboembolism with the combination of docetaxel and <e1> thalidomide </e1> in patients with metastatic androgen - independent <e2> prostate cancer </e2> .
CID	STUDY OBJECTIVE : To evaluate the frequency of <e2> venous thromboembolism </e2> ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with <e1> docetaxel </e1> alone or in combination with thalidomide .
CID	STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( <e2> VTE </e2> ) in patients with advanced androgen - independent prostate cancer who were treated with <e1> docetaxel </e1> alone or in combination with thalidomide .
NO_RELATION	STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent <e2> prostate cancer </e2> who were treated with <e1> docetaxel </e1> alone or in combination with thalidomide .
CID	STUDY OBJECTIVE : To evaluate the frequency of <e2> venous thromboembolism </e2> ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> .
CID	STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( <e2> VTE </e2> ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> .
NO_RELATION	STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent <e2> prostate cancer </e2> who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received <e1> docetaxel </e1> alone developed <e2> VTE </e2> , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received <e1> docetaxel </e1> alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed <e2> VTE </e2> ( p = 0 . 025 ) .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed <e2> VTE </e2> , whereas 9 of 47 patients ( 19 % ) who received <e1> docetaxel </e1> plus thalidomide developed VTE ( p = 0 . 025 ) .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received <e1> docetaxel </e1> plus thalidomide developed <e2> VTE </e2> ( p = 0 . 025 ) .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed <e2> VTE </e2> , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus <e1> thalidomide </e1> developed VTE ( p = 0 . 025 ) .
CID	MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus <e1> thalidomide </e1> developed <e2> VTE </e2> ( p = 0 . 025 ) .
NO_RELATION	CONCLUSION : The addition of <e1> thalidomide </e1> to docetaxel in the treatment of <e2> prostate cancer </e2> significantly increases the frequency of VTE .
CID	CONCLUSION : The addition of <e1> thalidomide </e1> to docetaxel in the treatment of prostate cancer significantly increases the frequency of <e2> VTE </e2> .
NO_RELATION	CONCLUSION : The addition of thalidomide to <e1> docetaxel </e1> in the treatment of <e2> prostate cancer </e2> significantly increases the frequency of VTE .
CID	CONCLUSION : The addition of thalidomide to <e1> docetaxel </e1> in the treatment of prostate cancer significantly increases the frequency of <e2> VTE </e2> .
NO_RELATION	<e1> UM - 272 </e1> ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced <e2> ventricular tachycardias </e2> .
NO_RELATION	UM - 272 ( <e1> N , N - dimethylpropranolol </e1> ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced <e2> ventricular tachycardias </e2> .
CID	UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with <e1> ouabain </e1> - induced <e2> ventricular tachycardias </e2> .
NO_RELATION	Sublingual <e1> UM - 272 </e1> converted <e2> ventricular tachycardia </e2> to sinus rhythm in all 5 dogs .
CID	Severe <e2> thrombocytopenia </e2> and haemolytic anaemia associated with <e1> ciprofloxacin </e1> : a case report with fatal outcome .
CID	Severe thrombocytopenia and <e2> haemolytic anaemia </e2> associated with <e1> ciprofloxacin </e1> : a case report with fatal outcome .
CID	A 30 - year old Caucasian man reported with <e2> abdominal pain </e2> and jaundice after 3 - day administration of oral <e1> ciprofloxacin </e1> for a suspect of urinary tract infection .
CID	A 30 - year old Caucasian man reported with abdominal pain and <e2> jaundice </e2> after 3 - day administration of oral <e1> ciprofloxacin </e1> for a suspect of urinary tract infection .
NO_RELATION	A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral <e1> ciprofloxacin </e1> for a suspect of <e2> urinary tract infection </e2> .
CID	This case report shows that <e1> ciprofloxacin </e1> may precipitate life - threatening <e2> thrombocytopenia </e2> and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .
CID	This case report shows that <e1> ciprofloxacin </e1> may precipitate life - threatening thrombocytopenia and <e2> haemolytic anaemia </e2> , even in the early phases of treatment and without apparent previous exposures .
CID	<e1> Simvastatin </e1> - induced bilateral leg <e2> compartment syndrome </e2> and myonecrosis associated with hypothyroidism .
NO_RELATION	<e1> Simvastatin </e1> - induced bilateral leg compartment syndrome and <e2> myonecrosis </e2> associated with hypothyroidism .
NO_RELATION	<e1> Simvastatin </e1> - induced bilateral leg compartment syndrome and myonecrosis associated with <e2> hypothyroidism </e2> .
NO_RELATION	A 54 - year - old <e2> hypothyroid </e2> male taking <e1> thyroxine </e1> and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .
NO_RELATION	A 54 - year - old hypothyroid male taking <e1> thyroxine </e1> and simvastatin presented with bilateral leg <e2> compartment syndrome </e2> and myonecrosis .
NO_RELATION	A 54 - year - old hypothyroid male taking <e1> thyroxine </e1> and simvastatin presented with bilateral leg compartment syndrome and <e2> myonecrosis </e2> .
NO_RELATION	A 54 - year - old <e2> hypothyroid </e2> male taking thyroxine and <e1> simvastatin </e1> presented with bilateral leg compartment syndrome and myonecrosis .
CID	A 54 - year - old hypothyroid male taking thyroxine and <e1> simvastatin </e1> presented with bilateral leg <e2> compartment syndrome </e2> and myonecrosis .
NO_RELATION	A 54 - year - old hypothyroid male taking thyroxine and <e1> simvastatin </e1> presented with bilateral leg compartment syndrome and <e2> myonecrosis </e2> .
NO_RELATION	<e2> Bile duct hamartoma </e2> occurring in association with long - term treatment with <e1> danazol </e1> .
NO_RELATION	We report a case of <e2> bile duct hamartoma </e2> which developed in a patient who had been on long - term <e1> danazol </e1> treatment .
NO_RELATION	<e2> Granulomatous hepatitis </e2> due to <e1> combination of amoxicillin and clavulanic acid </e1> .
CID	We report the case of a patient with <e1> amoxicillin - clavulanic acid </e1> - induced <e2> hepatitis </e2> with histologic multiple granulomas .
CID	We report the case of a patient with <e1> amoxicillin - clavulanic acid </e1> - induced hepatitis with histologic multiple <e2> granulomas </e2> .
NO_RELATION	METHODS : A review of admissions during a 6 - year period revealed 14 patients with <e1> cocaine </e1> - related <e2> aneurysms </e2> .
NO_RELATION	Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with <e1> cocaine </e1> - related <e2> aneurysms </e2> .
CID	CONCLUSION : <e1> Cocaine </e1> use predisposed <e2> aneurysmal rupture </e2> at a significantly earlier age and in much smaller aneurysms .
NO_RELATION	CONCLUSION : <e1> Cocaine </e1> use predisposed aneurysmal rupture at a significantly earlier age and in much smaller <e2> aneurysms </e2> .
CID	The authors present three patients with de novo <e2> absence epilepsy </e2> after administration of <e1> carbamazepine </e1> and vigabatrin .
CID	The authors present three patients with de novo <e2> absence epilepsy </e2> after administration of carbamazepine and <e1> vigabatrin </e1> .
NO_RELATION	The <e1> gamma - aminobutyric acid </e1> - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the <e2> absence epilepsy </e2> .
CID	<e1> Procainamide </e1> - induced polymorphous <e2> ventricular tachycardia </e2> .
CID	Seven cases of <e1> procainamide </e1> - induced polymorphous <e2> ventricular tachycardia </e2> are presented .
CID	In four patients , polymorphous <e2> ventricular tachycardia </e2> appeared after intravenous administration of 200 to 400 mg of <e1> procainamide </e1> for the treatment of sustained ventricular tachycardia .
CID	In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of <e1> procainamide </e1> for the treatment of sustained <e2> ventricular tachycardia </e2> .
NO_RELATION	In the remaining three patients , <e1> procainamide </e1> was administered orally for treatment of chronic <e2> premature ventricular contractions </e2> or atrial flutter .
NO_RELATION	In the remaining three patients , <e1> procainamide </e1> was administered orally for treatment of chronic premature ventricular contractions or <e2> atrial flutter </e2> .
CID	In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of <e1> procainamide </e1> therapy , polymorphous <e2> ventricular tachycardia </e2> did not reoccur .
NO_RELATION	These seven cases demonstrate that <e1> procainamide </e1> can produce an acquired <e2> prolonged Q - T syndrome </e2> with polymorphous ventricular tachycardia .
CID	These seven cases demonstrate that <e1> procainamide </e1> can produce an acquired prolonged Q - T syndrome with polymorphous <e2> ventricular tachycardia </e2> .
NO_RELATION	Role of activation of <e1> bradykinin </e1> B2 receptors in disruption of the blood - brain barrier during acute <e2> hypertension </e2> .
NO_RELATION	The goal of this study was to determine the role of synthesis / release of <e1> bradykinin </e1> to activate B2 receptors in disruption of the blood - brain barrier during acute <e2> hypertension </e2> .
NO_RELATION	Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled <e1> dextran </e1> before and during phenylephrine - induced acute <e2> hypertension </e2> in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .
CID	Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during <e1> phenylephrine </e1> - induced acute <e2> hypertension </e2> in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .
NO_RELATION	Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute <e2> hypertension </e2> in rats treated with vehicle and <e1> Hoe - 140 </e1> ( 0 . 1 microM ) .
NO_RELATION	These findings suggest that disruption of the blood - brain barrier during acute <e2> hypertension </e2> is not related to the synthesis / release of <e1> bradykinin </e1> to activate B2 receptors .
CID	<e1> 5 - azacytidine </e1> potentiates <e2> initiation induced by carcinogens </e2> in rat liver .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , <e1> 5 - azacytidine </e1> ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , 5 - azacytidine ( <e1> 5 - AzC </e1> ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , <e1> benzo [ a ] - pyrene </e1> ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , <e1> N - methyl - N - nitrosourea </e1> ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and <e1> 1 , 2 - dimethylhydrazine </e1> ( 1 , 2 - DMH ) ( 100 mg / kg ) .
CID	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the <e2> initiation of carcinogenic process </e2> , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( <e1> 1 , 2 - DMH </e1> ) ( 100 mg / kg ) .
NO_RELATION	<e2> Withdrawal - emergent rabbit syndrome </e2> during dose reduction of <e1> risperidone </e1> .
CID	The patient developed <e2> RS </e2> during dose reduction of <e1> risperidone </e1> .
NO_RELATION	The underlying mechanism of <e2> withdrawal - emergent RS </e2> in the present case may have been related to the pharmacological profile of <e1> risperidone </e1> , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
CID	The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of <e1> risperidone </e1> , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2> .
NO_RELATION	The underlying mechanism of <e2> withdrawal - emergent RS </e2> in the present case may have been related to the pharmacological profile of risperidone , a <e1> serotonin </e1> - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
NO_RELATION	The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a <e1> serotonin </e1> - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2> .
NO_RELATION	The underlying mechanism of <e2> withdrawal - emergent RS </e2> in the present case may have been related to the pharmacological profile of risperidone , a serotonin - <e1> dopamine </e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
NO_RELATION	The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - <e1> dopamine </e1> antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2> .
NO_RELATION	The underlying mechanism of <e2> withdrawal - emergent RS </e2> in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the <e1> serotonin </e1> system in the development of RS .
NO_RELATION	The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the <e1> serotonin </e1> system in the development of <e2> RS </e2> .
CID	<e1> Verapamil </e1> withdrawal as a possible cause of <e2> myocardial infarction </e2> in a hypertensive woman with a normal coronary angiogram .
NO_RELATION	<e1> Verapamil </e1> withdrawal as a possible cause of myocardial infarction in a <e2> hypertensive </e2> woman with a normal coronary angiogram .
NO_RELATION	We report a case in which <e2> myocardial infarction </e2> coincided with the introduction of <e1> captopril </e1> and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .
NO_RELATION	We report a case in which myocardial infarction coincided with the introduction of <e1> captopril </e1> and the withdrawal of verapamil in a previously asymptomatic woman with severe <e2> hypertension </e2> .
CID	We report a case in which <e2> myocardial infarction </e2> coincided with the introduction of captopril and the withdrawal of <e1> verapamil </e1> in a previously asymptomatic woman with severe hypertension .
NO_RELATION	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of <e1> verapamil </e1> in a previously asymptomatic woman with severe <e2> hypertension </e2> .
NO_RELATION	Remission induction of <e2> meningeal leukemia </e2> with high - dose intravenous <e1> methotrexate </e1> .
NO_RELATION	Twenty children with <e2> acute lymphoblastic leukemia </e2> who developed meningeal disease were treated with a high - dose intravenous <e1> methotrexate </e1> regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
NO_RELATION	Twenty children with acute lymphoblastic leukemia who developed <e2> meningeal disease </e2> were treated with a high - dose intravenous <e1> methotrexate </e1> regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
NO_RELATION	Twenty children with <e2> acute lymphoblastic leukemia </e2> who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1> methotrexate </e1> concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
NO_RELATION	Twenty children with acute lymphoblastic leukemia who developed <e2> meningeal disease </e2> were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1> methotrexate </e1> concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
NO_RELATION	The most common <e2> toxicities </e2> encountered were transient serum transaminase and <e1> bilirubin </e1> elevations , neutropenia , and mucositis .
NO_RELATION	The most common toxicities encountered were transient serum transaminase and <e1> bilirubin </e1> elevations , <e2> neutropenia </e2> , and mucositis .
NO_RELATION	The most common toxicities encountered were transient serum transaminase and <e1> bilirubin </e1> elevations , neutropenia , and <e2> mucositis </e2> .
NO_RELATION	High - dose intravenous <e1> methotrexate </e1> is an effective treatment for the induction of remission after meningeal relapse in <e2> acute lymphoblastic leukemia </e2> .
CID	<e2> Hypersensitivity </e2> to <e1> carbamazepine </e1> presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .
CID	Hypersensitivity to <e1> carbamazepine </e1> presenting with a <e2> leukemoid reaction </e2> , eosinophilia , erythroderma , and renal failure .
NO_RELATION	Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction , <e2> eosinophilia </e2> , erythroderma , and renal failure .
CID	Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction , eosinophilia , <e2> erythroderma </e2> , and renal failure .
CID	Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction , eosinophilia , erythroderma , and <e2> renal failure </e2> .
CID	We report a patient in whom <e2> hypersensitivity </e2> to <e1> carbamazepine </e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
CID	We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized <e2> erythroderma </e2> , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
CID	We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma , a severe <e2> leukemoid reaction </e2> , eosinophilia , hyponatremia , and renal failure .
NO_RELATION	We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma , a severe leukemoid reaction , <e2> eosinophilia </e2> , hyponatremia , and renal failure .
CID	We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , <e2> hyponatremia </e2> , and renal failure .
CID	We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and <e2> renal failure </e2> .
NO_RELATION	Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field <e2> locomotor hypoactivity </e2> caused by <e1> nicotine </e1> ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .
CID	Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by <e1> nicotine </e1> ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced <e2> hyperactivity </e2> , and raised spontaneous nocturnal activity .
NO_RELATION	Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field <e2> locomotor hypoactivity </e2> caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) <e1> nicotine </e1> - induced hyperactivity , and raised spontaneous nocturnal activity .
CID	Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) <e1> nicotine </e1> - induced <e2> hyperactivity </e2> , and raised spontaneous nocturnal activity .
CID	Assessment of a new non - invasive index of cardiac performance for detection of <e1> dobutamine </e1> - induced <e2> myocardial ischemia </e2> .
CID	BACKGROUND : Electrocardiography has a very low sensitivity in detecting <e1> dobutamine </e1> - induced <e2> myocardial ischemia </e2> .
CID	OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting <e1> dobutamine </e1> - induced <e2> myocardial ischemia </e2> , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
NO_RELATION	OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting <e1> dobutamine </e1> - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2> ischemia </e2> .
NO_RELATION	OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced <e2> myocardial ischemia </e2> , using <e1> Tc99m - Sestamibi </e1> single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
NO_RELATION	OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using <e1> Tc99m - Sestamibi </e1> single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2> ischemia </e2> .
NO_RELATION	<e2> Acute liver failure </e2> in two patients with regular <e1> alcohol </e1> consumption ingesting paracetamol at therapeutic dosage .
NO_RELATION	<e2> Acute liver failure </e2> in two patients with regular alcohol consumption ingesting <e1> paracetamol </e1> at therapeutic dosage .
NO_RELATION	BACKGROUND : The possible role of <e1> alcohol </e1> in the development of <e2> hepatotoxicity </e2> associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .
CID	BACKGROUND : The possible role of alcohol in the development of <e2> hepatotoxicity </e2> associated with therapeutic doses of <e1> paracetamol </e1> ( acetaminophen ) is currently debated .
CID	BACKGROUND : The possible role of alcohol in the development of <e2> hepatotoxicity </e2> associated with therapeutic doses of paracetamol ( <e1> acetaminophen </e1> ) is currently debated .
NO_RELATION	CASE REPORT : We describe 2 patients who were regular consumers of <e1> alcohol </e1> and who developed <e2> liver failure </e2> within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .
NO_RELATION	CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed <e2> liver failure </e2> within 3 - 5 days after hospitalization and stopping <e1> alcohol </e1> consumption while being treated with 4 g paracetamol / day .
CID	CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed <e2> liver failure </e2> within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g <e1> paracetamol </e1> / day .
CID	Possible risk factors for the development of <e2> hepatotoxicity </e2> in patients treated with therapeutic doses of <e1> paracetamol </e1> are discussed .
NO_RELATION	regular consumption of <e1> alcohol </e1> , <e2> liver failure </e2> is possible when therapeutic doses are ingested .
CID	<e1> Cocaine </e1> related <e2> chest pain </e2> : are we seeing the tip of an iceberg ?
CID	In particular , the tendency of <e1> cocaine </e1> to produce <e2> chest pain </e2> ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .
CID	In particular , the tendency of <e1> cocaine </e1> to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of <e2> chest pain </e2> who is otherwise at low risk .
CID	The mechanism of <e2> chest pain </e2> related to <e1> cocaine </e1> use is discussed and treatment dilemmas are discussed .
CID	Severe <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of <e1> simvastatin </e1> , amiodarone , and atazanavir .
CID	Severe rhabdomyolysis and <e2> acute renal failure </e2> secondary to concomitant use of <e1> simvastatin </e1> , amiodarone , and atazanavir .
CID	Severe <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of simvastatin , <e1> amiodarone </e1> , and atazanavir .
CID	Severe rhabdomyolysis and <e2> acute renal failure </e2> secondary to concomitant use of simvastatin , <e1> amiodarone </e1> , and atazanavir .
CID	Severe <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and <e1> atazanavir </e1> .
CID	Severe rhabdomyolysis and <e2> acute renal failure </e2> secondary to concomitant use of simvastatin , amiodarone , and <e1> atazanavir </e1> .
CID	OBJECTIVE : To report a case of a severe interaction between <e1> simvastatin </e1> , amiodarone , and atazanavir resulting in <e2> rhabdomyolysis </e2> and acute renal failure .
CID	OBJECTIVE : To report a case of a severe interaction between <e1> simvastatin </e1> , amiodarone , and atazanavir resulting in rhabdomyolysis and <e2> acute renal failure </e2> .
CID	OBJECTIVE : To report a case of a severe interaction between simvastatin , <e1> amiodarone </e1> , and atazanavir resulting in <e2> rhabdomyolysis </e2> and acute renal failure .
CID	OBJECTIVE : To report a case of a severe interaction between simvastatin , <e1> amiodarone </e1> , and atazanavir resulting in rhabdomyolysis and <e2> acute renal failure </e2> .
CID	OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and <e1> atazanavir </e1> resulting in <e2> rhabdomyolysis </e2> and acute renal failure .
CID	OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and <e1> atazanavir </e1> resulting in rhabdomyolysis and <e2> acute renal failure </e2> .
NO_RELATION	<e1> Simvastatin </e1> , amiodarone , and the patient ' s <e2> human immunodeficiency virus </e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
NO_RELATION	Simvastatin , <e1> amiodarone </e1> , and the patient ' s <e2> human immunodeficiency virus </e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
CID	DISCUSSION : The risk of <e2> rhabdomyolysis </e2> is increased in the presence of concomitant drugs that inhibit <e1> simvastatin </e1> metabolism .
NO_RELATION	Phase II trial of <e1> vinorelbine </e1> in metastatic <e2> squamous cell esophageal carcinoma </e2> .
NO_RELATION	PURPOSE : To evaluate the response rate and toxic effects of <e1> vinorelbine </e1> ( VNB ) administered as a single agent in metastatic <e2> squamous cell esophageal carcinoma </e2> .
NO_RELATION	PURPOSE : To evaluate the response rate and toxic effects of vinorelbine ( <e1> VNB </e1> ) administered as a single agent in metastatic <e2> squamous cell esophageal carcinoma </e2> .
NO_RELATION	Thirty patients without prior chemotherapy and 16 pretreated with <e1> cisplatin </e1> - based chemotherapy were assessable for <e2> toxicity </e2> and response .
NO_RELATION	<e1> VNB </e1> was well tolerated and zero instances of WHO grade 4 nonhematologic <e2> toxicity </e2> occurred .
NO_RELATION	CONCLUSION : These data indicate that <e1> VNB </e1> is an active agent in metastatic <e2> esophageal squamous cell carcinoma </e2> .
NO_RELATION	Given its excellent tolerance profile and low <e2> toxicity </e2> , further evaluation of <e1> VNB </e1> in combination therapy is warranted .
NO_RELATION	<e1> Paclitaxel </e1> , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2> .
NO_RELATION	Paclitaxel , <e1> cisplatin </e1> , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2> .
NO_RELATION	Paclitaxel , cisplatin , and <e1> gemcitabine </e1> combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2> .
NO_RELATION	BACKGROUND : <e1> Cisplatin </e1> - based chemotherapy combinations improve quality of life and survival in advanced <e2> nonsmall cell lung carcinoma </e2> ( NSCLC ) .
NO_RELATION	BACKGROUND : <e1> Cisplatin </e1> - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( <e2> NSCLC </e2> ) .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and <e2> toxicity </e2> of a <e1> paclitaxel </e1> , cisplatin , and gemcitabine combination to treat metastatic NSCLC .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a <e1> paclitaxel </e1> , cisplatin , and gemcitabine combination to treat metastatic <e2> NSCLC </e2> .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and <e2> toxicity </e2> of a paclitaxel , <e1> cisplatin </e1> , and gemcitabine combination to treat metastatic NSCLC .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , <e1> cisplatin </e1> , and gemcitabine combination to treat metastatic <e2> NSCLC </e2> .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and <e2> toxicity </e2> of a paclitaxel , cisplatin , and <e1> gemcitabine </e1> combination to treat metastatic NSCLC .
NO_RELATION	METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and <e1> gemcitabine </e1> combination to treat metastatic <e2> NSCLC </e2> .
NO_RELATION	Thirty - five consecutive chemotherapy - naive patients with Stage IV <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of <e1> paclitaxel </e1> ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
NO_RELATION	Thirty - five consecutive chemotherapy - naive patients with Stage IV <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , <e1> cisplatin </e1> ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
NO_RELATION	Thirty - five consecutive chemotherapy - naive patients with Stage IV <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and <e1> gemcitabine </e1> ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
NO_RELATION	CONCLUSIONS : The combination of <e1> paclitaxel </e1> , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic <e2> NSCLC </e2> .
NO_RELATION	CONCLUSIONS : The combination of paclitaxel , <e1> cisplatin </e1> , and gemcitabine is well tolerated and shows high activity in metastatic <e2> NSCLC </e2> .
NO_RELATION	CONCLUSIONS : The combination of paclitaxel , cisplatin , and <e1> gemcitabine </e1> is well tolerated and shows high activity in metastatic <e2> NSCLC </e2> .
CID	The <e2> ocular hypotensive </e2> effects were statistically significant for <e1> apraclonidine </e1> - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .
CID	The <e2> ocular hypotensive </e2> effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % <e1> apraclonidine </e1> .
CID	<e1> Carmofur </e1> - induced <e2> organic mental disorders </e2> .
CID	<e2> Organic mental disorder </e2> was observed in a 29 - year - old female in the prognostic period after the onset of <e1> carmofur </e1> - induced leukoencephalopathy .
CID	Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of <e1> carmofur </e1> - induced <e2> leukoencephalopathy </e2> .
CID	Consequently , <e1> carmofur </e1> - induced <e2> leukoencephalopathy </e2> may uncommonly result in organic personality syndrome in the residual state .
NO_RELATION	Consequently , <e1> carmofur </e1> - induced leukoencephalopathy may uncommonly result in <e2> organic personality syndrome </e2> in the residual state .
NO_RELATION	The antiarrhythmic effects of the sustained release form of <e1> mexiletine </e1> ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented <e2> myocardial infarction </e2> .
NO_RELATION	The antiarrhythmic effects of the sustained release form of mexiletine ( <e1> Mexitil - Perlongets </e1> ) were evaluated in a double - blind placebo trial in 630 patients with recent documented <e2> myocardial infarction </e2> .
NO_RELATION	There were more <e2> deaths </e2> in the <e1> mexiletine </e1> group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .
CID	Previously recognized side effects , particularly <e2> tremor </e2> and gastrointestinal problems , were more frequent in the <e1> mexiletine </e1> group than in the placebo group .
CID	Previously recognized side effects , particularly tremor and <e2> gastrointestinal problems </e2> , were more frequent in the <e1> mexiletine </e1> group than in the placebo group .
CID	Regional localization of the antagonism of <e1> amphetamine </e1> - induced <e2> hyperactivity </e2> by intracerebral calcitonin injections .
NO_RELATION	Regional localization of the antagonism of amphetamine - induced <e2> hyperactivity </e2> by intracerebral <e1> calcitonin </e1> injections .
CID	Fatal <e2> intracranial bleeding </e2> associated with prehospital use of <e1> epinephrine </e1> .
NO_RELATION	The sudden onset of <e2> respiratory distress </e2> , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1> epinephrine </e1> .
NO_RELATION	The sudden onset of respiratory distress , <e2> rash </e2> , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1> epinephrine </e1> .
CID	<e1> Epinephrine </e1> has a proven role in <e2> cardiac arrest </e2> in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .
NO_RELATION	<e1> Epinephrine </e1> has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected <e2> allergic reaction </e2> and severe hypertension should be viewed with caution .
NO_RELATION	<e1> Epinephrine </e1> has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe <e2> hypertension </e2> should be viewed with caution .
CID	A case of massive <e2> rhabdomyolysis </e2> following <e1> molindone </e1> administration .
NO_RELATION	The case of a <e2> schizophrenic </e2> patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following <e1> molindone </e1> administration .
CID	The case of a schizophrenic patient is reported to illustrate massive <e2> rhabdomyolysis </e2> and subsequent acute renal failure following <e1> molindone </e1> administration .
CID	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent <e2> acute renal failure </e2> following <e1> molindone </e1> administration .
NO_RELATION	<e2> Cardiovascular alterations </e2> in rat fetuses exposed to <e1> calcium </e1> channel blockers .
NO_RELATION	Preclinical toxicologic investigation suggested that a new <e1> calcium </e1> channel blocker , Ro 40 - 5967 , induced <e2> cardiovascular alterations </e2> in rat fetuses exposed to this agent during organogenesis .
CID	Preclinical toxicologic investigation suggested that a new calcium channel blocker , <e1> Ro 40 - 5967 </e1> , induced <e2> cardiovascular alterations </e2> in rat fetuses exposed to this agent during organogenesis .
NO_RELATION	The present study was designed to investigate the hypothesis that <e1> calcium </e1> channel blockers in general induce <e2> cardiovascular malformations </e2> indicating a pharmacologic class effect .
NO_RELATION	Pregnant rats were administered one of these <e1> calcium </e1> channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for <e2> cardiovascular malformations </e2> .
NO_RELATION	A low incidence of <e2> cardiovascular malformations </e2> was observed after exposure to each of the four <e1> calcium </e1> channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .
CID	A low incidence of <e2> cardiovascular malformations </e2> was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for <e1> verapamil </e1> and nifedipine .
CID	A low incidence of <e2> cardiovascular malformations </e2> was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and <e1> nifedipine </e1> .
NO_RELATION	The effects of <e1> sevoflurane </e1> on lidocaine - induced <e2> convulsions </e2> .
CID	The effects of sevoflurane on <e1> lidocaine </e1> - induced <e2> convulsions </e2> .
NO_RELATION	The influence of <e1> sevoflurane </e1> on lidocaine - induced <e2> convulsions </e2> was studied in cats .
CID	The influence of sevoflurane on <e1> lidocaine </e1> - induced <e2> convulsions </e2> was studied in cats .
NO_RELATION	There was no significant difference in the <e2> convulsive </e2> threshold between <e1> sevoflurane </e1> and enflurane .
NO_RELATION	There was no significant difference in the <e2> convulsive </e2> threshold between sevoflurane and <e1> enflurane </e1> .
NO_RELATION	The rise in blood pressure became less marked when higher concentrations of <e1> sevoflurane </e1> or enflurane were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .
NO_RELATION	The rise in blood pressure became less marked when higher concentrations of sevoflurane or <e1> enflurane </e1> were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .
NO_RELATION	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1 . 6 % <e1> sevoflurane </e1> , and in 0 . 8 % and 1 . 6 % enflurane .
NO_RELATION	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % <e1> enflurane </e1> .
NO_RELATION	<e1> Apamin </e1> ( 10 ng ) had a tendency to decrease the <e2> convulsive </e2> threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg .
NO_RELATION	It is suggested that <e1> sevoflurane </e1> reduces the <e2> convulsive </e2> effect of lidocaine toxicity but carries some risk due to circulatory depression .
NO_RELATION	It is suggested that <e1> sevoflurane </e1> reduces the convulsive effect of lidocaine <e2> toxicity </e2> but carries some risk due to circulatory depression .
NO_RELATION	It is suggested that <e1> sevoflurane </e1> reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory <e2> depression </e2> .
CID	It is suggested that sevoflurane reduces the <e2> convulsive </e2> effect of <e1> lidocaine </e1> toxicity but carries some risk due to circulatory depression .
NO_RELATION	It is suggested that sevoflurane reduces the convulsive effect of <e1> lidocaine </e1> <e2> toxicity </e2> but carries some risk due to circulatory depression .
NO_RELATION	It is suggested that sevoflurane reduces the convulsive effect of <e1> lidocaine </e1> toxicity but carries some risk due to circulatory <e2> depression </e2> .
NO_RELATION	Anti - oxidant effects of <e1> atorvastatin </e1> in dexamethasone - induced <e2> hypertension </e2> in the rat .
CID	Anti - oxidant effects of atorvastatin in <e1> dexamethasone </e1> - induced <e2> hypertension </e2> in the rat .
CID	<e1> Dexamethasone </e1> ( Dex ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .
CID	Dexamethasone ( <e1> Dex </e1> ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .
NO_RELATION	Dexamethasone ( Dex ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with <e1> nitric oxide </e1> ( NO ) deficiency and increased superoxide ( O2 - ) production .
NO_RELATION	Dexamethasone ( Dex ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide ( <e1> NO </e1> ) deficiency and increased superoxide ( O2 - ) production .
NO_RELATION	Dexamethasone ( Dex ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased <e1> superoxide </e1> ( O2 - ) production .
NO_RELATION	Dexamethasone ( Dex ) - induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( <e1> O2 - </e1> ) production .
NO_RELATION	<e1> Atorvastatin </e1> ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of <e2> hypertension </e2> .
NO_RELATION	Atorvastatin ( <e1> Ato </e1> ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of <e2> hypertension </e2> .
NO_RELATION	Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of <e1> NO </e1> and reduced O2 - production in various forms of <e2> hypertension </e2> .
NO_RELATION	Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced <e1> O2 - </e1> production in various forms of <e2> hypertension </e2> .
NO_RELATION	<e1> 99mTc - glucarate </e1> for detection of isoproterenol - induced <e2> myocardial infarction </e2> in rats .
CID	99mTc - glucarate for detection of <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	The animal model used to produce <e2> infarction </e2> implies artery ligation but chemical induction can be easily obtained with <e1> isoproterenol </e1> .
NO_RELATION	A new <e2> infarct </e2> - avid radiopharmaceutical based on <e1> glucaric acid </e1> was prepared in the hospital radiopharmacy of the INCMNSZ .
NO_RELATION	<e1> 99mTc - glucarate </e1> was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute <e2> myocardial infarction </e2> .
CID	99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with <e1> isoproterenol </e1> - induced acute <e2> myocardial infarction </e2> .
NO_RELATION	Histological studies demonstrated that the rats developed an <e2> infarct </e2> 18 h after <e1> isoproterenol </e1> administration .
NO_RELATION	A randomized , placebo - controlled dose - comparison trial of <e1> haloperidol </e1> for <e2> psychosis </e2> and disruptive behaviors in Alzheimer ' s disease .
NO_RELATION	A randomized , placebo - controlled dose - comparison trial of <e1> haloperidol </e1> for psychosis and <e2> disruptive behaviors </e2> in Alzheimer ' s disease .
NO_RELATION	A randomized , placebo - controlled dose - comparison trial of <e1> haloperidol </e1> for psychosis and disruptive behaviors in <e2> Alzheimer ' s disease </e2> .
NO_RELATION	OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of <e2> psychosis </e2> and disruptive behaviors in patients with Alzheimer ' s disease .
NO_RELATION	OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of psychosis and <e2> disruptive behaviors </e2> in patients with Alzheimer ' s disease .
NO_RELATION	OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of psychosis and disruptive behaviors in patients with <e2> Alzheimer ' s disease </e2> .
NO_RELATION	METHOD : In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , <e1> haloperidol </e1> , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with <e2> Alzheimer ' s disease </e2> .
NO_RELATION	METHOD : In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and <e1> haloperidol </e1> , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with <e2> Alzheimer ' s disease </e2> .
NO_RELATION	RESULTS : For the 60 patients who completed phase A , standard - dose <e1> haloperidol </e1> was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale <e2> psychosis </e2> factor and on psychomotor agitation .
NO_RELATION	RESULTS : For the 60 patients who completed phase A , standard - dose <e1> haloperidol </e1> was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2> psychomotor agitation </e2> .
NO_RELATION	RESULTS : For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose <e1> haloperidol </e1> and placebo for scores on the Brief Psychiatric Rating Scale <e2> psychosis </e2> factor and on psychomotor agitation .
NO_RELATION	RESULTS : For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose <e1> haloperidol </e1> and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2> psychomotor agitation </e2> .
CID	CONCLUSIONS : The results indicated a favorable therapeutic profile for <e1> haloperidol </e1> in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe <e2> extrapyramidal signs </e2> .
NO_RELATION	The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in <e2> Alzheimer ' s disease </e2> patients with psychosis and disruptive behaviors .
NO_RELATION	The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in Alzheimer ' s disease patients with <e2> psychosis </e2> and disruptive behaviors .
NO_RELATION	The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in Alzheimer ' s disease patients with psychosis and <e2> disruptive behaviors </e2> .
NO_RELATION	Individual differences in renal ACE activity in healthy rats predict susceptibility to <e1> adriamycin </e1> - induced <e2> renal damage </e2> .
NO_RELATION	Therefore , we studied the predictive effect of renal ACE activity for the severity of <e2> renal damage </e2> induced by a single injection of <e1> adriamycin </e1> in rats .
CID	After 1 week of recovery , <e2> proteinuria </e2> was induced by <e1> adriamycin </e1> [ 1 . 5 mg / kg intravenously ( i . v . ) n = 18 ; controls , saline i . v .
NO_RELATION	RESULTS : As anticipated , <e1> adriamycin </e1> elicited <e2> nephrotic </e2> range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .
CID	RESULTS : As anticipated , <e1> adriamycin </e1> elicited nephrotic range <e2> proteinuria </e2> , renal interstitial damage and mild focal glomerulosclerosis .
NO_RELATION	RESULTS : As anticipated , <e1> adriamycin </e1> elicited nephrotic range proteinuria , <e2> renal interstitial damage </e2> and mild focal glomerulosclerosis .
NO_RELATION	RESULTS : As anticipated , <e1> adriamycin </e1> elicited nephrotic range proteinuria , renal interstitial damage and mild <e2> focal glomerulosclerosis </e2> .
CID	Baseline renal ACE positively correlated with the relative rise in <e2> proteinuria </e2> after <e1> adriamycin </e1> ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .
NO_RELATION	CONCLUSION : Individual differences in renal ACE activity predict the severity of <e1> adriamycin </e1> - induced <e2> renal damage </e2> in this outbred rat strain .
NO_RELATION	Clinical <e2> nephrotoxicity </e2> of <e1> tobramycin </e1> and gentamicin .
NO_RELATION	Clinical <e2> nephrotoxicity </e2> of tobramycin and <e1> gentamicin </e1> .
NO_RELATION	<e1> Gentamicin sulfate </e1> and tobramycin sulfate continue to demonstrate <e2> ototoxicity </e2> and nephrotoxicity in both animal and clinical studies .
NO_RELATION	<e1> Gentamicin sulfate </e1> and tobramycin sulfate continue to demonstrate ototoxicity and <e2> nephrotoxicity </e2> in both animal and clinical studies .
NO_RELATION	Gentamicin sulfate and <e1> tobramycin sulfate </e1> continue to demonstrate <e2> ototoxicity </e2> and nephrotoxicity in both animal and clinical studies .
NO_RELATION	Gentamicin sulfate and <e1> tobramycin sulfate </e1> continue to demonstrate ototoxicity and <e2> nephrotoxicity </e2> in both animal and clinical studies .
CID	In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of <e1> gentamicin sulfate </e1> or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related <e2> renal failure </e2> , defined as at least a one - third reduction in renal function .
CID	In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or <e1> tobramycin sulfate </e1> for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related <e2> renal failure </e2> , defined as at least a one - third reduction in renal function .
NO_RELATION	In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of <e1> aminoglycoside </e1> - related <e2> renal failure </e2> , defined as at least a one - third reduction in renal function .
CID	Five of 33 ( 15 % ) of the <e1> tobramycin </e1> - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had <e2> renal failure </e2> .
CID	Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the <e1> gentamicin </e1> - treated patients had <e2> renal failure </e2> .
CID	Thus , <e1> gentamicin </e1> was associated with <e2> renal failure </e2> more than three times as often as was tobramycin .
CID	Thus , gentamicin was associated with <e2> renal failure </e2> more than three times as often as was <e1> tobramycin </e1> .
NO_RELATION	Neuroprotective action of <e1> MPEP </e1> , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic <e2> neurotoxicity </e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
NO_RELATION	Neuroprotective action of <e1> MPEP </e1> , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2> hyperthermia </e2> in rats .
NO_RELATION	Neuroprotective action of MPEP , a selective mGluR5 antagonist , in <e1> methamphetamine </e1> - induced dopaminergic <e2> neurotoxicity </e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
CID	Neuroprotective action of MPEP , a selective mGluR5 antagonist , in <e1> methamphetamine </e1> - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2> hyperthermia </e2> in rats .
NO_RELATION	Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic <e2> neurotoxicity </e2> is associated with a decrease in <e1> dopamine </e1> outflow and inhibition of hyperthermia in rats .
NO_RELATION	Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in <e1> dopamine </e1> outflow and inhibition of <e2> hyperthermia </e2> in rats .
CID	Moreover , it transiently diminished the <e1> methamphetamine </e1> ( 10 mg / kg sc ) - induced <e2> hyperthermia </e2> and reduced basal body temperature .
NO_RELATION	The results of this study suggest that the blockade of mGluR5 by <e1> MPEP </e1> may protect dopaminergic neurones against methamphetamine - induced <e2> toxicity </e2> .
NO_RELATION	The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against <e1> methamphetamine </e1> - induced <e2> toxicity </e2> .
NO_RELATION	Neuroprotection rendered by <e1> MPEP </e1> may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2> hyperthermia </e2> .
CID	Neuroprotection rendered by MPEP may be associated with the reduction of the <e1> methamphetamine </e1> - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2> hyperthermia </e2> .
NO_RELATION	Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced <e1> dopamine </e1> efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in <e2> hyperthermia </e2> .
CID	Fewer subjects reported adverse events following treatment with <e1> desipramine </e1> alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2> nausea </e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with <e1> desipramine </e1> alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2> headache </e2> ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1> desipramine </e1> with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2> nausea </e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1> desipramine </e1> with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2> headache </e2> ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1> cinacalcet </e1> ( 33 versus 86 % ) , the most frequent of which ( <e2> nausea </e2> and headache ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1> cinacalcet </e1> ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2> headache </e2> ) have been reported for patients treated with either desipramine or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2> nausea </e2> and headache ) have been reported for patients treated with either <e1> desipramine </e1> or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2> headache </e2> ) have been reported for patients treated with either <e1> desipramine </e1> or cinacalcet .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( <e2> nausea </e2> and headache ) have been reported for patients treated with either desipramine or <e1> cinacalcet </e1> .
CID	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and <e2> headache </e2> ) have been reported for patients treated with either desipramine or <e1> cinacalcet </e1> .
CID	Proteomic analysis of striatal proteins in the rat model of <e1> L - DOPA </e1> - induced <e2> dyskinesia </e2> .
CID	<e1> L - DOPA </e1> - induced <e2> dyskinesia </e2> ( LID ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with L - DOPA .
CID	<e1> L - DOPA </e1> - induced dyskinesia ( <e2> LID </e2> ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with L - DOPA .
NO_RELATION	<e1> L - DOPA </e1> - induced dyskinesia ( LID ) is among the motor complications that arise in <e2> Parkinson ' s disease </e2> ( PD ) patients after a prolonged treatment with L - DOPA .
NO_RELATION	<e1> L - DOPA </e1> - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson ' s disease ( <e2> PD </e2> ) patients after a prolonged treatment with L - DOPA .
CID	L - DOPA - induced <e2> dyskinesia </e2> ( LID ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with <e1> L - DOPA </e1> .
CID	L - DOPA - induced dyskinesia ( <e2> LID </e2> ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with <e1> L - DOPA </e1> .
NO_RELATION	L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in <e2> Parkinson ' s disease </e2> ( PD ) patients after a prolonged treatment with <e1> L - DOPA </e1> .
NO_RELATION	L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson ' s disease ( <e2> PD </e2> ) patients after a prolonged treatment with <e1> L - DOPA </e1> .
NO_RELATION	In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally <e1> 6 - hydroxydopamine </e1> - lesion rat model of <e2> PD </e2> treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
NO_RELATION	In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of <e2> PD </e2> treated with saline , <e1> L - DOPA </e1> or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
NO_RELATION	In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of <e2> PD </e2> treated with saline , L - DOPA or <e1> bromocriptine </e1> using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
CID	Rats treated with <e1> L - DOPA </e1> were allocated to two groups based on the presence or absence of <e2> LID </e2> .
NO_RELATION	Pseudo - <e2> allergic reactions </e2> to <e1> corticosteroids </e1> : diagnosis and alternatives .
NO_RELATION	Corticosteroids different from <e1> paramethasone </e1> also produced <e2> hypersensitivity </e2> reactions in these patients ; however , a few of them were tolerated .
NO_RELATION	To our knowledge , this is the first report of a pseudo - <e2> allergy </e2> caused by <e1> paramethasone </e1> .
CID	<e1> Valproic acid </e1> induced <e2> encephalopathy </e2> - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .
CID	Valproic acid induced <e2> encephalopathy </e2> - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to <e1> VPA </e1> - therapy not only in young children .
CID	Rare serious complications may occur in some patients , including haemorrhagic <e2> pancreatitis </e2> , bone marrow suppression , <e1> VPA </e1> - induced hepatotoxicity and VPA - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , <e2> bone marrow suppression </e2> , <e1> VPA </e1> - induced hepatotoxicity and VPA - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , <e1> VPA </e1> - induced <e2> hepatotoxicity </e2> and VPA - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , <e1> VPA </e1> - induced hepatotoxicity and VPA - induced <e2> encephalopathy </e2> .
CID	Rare serious complications may occur in some patients , including haemorrhagic <e2> pancreatitis </e2> , bone marrow suppression , VPA - induced hepatotoxicity and <e1> VPA </e1> - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , <e2> bone marrow suppression </e2> , VPA - induced hepatotoxicity and <e1> VPA </e1> - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced <e2> hepatotoxicity </e2> and <e1> VPA </e1> - induced encephalopathy .
CID	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and <e1> VPA </e1> - induced <e2> encephalopathy </e2> .
CID	The typical signs of <e1> VPA </e1> - induced <e2> encephalopathy </e2> are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
CID	The typical signs of <e1> VPA </e1> - induced encephalopathy are <e2> impaired consciousness </e2> , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
NO_RELATION	The typical signs of <e1> VPA </e1> - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased <e2> seizure </e2> frequency , with or without hyperammonemia .
NO_RELATION	The typical signs of <e1> VPA </e1> - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without <e2> hyperammonemia </e2> .
CID	There is still no proof of causative effect of <e1> VPA </e1> in patients with <e2> encephalopathy </e2> , but only of an association with an assumed causal relation .
CID	We report 19 patients with <e1> VPA </e1> - associated <e2> encephalopathy </e2> in Germany from the years 1994 to 2003 , none of whom had been published previously .
CID	<e2> Haemolytic - uraemic syndrome </e2> after treatment with <e1> metronidazole </e1> .
CID	This paper describes the clinical features of six children who developed the <e2> haemolytic - uraemic syndrome </e2> after treatment with <e1> metronidazole </e1> .
CID	While the involvement of <e1> metronidazole </e1> in the aetiology of the <e2> haemolytic - uraemic syndrome </e2> is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .
CID	While the involvement of <e1> metronidazole </e1> in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the <e2> haemolytic - uraemic syndrome </e2> suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .
CID	While the involvement of <e1> metronidazole </e1> in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the <e2> haemolytic - uraemic syndrome </e2> .
CID	While the involvement of metronidazole in the aetiology of the <e2> haemolytic - uraemic syndrome </e2> is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between <e1> metronidazole </e1> treatment and some cases of the haemolytic - uraemic syndrome .
CID	While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the <e2> haemolytic - uraemic syndrome </e2> suggest a possible link between <e1> metronidazole </e1> treatment and some cases of the haemolytic - uraemic syndrome .
CID	While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between <e1> metronidazole </e1> treatment and some cases of the <e2> haemolytic - uraemic syndrome </e2> .
NO_RELATION	<e2> Ototoxicity </e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly <e1> aminoglycosides </e1> and furosemide .
NO_RELATION	Ototoxicity appeared closely related to a prolonged administration and higher total dose of <e2> ototoxic </e2> drugs , particularly <e1> aminoglycosides </e1> and furosemide .
NO_RELATION	<e2> Ototoxicity </e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and <e1> furosemide </e1> .
NO_RELATION	Ototoxicity appeared closely related to a prolonged administration and higher total dose of <e2> ototoxic </e2> drugs , particularly aminoglycosides and <e1> furosemide </e1> .
CID	Pharmacokinetic and clinical studies in patients with <e1> cimetidine </e1> - associated mental <e2> confusion </e2> .
CID	15 cases of <e1> cimetidine </e1> - associated mental <e2> confusion </e2> have been reported .
NO_RELATION	These 6 patients had both <e2> renal and liver dysfunction </e2> ( P less than 0 . 05 ) , as well as <e1> cimetidine </e1> trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .
CID	We used rat models of <e2> intrahepatic cholestasis </e2> by <e1> ethinyl estradiol </e1> ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
NO_RELATION	We used rat models of intrahepatic cholestasis by <e1> ethinyl estradiol </e1> ( EE ) treatment and <e2> extrahepatic cholestasis </e2> by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
CID	We used rat models of <e2> intrahepatic cholestasis </e2> by ethinyl estradiol ( <e1> EE </e1> ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
NO_RELATION	We used rat models of intrahepatic cholestasis by ethinyl estradiol ( <e1> EE </e1> ) treatment and <e2> extrahepatic cholestasis </e2> by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
NO_RELATION	No <e2> ototoxic </e2> factor , other than <e1> DFO </e1> , was present in any of the patients .
CID	Subjects with <e2> SNHL </e2> were submitted to <e1> DFO </e1> reduction or temporary withdrawal .
NO_RELATION	CONCLUSION : The findings are indicative of <e1> DFO </e1> ' s contributing role in the development of <e2> hearing impairment </e2> .
NO_RELATION	Design and analysis of the HYPREN - trial : safety of <e1> enalapril </e1> and prazosin in the initial treatment phase of patients with <e2> congestive heart failure </e2> .
NO_RELATION	Design and analysis of the HYPREN - trial : safety of enalapril and <e1> prazosin </e1> in the initial treatment phase of patients with <e2> congestive heart failure </e2> .
NO_RELATION	Since the introduction of <e1> angiotensin converting enzyme ( ACE ) inhibitors </e1> into the adjunctive treatment of patients with <e2> congestive heart failure </e2> , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .
CID	Since the introduction of <e1> angiotensin converting enzyme ( ACE ) inhibitors </e1> into the adjunctive treatment of patients with congestive heart failure , cases of severe <e2> hypotension </e2> , especially on the first day of treatment , have occasionally been reported .
CID	To assess the safety of the <e1> ACE inhibitor </e1> enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment .
NO_RELATION	To assess the safety of the ACE inhibitor <e1> enalapril </e1> a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment .
CID	To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , <e1> prazosin </e1> - controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment .
NO_RELATION	Patients who received <e1> enalapril </e1> experienced clinically and statistically significantly less symptomatic <e2> hypotension </e2> ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .
CID	Patients who received enalapril experienced clinically and statistically significantly less symptomatic <e2> hypotension </e2> ( 5 . 2 % ) than the patients who received <e1> prazosin </e1> ( 12 . 9 % ) .
CID	Antagonism between interleukin 3 and erythropoietin in mice with <e1> azidothymidine </e1> - induced <e2> anemia </e2> and in bone marrow endothelial cells .
CID	<e1> Azidothymidine </e1> ( AZT ) - induced <e2> anemia </e2> in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .
CID	Azidothymidine ( <e1> AZT </e1> ) - induced <e2> anemia </e2> in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .
CID	Dose - dependent <e2> bradycardia </e2> induced by <e1> verapamil </e1> was potentiated by LNa , LCa , and HCa .
NO_RELATION	<e1> Sodium </e1> status influences chronic amphotericin B <e2> nephrotoxicity </e2> in rats .
CID	Sodium status influences chronic <e1> amphotericin B </e1> <e2> nephrotoxicity </e2> in rats .
CID	The <e2> nephrotoxic </e2> potential of <e1> amphotericin B </e1> ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .
CID	Reversible <e2> inferior colliculus lesion </e2> in <e1> metronidazole </e1> - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .
CID	Reversible inferior colliculus lesion in <e1> metronidazole </e1> - induced <e2> encephalopathy </e2> : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .
CID	OBJECTIVE : This is to present reversible <e2> inferior colliculus lesions </e2> in <e1> metronidazole </e1> - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
CID	OBJECTIVE : This is to present reversible inferior colliculus lesions in <e1> metronidazole </e1> - induced <e2> encephalopathy </e2> , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
CID	MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having <e1> metronidazole </e1> - induced <e2> encephalopathy </e2> ( age range ; 43 - 78 years ) .
NO_RELATION	They had been taking <e1> metronidazole </e1> ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the <e2> infection </e2> in various organs .
CID	CONCLUSIONS : Reversible <e2> inferior colliculus lesions </e2> could be considered as the characteristic for <e1> metronidazole </e1> - induced encephalopathy , next to the dentate nucleus involvement .
CID	CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for <e1> metronidazole </e1> - induced <e2> encephalopathy </e2> , next to the dentate nucleus involvement .
NO_RELATION	Both <e2> obstructive ( P less than 0 . 05 ) and central apnoea </e2> ( P less than 0 . 05 ) occurred more frequently in patients who had a <e1> morphine </e1> infusion .
NO_RELATION	There was also a higher incidence of <e2> tachyarrhythmias </e2> ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the <e1> morphine </e1> infusion group .
CID	There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and <e2> ventricular ectopic beats </e2> ( P less than 0 . 05 ) in the <e1> morphine </e1> infusion group .
NO_RELATION	Magnetic resonance volumetry of the cerebellum in <e2> epileptic </e2> patients after <e1> phenytoin </e1> overdosages .
CID	Magnetic resonance volumetry of the cerebellum in epileptic patients after <e1> phenytoin </e1> <e2> overdosages </e2> .
NO_RELATION	The aim of this study was to evaluate the relationship between <e1> phenytoin </e1> medication and <e2> cerebellar atrophy </e2> in patients who had experienced clinical intoxication .
NO_RELATION	Using linear regression we found that no correlation exists between <e2> seizure </e2> duration , elevation of <e1> phenytoin </e1> serum levels and cerebellar volume .
CID	We conclude that <e1> phenytoin </e1> <e2> overdosage </e2> does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
NO_RELATION	We conclude that <e1> phenytoin </e1> overdosage does not necessarily result in <e2> cerebellar atrophy </e2> and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
NO_RELATION	We conclude that <e1> phenytoin </e1> overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of <e2> cerebellar atrophy </e2> in the remaining patients .
CID	We conclude that phenytoin <e2> overdosage </e2> does not necessarily result in cerebellar atrophy and it is unlikely that <e1> phenytoin </e1> medication was the only cause of cerebellar atrophy in the remaining patients .
NO_RELATION	We conclude that phenytoin overdosage does not necessarily result in <e2> cerebellar atrophy </e2> and it is unlikely that <e1> phenytoin </e1> medication was the only cause of cerebellar atrophy in the remaining patients .
NO_RELATION	We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that <e1> phenytoin </e1> medication was the only cause of <e2> cerebellar atrophy </e2> in the remaining patients .
CID	Evaluation of cardiac troponin I and T levels as markers of <e2> myocardial damage </e2> in <e1> doxorubicin </e1> - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .
CID	Evaluation of cardiac troponin I and T levels as markers of myocardial damage in <e1> doxorubicin </e1> - induced <e2> cardiomyopathy </e2> rats , and their relationship with echocardiographic and histological findings .
CID	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of <e2> myocardial damage </e2> in a rat model of <e1> doxorubicin </e1> ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
CID	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1> doxorubicin </e1> ( DOX ) - induced <e2> cardiomyopathy </e2> , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
NO_RELATION	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1> doxorubicin </e1> ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of <e2> cardiac disorders </e2> monitored by echocardiography and histological examinations in this model .
CID	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of <e2> myocardial damage </e2> in a rat model of doxorubicin ( <e1> DOX </e1> ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
CID	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( <e1> DOX </e1> ) - induced <e2> cardiomyopathy </e2> , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
NO_RELATION	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( <e1> DOX </e1> ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of <e2> cardiac disorders </e2> monitored by echocardiography and histological examinations in this model .
NO_RELATION	RESULTS : Eighteen of the <e1> DOX </e1> rats died prematurely of general <e2> toxicity </e2> during the 9 - week period .
NO_RELATION	Histological evaluation of hearts from all rats given <e1> DOX </e1> revealed significant slight degrees of perivascular and interstitial <e2> fibrosis </e2> .
NO_RELATION	CONCLUSIONS : Among markers of <e2> ischemic injury </e2> after <e1> DOX </e1> in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .
CID	CONCLUSIONS : Among markers of ischemic injury after <e1> DOX </e1> in rats , cTnT showed the greatest ability to detect <e2> myocardial damage </e2> assessed by echocardiographic detection and histological changes .
NO_RELATION	Although there was a discrepancy between the amount of cTnI and cTnT after <e1> DOX </e1> , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2> cardiotoxicity </e2> and possibly for cardioprotective experiments .
NO_RELATION	Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after <e1> DOX </e1> indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2> cardiotoxicity </e2> and possibly for cardioprotective experiments .
CID	The reduction of <e1> cyclosporine </e1> - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of <e2> pain </e2> .
CID	The reduction of cyclosporine - or <e1> tacrolimus </e1> trough levels and the administration of calcium channel blockers led to relief of <e2> pain </e2> .
NO_RELATION	The reduction of cyclosporine - or tacrolimus trough levels and the administration of <e1> calcium </e1> channel blockers led to relief of <e2> pain </e2> .
CID	The Calcineurin - inhibitor Induced <e2> Pain </e2> Syndrome ( CIPS ) is a rare but severe side effect of <e1> cyclosporine </e1> or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
NO_RELATION	The Calcineurin - inhibitor Induced Pain Syndrome ( <e2> CIPS </e2> ) is a rare but severe side effect of <e1> cyclosporine </e1> or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
CID	The Calcineurin - inhibitor Induced <e2> Pain </e2> Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or <e1> tacrolimus </e1> and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
NO_RELATION	The Calcineurin - inhibitor Induced Pain Syndrome ( <e2> CIPS </e2> ) is a rare but severe side effect of cyclosporine or <e1> tacrolimus </e1> and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
NO_RELATION	We investigated the safety and efficacy of adding different doses of <e1> ephedrine </e1> to propofol in order to obtund the <e2> hypotensive </e2> response .
CID	We investigated the safety and efficacy of adding different doses of ephedrine to <e1> propofol </e1> in order to obtund the <e2> hypotensive </e2> response .
NO_RELATION	The addition of <e1> ephedrine </e1> to propofol appears to be an effective method of obtunding the <e2> hypotensive </e2> response to propofol at all doses used in this study .
CID	The addition of ephedrine to <e1> propofol </e1> appears to be an effective method of obtunding the <e2> hypotensive </e2> response to propofol at all doses used in this study .
CID	The addition of ephedrine to propofol appears to be an effective method of obtunding the <e2> hypotensive </e2> response to <e1> propofol </e1> at all doses used in this study .
CID	However , marked <e2> tachycardia </e2> associated with the use of <e1> ephedrine </e1> in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .
CID	However , marked <e2> tachycardia </e2> associated with the use of ephedrine in combination with <e1> propofol </e1> occurred in the majority of patients , occasionally reaching high levels in individual patients .
CID	Due to the risk of this <e2> tachycardia </e2> inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the <e1> ephedrine </e1> / propofol / mixtures studied .
NO_RELATION	Due to the risk of this tachycardia inducing <e2> myocardial ischemia </e2> , we would not recommend the use in elderly patients of any of the <e1> ephedrine </e1> / propofol / mixtures studied .
CID	Due to the risk of this <e2> tachycardia </e2> inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / <e1> propofol </e1> / mixtures studied .
NO_RELATION	Due to the risk of this tachycardia inducing <e2> myocardial ischemia </e2> , we would not recommend the use in elderly patients of any of the ephedrine / <e1> propofol </e1> / mixtures studied .
NO_RELATION	<e2> Neurotoxicity </e2> of <e1> halogenated hydroxyquinolines </e1> : clinical analysis of cases reported outside Japan .
NO_RELATION	An analysis is presented of 220 cases of possible <e2> neurotoxic </e2> reactions to <e1> halogenated hydroxyquinolines </e1> reported from outside Japan .
NO_RELATION	In six of the probable cases the <e2> neurological disturbance </e2> consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of <e1> clioquinol </e1> over a short period .
CID	In six of the probable cases the neurological disturbance consisted of an acute reversible <e2> encephalopathy </e2> usually related to the ingestion of a high dose of <e1> clioquinol </e1> over a short period .
NO_RELATION	This was most frequently found in children , many of whom had received <e1> clioquinol </e1> as treatment for <e2> acrodermatitis enteropathica </e2> .
NO_RELATION	<e2> Epileptic seizures </e2> following cortical application of fibrin sealants containing <e1> tranexamic acid </e1> in rats .
NO_RELATION	However , <e1> tAMCA </e1> has been shown to cause <e2> epileptic seizures </e2> .
CID	We wanted to study whether <e1> tAMCA </e1> retains its <e2> convulsive </e2> action if incorporated into a FS .
CID	FINDINGS : FS containing <e1> tAMCA </e1> caused paroxysmal brain activity which was associated with distinct <e2> convulsive </e2> behaviours .
CID	The degree of these <e2> seizures </e2> increased with increasing concentration of <e1> tAMCA </e1> .
CID	Thus , FS containing 47 . 5 mg / ml <e1> tAMCA </e1> evoked <e2> generalized seizures </e2> in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .
CID	Thus , FS containing 47 . 5 mg / ml <e1> tAMCA </e1> evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated <e2> convulsive </e2> potentials in 1 of 6 rats .
CID	Thus , FS containing 47 . 5 mg / ml tAMCA evoked <e2> generalized seizures </e2> in all tested rats ( n = 6 ) while the lowest concentration of <e1> tAMCA </e1> ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .
CID	Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of <e1> tAMCA </e1> ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated <e2> convulsive </e2> potentials in 1 of 6 rats .
CID	INTERPRETATION : <e1> Tranexamic acid </e1> retains its <e2> convulsive </e2> action within FS .
NO_RELATION	A diet promoting <e2> sugar dependency </e2> causes behavioral cross - sensitization to a low dose of <e1> amphetamine </e1> .
CID	A diet promoting sugar dependency causes <e2> behavioral cross - sensitization </e2> to a low dose of <e1> amphetamine </e1> .
CID	The present study examined whether female rats on various regimens of sugar access would show <e2> behavioral cross - sensitization </e2> to a low dose of <e1> amphetamine </e1> .
CID	The animals that had experienced cyclic <e1> sucrose </e1> and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to <e1> amphetamine </e1> compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % <e1> sucrose </e1> and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by <e1> amphetamine </e1> injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by <e1> amphetamine </e1> injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with <e1> amphetamine </e1> , or cyclic 10 % sucrose and chow with a saline injection ) .
CID	The animals that had experienced cyclic sucrose and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % <e1> sucrose </e1> and chow with a saline injection ) .
CID	<e1> D - penicillamine </e1> - induced <e2> angiopathy </e2> in rats .
NO_RELATION	Brain natriuretic peptide is a predictor of <e1> anthracycline </e1> - induced <e2> cardiotoxicity </e2> .
NO_RELATION	<e1> Anthracyclines </e1> are effective antineoplastic drugs , but they frequently cause dose - related <e2> cardiotoxicity </e2> .
NO_RELATION	The <e2> cardiotoxicity </e2> of conventional <e1> anthracycline </e1> therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .
NO_RELATION	The cardiotoxicity of conventional <e1> anthracycline </e1> therapy highlights a need to search for methods that are highly sensitive and capable of predicting <e2> cardiac dysfunction </e2> .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of <e1> anthracycline </e1> - induced <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of <e1> anthracycline </e1> - induced cardiotoxicity in patients with <e2> acute leukemia </e2> treated with a daunorubicin ( DNR ) - containing regimen .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a <e1> daunorubicin </e1> ( DNR ) - containing regimen .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with <e2> acute leukemia </e2> treated with a <e1> daunorubicin </e1> ( DNR ) - containing regimen .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a daunorubicin ( <e1> DNR </e1> ) - containing regimen .
NO_RELATION	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with <e2> acute leukemia </e2> treated with a daunorubicin ( <e1> DNR </e1> ) - containing regimen .
NO_RELATION	Thirteen patients with <e2> acute leukemia </e2> were treated with a <e1> DNR </e1> - containing regimen .
CID	On the other hand , BNP did not increase in the patients without <e2> heart failure </e2> given <e1> DNR </e1> , even at more than 700 mg / m ( 2 ) .
NO_RELATION	These preliminary results suggest that BNP may be useful as an early and sensitive indicator of <e1> anthracycline </e1> - induced <e2> cardiotoxicity </e2> .
CID	<e1> Sulfonamides </e1> were associated with <e2> anencephaly </e2> ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Sulfonamides </e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , <e2> hypoplastic left heart syndrome </e2> ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Sulfonamides </e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , <e2> coarctation of the aorta </e2> ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Sulfonamides </e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , <e2> choanal atresia </e2> ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Sulfonamides </e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , <e2> transverse limb deficiency </e2> ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Sulfonamides </e1> were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and <e2> diaphragmatic hernia </e2> ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
CID	<e1> Nitrofurantoins </e1> were associated with <e2> anophthalmia </e2> or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
CID	<e1> Nitrofurantoins </e1> were associated with anophthalmia or <e2> microphthalmos </e2> ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
CID	<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , <e2> hypoplastic left heart syndrome </e2> ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
CID	<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , <e2> atrial septal defects </e2> ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
CID	<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and <e2> cleft lip </e2> with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
CID	<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with <e2> cleft palate </e2> ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
NO_RELATION	CONCLUSIONS : Reassuringly , <e1> penicillins </e1> , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many <e2> birth defects </e2> .
NO_RELATION	CONCLUSIONS : Reassuringly , penicillins , <e1> erythromycins </e1> , and cephalosporins , although used commonly by pregnant women , were not associated with many <e2> birth defects </e2> .
NO_RELATION	CONCLUSIONS : Reassuringly , penicillins , erythromycins , and <e1> cephalosporins </e1> , although used commonly by pregnant women , were not associated with many <e2> birth defects </e2> .
CID	<e1> Sulfonamides </e1> and nitrofurantoins were associated with several <e2> birth defects </e2> , indicating a need for additional scrutiny .
CID	Sulfonamides and <e1> nitrofurantoins </e1> were associated with several <e2> birth defects </e2> , indicating a need for additional scrutiny .
CID	Patients treated with <e1> alkylating agents </e1> have an increased risk of development of <e2> acute nonlymphocytic leukemia </e2> , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin ' s lymphoma .
CID	Patients treated with <e1> alkylating agents </e1> have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of <e2> non - Hodgkin ' s lymphoma </e2> .
CID	Patients treated with alkylating agents have an increased risk of development of <e2> acute nonlymphocytic leukemia </e2> , and both <e1> alkylating agents </e1> and azathioprine are associated with the development of non - Hodgkin ' s lymphoma .
CID	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both <e1> alkylating agents </e1> and azathioprine are associated with the development of <e2> non - Hodgkin ' s lymphoma </e2> .
NO_RELATION	Patients treated with alkylating agents have an increased risk of development of <e2> acute nonlymphocytic leukemia </e2> , and both alkylating agents and <e1> azathioprine </e1> are associated with the development of non - Hodgkin ' s lymphoma .
CID	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and <e1> azathioprine </e1> are associated with the development of <e2> non - Hodgkin ' s lymphoma </e2> .
NO_RELATION	<e1> Cyclophosphamide </e1> therapy increases the risk of <e2> carcinoma of the bladder </e2> .
NO_RELATION	There have been several long - term studies of patients with <e2> rheumatoid arthritis </e2> treated with <e1> azathioprine </e1> and cyclophosphamide and the incidence of most of the common cancers is not increased .
NO_RELATION	There have been several long - term studies of patients with rheumatoid arthritis treated with <e1> azathioprine </e1> and cyclophosphamide and the incidence of most of the common <e2> cancers </e2> is not increased .
NO_RELATION	There have been several long - term studies of patients with <e2> rheumatoid arthritis </e2> treated with azathioprine and <e1> cyclophosphamide </e1> and the incidence of most of the common cancers is not increased .
NO_RELATION	There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and <e1> cyclophosphamide </e1> and the incidence of most of the common <e2> cancers </e2> is not increased .
NO_RELATION	Data on the possible increased risk of <e2> malignancy </e2> in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1> alkylating agents </e1> , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .
NO_RELATION	Data on the possible increased risk of malignancy in <e2> rheumatoid arthritis </e2> are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1> alkylating agents </e1> , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .
NO_RELATION	Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly <e1> alkylating agents </e1> , in the treatment of <e2> rheumatoid arthritis </e2> should be reserved for patients with severe progressive disease or life - threatening complications .
CID	Patterns of <e2> hepatic injury </e2> induced by <e1> methyldopa </e1> .
NO_RELATION	Twelve patients with <e2> liver disease </e2> related to <e1> methyldopa </e1> were seen between 1967 and 1977 .
NO_RELATION	One patient died , having presented in <e2> hepatic failure </e2> , and another , who had been taking <e1> methyldopa </e1> for 7 years , showed slower clinical and biochemical resolution over a period of several months .
NO_RELATION	The remaining patient in the series developed <e2> fulminant hepatitis </e2> when the drug was accidentally recommenced 1 year after a prior episode of <e1> methyldopa </e1> - induced hepatitis .
CID	The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of <e1> methyldopa </e1> - induced <e2> hepatitis </e2> .
NO_RELATION	In this latter patient , and in 2 others , the causal relationship between <e1> methyldopa </e1> and <e2> hepatic dysfunction </e2> was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .
CID	In this latter patient , and in 2 others , the causal relationship between <e1> methyldopa </e1> and hepatic dysfunction was proved with the recurrence of <e2> hepatitis </e2> within 2 weeks of re - exposure to the drug .
NO_RELATION	A phase I / II study of <e1> paclitaxel </e1> plus cisplatin as first - line therapy for <e2> head and neck cancers </e2> : preliminary results .
NO_RELATION	A phase I / II study of paclitaxel plus <e1> cisplatin </e1> as first - line therapy for <e2> head and neck cancers </e2> : preliminary results .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent <e1> paclitaxel </e1> ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2> head and neck cancer </e2> , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent <e1> paclitaxel </e1> ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( <e1> Taxol </e1> ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2> head and neck cancer </e2> , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( <e1> Taxol </e1> ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2> head and neck cancer </e2> , and the <e1> paclitaxel </e1> / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the <e1> paclitaxel </e1> / cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with <e2> head and neck cancer </e2> , and the paclitaxel / <e1> cisplatin </e1> combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
NO_RELATION	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / <e1> cisplatin </e1> combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients .
NO_RELATION	We initiated a phase I / II trial to determine the response and <e2> toxicity </e2> of escalating <e1> paclitaxel </e1> doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
NO_RELATION	We initiated a phase I / II trial to determine the response and toxicity of escalating <e1> paclitaxel </e1> doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable <e2> head and neck carcinoma </e2> .
NO_RELATION	We initiated a phase I / II trial to determine the response and <e2> toxicity </e2> of escalating paclitaxel doses combined with fixed - dose <e1> cisplatin </e1> with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
NO_RELATION	We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose <e1> cisplatin </e1> with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable <e2> head and neck carcinoma </e2> .
NO_RELATION	The dose levels incorporate escalating <e1> paclitaxel </e1> doses , and intrapatient escalations within a given dose level are permitted if <e2> toxicity </e2> permits .
NO_RELATION	<e1> Paclitaxel </e1> / cisplatin is an effective first - line regimen for locoregionally advanced <e2> head and neck cancer </e2> and continued study is warranted .
NO_RELATION	Paclitaxel / <e1> cisplatin </e1> is an effective first - line regimen for locoregionally advanced <e2> head and neck cancer </e2> and continued study is warranted .
NO_RELATION	A Phase I study of intravenous ( IV ) bolus <e1> 4 ' - 0 - tetrahydropyranyladriamycin </e1> ( Pirarubicin ) was done in 55 patients in good performance status with refractory <e2> tumors </e2> .
NO_RELATION	A Phase I study of intravenous ( IV ) bolus 4 ' - 0 - tetrahydropyranyladriamycin ( <e1> Pirarubicin </e1> ) was done in 55 patients in good performance status with refractory <e2> tumors </e2> .
NO_RELATION	Differential effects of <e1> gamma - hexachlorocyclohexane </e1> ( lindane ) on pharmacologically - induced <e2> seizures </e2> .
NO_RELATION	Differential effects of gamma - hexachlorocyclohexane ( <e1> lindane </e1> ) on pharmacologically - induced <e2> seizures </e2> .
NO_RELATION	<e1> Gamma - hexachlorocyclohexane </e1> ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	<e1> Gamma - hexachlorocyclohexane </e1> ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( <e1> gamma - HCH </e1> ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( <e1> gamma - HCH </e1> ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide <e1> lindane </e1> , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide <e1> lindane </e1> , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
CID	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( <e1> PTZ </e1> ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
CID	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( <e1> PTZ </e1> ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to <e1> gamma - HCH </e1> and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to <e1> gamma - HCH </e1> and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
CID	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to <e1> PTZ </e1> - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al .
CID	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to <e1> PTZ </e1> - induced <e2> seizures </e2> 24 h after exposure to gamma - HCH ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to <e1> gamma - HCH </e1> ( Vohland et al .
NO_RELATION	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced <e2> seizures </e2> 24 h after exposure to <e1> gamma - HCH </e1> ( Vohland et al .
NO_RELATION	In this study , the severity of response to other <e2> seizure </e2> - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg <e1> gamma - HCH </e1> .
NO_RELATION	One hour after the administration of <e1> gamma - HCH </e1> , the activity of <e2> seizure </e2> - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .
NO_RELATION	One hour after the administration of gamma - HCH , the activity of <e2> seizure </e2> - inducing agents was increased , regardless of their mechanism , while 24 h after <e1> gamma - HCH </e1> a differential response was observed .
CID	<e2> Seizure </e2> activity due to <e1> PTZ </e1> and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to <e1> PTZ </e1> and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and <e1> picrotoxin </e1> ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and <e1> picrotoxin </e1> ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( <e1> PTX </e1> ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( <e1> PTX </e1> ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to <e1> 3 - mercaptopropionic acid </e1> ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to <e1> 3 - mercaptopropionic acid </e1> ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( <e1> MPA </e1> ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( <e1> MPA </e1> ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , <e1> bicuculline </e1> ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , <e1> bicuculline </e1> ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( <e1> BCC </e1> ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( <e1> BCC </e1> ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , <e1> methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate </e1> ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , <e1> methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate </e1> ( DMCM ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( <e1> DMCM </e1> ) , or strychnine ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( <e1> DMCM </e1> ) , or strychnine ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or <e1> strychnine </e1> ( STR ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or <e1> strychnine </e1> ( STR ) was not different from control .
CID	<e2> Seizure </e2> activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( <e1> STR </e1> ) was not different from control .
CID	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , <e2> seizure </e2> activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( <e1> STR </e1> ) was not different from control .
CID	The pharmacological challenge data suggest that tolerance may occur to <e2> seizure </e2> activity induced by <e1> PTZ </e1> and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .
CID	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by <e1> PTZ </e1> and PTX 24 h after gamma - HCH , since the response to only these two <e2> seizure </e2> - inducing agents is decreased .
CID	The pharmacological challenge data suggest that tolerance may occur to <e2> seizure </e2> activity induced by PTZ and <e1> PTX </e1> 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .
CID	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and <e1> PTX </e1> 24 h after gamma - HCH , since the response to only these two <e2> seizure </e2> - inducing agents is decreased .
NO_RELATION	The pharmacological challenge data suggest that tolerance may occur to <e2> seizure </e2> activity induced by PTZ and PTX 24 h after <e1> gamma - HCH </e1> , since the response to only these two seizure - inducing agents is decreased .
NO_RELATION	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after <e1> gamma - HCH </e1> , since the response to only these two <e2> seizure </e2> - inducing agents is decreased .
NO_RELATION	The in vitro data suggest that the site responsible for the decrease in <e2> seizure </e2> activity 24 h after <e1> gamma - HCH </e1> may be the GABA - A receptor - linked chloride channel .
NO_RELATION	The in vitro data suggest that the site responsible for the decrease in <e2> seizure </e2> activity 24 h after gamma - HCH may be the <e1> GABA </e1> - A receptor - linked chloride channel .
NO_RELATION	Severe <e2> ocular and orbital toxicity </e2> after intracarotid injection of <e1> carboplatin </e1> for recurrent glioblastomas .
NO_RELATION	Severe ocular and orbital toxicity after intracarotid injection of <e1> carboplatin </e1> for recurrent <e2> glioblastomas </e2> .
NO_RELATION	Generally , <e1> carboplatin </e1> is said to have milder side effects than cisplatin , whose <e2> ocular and orbital toxicity </e2> are well known .
NO_RELATION	Generally , carboplatin is said to have milder side effects than <e1> cisplatin </e1> , whose <e2> ocular and orbital toxicity </e2> are well known .
NO_RELATION	However , we experienced a case of severe <e2> ocular and orbital toxicity </e2> after intracarotid injection of <e1> carboplatin </e1> , which is infrequently reported .
NO_RELATION	CASE : A 58 - year - old man received an intracarotid injection of <e1> carboplatin </e1> for recurrent <e2> glioblastomas </e2> in his left temporal lobe .
NO_RELATION	Various ocular symptoms and findings caused by <e1> carboplatin </e1> <e2> toxicity </e2> were seen .
NO_RELATION	CONCLUSION : When performing intracarotid injection of <e1> carboplatin </e1> , we must be aware of its potentially blinding <e2> ocular toxicity </e2> .
NO_RELATION	Phase II study of the <e1> amsacrine </e1> analogue CI - 921 ( NSC 343499 ) in <e2> non - small cell lung cancer </e2> .
NO_RELATION	Phase II study of the amsacrine analogue <e1> CI - 921 </e1> ( NSC 343499 ) in <e2> non - small cell lung cancer </e2> .
NO_RELATION	Phase II study of the amsacrine analogue CI - 921 ( <e1> NSC 343499 </e1> ) in <e2> non - small cell lung cancer </e2> .
NO_RELATION	<e1> Alpha - lipoic acid </e1> prevents <e2> mitochondrial damage </e2> and neurotoxicity in experimental chemotherapy neuropathy .
NO_RELATION	<e1> Alpha - lipoic acid </e1> prevents mitochondrial damage and <e2> neurotoxicity </e2> in experimental chemotherapy neuropathy .
NO_RELATION	<e1> Alpha - lipoic acid </e1> prevents mitochondrial damage and neurotoxicity in experimental chemotherapy <e2> neuropathy </e2> .
NO_RELATION	The study investigates if <e1> alpha - lipoic acid </e1> is neuroprotective against chemotherapy induced <e2> neurotoxicity </e2> , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .
NO_RELATION	The study investigates if <e1> alpha - lipoic acid </e1> is neuroprotective against chemotherapy induced neurotoxicity , if <e2> mitochondrial damage </e2> plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .
NO_RELATION	The study investigates if <e1> alpha - lipoic acid </e1> is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in <e2> toxic neurodegenerative cascade </e2> , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .
NO_RELATION	The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced <e2> neurotoxicity </e2> , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of <e1> alpha - lipoic acid </e1> depend on mitochondria protection .
NO_RELATION	The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if <e2> mitochondrial damage </e2> plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of <e1> alpha - lipoic acid </e1> depend on mitochondria protection .
NO_RELATION	The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in <e2> toxic neurodegenerative cascade </e2> , and if neuroprotective effects of <e1> alpha - lipoic acid </e1> depend on mitochondria protection .
CID	We used an in vitro model of chemotherapy induced <e2> peripheral neuropathy </e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to <e1> paclitaxel </e1> and cisplatin , two widely used and highly effective chemotherapeutic drugs .
CID	We used an in vitro model of chemotherapy induced <e2> peripheral neuropathy </e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and <e1> cisplatin </e1> , two widely used and highly effective chemotherapeutic drugs .
NO_RELATION	This approach allowed investigating the efficacy of <e1> alpha - lipoic acid </e1> in preventing <e2> axonal damage </e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .
NO_RELATION	This approach allowed investigating the efficacy of alpha - lipoic acid in preventing <e2> axonal damage </e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and <e1> alpha - lipoic acid </e1> .
NO_RELATION	Our results demonstrate that both <e1> cisplatin </e1> and paclitaxel cause early <e2> mitochondrial impairment </e2> with loss of membrane potential and induction of autophagic vacuoles in neurons .
NO_RELATION	Our results demonstrate that both cisplatin and <e1> paclitaxel </e1> cause early <e2> mitochondrial impairment </e2> with loss of membrane potential and induction of autophagic vacuoles in neurons .
NO_RELATION	<e1> Alpha - lipoic acid </e1> exerts neuroprotective effects against chemotherapy induced <e2> neurotoxicity </e2> in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .
NO_RELATION	<e1> Alpha - lipoic acid </e1> exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the <e2> mitochondrial toxicity </e2> and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .
NO_RELATION	In conclusion <e2> mitochondrial toxicity </e2> is an early common event both in <e1> paclitaxel </e1> and cisplatin induced neurotoxicity .
NO_RELATION	In conclusion mitochondrial toxicity is an early common event both in <e1> paclitaxel </e1> and cisplatin induced <e2> neurotoxicity </e2> .
NO_RELATION	In conclusion <e2> mitochondrial toxicity </e2> is an early common event both in paclitaxel and <e1> cisplatin </e1> induced neurotoxicity .
NO_RELATION	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and <e1> cisplatin </e1> induced <e2> neurotoxicity </e2> .
NO_RELATION	These findings suggest that <e1> alpha - lipoic acid </e1> might reduce the risk of developing <e2> peripheral nerve toxicity </e2> in patients undergoing chemotherapy and encourage further confirmatory clinical trials .
NO_RELATION	Pooled data from trials comparing antithrombotic treatment with placebo have shown that <e1> warfarin </e1> reduces the risk of <e2> stroke </e2> by 62 % , and that aspirin alone reduces the risk by 22 % .
NO_RELATION	Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of <e2> stroke </e2> by 62 % , and that <e1> aspirin </e1> alone reduces the risk by 22 % .
NO_RELATION	Overall , in high - risk patients , <e1> warfarin </e1> is superior to aspirin in preventing <e2> strokes </e2> , with a relative risk reduction of 36 % .
NO_RELATION	Overall , in high - risk patients , warfarin is superior to <e1> aspirin </e1> in preventing <e2> strokes </e2> , with a relative risk reduction of 36 % .
NO_RELATION	<e1> Ximelagatran </e1> , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of <e2> embolic events </e2> , but has been recently withdrawn because of abnormal liver function tests .
CID	<e1> Ximelagatran </e1> , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of <e2> abnormal liver function </e2> tests .
NO_RELATION	Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as <e1> vitamin K </e1> antagonist drugs in the prevention of <e2> embolic events </e2> , but has been recently withdrawn because of abnormal liver function tests .
NO_RELATION	Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as <e1> vitamin K </e1> antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of <e2> abnormal liver function </e2> tests .
NO_RELATION	The ACTIVE - W ( <e2> Atrial Fibrillation </e2> <e1> Clopidogrel </e1> Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
NO_RELATION	The ACTIVE - W ( Atrial Fibrillation <e1> Clopidogrel </e1> Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2> embolic events </e2> .
NO_RELATION	The ACTIVE - W ( <e2> Atrial Fibrillation </e2> Clopidogrel Trial with <e1> Irbesartan </e1> for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
NO_RELATION	The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with <e1> Irbesartan </e1> for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2> embolic events </e2> .
NO_RELATION	The ACTIVE - W ( <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that <e1> warfarin </e1> is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
NO_RELATION	The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that <e1> warfarin </e1> is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af <e2> embolic events </e2> .
NO_RELATION	The ACTIVE - W ( <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( <e1> clopidogrel </e1> plus aspirin ) in the prevention af embolic events .
NO_RELATION	The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( <e1> clopidogrel </e1> plus aspirin ) in the prevention af <e2> embolic events </e2> .
NO_RELATION	The ACTIVE - W ( <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus <e1> aspirin </e1> ) in the prevention af embolic events .
NO_RELATION	The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus <e1> aspirin </e1> ) in the prevention af <e2> embolic events </e2> .
NO_RELATION	<e1> Idraparinux </e1> , a Factor Xa inhibitor , is being evaluated in patients with <e2> atrial fibrillation </e2> .
NO_RELATION	<e1> Angiotensin </e1> - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in <e2> atrial fibrillation </e2> through cardiac remodelling .
NO_RELATION	<e1> Angiotensin </e1> - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through <e2> cardiac remodelling </e2> .
NO_RELATION	Angiotensin - converting enzyme inhibitors and <e1> angiotensin II </e1> receptor - blocking drugs hold promise in <e2> atrial fibrillation </e2> through cardiac remodelling .
NO_RELATION	Angiotensin - converting enzyme inhibitors and <e1> angiotensin II </e1> receptor - blocking drugs hold promise in atrial fibrillation through <e2> cardiac remodelling </e2> .
NO_RELATION	A synergistic effect of <e1> etoposide </e1> and cyclosporin A was observed in a patient with <e2> acute T - lymphocytic leukemia </e2> in relapse .
NO_RELATION	A synergistic effect of etoposide and <e1> cyclosporin A </e1> was observed in a patient with <e2> acute T - lymphocytic leukemia </e2> in relapse .
NO_RELATION	The concomitant administration of <e1> etoposide </e1> and cyclosporin A resulted in eradication of hitherto refractory <e2> leukemic infiltration </e2> of bone marrow .
NO_RELATION	The concomitant administration of etoposide and <e1> cyclosporin A </e1> resulted in eradication of hitherto refractory <e2> leukemic infiltration </e2> of bone marrow .
NO_RELATION	The hematologic effects of <e1> cefonicid </e1> and cefazedone in the dog : a potential model of cephalosporin <e2> hematotoxicity </e2> in man .
NO_RELATION	The hematologic effects of cefonicid and <e1> cefazedone </e1> in the dog : a potential model of cephalosporin <e2> hematotoxicity </e2> in man .
NO_RELATION	The hematologic effects of cefonicid and cefazedone in the dog : a potential model of <e1> cephalosporin </e1> <e2> hematotoxicity </e2> in man .
NO_RELATION	<e1> Cephalosporin </e1> antibiotics cause a variety of <e2> hematologic disturbances </e2> in man , the pathogeneses and hematopathology of which remain poorly characterized .
NO_RELATION	In four subacute <e2> toxicity </e2> studies , the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose - dependent incidence of <e2> anemia </e2> , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , <e2> neutropenia </e2> , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and <e2> thrombocytopenia </e2> after 1 - 3 months of treatment .
NO_RELATION	In four subacute <e2> toxicity </e2> studies , the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose - dependent incidence of <e2> anemia </e2> , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose - dependent incidence of anemia , <e2> neutropenia </e2> , and thrombocytopenia after 1 - 3 months of treatment .
CID	In four subacute toxicity studies , the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and <e2> thrombocytopenia </e2> after 1 - 3 months of treatment .
CID	A nonregenerative <e2> anemia </e2> was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg <e1> cefonicid </e1> or 540 - 840 mg / kg cefazedone .
NO_RELATION	A nonregenerative anemia was the most compromising of the <e2> cytopenias </e2> and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg <e1> cefonicid </e1> or 540 - 840 mg / kg cefazedone .
CID	A nonregenerative <e2> anemia </e2> was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg <e1> cefazedone </e1> .
NO_RELATION	A nonregenerative anemia was the most compromising of the <e2> cytopenias </e2> and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg <e1> cefazedone </e1> .
NO_RELATION	Upon rechallenge with either <e1> cephalosporin </e1> , the <e2> hematologic syndrome </e2> was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .
NO_RELATION	Upon rechallenge with either cephalosporin , the <e2> hematologic syndrome </e2> was reproduced in most dogs tested ; <e1> cefonicid </e1> ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .
NO_RELATION	Upon rechallenge with either cephalosporin , the <e2> hematologic syndrome </e2> was reproduced in most dogs tested ; cefonicid ( but not <e1> cefazedone </e1> ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .
NO_RELATION	We conclude that the administration of high doses of <e1> cefonicid </e1> or cefazedone to dogs can induce <e2> hematotoxicity </e2> similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	We conclude that the administration of high doses of <e1> cefonicid </e1> or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	We conclude that the administration of high doses of cefonicid or <e1> cefazedone </e1> to dogs can induce <e2> hematotoxicity </e2> similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	We conclude that the administration of high doses of cefonicid or <e1> cefazedone </e1> to dogs can induce hematotoxicity similar to the cephalosporin - induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce <e2> hematotoxicity </e2> similar to the <e1> cephalosporin </e1> - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the <e1> cephalosporin </e1> - induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders .
NO_RELATION	A <e1> pyridoxine </e1> - dependent <e2> behavioral disorder </e2> unmasked by isoniazid .
CID	A pyridoxine - dependent <e2> behavioral disorder </e2> unmasked by <e1> isoniazid </e1> .
CID	A 3 - year - old girl had <e2> behavioral deterioration </e2> , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> .
CID	A 3 - year - old girl had behavioral deterioration , with <e2> hyperkinesis </e2> , irritability , and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> .
NO_RELATION	A 3 - year - old girl had behavioral deterioration , with hyperkinesis , <e2> irritability </e2> , and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> .
NO_RELATION	A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and <e2> sleeping difficulties </e2> after the therapeutic administration of <e1> isoniazid </e1> .
NO_RELATION	Periodic withdrawal of <e1> pyridoxine </e1> was associated with return of the <e2> hyperkinesis </e2> .
NO_RELATION	<e1> NRA0160 </e1> and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine ( MAP ) in mice .
NO_RELATION	NRA0160 and <e1> clozapine </e1> antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine ( MAP ) in mice .
CID	NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by <e1> methamphetamine </e1> ( MAP ) in mice .
CID	NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine ( <e1> MAP </e1> ) in mice .
CID	<e1> NRA0160 </e1> and clozapine significantly induced <e2> catalepsy </e2> in rats , although their effects did not exceed 50 % induction even at the highest dose given .
CID	NRA0160 and <e1> clozapine </e1> significantly induced <e2> catalepsy </e2> in rats , although their effects did not exceed 50 % induction even at the highest dose given .
CID	Prolonged <e2> cholestasis </e2> after <e1> troleandomycin </e1> - induced acute hepatitis .
CID	Prolonged cholestasis after <e1> troleandomycin </e1> - induced acute <e2> hepatitis </e2> .
CID	We report the case of a patient in whom <e1> troleandomycin </e1> - induced <e2> hepatitis </e2> was followed by prolonged anicteric cholestasis .
CID	We report the case of a patient in whom <e1> troleandomycin </e1> - induced hepatitis was followed by prolonged anicteric <e2> cholestasis </e2> .
CID	<e2> Jaundice </e2> occurred after administration of <e1> troleandomycin </e1> for 7 days and was associated with hypereosinophilia .
CID	Jaundice occurred after administration of <e1> troleandomycin </e1> for 7 days and was associated with <e2> hypereosinophilia </e2> .
CID	This observation demonstrates that prolonged <e2> cholestasis </e2> can follow <e1> troleandomycin </e1> - induced acute hepatitis .
CID	This observation demonstrates that prolonged cholestasis can follow <e1> troleandomycin </e1> - induced acute <e2> hepatitis </e2> .
NO_RELATION	<e2> Myopathy </e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with <e1> lovastatin </e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
CID	Myopathy , associated in some cases with <e2> myoglobinuria </e2> , and in 2 cases with transient renal failure , has been rarely reported with <e1> lovastatin </e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
CID	Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2> renal failure </e2> , has been rarely reported with <e1> lovastatin </e1> , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
CID	<e2> Myopathy </e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1> cyclosporin </e1> , gemfibrozil or niacin .
NO_RELATION	Myopathy , associated in some cases with <e2> myoglobinuria </e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1> cyclosporin </e1> , gemfibrozil or niacin .
NO_RELATION	Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2> renal failure </e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with <e1> cyclosporin </e1> , gemfibrozil or niacin .
CID	<e2> Myopathy </e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1> gemfibrozil </e1> or niacin .
NO_RELATION	Myopathy , associated in some cases with <e2> myoglobinuria </e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1> gemfibrozil </e1> or niacin .
NO_RELATION	Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2> renal failure </e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , <e1> gemfibrozil </e1> or niacin .
CID	<e2> Myopathy </e2> , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1> niacin </e1> .
NO_RELATION	Myopathy , associated in some cases with <e2> myoglobinuria </e2> , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1> niacin </e1> .
NO_RELATION	Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient <e2> renal failure </e2> , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or <e1> niacin </e1> .
CID	<e1> Sulfasalazine </e1> - induced <e2> lupus erythematosus </e2> .
CID	<e2> Pneumonitis </e2> , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term <e1> sulfasalazine </e1> therapy for chronic ulcerative colitis .
CID	Pneumonitis , bilateral <e2> pleural effusions </e2> , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term <e1> sulfasalazine </e1> therapy for chronic ulcerative colitis .
CID	Pneumonitis , bilateral pleural effusions , echocardiographic evidence of <e2> cardiac tamponade </e2> , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term <e1> sulfasalazine </e1> therapy for chronic ulcerative colitis .
NO_RELATION	Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term <e1> sulfasalazine </e1> therapy for chronic <e2> ulcerative colitis </e2> .
CID	It is suggested that the patient had <e1> sulfasalazine </e1> - induced <e2> lupus </e2> , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .
NO_RELATION	It is suggested that the patient had <e1> sulfasalazine </e1> - induced lupus , which manifested with <e2> serositis </e2> and pulmonary parenchymal involvement in the absence of joint symptoms .
NO_RELATION	Physicians who use <e1> sulfasalazine </e1> to treat patients with <e2> inflammatory bowel disease </e2> should be aware of the signs of sulfasalazine - induced lupus syndrome .
CID	Physicians who use <e1> sulfasalazine </e1> to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced <e2> lupus syndrome </e2> .
NO_RELATION	Physicians who use sulfasalazine to treat patients with <e2> inflammatory bowel disease </e2> should be aware of the signs of <e1> sulfasalazine </e1> - induced lupus syndrome .
CID	Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of <e1> sulfasalazine </e1> - induced <e2> lupus syndrome </e2> .
NO_RELATION	While there is no single correct starting dose for <e1> levodopa </e1> therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of " normality , " which can lead to <e2> toxicity </e2> .
NO_RELATION	While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate <e1> carbidopa </e1> - levodopa to the point of " normality , " which can lead to <e2> toxicity </e2> .
NO_RELATION	While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - <e1> levodopa </e1> to the point of " normality , " which can lead to <e2> toxicity </e2> .
CID	Other possible adverse effects - - such as <e2> gastrointestinal disorders </e2> , orthostatic hypotension , <e1> levodopa </e1> - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
CID	Other possible adverse effects - - such as gastrointestinal disorders , <e2> orthostatic hypotension </e2> , <e1> levodopa </e1> - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
NO_RELATION	Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , <e1> levodopa </e1> - induced <e2> psychosis </e2> , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
NO_RELATION	Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , <e1> levodopa </e1> - induced psychosis , <e2> sleep disturbances </e2> or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
CID	Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , <e1> levodopa </e1> - induced psychosis , sleep disturbances or <e2> parasomnias </e2> , or drug interactions - - also require carefully monitored individual treatment .
NO_RELATION	Three patients received high doses of <e1> chlormethiazole </e1> for alcohol <e2> withdrawal symptoms </e2> , and one took a suicidal overdose of nitrazepam .
NO_RELATION	Three patients received high doses of <e1> chlormethiazole </e1> for alcohol withdrawal symptoms , and one took a suicidal <e2> overdose </e2> of nitrazepam .
NO_RELATION	Three patients received high doses of chlormethiazole for <e1> alcohol </e1> <e2> withdrawal symptoms </e2> , and one took a suicidal overdose of nitrazepam .
NO_RELATION	Three patients received high doses of chlormethiazole for <e1> alcohol </e1> withdrawal symptoms , and one took a suicidal <e2> overdose </e2> of nitrazepam .
NO_RELATION	Three patients received high doses of chlormethiazole for alcohol <e2> withdrawal symptoms </e2> , and one took a suicidal overdose of <e1> nitrazepam </e1> .
CID	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal <e2> overdose </e2> of <e1> nitrazepam </e1> .
CID	The patient with <e1> nitrazepam </e1> <e2> overdose </e2> and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
CID	The patient with <e1> nitrazepam </e1> overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha <e2> coma </e2> ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
NO_RELATION	The patient with nitrazepam <e2> overdose </e2> and two of those with <e1> chlormethiazole </e1> intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
CID	The patient with nitrazepam overdose and two of those with <e1> chlormethiazole </e1> intoxication conformed to the criteria of ' alpha <e2> coma </e2> ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
NO_RELATION	Omitting <e1> fentanyl </e1> reduces <e2> nausea </e2> and vomiting , without increasing pain , after sevoflurane for day surgery .
NO_RELATION	Omitting <e1> fentanyl </e1> reduces nausea and <e2> vomiting </e2> , without increasing pain , after sevoflurane for day surgery .
NO_RELATION	Omitting <e1> fentanyl </e1> reduces nausea and vomiting , without increasing <e2> pain </e2> , after sevoflurane for day surgery .
NO_RELATION	Omitting fentanyl reduces <e2> nausea </e2> and vomiting , without increasing pain , after <e1> sevoflurane </e1> for day surgery .
NO_RELATION	Omitting fentanyl reduces nausea and <e2> vomiting </e2> , without increasing pain , after <e1> sevoflurane </e1> for day surgery .
NO_RELATION	Omitting fentanyl reduces nausea and vomiting , without increasing <e2> pain </e2> , after <e1> sevoflurane </e1> for day surgery .
NO_RELATION	BACKGROUND AND OBJECTIVE : Despite advantages of induction and maintenance of anaesthesia with <e1> sevoflurane </e1> , <e2> postoperative nausea and vomiting </e2> occurs frequently .
NO_RELATION	METHODS : This double - blind study examined the incidence and severity of <e2> postoperative nausea and vomiting </e2> and pain in the first 24 h after <e1> sevoflurane </e1> anaesthesia in 216 adult day surgery patients .
NO_RELATION	METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and <e2> pain </e2> in the first 24 h after <e1> sevoflurane </e1> anaesthesia in 216 adult day surgery patients .
CID	RESULTS : Omission of <e1> fentanyl </e1> did not reduce the overall incidence of <e2> postoperative nausea and vomiting </e2> , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of <e1> fentanyl </e1> did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2> vomiting </e2> and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of <e1> fentanyl </e1> did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe <e2> nausea </e2> prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
CID	RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2> postoperative nausea and vomiting </e2> , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with <e1> fentanyl </e1> and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2> vomiting </e2> and / or moderate to severe nausea prior to discharge from 20 % and 17 % with <e1> fentanyl </e1> and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe <e2> nausea </e2> prior to discharge from 20 % and 17 % with <e1> fentanyl </e1> and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
CID	RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2> postoperative nausea and vomiting </e2> , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1> fentanyl </e1> - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2> vomiting </e2> and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and <e1> fentanyl </e1> - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe <e2> nausea </e2> prior to discharge from 20 % and 17 % with fentanyl and <e1> fentanyl </e1> - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of <e2> postoperative nausea and vomiting </e2> , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - <e1> dexamethasone </e1> , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of <e2> vomiting </e2> and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - <e1> dexamethasone </e1> , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe <e2> nausea </e2> prior to discharge from 20 % and 17 % with fentanyl and fentanyl - <e1> dexamethasone </e1> , respectively , to 5 % ( P = 0 . 013 ) .
NO_RELATION	<e1> Dexamethasone </e1> had no significant effect on the incidence or severity of <e2> postoperative nausea and vomiting </e2> .
CID	Combining the two <e1> fentanyl </e1> groups revealed further significant benefits from the avoidance of opioids , reducing <e2> postoperative nausea and vomiting </e2> and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0 . 034 ) .
NO_RELATION	Combining the two <e1> fentanyl </e1> groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and <e2> nausea </e2> prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0 . 034 ) .
NO_RELATION	Combining the two <e1> fentanyl </e1> groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while <e2> nausea </e2> in the first 24 h was decreased from 42 % to 27 % ( P = 0 . 034 ) .
NO_RELATION	<e2> Pain </e2> severity and analgesic requirements were unaffected by the omission of <e1> fentanyl </e1> .
CID	<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased <e2> respiratory depression </e2> , hypotension and bradycardia .
CID	<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , <e2> hypotension </e2> and bradycardia .
CID	<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and <e2> bradycardia </e2> .
NO_RELATION	Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1> - sparing effect and increased <e2> respiratory depression </e2> , hypotension and bradycardia .
NO_RELATION	Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1> - sparing effect and increased respiratory depression , <e2> hypotension </e2> and bradycardia .
NO_RELATION	Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1> - sparing effect and increased respiratory depression , hypotension and <e2> bradycardia </e2> .
CID	CONCLUSION : As <e1> fentanyl </e1> exacerbated <e2> postoperative nausea and vomiting </e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
NO_RELATION	CONCLUSION : As <e1> fentanyl </e1> exacerbated postoperative nausea and vomiting without an improvement in <e2> postoperative pain </e2> and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
NO_RELATION	CONCLUSION : As fentanyl exacerbated <e2> postoperative nausea and vomiting </e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to <e1> sevoflurane </e1> in day surgery .
NO_RELATION	CONCLUSION : As fentanyl exacerbated postoperative nausea and vomiting without an improvement in <e2> postoperative pain </e2> and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to <e1> sevoflurane </e1> in day surgery .
NO_RELATION	<e1> Lamivudine </e1> was added because of de nova <e2> hepatitis B infection </e2> during her follow - up .
NO_RELATION	Although <e1> tacrolimus </e1> was suspected to be the cause of late post - transplant renal <e2> acidosis </e2> and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .
NO_RELATION	Although <e1> tacrolimus </e1> was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , <e2> acidosis </e2> , and electrolyte imbalance got worse .
NO_RELATION	Although tacrolimus was suspected to be the cause of late post - transplant renal <e2> acidosis </e2> and was replaced by <e1> sirolimus </e1> , acidosis , and electrolyte imbalance got worse .
NO_RELATION	Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by <e1> sirolimus </e1> , <e2> acidosis </e2> , and electrolyte imbalance got worse .
CID	We suggest that our patient ' s <e2> tubular dysfunction </e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by <e1> tacrolimus </e1> and augmented by lamivudine .
CID	We suggest that our patient ' s tubular dysfunction and <e2> myopathy </e2> may have resulted from mitochondrial dysfunction which is triggered by <e1> tacrolimus </e1> and augmented by lamivudine .
NO_RELATION	We suggest that our patient ' s tubular dysfunction and myopathy may have resulted from <e2> mitochondrial dysfunction </e2> which is triggered by <e1> tacrolimus </e1> and augmented by lamivudine .
CID	We suggest that our patient ' s <e2> tubular dysfunction </e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> .
CID	We suggest that our patient ' s tubular dysfunction and <e2> myopathy </e2> may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> .
NO_RELATION	We suggest that our patient ' s tubular dysfunction and myopathy may have resulted from <e2> mitochondrial dysfunction </e2> which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> .
NO_RELATION	The present study was designed to study the effect of <e1> histamine </e1> H ( 3 ) - receptor ligands on neuroleptic - induced <e2> catalepsy </e2> , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .
NO_RELATION	The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced <e2> catalepsy </e2> , <e1> apomorphine </e1> - induced climbing behavior and amphetamine - induced locomotor activities in mice .
NO_RELATION	The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced <e2> catalepsy </e2> , apomorphine - induced climbing behavior and <e1> amphetamine </e1> - induced locomotor activities in mice .
CID	<e2> Catalepsy </e2> was induced by <e1> haloperidol </e1> ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .
NO_RELATION	<e2> Catalepsy </e2> was induced by haloperidol ( 2 mg / kg p . o . ) , while <e1> apomorphine </e1> ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .
NO_RELATION	<e2> Catalepsy </e2> was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and <e1> amphetamine </e1> ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .
NO_RELATION	<e1> ( R ) - alpha - methylhistamine </e1> ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause <e2> catalepsy </e2> .
NO_RELATION	( R ) - alpha - methylhistamine ( <e1> RAMH </e1> ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause <e2> catalepsy </e2> .
CID	( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and <e1> thioperamide </e1> ( THP ) ( 15 mg / kg i . p . ) , per se did not cause <e2> catalepsy </e2> .
CID	( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( <e1> THP </e1> ) ( 15 mg / kg i . p . ) , per se did not cause <e2> catalepsy </e2> .
CID	Administration of <e1> THP </e1> ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . ) 1 h prior to haloperidol resulted in a dose - dependent increase in the <e2> catalepsy </e2> times ( P < 0 . 05 ) .
CID	Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . ) 1 h prior to <e1> haloperidol </e1> resulted in a dose - dependent increase in the <e2> catalepsy </e2> times ( P < 0 . 05 ) .
CID	On <e1> amphetamine </e1> - induced <e2> hyperactivity </e2> , THP ( 3 . 75 and 7 . 5 mg / kg i . p . ) reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .
NO_RELATION	On amphetamine - induced <e2> hyperactivity </e2> , <e1> THP </e1> ( 3 . 75 and 7 . 5 mg / kg i . p . ) reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .
CID	<e1> THP </e1> exhibited an antipsychotic - like profile by potentiating haloperidol - induced <e2> catalepsy </e2> , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .
NO_RELATION	<e1> THP </e1> exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced <e2> hyperactivity </e2> and reducing apomorphine - induced climbing in mice .
CID	THP exhibited an antipsychotic - like profile by potentiating <e1> haloperidol </e1> - induced <e2> catalepsy </e2> , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .
NO_RELATION	THP exhibited an antipsychotic - like profile by potentiating <e1> haloperidol </e1> - induced catalepsy , reducing amphetamine - induced <e2> hyperactivity </e2> and reducing apomorphine - induced climbing in mice .
NO_RELATION	THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced <e2> catalepsy </e2> , reducing <e1> amphetamine </e1> - induced hyperactivity and reducing apomorphine - induced climbing in mice .
CID	THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing <e1> amphetamine </e1> - induced <e2> hyperactivity </e2> and reducing apomorphine - induced climbing in mice .
NO_RELATION	THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced <e2> catalepsy </e2> , reducing amphetamine - induced hyperactivity and reducing <e1> apomorphine </e1> - induced climbing in mice .
NO_RELATION	THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced <e2> hyperactivity </e2> and reducing <e1> apomorphine </e1> - induced climbing in mice .
NO_RELATION	Transient <e2> platypnea - orthodeoxia - like syndrome </e2> induced by <e1> propafenone </e1> overdose in a young woman with Ebstein ' s anomaly .
NO_RELATION	Transient platypnea - orthodeoxia - like syndrome induced by <e1> propafenone </e1> <e2> overdose </e2> in a young woman with Ebstein ' s anomaly .
NO_RELATION	Transient platypnea - orthodeoxia - like syndrome induced by <e1> propafenone </e1> overdose in a young woman with <e2> Ebstein ' s anomaly </e2> .
NO_RELATION	This shunt of blood via a <e2> patent foramen ovale </e2> occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a <e1> propafenone </e1> overdose .
NO_RELATION	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a <e1> propafenone </e1> <e2> overdose </e2> .
NO_RELATION	A Phase II trial of <e1> cisplatin </e1> plus WR - 2721 ( amifostine ) for metastatic <e2> breast carcinoma </e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
NO_RELATION	A Phase II trial of cisplatin plus <e1> WR - 2721 </e1> ( amifostine ) for metastatic <e2> breast carcinoma </e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
NO_RELATION	A Phase II trial of cisplatin plus WR - 2721 ( <e1> amifostine </e1> ) for metastatic <e2> breast carcinoma </e2> : an Eastern Cooperative Oncology Group Study ( E8188 ) .
NO_RELATION	BACKGROUND : <e1> Cisplatin </e1> has minimal antitumor activity when used as second - or third - line treatment of metastatic <e2> breast carcinoma </e2> .
NO_RELATION	Although a dose - response effect has been observed with <e1> cisplatin </e1> , the dose - limiting <e2> toxicities </e2> associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
CID	Although a dose - response effect has been observed with <e1> cisplatin </e1> , the dose - limiting toxicities associated with cisplatin ( e . g . , <e2> nephrotoxicity </e2> , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
CID	Although a dose - response effect has been observed with <e1> cisplatin </e1> , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , <e2> ototoxicity </e2> , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
NO_RELATION	Although a dose - response effect has been observed with <e1> cisplatin </e1> , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and <e2> neurotoxicity </e2> ) have limited its use as a treatment for breast carcinoma .
NO_RELATION	Although a dose - response effect has been observed with <e1> cisplatin </e1> , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for <e2> breast carcinoma </e2> .
NO_RELATION	Although a dose - response effect has been observed with cisplatin , the dose - limiting <e2> toxicities </e2> associated with <e1> cisplatin </e1> ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
CID	Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with <e1> cisplatin </e1> ( e . g . , <e2> nephrotoxicity </e2> , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
CID	Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with <e1> cisplatin </e1> ( e . g . , nephrotoxicity , <e2> ototoxicity </e2> , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
NO_RELATION	Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with <e1> cisplatin </e1> ( e . g . , nephrotoxicity , ototoxicity , and <e2> neurotoxicity </e2> ) have limited its use as a treatment for breast carcinoma .
NO_RELATION	Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with <e1> cisplatin </e1> ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for <e2> breast carcinoma </e2> .
CID	Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin - induced <e2> nephrotoxicity </e2> , ototoxicity , and neuropathy were reduced .
CID	Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , <e2> ototoxicity </e2> , and neuropathy were reduced .
CID	Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and <e2> neuropathy </e2> were reduced .
NO_RELATION	Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin - induced <e2> nephrotoxicity </e2> , ototoxicity , and neuropathy were reduced .
NO_RELATION	Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , <e2> ototoxicity </e2> , and neuropathy were reduced .
NO_RELATION	Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and <e2> neuropathy </e2> were reduced .
CID	Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1> - induced <e2> nephrotoxicity </e2> , ototoxicity , and neuropathy were reduced .
CID	Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1> - induced nephrotoxicity , <e2> ototoxicity </e2> , and neuropathy were reduced .
CID	Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1> - induced nephrotoxicity , ototoxicity , and <e2> neuropathy </e2> were reduced .
NO_RELATION	METHODS : A Phase II study of the combination of <e1> cisplatin </e1> plus amifostine was conducted in patients with progressive metastatic <e2> breast carcinoma </e2> who had received one , but not more than one , chemotherapy regimen for metastatic disease .
NO_RELATION	METHODS : A Phase II study of the combination of cisplatin plus <e1> amifostine </e1> was conducted in patients with progressive metastatic <e2> breast carcinoma </e2> who had received one , but not more than one , chemotherapy regimen for metastatic disease .
NO_RELATION	Neither a <e2> tumor </e2> - protective effect nor reduced toxicity to normal tissues was observed with the addition of <e1> amifostine </e1> to cisplatin in this trial .
NO_RELATION	Neither a tumor - protective effect nor reduced <e2> toxicity </e2> to normal tissues was observed with the addition of <e1> amifostine </e1> to cisplatin in this trial .
NO_RELATION	Neither a <e2> tumor </e2> - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to <e1> cisplatin </e1> in this trial .
NO_RELATION	Neither a tumor - protective effect nor reduced <e2> toxicity </e2> to normal tissues was observed with the addition of amifostine to <e1> cisplatin </e1> in this trial .
NO_RELATION	<e1> Warfarin </e1> - induced iliopsoas <e2> hemorrhage </e2> with subsequent femoral nerve palsy .
CID	<e1> Warfarin </e1> - induced iliopsoas hemorrhage with subsequent <e2> femoral nerve palsy </e2> .
CID	We present the case of a 28 - year - old man on chronic <e1> warfarin </e1> therapy who sustained a minor <e2> muscle tear </e2> and developed increasing pain and a flexure contracture of the right hip .
NO_RELATION	We present the case of a 28 - year - old man on chronic <e1> warfarin </e1> therapy who sustained a minor muscle tear and developed increasing <e2> pain </e2> and a flexure contracture of the right hip .
NO_RELATION	We present the case of a 28 - year - old man on chronic <e1> warfarin </e1> therapy who sustained a minor muscle tear and developed increasing pain and a flexure <e2> contracture </e2> of the right hip .
CID	Anticoagulant - induced <e2> femoral nerve palsy </e2> represents the most common form of <e1> warfarin </e1> - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
NO_RELATION	Anticoagulant - induced femoral nerve palsy represents the most common form of <e1> warfarin </e1> - induced <e2> peripheral neuropathy </e2> ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
NO_RELATION	Anticoagulant - induced femoral nerve palsy represents the most common form of <e1> warfarin </e1> - induced peripheral neuropathy ; it is characterized by severe <e2> pain </e2> in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
NO_RELATION	Anticoagulant - induced femoral nerve palsy represents the most common form of <e1> warfarin </e1> - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of <e2> motor and sensory impairment </e2> , and flexure contracture of the involved extremity .
NO_RELATION	Anticoagulant - induced femoral nerve palsy represents the most common form of <e1> warfarin </e1> - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure <e2> contracture </e2> of the involved extremity .
CID	<e2> Myasthenia gravis </e2> caused by <e1> penicillamine </e1> and chloroquine therapy for rheumatoid arthritis .
NO_RELATION	Myasthenia gravis caused by <e1> penicillamine </e1> and chloroquine therapy for <e2> rheumatoid arthritis </e2> .
CID	<e2> Myasthenia gravis </e2> caused by penicillamine and <e1> chloroquine </e1> therapy for rheumatoid arthritis .
NO_RELATION	Myasthenia gravis caused by penicillamine and <e1> chloroquine </e1> therapy for <e2> rheumatoid arthritis </e2> .
CID	We have described a unique patient who had reversible and dose - related <e2> myasthenia gravis </e2> after <e1> penicillamine </e1> and chloroquine therapy for rheumatoid arthritis .
NO_RELATION	We have described a unique patient who had reversible and dose - related myasthenia gravis after <e1> penicillamine </e1> and chloroquine therapy for <e2> rheumatoid arthritis </e2> .
CID	We have described a unique patient who had reversible and dose - related <e2> myasthenia gravis </e2> after penicillamine and <e1> chloroquine </e1> therapy for rheumatoid arthritis .
NO_RELATION	We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and <e1> chloroquine </e1> therapy for <e2> rheumatoid arthritis </e2> .
NO_RELATION	<e2> Nephrotoxicity </e2> of combined <e1> cephalothin </e1> - gentamicin regimen .
NO_RELATION	<e2> Nephrotoxicity </e2> of combined cephalothin - <e1> gentamicin </e1> regimen .
CID	Two patients developed <e2> acute tubular necrosis </e2> , characterized clinically by acute oliguric renal failure , while they were receiving a combination of <e1> cephalothin sodium </e1> and gentamicin sulfate therapy .
NO_RELATION	Two patients developed acute tubular necrosis , characterized clinically by acute <e2> oliguric renal failure </e2> , while they were receiving a combination of <e1> cephalothin sodium </e1> and gentamicin sulfate therapy .
CID	Two patients developed <e2> acute tubular necrosis </e2> , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and <e1> gentamicin sulfate </e1> therapy .
NO_RELATION	Two patients developed acute tubular necrosis , characterized clinically by acute <e2> oliguric renal failure </e2> , while they were receiving a combination of cephalothin sodium and <e1> gentamicin sulfate </e1> therapy .
NO_RELATION	Components of lemon essential oil attenuate <e2> dementia </e2> induced by <e1> scopolamine </e1> .
NO_RELATION	The anti - <e2> dementia </e2> effects of <e1> s - limonene </e1> and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
NO_RELATION	The anti - <e2> dementia </e2> effects of s - limonene and <e1> s - perillyl alcohol </e1> were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
CID	These lemon essential oils showed strong ability to improve <e2> memory impaired </e2> by <e1> scopolamine </e1> ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .
CID	These lemon essential oils showed strong ability to improve memory impaired by <e1> scopolamine </e1> ; however , s - perillyl alcohol relieved the <e2> deficit of associative memory </e2> in PA only , and did not improve non - associative memory significantly in OFH .
NO_RELATION	These lemon essential oils showed strong ability to improve <e2> memory impaired </e2> by scopolamine ; however , <e1> s - perillyl alcohol </e1> relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .
NO_RELATION	These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , <e1> s - perillyl alcohol </e1> relieved the <e2> deficit of associative memory </e2> in PA only , and did not improve non - associative memory significantly in OFH .
NO_RELATION	The selective 5 - HT6 receptor antagonist <e1> Ro4368554 </e1> restores memory performance in cholinergic and serotonergic models of <e2> memory deficiency </e2> in the rat .
NO_RELATION	Both , <e1> Ro4368554 </e1> ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed <e2> memory deficits </e2> induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
NO_RELATION	Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and <e1> metrifonate </e1> ( 10 mg / kg , p . o . , respectively ) reversed <e2> memory deficits </e2> induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
CID	Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed <e2> memory deficits </e2> induced by <e1> scopolamine </e1> and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
NO_RELATION	Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed <e2> memory deficits </e2> induced by scopolamine and <e1> TRP </e1> depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
NO_RELATION	In conclusion , although <e1> Ro4368554 </e1> did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic <e2> memory deficit </e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .
NO_RELATION	In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic <e2> memory deficit </e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by <e1> Ro4368554 </e1> and , possibly , other 5 - HT ( 6 ) receptor antagonists .
NO_RELATION	In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic <e2> memory deficit </e2> , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other <e1> 5 - HT </e1> ( 6 ) receptor antagonists .
CID	Lone <e2> atrial fibrillation </e2> associated with <e1> creatine </e1> monohydrate supplementation .
NO_RELATION	Previous anecdotal reports have linked <e1> creatine </e1> to the development of <e2> arrhythmia </e2> .
NO_RELATION	Comparison of developmental <e2> toxicity </e2> of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - <e1> DFU </e1> and piroxicam study .
NO_RELATION	Comparison of developmental <e2> toxicity </e2> of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and <e1> piroxicam </e1> study .
NO_RELATION	The aim of the experiment was to evaluate the developmental <e2> toxicity </e2> of the non - selective ( <e1> piroxicam </e1> ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .
NO_RELATION	The aim of the experiment was to evaluate the developmental <e2> toxicity </e2> of the non - selective ( piroxicam ) and selective ( <e1> DFU </e1> ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .
NO_RELATION	The aim of the experiment was to evaluate the developmental <e2> toxicity </e2> of the non - selective ( piroxicam ) and selective ( DFU ; <e1> 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon </e1> ) COX - 2 inhibitors .
NO_RELATION	The pooled statistical analysis for <e2> ventricular septal ( VSD ) and midline ( MD ) defects </e2> was performed for rat fetuses exposed to <e1> piroxicam </e1> , selective and non - selective COX - 2 inhibitor based on present and historic data .
NO_RELATION	RESULTS : Maternal <e2> toxicity </e2> , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of <e1> piroxicam </e1> .
CID	RESULTS : Maternal toxicity , <e2> intrauterine growth retardation </e2> , and increase of external and skeletal variations were found in rats treated with the highest dose of <e1> piroxicam </e1> .
CID	RESULTS : Maternal toxicity , intrauterine growth retardation , and <e2> increase of external and skeletal variations </e2> were found in rats treated with the highest dose of <e1> piroxicam </e1> .
NO_RELATION	Decrease of fetal length was the only signs of the <e1> DFU </e1> developmental <e2> toxicity </e2> observed in pups exposed to the highest compound dose .
NO_RELATION	Protective efficacy of neuroactive <e1> steroids </e1> against cocaine kindled - <e2> seizures </e2> in mice .
CID	Protective efficacy of neuroactive steroids against <e1> cocaine </e1> kindled - <e2> seizures </e2> in mice .
NO_RELATION	Neuroactive <e1> steroids </e1> demonstrate pharmacological actions that have relevance for a host of <e2> neurological and psychiatric disorders </e2> .
NO_RELATION	The present study was designed to evaluate two endogenous and one synthetic neuroactive <e1> steroid </e1> that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2> seizure </e2> kindling ) .
NO_RELATION	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the <e1> gamma - aminobutyric acid </e1> ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2> seizure </e2> kindling ) .
NO_RELATION	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( <e1> GABA </e1> ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( <e2> seizure </e2> kindling ) .
CID	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of <e1> cocaine </e1> engendered by repeated cocaine administration ( <e2> seizure </e2> kindling ) .
CID	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated <e1> cocaine </e1> administration ( <e2> seizure </e2> kindling ) .
NO_RELATION	<e1> Allopregnanolone </e1> ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( <e1> 3alpha - hydroxy - 5alpha - pregnan - 20 - one </e1> ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , <e1> pregnanolone </e1> ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( <e1> 3alpha - hydroxy - 5beta - pregnan - 20 - one </e1> ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and <e1> ganaxolone </e1> ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of <e1> allopregnanolone </e1> 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
NO_RELATION	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone <e1> 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one </e1> ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
CID	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of <e1> cocaine </e1> - kindled <e2> seizures </e2> in male , Swiss - Webster mice .
CID	Kindled <e2> seizures </e2> were induced by daily administration of 60 mg / kg <e1> cocaine </e1> for 5 days .
NO_RELATION	All of these positive <e1> GABA </e1> ( A ) modulators suppressed the expression of kindled <e2> seizures </e2> , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .
NO_RELATION	All of these positive GABA ( A ) modulators suppressed the expression of kindled <e2> seizures </e2> , whereas only <e1> allopregnanolone </e1> and ganaxolone inhibited the development of kindling .
NO_RELATION	All of these positive GABA ( A ) modulators suppressed the expression of kindled <e2> seizures </e2> , whereas only allopregnanolone and <e1> ganaxolone </e1> inhibited the development of kindling .
CID	These are <e2> nephrotoxic </e2> , but <e1> SRL </e1> seems to act differently displaying only minor nephrotoxic effects , although this question is still open .
CID	These are nephrotoxic , but <e1> SRL </e1> seems to act differently displaying only minor <e2> nephrotoxic </e2> effects , although this question is still open .
CID	In a number of treatment protocols where <e1> SRL </e1> was combined with a calcineurin inhibitor indications of a synergistic <e2> nephrotoxic </e2> effect were described .
NO_RELATION	The semi - quantitative scoring was significantly worst in the group treated with <e1> CsA </e1> plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of <e2> fibrosis </e2> also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .
NO_RELATION	The semi - quantitative scoring was significantly worst in the group treated with CsA plus <e1> SRL </e1> ( P < 0 . 001 compared with controls ) and the analysis of the total grade of <e2> fibrosis </e2> also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .
NO_RELATION	The <e1> FK506 </e1> plus SRL combination showed only a marginally higher degree of <e2> fibrosis </e2> as compared with controls ( P = 0 . 05 ) .
NO_RELATION	The FK506 plus <e1> SRL </e1> combination showed only a marginally higher degree of <e2> fibrosis </e2> as compared with controls ( P = 0 . 05 ) .
CID	CONCLUSION : This rat study demonstrated a synergistic <e2> nephrotoxic </e2> effect of <e1> CsA </e1> plus SRL , whereas FK506 plus SRL was better tolerated .
CID	CONCLUSION : This rat study demonstrated a synergistic <e2> nephrotoxic </e2> effect of CsA plus <e1> SRL </e1> , whereas FK506 plus SRL was better tolerated .
CID	CONCLUSION : This rat study demonstrated a synergistic <e2> nephrotoxic </e2> effect of CsA plus SRL , whereas <e1> FK506 </e1> plus SRL was better tolerated .
CID	CONCLUSION : This rat study demonstrated a synergistic <e2> nephrotoxic </e2> effect of CsA plus SRL , whereas FK506 plus <e1> SRL </e1> was better tolerated .
NO_RELATION	Effect of <e1> fucoidan </e1> treatment on collagenase - induced <e2> intracerebral hemorrhage </e2> in rats .
NO_RELATION	We tested the sulfated polysaccharide <e1> fucoidan </e1> , which has been reported to reduce inflammatory <e2> brain damage </e2> , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .
NO_RELATION	We tested the sulfated polysaccharide <e1> fucoidan </e1> , which has been reported to reduce inflammatory brain damage , in a rat model of <e2> intracerebral hemorrhage </e2> induced by injection of bacterial collagenase into the caudate nucleus .
CID	<e1> Fucoidan </e1> - treated rats exhibited evidence of <e2> impaired blood clotting </e2> and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
CID	<e1> Fucoidan </e1> - treated rats exhibited evidence of impaired blood clotting and <e2> hemodilution </e2> , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
NO_RELATION	<e1> Fucoidan </e1> - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger <e2> hematomas </e2> , and tended to have less inflammation in the vicinity of the hematoma after three days .
NO_RELATION	<e1> Fucoidan </e1> - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less <e2> inflammation </e2> in the vicinity of the hematoma after three days .
NO_RELATION	<e1> Fucoidan </e1> - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the <e2> hematoma </e2> after three days .
NO_RELATION	<e1> Paracetamol </e1> - associated <e2> coma </e2> , metabolic acidosis , renal and hepatic failure .
CID	<e1> Paracetamol </e1> - associated coma , <e2> metabolic acidosis </e2> , renal and hepatic failure .
NO_RELATION	<e1> Paracetamol </e1> - associated coma , metabolic acidosis , <e2> renal and hepatic failure </e2> .
CID	A case of <e2> metabolic acidosis </e2> , acute renal failure and hepatic failure following <e1> paracetamol </e1> ingestion is presented .
NO_RELATION	A case of metabolic acidosis , <e2> acute renal failure and hepatic failure </e2> following <e1> paracetamol </e1> ingestion is presented .
NO_RELATION	In two of the three <e2> deaths </e2> probably associated with <e1> ketoconazole </e1> treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .
CID	In two of the three deaths probably associated with <e1> ketoconazole </e1> treatment the drug had been continued after the onset of <e2> jaundice </e2> and other symptoms of hepatitis .
CID	In two of the three deaths probably associated with <e1> ketoconazole </e1> treatment the drug had been continued after the onset of jaundice and other symptoms of <e2> hepatitis </e2> .
CID	Clinical and biochemical monitoring at regular intervals for evidence of <e2> hepatitis </e2> is advised during long term treatment with <e1> ketoconazole </e1> to prevent possible serious hepatic injury .
CID	Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with <e1> ketoconazole </e1> to prevent possible serious <e2> hepatic injury </e2> .
CID	Combined effects of prolonged <e1> prostaglandin E1 </e1> - induced <e2> hypotension </e2> and haemodilution on human hepatic function .
NO_RELATION	Combined effects of prolonged <e1> prostaglandin E1 </e1> - induced hypotension and <e2> haemodilution </e2> on human hepatic function .
CID	Combined effects of prolonged <e1> prostaglandin E1 </e1> ( PGE1 ) - induced <e2> hypotension </e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
NO_RELATION	Combined effects of prolonged <e1> prostaglandin E1 </e1> ( PGE1 ) - induced hypotension and <e2> haemodilution </e2> on hepatic function were studied in 30 patients undergoing hip surgery .
CID	Combined effects of prolonged prostaglandin E1 ( <e1> PGE1 </e1> ) - induced <e2> hypotension </e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
NO_RELATION	Combined effects of prolonged prostaglandin E1 ( <e1> PGE1 </e1> ) - induced hypotension and <e2> haemodilution </e2> on hepatic function were studied in 30 patients undergoing hip surgery .
NO_RELATION	<e2> Haemodilution </e2> in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of <e1> dextran </e1> solution , and final haematocrit values were 21 or 22 % .
CID	Controlled <e2> hypotension </e2> in groups A and C was induced with <e1> PGE1 </e1> to maintain mean arterial blood pressure at 55 mmHg for 180 min .
NO_RELATION	In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of <e2> hypotension </e2> and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total <e1> bilirubin </e1> showed significant increases after operation .
CID	The results suggest that a prolonged combination of more than 120 min of <e1> PGE1 </e1> - induced <e2> hypotension </e2> and moderate haemodilution would cause impairment of hepatic function .
NO_RELATION	The results suggest that a prolonged combination of more than 120 min of <e1> PGE1 </e1> - induced hypotension and moderate <e2> haemodilution </e2> would cause impairment of hepatic function .
CID	The results suggest that a prolonged combination of more than 120 min of <e1> PGE1 </e1> - induced hypotension and moderate haemodilution would cause <e2> impairment of hepatic function </e2> .
CID	<e1> Levodopa </e1> - induced <e2> dyskinesias </e2> in patients with Parkinson ' s disease : filling the bench - to - bedside gap .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesias in patients with <e2> Parkinson ' s disease </e2> : filling the bench - to - bedside gap .
NO_RELATION	<e1> Levodopa </e1> is the most effective drug for the treatment of <e2> Parkinson ' s disease </e2> .
NO_RELATION	However , the long - term use of this <e1> dopamine </e1> precursor is complicated by highly disabling fluctuations and <e2> dyskinesias </e2> .
CID	Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying <e1> levodopa </e1> - induced <e2> dyskinesias </e2> , their pathogenesis is still unclear .
NO_RELATION	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , <e1> dopamine </e1> receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced <e2> dyskinesias </e2> .
NO_RELATION	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic <e1> glutamate </e1> receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced <e2> dyskinesias </e2> .
CID	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of <e1> levodopa </e1> - induced <e2> dyskinesias </e2> .
CID	In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of <e2> epilepsy </e2> induced by <e1> pilocarpine </e1> in rats .
NO_RELATION	Cardioprotective effect of <e1> salvianolic acid A </e1> on isoproterenol - induced <e2> myocardial infarction </e2> in rats .
CID	Cardioprotective effect of salvianolic acid A on <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	The present study was designed to evaluate the cardioprotective potential of <e1> salvianolic acid A </e1> on isoproterenol - induced <e2> myocardial infarction </e2> in rats .
CID	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> in rats .
NO_RELATION	In addition , mitochondrial <e2> respiratory dysfunction </e2> characterized by decreased respiratory control ratio and <e1> ADP </e1> / O was observed in isoproterenol - treated rats .
NO_RELATION	In addition , mitochondrial <e2> respiratory dysfunction </e2> characterized by decreased respiratory control ratio and ADP / O was observed in <e1> isoproterenol </e1> - treated rats .
NO_RELATION	Administration of <e1> salvianolic acid A </e1> for a period of 8 days significantly attenuated isoproterenol - induced <e2> cardiac dysfunction </e2> and myocardial injury and improved mitochondrial respiratory function .
NO_RELATION	Administration of <e1> salvianolic acid A </e1> for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and <e2> myocardial injury </e2> and improved mitochondrial respiratory function .
NO_RELATION	Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1> isoproterenol </e1> - induced <e2> cardiac dysfunction </e2> and myocardial injury and improved mitochondrial respiratory function .
NO_RELATION	Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1> isoproterenol </e1> - induced cardiac dysfunction and <e2> myocardial injury </e2> and improved mitochondrial respiratory function .
NO_RELATION	The protective role of <e1> salvianolic acid A </e1> against isoproterenol - induced <e2> myocardial damage </e2> was further confirmed by histopathological examination .
NO_RELATION	The protective role of salvianolic acid A against <e1> isoproterenol </e1> - induced <e2> myocardial damage </e2> was further confirmed by histopathological examination .
NO_RELATION	The results of our study suggest that <e1> salvianolic acid A </e1> possessing antioxidant activity has a significant protective effect against isoproterenol - induced <e2> myocardial infarction </e2> .
CID	The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> .
NO_RELATION	Acute effects of <e1> N - ( 2 - propylpentanoyl ) urea </e1> on hippocampal amino acid neurotransmitters in pilocarpine - induced <e2> seizure </e2> in rats .
NO_RELATION	Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal <e1> amino acid </e1> neurotransmitters in pilocarpine - induced <e2> seizure </e2> in rats .
CID	Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in <e1> pilocarpine </e1> - induced <e2> seizure </e2> in rats .
NO_RELATION	<e1> VPU </e1> was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg / kg .
NO_RELATION	VPU was more potent than <e1> VPA </e1> , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg / kg .
CID	VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against <e1> pilocarpine </e1> - induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg / kg .
NO_RELATION	VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced <e2> seizure </e2> whereas the corresponding value for <e1> VPA </e1> was 322 mg / kg .
NO_RELATION	Based on the finding that <e1> VPU </e1> and VPA could protect the animals against pilocarpine - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
NO_RELATION	Based on the finding that VPU and <e1> VPA </e1> could protect the animals against pilocarpine - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
CID	Based on the finding that VPU and VPA could protect the animals against <e1> pilocarpine </e1> - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
NO_RELATION	Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory <e1> amino acid </e1> neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
NO_RELATION	Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <e1> glutamate </e1> and aspartate .
NO_RELATION	Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and <e1> aspartate </e1> .
NO_RELATION	Therefore , like <e1> VPA </e1> , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced <e2> seizure </e2> in experimental animals .
NO_RELATION	Therefore , like VPA , the finding that <e1> VPU </e1> could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced <e2> seizure </e2> in experimental animals .
CID	Therefore , like VPA , the finding that VPU could drastically reduce <e1> pilocarpine </e1> - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced <e2> seizure </e2> in experimental animals .
NO_RELATION	Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in <e1> glutamate </e1> and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced <e2> seizure </e2> in experimental animals .
NO_RELATION	Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and <e1> aspartate </e1> should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced <e2> seizure </e2> in experimental animals .
CID	Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in <e1> pilocarpine </e1> - induced <e2> seizure </e2> in experimental animals .
CID	Acute <e2> hepatitis </e2> attack after exposure to <e1> telithromycin </e1> .
NO_RELATION	He had been prescribed <e1> telithromycin </e1> 400 mg / d PO to treat an <e2> upper respiratory tract infection </e2> 7 days prior .
CID	The patient had suffered a previous episode of " acute <e2> hepatitis </e2> of unknown origin , " that occurred after <e1> telithromycin </e1> usage .
NO_RELATION	Based on a score of 8 on the Naranjo <e2> adverse drug reaction </e2> probability scale , <e1> telithromycin </e1> was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .
CID	Based on a score of 8 on the Naranjo adverse drug reaction probability scale , <e1> telithromycin </e1> was the probable cause of acute <e2> hepatitis </e2> in this patient , and pathological findings suggested drug - induced toxic hepatitis .
CID	Based on a score of 8 on the Naranjo adverse drug reaction probability scale , <e1> telithromycin </e1> was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced <e2> toxic hepatitis </e2> .
CID	Recurrence of <e2> hepatitis </e2> attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed <e1> telithromycin </e1> the second time .
CID	CONCLUSION : Here we report a case of acute <e2> hepatitis </e2> probably associated with the administration of <e1> telithromycin </e1> .
CID	<e1> Spironolactone </e1> - induced <e2> renal insufficiency </e2> and hyperkalemia in patients with heart failure .
CID	<e1> Spironolactone </e1> - induced renal insufficiency and <e2> hyperkalemia </e2> in patients with heart failure .
NO_RELATION	<e1> Spironolactone </e1> - induced renal insufficiency and hyperkalemia in patients with <e2> heart failure </e2> .
NO_RELATION	BACKGROUND : A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in <e2> heart failure </e2> patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .
CID	BACKGROUND : A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in heart failure patients reported a low risk of <e2> hyperkalemia </e2> ( 2 % ) and renal insufficiency ( 0 % ) .
CID	BACKGROUND : A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and <e2> renal insufficiency </e2> ( 0 % ) .
NO_RELATION	Because treatments for <e2> heart failure </e2> have changed since the benefits of <e1> spironolactone </e1> were reported , the prevalence of these complications may differ in current clinical practice .
CID	We therefore sought to determine the prevalence and clinical associations of <e2> hyperkalemia </e2> and renal insufficiency in heart failure patients treated with <e1> spironolactone </e1> .
CID	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and <e2> renal insufficiency </e2> in heart failure patients treated with <e1> spironolactone </e1> .
NO_RELATION	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in <e2> heart failure </e2> patients treated with <e1> spironolactone </e1> .
NO_RELATION	METHODS : We performed a case control study of <e2> heart failure </e2> patients treated with <e1> spironolactone </e1> in our clinical practice .
NO_RELATION	Cases were patients who developed <e2> hyperkalemia </e2> ( <e1> K </e1> ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
NO_RELATION	Cases were patients who developed hyperkalemia ( <e1> K </e1> ( + ) > 5 . 0 mEq / L ) or <e2> renal insufficiency </e2> ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
NO_RELATION	Cases were patients who developed <e2> hyperkalemia </e2> ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( <e1> Cr </e1> > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
NO_RELATION	Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or <e2> renal insufficiency </e2> ( <e1> Cr </e1> > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
CID	RESULTS : Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of <e1> spironolactone </e1> due to <e2> hyperkalemia </e2> ( n = 33 ) or renal failure ( n = 34 ) .
CID	RESULTS : Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of <e1> spironolactone </e1> due to hyperkalemia ( n = 33 ) or <e2> renal failure </e2> ( n = 34 ) .
NO_RELATION	Patients who developed <e2> hyperkalemia </e2> were older and more likely to have diabetes , had higher baseline serum <e1> potassium </e1> levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
NO_RELATION	Patients who developed hyperkalemia were older and more likely to have <e2> diabetes </e2> , had higher baseline serum <e1> potassium </e1> levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
NO_RELATION	Patients who developed <e2> hyperkalemia </e2> were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline <e1> potassium </e1> supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
NO_RELATION	Patients who developed hyperkalemia were older and more likely to have <e2> diabetes </e2> , had higher baseline serum potassium levels and lower baseline <e1> potassium </e1> supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
NO_RELATION	Patients who developed <e2> renal insufficiency </e2> had lower baseline body weight and higher baseline serum <e1> creatinine </e1> , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .
NO_RELATION	Patients who developed <e2> renal insufficiency </e2> had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with <e1> thiazide </e1> diuretics than controls .
CID	CONCLUSIONS : <e1> Spironolactone </e1> - induced <e2> hyperkalemia </e2> and renal insufficiency are more common in our clinical experience than reported previously .
CID	CONCLUSIONS : <e1> Spironolactone </e1> - induced hyperkalemia and <e2> renal insufficiency </e2> are more common in our clinical experience than reported previously .
CID	BACKGROUND : The calcineurin inhibitors <e1> cyclosporine </e1> and tacrolimus are both known to be <e2> nephrotoxic </e2> .
CID	BACKGROUND : The calcineurin inhibitors cyclosporine and <e1> tacrolimus </e1> are both known to be <e2> nephrotoxic </e2> .
NO_RELATION	Patients were divided into three groups : Controls , no <e2> CRF </e2> or ESRD , n = 748 ; CRF , sustained serum <e1> creatinine </e1> > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .
NO_RELATION	Patients were divided into three groups : Controls , no CRF or <e2> ESRD </e2> , n = 748 ; CRF , sustained serum <e1> creatinine </e1> > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .
NO_RELATION	Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; <e2> CRF </e2> , sustained serum <e1> creatinine </e1> > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .
NO_RELATION	Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum <e1> creatinine </e1> > 2 . 5 mg / dl , n = 41 ; and <e2> ESRD </e2> , n = 45 .
NO_RELATION	Compared with control patients , <e2> CRF </e2> and ESRD patients had higher preoperative serum <e1> creatinine </e1> levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .
NO_RELATION	Compared with control patients , CRF and <e2> ESRD </e2> patients had higher preoperative serum <e1> creatinine </e1> levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .
NO_RELATION	Compared with control patients , CRF and ESRD patients had higher preoperative serum <e1> creatinine </e1> levels , a greater percentage of patients with <e2> hepatorenal syndrome </e2> , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .
NO_RELATION	Compared with control patients , <e2> CRF </e2> and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum <e1> creatinine </e1> .
NO_RELATION	Compared with control patients , CRF and <e2> ESRD </e2> patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum <e1> creatinine </e1> .
NO_RELATION	Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with <e2> hepatorenal syndrome </e2> , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum <e1> creatinine </e1> .
NO_RELATION	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1> creatinine </e1> compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of <e2> CRF </e2> or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .
NO_RELATION	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1> creatinine </e1> compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or <e2> ESRD </e2> with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .
NO_RELATION	Patients who develop <e2> ESRD </e2> have a higher preoperative and 1 - year serum <e1> creatinine </e1> and are more likely to have hepatorenal syndrome .
NO_RELATION	Patients who develop ESRD have a higher preoperative and 1 - year serum <e1> creatinine </e1> and are more likely to have <e2> hepatorenal syndrome </e2> .
NO_RELATION	However , an increase of serum <e1> creatinine </e1> at various times postoperatively is more predictive of the development of <e2> CRF </e2> or ESRD .
NO_RELATION	However , an increase of serum <e1> creatinine </e1> at various times postoperatively is more predictive of the development of CRF or <e2> ESRD </e2> .
NO_RELATION	Effect of intravenous <e1> nimodipine </e1> on blood pressure and outcome after <e2> acute stroke </e2> .
NO_RELATION	BACKGROUND AND PURPOSE : The Intravenous <e1> Nimodipine </e1> West European <e2> Stroke </e2> Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
CID	BACKGROUND AND PURPOSE : The Intravenous <e1> Nimodipine </e1> West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced <e2> reduction in blood pressure </e2> ( BP ) and an unfavorable outcome in acute stroke .
NO_RELATION	BACKGROUND AND PURPOSE : The Intravenous <e1> Nimodipine </e1> West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in <e2> acute stroke </e2> .
NO_RELATION	BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European <e2> Stroke </e2> Trial ( INWEST ) found a correlation between <e1> nimodipine </e1> - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
CID	BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between <e1> nimodipine </e1> - induced <e2> reduction in blood pressure </e2> ( BP ) and an unfavorable outcome in acute stroke .
NO_RELATION	BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between <e1> nimodipine </e1> - induced reduction in blood pressure ( BP ) and an unfavorable outcome in <e2> acute stroke </e2> .
NO_RELATION	METHODS : Patients with a clinical diagnosis of <e2> ischemic stroke </e2> ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) <e1> nimodipine </e1> ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .
NO_RELATION	METHODS : Patients with a clinical diagnosis of <e2> ischemic stroke </e2> ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) <e1> nimodipine </e1> ( n = 94 ) .
CID	<e1> Nimodipine </e1> treatment resulted in a statistically significant <e2> reduction in systolic BP </e2> ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .
NO_RELATION	CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose <e1> nimodipine </e1> after <e2> acute stroke </e2> .
CID	<e2> Transient neurologic symptoms </e2> after spinal anesthesia : a lower incidence with <e1> prilocaine </e1> and bupivacaine than with lidocaine .
NO_RELATION	<e2> Transient neurologic symptoms </e2> after spinal anesthesia : a lower incidence with prilocaine and <e1> bupivacaine </e1> than with lidocaine .
CID	<e2> Transient neurologic symptoms </e2> after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with <e1> lidocaine </e1> .
CID	BACKGROUND : Recent evidence suggests that <e2> transient neurologic symptoms </e2> ( TNSs ) frequently follow <e1> lidocaine </e1> spinal anesthesia but are infrequent with bupivacaine .
CID	BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( <e2> TNSs </e2> ) frequently follow <e1> lidocaine </e1> spinal anesthesia but are infrequent with bupivacaine .
NO_RELATION	BACKGROUND : Recent evidence suggests that <e2> transient neurologic symptoms </e2> ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with <e1> bupivacaine </e1> .
NO_RELATION	BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( <e2> TNSs </e2> ) frequently follow lidocaine spinal anesthesia but are infrequent with <e1> bupivacaine </e1> .
CID	Accordingly , the present , prospective double - blind study compares <e1> prilocaine </e1> with lidocaine and bupivacaine with respect to duration of action and relative risk of <e2> TNSs </e2> .
CID	Accordingly , the present , prospective double - blind study compares prilocaine with <e1> lidocaine </e1> and bupivacaine with respect to duration of action and relative risk of <e2> TNSs </e2> .
NO_RELATION	Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and <e1> bupivacaine </e1> with respect to duration of action and relative risk of <e2> TNSs </e2> .
CID	RESULTS : Nine of 30 patients receiving <e1> lidocaine </e1> experienced <e2> TNSs </e2> , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
CID	RESULTS : Nine of 30 patients receiving <e1> lidocaine </e1> experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had <e2> TNSs </e2> .
CID	RESULTS : Nine of 30 patients receiving lidocaine experienced <e2> TNSs </e2> , 1 of 30 patients receiving <e1> prilocaine </e1> ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
CID	RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving <e1> prilocaine </e1> ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had <e2> TNSs </e2> .
NO_RELATION	RESULTS : Nine of 30 patients receiving lidocaine experienced <e2> TNSs </e2> , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving <e1> bupivacaine </e1> had TNSs .
NO_RELATION	RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving <e1> bupivacaine </e1> had <e2> TNSs </e2> .
CID	CONCLUSIONS : <e1> Prilocaine </e1> may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of <e2> TNSs </e2> .
CID	CONCLUSIONS : Prilocaine may be preferable to <e1> lidocaine </e1> for short surgical procedures because it has a similar duration of action but a lower incidence of <e2> TNSs </e2> .
CID	The role of <e1> nicotine </e1> in smoking - related <e2> cardiovascular disease </e2> .
CID	<e1> Nicotine </e1> activates the sympathetic nervous system and in this way could contribute to <e2> cardiovascular disease </e2> .
CID	Animal studies and mechanistic studies indicate that <e1> nicotine </e1> could play a role in accelerating <e2> atherosclerosis </e2> , but evidence among humans is too inadequate to be definitive about such an effect .
NO_RELATION	<e1> Nicotine </e1> does not appear to enhance <e2> thrombosis </e2> among humans .
CID	<e2> Seizure </e2> resulting from a <e1> venlafaxine </e1> overdose .
CID	Seizure resulting from a <e1> venlafaxine </e1> <e2> overdose </e2> .
CID	OBJECTIVE : To report a case of <e1> venlafaxine </e1> <e2> overdose </e2> .
NO_RELATION	CASE SUMMARY : A 40 - year - old woman with <e2> major depression </e2> took an overdose of <e1> venlafaxine </e1> in an apparent suicide attempt .
CID	CASE SUMMARY : A 40 - year - old woman with major depression took an <e2> overdose </e2> of <e1> venlafaxine </e1> in an apparent suicide attempt .
CID	After the ingestion of 26 <e1> venlafaxine </e1> 50 - mg tablets , the patient experienced a witnessed generalized <e2> seizure </e2> .
CID	DISCUSSION : To our knowledge , this is the first reported case of <e1> venlafaxine </e1> <e2> overdose </e2> that resulted in a generalized seizure .
CID	DISCUSSION : To our knowledge , this is the first reported case of <e1> venlafaxine </e1> overdose that resulted in a generalized <e2> seizure </e2> .
CID	CONCLUSIONS : The <e1> venlafaxine </e1> <e2> overdose </e2> in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .
CID	CONCLUSIONS : The <e1> venlafaxine </e1> overdose in our patient resulted in a single episode of generalized <e2> seizure </e2> but elicited no further sequelae .
CID	Two groups of patients receiving <e1> tacrolimus </e1> were compared over a period of 1 year , one group comprising <e2> hypertensive </e2> patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .
NO_RELATION	Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising <e2> hypertensive </e2> patients who were receiving <e1> nifedipine </e1> , and the other comprising nonhypertensive patients not receiving nifedipine .
NO_RELATION	Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising <e2> hypertensive </e2> patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving <e1> nifedipine </e1> .
NO_RELATION	The observed positive impact of <e1> nifedipine </e1> on reducing the <e2> nephrotoxicity </e2> associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
NO_RELATION	The observed positive impact of <e1> nifedipine </e1> on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat <e2> hypertension </e2> in this population .
NO_RELATION	The observed positive impact of nifedipine on reducing the <e2> nephrotoxicity </e2> associated with <e1> tacrolimus </e1> in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
CID	The observed positive impact of nifedipine on reducing the nephrotoxicity associated with <e1> tacrolimus </e1> in liver transplant recipients should be an important factor in selecting an agent to treat <e2> hypertension </e2> in this population .
CID	<e2> Sinus arrest </e2> associated with continuous - infusion <e1> cimetidine </e1> .
CID	The administration of intermittent intravenous infusions of <e1> cimetidine </e1> is infrequently associated with the development of <e2> bradyarrhythmias </e2> .
NO_RELATION	A 40 - year - old man with <e2> leukemia </e2> and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion <e1> cimetidine </e1> 50 mg / hour .
NO_RELATION	A 40 - year - old man with leukemia and no history of <e2> cardiac disease </e2> developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion <e1> cimetidine </e1> 50 mg / hour .
CID	A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent <e2> sinus arrest </e2> while receiving continuous - infusion <e1> cimetidine </e1> 50 mg / hour .
NO_RELATION	The <e2> arrhythmias </e2> were temporally related to <e1> cimetidine </e1> administration , disappeared after dechallenge , and did not recur during ranitidine treatment .
NO_RELATION	The <e2> arrhythmias </e2> were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during <e1> ranitidine </e1> treatment .
CID	This is the first reported case of <e2> sinus arrest </e2> associated with continuous - infusion <e1> cimetidine </e1> .
CID	Composition of <e2> gall bladder stones </e2> associated with <e1> octreotide </e1> : response to oral ursodeoxycholic acid .
NO_RELATION	Composition of <e2> gall bladder stones </e2> associated with octreotide : response to oral <e1> ursodeoxycholic acid </e1> .
NO_RELATION	<e1> Octreotide </e1> , an effective treatment for <e2> acromegaly </e2> , induces gall bladder stones in 13 - 60 % of patients .
CID	<e1> Octreotide </e1> , an effective treatment for acromegaly , induces <e2> gall bladder stones </e2> in 13 - 60 % of patients .
NO_RELATION	Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 <e1> octreotide </e1> treated <e2> acromegalic </e2> patients with gall stones .
CID	Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 <e1> octreotide </e1> treated acromegalic patients with <e2> gall stones </e2> .
NO_RELATION	Chemical analysis of <e2> gall stones </e2> retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % <e1> cholesterol </e1> by weight .
NO_RELATION	After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) <e2> gall stone </e2> dissolution , suggesting that their stones were <e1> cholesterol </e1> rich .
CID	In conclusion , <e1> octreotide </e1> induced <e2> gall stones </e2> are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
CID	In conclusion , <e1> octreotide </e1> induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous <e2> gall stone disease </e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
CID	In conclusion , <e1> octreotide </e1> induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2> gall stones </e2> containing calcium .
NO_RELATION	In conclusion , octreotide induced <e2> gall stones </e2> are generally small , multiple , and <e1> cholesterol </e1> rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
NO_RELATION	In conclusion , octreotide induced gall stones are generally small , multiple , and <e1> cholesterol </e1> rich although , in common with spontaneous <e2> gall stone disease </e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
NO_RELATION	In conclusion , octreotide induced gall stones are generally small , multiple , and <e1> cholesterol </e1> rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2> gall stones </e2> containing calcium .
NO_RELATION	In conclusion , octreotide induced <e2> gall stones </e2> are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing <e1> calcium </e1> .
NO_RELATION	In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous <e2> gall stone disease </e2> , at presentation some patients will have a blocked cystic duct and some gall stones containing <e1> calcium </e1> .
NO_RELATION	In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some <e2> gall stones </e2> containing <e1> calcium </e1> .
CID	<e2> Cardiovascular complications </e2> associated with <e1> terbutaline </e1> treatment for preterm labor .
NO_RELATION	Cardiovascular complications associated with <e1> terbutaline </e1> treatment for <e2> preterm labor </e2> .
CID	Severe <e2> cardiovascular complications </e2> occurred in eight of 160 patients treated with <e1> terbutaline </e1> for preterm labor .
NO_RELATION	Severe cardiovascular complications occurred in eight of 160 patients treated with <e1> terbutaline </e1> for <e2> preterm labor </e2> .
CID	Of the 20 animals that received subarachnoid injection of <e1> 2 - chloroprocaine - CE </e1> seven ( 35 % ) developed hind - limb <e2> paralysis </e2> .
NO_RELATION	None of the animals that received <e1> bupivacaine </e1> , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb <e2> paralysis </e2> .
CID	Of the 15 spinal cords of the animals that received <e1> 2 - chloroprocaine - CE </e1> , 13 showed <e2> subpial necrosis </e2> ; the nerve roots and subarachnoid vessels were normal .
NO_RELATION	Early adjuvant <e1> adriamycin </e1> in superficial <e2> bladder carcinoma </e2> .
NO_RELATION	<e1> Adriamycin </e1> ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) <e2> bladder tumors </e2> .
CID	<e2> Hyperkalemia </e2> associated with <e1> sulindac </e1> therapy .
CID	<e2> Hyperkalemia </e2> has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as <e1> indomethacin </e1> .
CID	We describe 4 patients in whom <e2> hyperkalemia </e2> ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of <e1> sulindac </e1> administration .
NO_RELATION	As no other medications known to effect serum <e1> potassium </e1> had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and <e2> hyperkalemia </e2> .
CID	As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between <e1> sulindac </e1> and <e2> hyperkalemia </e2> .
CID	<e2> Ventricular tachyarrhythmias </e2> during cesarean section after <e1> ritodrine </e1> therapy : interaction with anesthetics .
NO_RELATION	This case illustrates that patients receiving <e1> ritodrine </e1> for <e2> preterm labor </e2> may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .
NO_RELATION	This case illustrates that patients receiving ritodrine for <e2> preterm labor </e2> may risk interactions between the residual betamimetic effects of <e1> ritodrine </e1> and the effects of anesthetics during cesarean section .
NO_RELATION	Such interactions may result in serious <e2> cardiovascular complications </e2> even after cessation of an infusion of <e1> ritodrine </e1> .
NO_RELATION	After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as <e1> phenylephrine </e1> to treat <e2> hypotensive </e2> patients with tachycardia .
NO_RELATION	After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as <e1> phenylephrine </e1> to treat hypotensive patients with <e2> tachycardia </e2> .
CID	Immunohistochemical , electron microscopic and morphometric studies of <e1> estrogen </e1> - induced rat <e2> prolactinomas </e2> after bromocriptine treatment .
NO_RELATION	Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat <e2> prolactinomas </e2> after <e1> bromocriptine </e1> treatment .
NO_RELATION	To clarify the effects of <e1> bromocriptine </e1> on <e2> prolactinoma </e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
NO_RELATION	To clarify the effects of <e1> bromocriptine </e1> on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat <e2> prolactinoma </e2> cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
CID	To clarify the effects of bromocriptine on <e2> prolactinoma </e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to <e1> estrogen </e1> - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
CID	To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to <e1> estrogen </e1> - induced rat <e2> prolactinoma </e2> cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
NO_RELATION	To clarify the effects of bromocriptine on <e2> prolactinoma </e2> cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of <e1> bromocriptine </e1> ( 3 mg / kg of body weight ) .
NO_RELATION	To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat <e2> prolactinoma </e2> cells 1 h and 6 h after injection of <e1> bromocriptine </e1> ( 3 mg / kg of body weight ) .
NO_RELATION	However , only secretory granules showed the positive reaction products for prolactin 6 h after <e1> bromocriptine </e1> treatment of the <e2> adenoma </e2> cells .
CID	<e2> Liver enlargement </e2> and muscle wastage occurred in Wistar rats following the subcutaneous administration of <e1> prednisolone </e1> .
CID	Liver enlargement and <e2> muscle wastage </e2> occurred in Wistar rats following the subcutaneous administration of <e1> prednisolone </e1> .
CID	Possible intramuscular <e1> midazolam </e1> - associated <e2> cardiorespiratory arrest </e2> and death .
NO_RELATION	Possible intramuscular <e1> midazolam </e1> - associated cardiorespiratory arrest and <e2> death </e2> .
CID	This report describes the first published case of <e2> cardiorespiratory arrest </e2> and death associated with intramuscular administration of <e1> midazolam </e1> .
NO_RELATION	This report describes the first published case of cardiorespiratory arrest and <e2> death </e2> associated with intramuscular administration of <e1> midazolam </e1> .
CID	Serial <e2> epilepsy </e2> caused by <e1> levodopa / carbidopa </e1> administration in two patients on hemodialysis .
NO_RELATION	Two patients with similar clinical features are presented : both patients had <e2> chronic renal failure </e2> , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a <e1> carbidopa / levodopa </e1> preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .
NO_RELATION	Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a <e1> carbidopa / levodopa </e1> preparation ; and both had the onset of <e2> hallucinosis </e2> and recurrent seizures , which were refractory to anticonvulsants .
NO_RELATION	Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a <e1> carbidopa / levodopa </e1> preparation ; and both had the onset of hallucinosis and recurrent <e2> seizures </e2> , which were refractory to anticonvulsants .
NO_RELATION	Effect of <e1> L - alpha - glyceryl - phosphorylcholine </e1> on <e2> amnesia </e2> caused by scopolamine .
NO_RELATION	Effect of L - alpha - glyceryl - phosphorylcholine on <e2> amnesia </e2> caused by <e1> scopolamine </e1> .
NO_RELATION	The present study was carried out to test the effects of <e1> L - alpha - glycerylphosphorylcholine </e1> ( L - alpha - GFC ) on <e2> memory impairment </e2> induced by scopolamine in man .
NO_RELATION	The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( <e1> L - alpha - GFC </e1> ) on <e2> memory impairment </e2> induced by scopolamine in man .
CID	The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on <e2> memory impairment </e2> induced by <e1> scopolamine </e1> in man .
CID	The findings of this study indicate that the drug is able to antagonize <e2> impairment of attention and memory </e2> induced by <e1> scopolamine </e1> .
CID	<e2> Seizures </e2> induced by the <e1> cocaine </e1> metabolite benzoylecgonine in rats .
CID	<e2> Seizures </e2> induced by the cocaine metabolite <e1> benzoylecgonine </e1> in rats .
CID	The half - life ( t1 / 2 ) of <e1> cocaine </e1> is relatively short , but some of the consequences of its use , such as <e2> seizures </e2> and strokes , can occur hours after exposure .
NO_RELATION	The half - life ( t1 / 2 ) of <e1> cocaine </e1> is relatively short , but some of the consequences of its use , such as seizures and <e2> strokes </e2> , can occur hours after exposure .
CID	We evaluated the potential of the major metabolite of <e1> cocaine </e1> , benzoylecgonine ( BE ) , to cause <e2> seizures </e2> .
CID	We evaluated the potential of the major metabolite of cocaine , <e1> benzoylecgonine </e1> ( BE ) , to cause <e2> seizures </e2> .
CID	We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( <e1> BE </e1> ) , to cause <e2> seizures </e2> .
CID	<e1> BE </e1> - Induced <e2> seizures </e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .
CID	BE - Induced <e2> seizures </e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of <e1> cocaine </e1> .
CID	Whereas <e1> cocaine </e1> - induced <e2> seizures </e2> were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
NO_RELATION	Whereas <e1> cocaine </e1> - induced seizures were best characterized as brief , generalized , and tonic and resulted in <e2> death </e2> , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
NO_RELATION	Whereas <e1> cocaine </e1> - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in <e2> death </e2> .
CID	Whereas cocaine - induced <e2> seizures </e2> were best characterized as brief , generalized , and tonic and resulted in death , those induced by <e1> BE </e1> were prolonged , often multiple and mixed in type , and rarely resulted in death .
NO_RELATION	Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in <e2> death </e2> , those induced by <e1> BE </e1> were prolonged , often multiple and mixed in type , and rarely resulted in death .
NO_RELATION	Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by <e1> BE </e1> were prolonged , often multiple and mixed in type , and rarely resulted in <e2> death </e2> .
CID	<e1> BE </e1> - Injected rats that did not have <e2> seizures </e2> had significantly more locomotor activity than cocaine - injected animals without seizures .
CID	<e1> BE </e1> - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without <e2> seizures </e2> .
CID	BE - Injected rats that did not have <e2> seizures </e2> had significantly more locomotor activity than <e1> cocaine </e1> - injected animals without seizures .
CID	BE - Injected rats that did not have seizures had significantly more locomotor activity than <e1> cocaine </e1> - injected animals without <e2> seizures </e2> .
CID	The finding that <e1> cocaine </e1> - and BE - induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that <e1> cocaine </e1> - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that cocaine - and <e1> BE </e1> - induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that cocaine - and <e1> BE </e1> - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that cocaine - and BE - induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for <e1> cocaine </e1> - induced seizures and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for <e1> cocaine </e1> - induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite , BE .
CID	The finding that cocaine - and BE - induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a <e1> cocaine </e1> metabolite , BE .
CID	The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced <e2> seizures </e2> and emphasizes the importance of a <e1> cocaine </e1> metabolite , BE .
CID	The finding that cocaine - and BE - induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , <e1> BE </e1> .
CID	The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite , <e1> BE </e1> .
CID	Protection against <e1> amphetamine </e1> - induced <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .
NO_RELATION	Protection against amphetamine - induced <e2> neurotoxicity </e2> toward striatal <e1> dopamine </e1> neurons in rodents by LY274614 , an excitatory amino acid antagonist .
NO_RELATION	Protection against amphetamine - induced <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by <e1> LY274614 </e1> , an excitatory amino acid antagonist .
NO_RELATION	Protection against amphetamine - induced <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614 , an excitatory <e1> amino acid </e1> antagonist .
CID	The data strengthen the evidence that the <e2> neurotoxic </e2> effect of <e1> amphetamine </e1> and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
NO_RELATION	The data strengthen the evidence that the <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal <e1> dopamine </e1> neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
NO_RELATION	The data strengthen the evidence that the <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves <e1> NMDA </e1> receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
NO_RELATION	The data strengthen the evidence that the <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that <e1> LY274614 </e1> is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
NO_RELATION	The data strengthen the evidence that the <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an <e1> NMDA </e1> receptor antagonist with long - lasting in vivo effects in rats .
NO_RELATION	Neonatal <e1> pyridoxine </e1> responsive <e2> convulsions </e2> due to isoniazid therapy .
CID	Neonatal pyridoxine responsive <e2> convulsions </e2> due to <e1> isoniazid </e1> therapy .
NO_RELATION	A 17 - day - old infant on <e1> isoniazid </e1> therapy 13 mg / kg daily from birth because of maternal <e2> tuberculosis </e2> was admitted after 4 days of clonic fits .
CID	A 17 - day - old infant on <e1> isoniazid </e1> therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of <e2> clonic fits </e2> .
NO_RELATION	The <e2> fits </e2> ceased within 4 hours of administering intramuscular <e1> pyridoxine </e1> , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .
NO_RELATION	The <e2> fits </e2> ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of <e1> pyridoxine </e1> deficiency secondary to isoniazid medication .
CID	The <e2> fits </e2> ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to <e1> isoniazid </e1> medication .
NO_RELATION	Reversal by <e1> phenylephrine </e1> of the beneficial effects of intravenous nitroglycerin in patients with <e2> acute myocardial infarction </e2> .
NO_RELATION	Reversal by phenylephrine of the beneficial effects of intravenous <e1> nitroglycerin </e1> in patients with <e2> acute myocardial infarction </e2> .
NO_RELATION	<e1> Nitroglycerin </e1> has been shown to reduce ST - segment elevation during <e2> acute myocardial infarction </e2> , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .
CID	<e1> Nitroglycerin </e1> has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced <e2> hypotension </e2> .
NO_RELATION	Nitroglycerin has been shown to reduce ST - segment elevation during <e2> acute myocardial infarction </e2> , an effect potentiated in the dog by agents that reverse <e1> nitroglycerin </e1> - induced hypotension .
CID	Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse <e1> nitroglycerin </e1> - induced <e2> hypotension </e2> .
NO_RELATION	Ten patients with acute transmural <e2> myocardial infarctions </e2> received intravenous <e1> nitroglycerin </e1> , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / - 6 mm Hg ( P less than 0 . 001 ) , for 60 minutes .
NO_RELATION	Our results suggest that addition of <e1> phenylephrine </e1> to nitroglycerin is not beneficial in the treatment of patients with <e2> acute myocardial infarction </e2> .
NO_RELATION	Our results suggest that addition of phenylephrine to <e1> nitroglycerin </e1> is not beneficial in the treatment of patients with <e2> acute myocardial infarction </e2> .
CID	Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features <e1> CaCl2 </e1> - induced <e2> thoracic aortic aneurysm </e2> in a rat model .
CID	PURPOSE : This study was designed to establish a rat model of <e2> thoracic aortic aneurysm </e2> ( TAA ) by <e1> calcium chloride </e1> ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
CID	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( <e2> TAA </e2> ) by <e1> calcium chloride </e1> ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
NO_RELATION	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by <e1> calcium chloride </e1> ( CaCl ( 2 ) ) - induced <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
CID	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by <e1> calcium chloride </e1> ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in <e2> TAA </e2> formation .
CID	PURPOSE : This study was designed to establish a rat model of <e2> thoracic aortic aneurysm </e2> ( TAA ) by calcium chloride ( <e1> CaCl ( 2 ) </e1> ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
CID	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( <e2> TAA </e2> ) by calcium chloride ( <e1> CaCl ( 2 ) </e1> ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
NO_RELATION	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( <e1> CaCl ( 2 ) </e1> ) - induced <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
CID	PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( <e1> CaCl ( 2 ) </e1> ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in <e2> TAA </e2> formation .
CID	CONCLUSION : This study establishes a <e2> TAA </e2> model by periarterial <e1> CaCl ( 2 ) </e1> exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .
CID	However , a bolus of <e1> epinephrine </e1> injected through an alternative catheter provoked a <e2> hypertensive </e2> crisis .
NO_RELATION	Long - term <e1> glutamate </e1> supplementation failed to protect against <e2> peripheral neurotoxicity </e2> of paclitaxel .
CID	Long - term glutamate supplementation failed to protect against <e2> peripheral neurotoxicity </e2> of <e1> paclitaxel </e1> .
CID	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with <e1> paclitaxel </e1> ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with <e1> paclitaxel </e1> ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2> .
CID	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel ( <e1> PAC </e1> ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( <e1> PAC </e1> ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2> .
NO_RELATION	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although <e1> glutamate </e1> and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although <e1> glutamate </e1> and its closely related amino acid glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2> .
NO_RELATION	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related <e1> amino acid </e1> glutamine were claimed to ameliorate PAC neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related <e1> amino acid </e1> glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2> .
NO_RELATION	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid <e1> glutamine </e1> were claimed to ameliorate PAC neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid <e1> glutamine </e1> were claimed to ameliorate PAC <e2> neurotoxicity </e2> .
CID	Toxic <e2> peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1> PAC </e1> neurotoxicity .
NO_RELATION	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1> PAC </e1> <e2> neurotoxicity </e2> .
NO_RELATION	This pilot trial aimed to evaluate the role of <e1> glutamate </e1> supplementation for preventing PAC - induced <e2> peripheral neuropathy </e2> in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .
CID	This pilot trial aimed to evaluate the role of glutamate supplementation for preventing <e1> PAC </e1> - induced <e2> peripheral neuropathy </e2> in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .
NO_RELATION	Forty - three <e2> ovarian cancer </e2> patients were available for analysis following six cycles of the same <e1> PAC </e1> - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
NO_RELATION	Forty - three <e2> ovarian cancer </e2> patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by <e1> glutamate </e1> all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
NO_RELATION	This pilot study leads to the conclusion that <e1> glutamate </e1> supplementation at the chosen regimen fails to protect against <e2> peripheral neurotoxicity </e2> of PAC .
CID	This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against <e2> peripheral neurotoxicity </e2> of <e1> PAC </e1> .
NO_RELATION	Attentional modulation of perceived <e2> pain </e2> intensity in <e1> capsaicin </e1> - induced secondary hyperalgesia .
CID	Attentional modulation of perceived pain intensity in <e1> capsaicin </e1> - induced secondary <e2> hyperalgesia </e2> .
NO_RELATION	However , it is not known that how <e2> pain </e2> intensity ratings are affected by attention in <e1> capsaicin </e1> - induced secondary hyperalgesia .
CID	However , it is not known that how pain intensity ratings are affected by attention in <e1> capsaicin </e1> - induced secondary <e2> hyperalgesia </e2> .
CID	Furthermore , it was found that the magnitude of attentional modulation in secondary <e2> hyperalgesia </e2> is very similar to that of <e1> capsaicin </e1> - untreated , control condition .
CID	Our findings , showing no interaction between <e1> capsaicin </e1> treatment and attentional modulation suggest that capsaicin - induced secondary <e2> hyperalgesia </e2> and attention might affect mechanical pain through independent mechanisms .
NO_RELATION	Our findings , showing no interaction between <e1> capsaicin </e1> treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical <e2> pain </e2> through independent mechanisms .
CID	Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that <e1> capsaicin </e1> - induced secondary <e2> hyperalgesia </e2> and attention might affect mechanical pain through independent mechanisms .
NO_RELATION	Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that <e1> capsaicin </e1> - induced secondary hyperalgesia and attention might affect mechanical <e2> pain </e2> through independent mechanisms .
NO_RELATION	<e1> Testosterone </e1> - dependent <e2> hypertension </e2> and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .
NO_RELATION	Testosterone - dependent <e2> hypertension </e2> and upregulation of intrarenal angiotensinogen in Dahl <e1> salt </e1> - sensitive rats .
NO_RELATION	In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by <e1> testosterone </e1> that also causes increases in BP and <e2> renal injury </e2> .
NO_RELATION	<e1> Testosterone </e1> replacement in castrated DS rats increased BP , <e2> renal injury </e2> , and upregulation of renal angiotensinogen associated with HS diet .
NO_RELATION	<e1> Testosterone </e1> contributes to the development of <e2> hypertension </e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .
NO_RELATION	<e1> Testosterone </e1> contributes to the development of hypertension and <e2> renal injury </e2> in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .
NO_RELATION	Testosterone contributes to the development of <e2> hypertension </e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - <e1> angiotensin </e1> system .
NO_RELATION	Testosterone contributes to the development of hypertension and <e2> renal injury </e2> in male DS rats on HS diet possibly through upregulation of the intrarenal renin - <e1> angiotensin </e1> system .
CID	No changes in <e1> haloperidol </e1> - induced <e2> catalepsy </e2> or MK - 801 - induced locomotion were seen following PD .
NO_RELATION	No changes in haloperidol - induced <e2> catalepsy </e2> or <e1> MK - 801 </e1> - induced locomotion were seen following PD .
NO_RELATION	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of <e1> rapamycin </e1> ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with <e2> chronic allograft nephropathy </e2> .
NO_RELATION	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially <e1> sirolimus </e1> , in renal transplant recipients with <e2> chronic allograft nephropathy </e2> .
CID	Whether <e2> proteinuria </e2> was due to <e1> sirolimus </e1> or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
CID	Whether proteinuria was due to <e1> sirolimus </e1> or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2> proteinuria </e2> has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
CID	Whether <e2> proteinuria </e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during <e1> sirolimus </e1> therapy in islet transplantation and in patients who received sirolimus de novo .
CID	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2> proteinuria </e2> has been observed during <e1> sirolimus </e1> therapy in islet transplantation and in patients who received sirolimus de novo .
CID	Whether <e2> proteinuria </e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received <e1> sirolimus </e1> de novo .
CID	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2> proteinuria </e2> has been observed during sirolimus therapy in islet transplantation and in patients who received <e1> sirolimus </e1> de novo .
NO_RELATION	Hypothalamic prolactin receptor messenger <e1> ribonucleic acid </e1> levels , prolactin signaling , and <e2> hyperprolactinemic </e2> inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .
NO_RELATION	Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and <e2> hyperprolactinemic </e2> inhibition of pulsatile luteinizing hormone secretion are dependent on <e1> estradiol </e1> .
NO_RELATION	We first tested whether chronic <e2> hyperprolactinemia </e2> inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the <e1> estrogen </e1> - induced LH surge .
NO_RELATION	Chronic <e2> hyperprolactinemia </e2> induced by the <e1> dopamine </e1> antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
CID	Chronic <e2> hyperprolactinemia </e2> induced by the dopamine antagonist <e1> sulpiride </e1> caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
NO_RELATION	Chronic <e2> hyperprolactinemia </e2> induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of <e1> estradiol </e1> .
NO_RELATION	These data show that GnRH pulse frequency is inhibited by chronic <e2> hyperprolactinemia </e2> in a <e1> steroid </e1> - dependent manner .
CID	We have previously demonstrated that <e1> ritonavir </e1> treatment increases <e2> atherosclerotic lesion </e2> formation in male mice to a greater extent than in female mice .
CID	A comparable overexpression of Pgp in the BBB was obtained after <e1> pilocarpine </e1> - induced <e2> seizures </e2> in wild - type Wistar rats .
NO_RELATION	QTLs for susceptibility to <e1> pilocarpine </e1> - induced <e2> seizures </e2> , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
CID	QTLs for susceptibility to <e1> pilocarpine </e1> - induced seizures , a model of <e2> temporal lobe epilepsy </e2> , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
NO_RELATION	QTLs for susceptibility to <e1> pilocarpine </e1> - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize <e2> seizure </e2> susceptibility genes .
NO_RELATION	We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to <e1> pilocarpine </e1> - induced <e2> seizures </e2> .
NO_RELATION	Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to <e1> pilocarpine </e1> - induced <e2> seizures </e2> .
NO_RELATION	Investigation of mitochondrial involvement in the experimental model of <e2> epilepsy </e2> induced by <e1> pilocarpine </e1> .
NO_RELATION	In this study , we investigated whether increased generation of FR during <e2> status epilepticus </e2> would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the <e1> pilocarpine </e1> model of temporal lobe epilepsy .
CID	In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the <e1> pilocarpine </e1> model of <e2> temporal lobe epilepsy </e2> .
NO_RELATION	Other causes include drug - related ( <e1> cyclosporine </e1> , tacrolimus ) <e2> toxicity </e2> , procoagulant status , and antibody - mediated rejection .
NO_RELATION	Other causes include drug - related ( cyclosporine , <e1> tacrolimus </e1> ) <e2> toxicity </e2> , procoagulant status , and antibody - mediated rejection .
CID	We found that the most - frequent cause of <e2> thrombotic microangiopathy </e2> was drug related , secondary mainly to <e1> cyclosporine </e1> .
NO_RELATION	Severe reversible <e2> left ventricular systolic and diastolic dysfunction </e2> due to accidental iatrogenic <e1> epinephrine </e1> overdose .
NO_RELATION	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic <e1> epinephrine </e1> <e2> overdose </e2> .
NO_RELATION	<e1> Catecholamine </e1> - induced <e2> cardiomyopathy </e2> due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .
NO_RELATION	Catecholamine - induced <e2> cardiomyopathy </e2> due to chronic excess of endogenous <e1> catecholamines </e1> has been recognized for decades as a clinical phenomenon .
CID	A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of <e1> epinephrine </e1> developed <e2> myocardial stunning </e2> that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .
NO_RELATION	A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of <e1> epinephrine </e1> developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , <e2> left ventricular systolic and diastolic dysfunction </e2> , and only modestly elevated biochemical markers of myocardial necrosis .
NO_RELATION	A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of <e1> epinephrine </e1> developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of <e2> myocardial necrosis </e2> .
CID	<e2> Urinary bladder cancer </e2> in Wegener ' s granulomatosis : risks and relation to <e1> cyclophosphamide </e1> .
NO_RELATION	Urinary bladder cancer in <e2> Wegener ' s granulomatosis </e2> : risks and relation to <e1> cyclophosphamide </e1> .
CID	OBJECTIVE : To assess and characterise the risk of <e2> bladder cancer </e2> , and its relation to <e1> cyclophosphamide </e1> , in patients with Wegener ' s granulomatosis .
NO_RELATION	OBJECTIVE : To assess and characterise the risk of bladder cancer , and its relation to <e1> cyclophosphamide </e1> , in patients with <e2> Wegener ' s granulomatosis </e2> .
CID	Nested within the cohort , a matched case - control study was performed to estimate the association between <e1> cyclophosphamide </e1> and <e2> bladder cancer </e2> using odds ratios ( ORs ) as relative risk .
CID	The risk of <e2> bladder cancer </e2> doubled for every 10 g increment in <e1> cyclophosphamide </e1> ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .
CID	CONCLUSION : The results indicate a dose - response relationship between <e1> cyclophosphamide </e1> and the risk of <e2> bladder cancer </e2> , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener ' s granulomatosis .
NO_RELATION	CONCLUSION : The results indicate a dose - response relationship between <e1> cyclophosphamide </e1> and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before <e2> Wegener ' s granulomatosis </e2> .
NO_RELATION	<e1> L - arginine </e1> transport in humans with cortisol - induced <e2> hypertension </e2> .
NO_RELATION	L - arginine transport in humans with <e1> cortisol </e1> - induced <e2> hypertension </e2> .
NO_RELATION	A deficient <e1> L - arginine </e1> - nitric oxide system is implicated in cortisol - induced <e2> hypertension </e2> .
NO_RELATION	A deficient L - arginine - <e1> nitric oxide </e1> system is implicated in cortisol - induced <e2> hypertension </e2> .
NO_RELATION	A deficient L - arginine - nitric oxide system is implicated in <e1> cortisol </e1> - induced <e2> hypertension </e2> .
NO_RELATION	We conclude that <e1> cortisol </e1> - induced <e2> increases in blood pressure </e2> are not associated with abnormalities in the l - arginine transport system .
NO_RELATION	We conclude that cortisol - induced <e2> increases in blood pressure </e2> are not associated with abnormalities in the <e1> l - arginine </e1> transport system .
NO_RELATION	MR imaging with quantitative diffusion mapping of <e1> tacrolimus </e1> - induced <e2> neurotoxicity </e2> in organ transplant patients .
NO_RELATION	Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving <e1> tacrolimus </e1> who developed <e2> neurologic complications </e2> .
NO_RELATION	Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of <e1> tacrolimus </e1> - induced <e2> neurotoxicity </e2> .
NO_RELATION	<e1> Octreotide </e1> - induced <e2> hypoxemia </e2> and pulmonary hypertension in premature neonates .
CID	<e1> Octreotide </e1> - induced hypoxemia and <e2> pulmonary hypertension </e2> in premature neonates .
CID	<e2> Pulmonary hypertension </e2> developed after administration of a somatostatin analogue , <e1> octreotide </e1> , to enhance resolution of the fistula .
NO_RELATION	Pulmonary hypertension developed after administration of a somatostatin analogue , <e1> octreotide </e1> , to enhance resolution of the <e2> fistula </e2> .
NO_RELATION	We observed the <e2> exencephaly </e2> induced by <e1> 5 - azacytidine </e1> at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .
CID	Acute <e1> cocaine </e1> - induced <e2> seizures </e2> : differential sensitivity of six inbred mouse strains .
CID	Mature male and female mice from six inbred stains were tested for susceptibility to behavioral <e2> seizures </e2> induced by a single injection of <e1> cocaine </e1> .
CID	Additional studies of these murine strains may be useful for investigating genetic influences on <e1> cocaine </e1> - induced <e2> seizures </e2> .
CID	<e2> Microangiopathic hemolytic anemia </e2> complicating <e1> FK506 </e1> ( tacrolimus ) therapy .
CID	<e2> Microangiopathic hemolytic anemia </e2> complicating FK506 ( <e1> tacrolimus </e1> ) therapy .
CID	We describe 3 episodes of <e2> microangiopathic hemolytic anemia </e2> ( MAHA ) in 2 solid organ recipients under <e1> FK506 </e1> ( tacrolimus ) therapy .
CID	We describe 3 episodes of microangiopathic hemolytic anemia ( <e2> MAHA </e2> ) in 2 solid organ recipients under <e1> FK506 </e1> ( tacrolimus ) therapy .
CID	We describe 3 episodes of <e2> microangiopathic hemolytic anemia </e2> ( MAHA ) in 2 solid organ recipients under FK506 ( <e1> tacrolimus </e1> ) therapy .
CID	We describe 3 episodes of microangiopathic hemolytic anemia ( <e2> MAHA </e2> ) in 2 solid organ recipients under FK506 ( <e1> tacrolimus </e1> ) therapy .
CID	In both cases , discontinuation of <e1> FK506 </e1> and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of <e2> MAHA </e2> .
NO_RELATION	In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , <e1> corticosteroids </e1> , aspirin , and dipyridamole led to resolution of <e2> MAHA </e2> .
NO_RELATION	In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , <e1> aspirin </e1> , and dipyridamole led to resolution of <e2> MAHA </e2> .
NO_RELATION	In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and <e1> dipyridamole </e1> led to resolution of <e2> MAHA </e2> .
CID	In one patient , reintroduction of <e1> FK506 </e1> led to rapid recurrence of <e2> MAHA </e2> .
CID	<e1> FK506 </e1> - associated <e2> MAHA </e2> is probably rare but physicians must be aware of this severe complication .
CID	In our experience and according to the literature , <e1> FK506 </e1> does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce <e2> MAHA </e2> .
NO_RELATION	In our experience and according to the literature , FK506 does not seem to cross - react with <e1> cyclosporin A </e1> ( CyA ) , an immuno - suppressive drug already known to induce <e2> MAHA </e2> .
NO_RELATION	In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( <e1> CyA </e1> ) , an immuno - suppressive drug already known to induce <e2> MAHA </e2> .
CID	Variant <e2> ventricular tachycardia </e2> in <e1> desipramine </e1> toxicity .
NO_RELATION	Variant ventricular tachycardia in <e1> desipramine </e1> <e2> toxicity </e2> .
CID	We report a case of variant <e2> ventricular tachycardia </e2> induced by <e1> desipramine </e1> toxicity .
NO_RELATION	We report a case of variant ventricular tachycardia induced by <e1> desipramine </e1> <e2> toxicity </e2> .
CID	<e1> Desipramine </e1> - induced <e2> delirium </e2> at " subtherapeutic " concentrations : a case report .
CID	An elderly patient treated with low dose <e1> Desipramine </e1> developed a <e2> delirium </e2> while her plasma level was in the " subtherapeutic " range .
NO_RELATION	The initial dose of <e1> amantadine </e1> <e2> depressed </e2> locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .
CID	Readministration of <e1> amantadine </e1> , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where <e2> suppression of motility </e2> occurred .
NO_RELATION	The biochemical results of brain biogenic <e1> amines </e1> of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB / C mice .
NO_RELATION	The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of <e1> catecholamine </e1> turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB / C mice .
NO_RELATION	The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of <e1> norepinephrine </e1> which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB / C mice .
CID	The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a <e2> behavioral depression </e2> caused by <e1> amantadine </e1> in the BALB / C mice .
CID	No hepatic preneoplastic nodules or <e2> hepatocellular carcinomas </e2> developed in rats fed the plain <e1> choline </e1> - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .
CID	No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain <e1> choline </e1> - supplemented diet , while one preneoplastic nodule and one <e2> hepatocellular carcinoma </e2> developed in two rats fed the same diet containing phenobarbital .
NO_RELATION	No hepatic preneoplastic nodules or <e2> hepatocellular carcinomas </e2> developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing <e1> phenobarbital </e1> .
NO_RELATION	No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one <e2> hepatocellular carcinoma </e2> developed in two rats fed the same diet containing <e1> phenobarbital </e1> .
CID	The incidence of preneoplastic nodules and of <e2> hepatocellular carcinomas </e2> was 10 % and 37 % , respectively , in rats fed the plain <e1> choline </e1> - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .
NO_RELATION	The incidence of preneoplastic nodules and of <e2> hepatocellular carcinomas </e2> was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the <e1> phenobarbital </e1> - containing choline - devoid diet .
CID	The incidence of preneoplastic nodules and of <e2> hepatocellular carcinomas </e2> was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing <e1> choline </e1> - devoid diet .
NO_RELATION	Effect of direct intracoronary administration of <e1> methylergonovine </e1> in patients with and without <e2> variant angina </e2> .
NO_RELATION	The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with <e2> variant angina </e2> and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .
NO_RELATION	The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with variant angina and 22 patients with atypical <e2> chest pain </e2> and in others without angina pectoris ( control group ) .
NO_RELATION	The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without <e2> angina pectoris </e2> ( control group ) .
NO_RELATION	These results suggest that <e2> spasm </e2> provocation tests , which use an intracoronary injection of a relatively low dose of <e1> methylergonovine </e1> , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
NO_RELATION	These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of <e1> methylergonovine </e1> , have a high sensitivity in <e2> variant angina </e2> and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
NO_RELATION	<e1> Dobutamine </e1> stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood <e2> cancer </e2> .
NO_RELATION	Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic <e1> doxorubicin </e1> - treated long - term survivors of childhood <e2> cancer </e2> .
CID	<e1> Doxorubicin </e1> is an effective anticancer chemotherapeutic agent known to cause acute and chronic <e2> cardiomyopathy </e2> .
NO_RELATION	To develop a more sensitive echocardiographic screening test for <e2> cardiac damage </e2> due to <e1> doxorubicin </e1> , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
NO_RELATION	To develop a more sensitive echocardiographic screening test for cardiac damage due to <e1> doxorubicin </e1> , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood <e2> cancer </e2> treated with doxorubicin from healthy control subjects .
NO_RELATION	To develop a more sensitive echocardiographic screening test for <e2> cardiac damage </e2> due to doxorubicin , a cohort study was performed using <e1> dobutamine </e1> infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
NO_RELATION	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using <e1> dobutamine </e1> infusion to differentiate asymptomatic long - term survivors of childhood <e2> cancer </e2> treated with doxorubicin from healthy control subjects .
NO_RELATION	To develop a more sensitive echocardiographic screening test for <e2> cardiac damage </e2> due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with <e1> doxorubicin </e1> from healthy control subjects .
NO_RELATION	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood <e2> cancer </e2> treated with <e1> doxorubicin </e1> from healthy control subjects .
CID	Effects of <e1> aminophylline </e1> on the threshold for initiating <e2> ventricular fibrillation </e2> during respiratory failure .
NO_RELATION	Effects of <e1> aminophylline </e1> on the threshold for initiating ventricular fibrillation during <e2> respiratory failure </e2> .
CID	The effects of <e1> aminophylline </e1> on the <e2> ventricular fibrillation </e2> threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .
NO_RELATION	The effects of <e1> aminophylline </e1> on the ventricular fibrillation threshold during normal acid - base conditions and during <e2> respiratory failure </e2> were studied in anesthetized open chest dogs .
CID	During the infusion of <e1> aminophylline </e1> , the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
NO_RELATION	During the infusion of aminophylline , the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of <e1> oxygen </e1> ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
NO_RELATION	During the infusion of aminophylline , the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( <e1> PO2 </e1> ) and carbon dioxide ( CO2 ) were kept within normal limits .
NO_RELATION	During the infusion of aminophylline , the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and <e1> carbon dioxide </e1> ( CO2 ) were kept within normal limits .
NO_RELATION	During the infusion of aminophylline , the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( <e1> CO2 </e1> ) were kept within normal limits .
NO_RELATION	When <e2> respiratory failure </e2> was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1> aminophylline </e1> resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
NO_RELATION	When respiratory failure was produced by <e2> hypoventilation </e2> ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1> aminophylline </e1> resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
CID	When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of <e1> aminophylline </e1> resulted in an even greater decrease in <e2> ventricular fibrillation </e2> threshold to 60 percent of the control level .
NO_RELATION	These experiments suggest that although many factors may contribute to the increased incidence of <e2> ventricular arrhythmias </e2> in respiratory failure , pharmacologic agents , particularly <e1> aminophylline </e1> , may play a significant role .
NO_RELATION	These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in <e2> respiratory failure </e2> , pharmacologic agents , particularly <e1> aminophylline </e1> , may play a significant role .
NO_RELATION	Crossover comparison of efficacy and preference for <e1> rizatriptan </e1> 10 mg versus ergotamine / caffeine in <e2> migraine </e2> .
NO_RELATION	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus <e1> ergotamine </e1> / caffeine in <e2> migraine </e2> .
NO_RELATION	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / <e1> caffeine </e1> in <e2> migraine </e2> .
NO_RELATION	<e1> Rizatriptan </e1> is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2> migraine </e2> .
NO_RELATION	Rizatriptan is a selective <e1> 5 - HT </e1> ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2> migraine </e2> .
NO_RELATION	This randomized double - blind crossover outpatient study assessed the preference for 1 <e1> rizatriptan </e1> 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy .
NO_RELATION	This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 <e1> ergotamine </e1> 1 mg / caffeine 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy .
NO_RELATION	This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / <e1> caffeine </e1> 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy .
NO_RELATION	Faster relief of <e2> headache </e2> was the most important reason for preference , cited by 67 . 3 % of patients preferring <e1> rizatriptan </e1> and 54 . 2 % of patients who preferred ergotamine / caffeine .
NO_RELATION	Faster relief of <e2> headache </e2> was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred <e1> ergotamine </e1> / caffeine .
NO_RELATION	Faster relief of <e2> headache </e2> was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / <e1> caffeine </e1> .
NO_RELATION	The co - primary endpoint of being <e2> pain </e2> free at 2 h was also in favor of <e1> rizatriptan </e1> .
NO_RELATION	Forty - nine percent of patients were <e2> pain </e2> free 2 h after <e1> rizatriptan </e1> , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .
NO_RELATION	Forty - nine percent of patients were <e2> pain </e2> free 2 h after rizatriptan , compared with 24 . 3 % treated with <e1> ergotamine </e1> / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .
NO_RELATION	Forty - nine percent of patients were <e2> pain </e2> free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / <e1> caffeine </e1> ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .
NO_RELATION	Forty - nine percent of patients were <e2> pain </e2> free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , <e1> rizatriptan </e1> being superior within 1 h of treatment .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for <e1> rizatriptan </e1> and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for <e1> ergotamine </e1> / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / <e1> caffeine </e1> ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with <e1> rizatriptan </e1> being superior to ergotamine / caffeine within 30 min of dosing .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to <e1> ergotamine </e1> / caffeine within 30 min of dosing .
NO_RELATION	<e2> Headache </e2> relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / <e1> caffeine </e1> within 30 min of dosing .
NO_RELATION	Almost 36 % of patients taking <e1> rizatriptan </e1> were <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .
NO_RELATION	Almost 36 % of patients taking rizatriptan were <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on <e1> ergotamine </e1> / caffeine ( p < or = 0 . 001 ) .
NO_RELATION	Almost 36 % of patients taking rizatriptan were <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / <e1> caffeine </e1> ( p < or = 0 . 001 ) .
CID	<e1> Rizatriptan </e1> was also superior to ergotamine / caffeine in the proportions of patients with no <e2> nausea </e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	<e1> Rizatriptan </e1> was also superior to ergotamine / caffeine in the proportions of patients with no nausea , <e2> vomiting </e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	<e1> Rizatriptan </e1> was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	<e1> Rizatriptan </e1> was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to <e1> ergotamine </e1> / caffeine in the proportions of patients with no <e2> nausea </e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to <e1> ergotamine </e1> / caffeine in the proportions of patients with no nausea , <e2> vomiting </e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to <e1> ergotamine </e1> / caffeine in the proportions of patients with no nausea , vomiting , <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to <e1> ergotamine </e1> / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to ergotamine / <e1> caffeine </e1> in the proportions of patients with no <e2> nausea </e2> , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to ergotamine / <e1> caffeine </e1> in the proportions of patients with no nausea , <e2> vomiting </e2> , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to ergotamine / <e1> caffeine </e1> in the proportions of patients with no nausea , vomiting , <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
NO_RELATION	Rizatriptan was also superior to ergotamine / <e1> caffeine </e1> in the proportions of patients with no nausea , vomiting , phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
CID	The most common adverse events ( incidence > or = 5 % in one group ) after <e1> rizatriptan </e1> and ergotamine / caffeine , respectively , were <e2> dizziness </e2> ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
CID	The most common adverse events ( incidence > or = 5 % in one group ) after <e1> rizatriptan </e1> and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , <e2> nausea </e2> ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after <e1> rizatriptan </e1> and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and <e2> somnolence </e2> ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1> ergotamine </e1> / caffeine , respectively , were <e2> dizziness </e2> ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1> ergotamine </e1> / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , <e2> nausea </e2> ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and <e1> ergotamine </e1> / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and <e2> somnolence </e2> ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / <e1> caffeine </e1> , respectively , were <e2> dizziness </e2> ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / <e1> caffeine </e1> , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , <e2> nausea </e2> ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / <e1> caffeine </e1> , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and <e2> somnolence </e2> ( 5 . 5 and 2 . 3 % ) .
NO_RELATION	Five patients with <e2> carcinoma </e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1> cisplatin </e1> , bleomycin , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed <e2> thrombotic microangiopathy </e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1> cisplatin </e1> , bleomycin , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2> renal insufficiency </e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with <e1> cisplatin </e1> , bleomycin , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2> microangiopathic hemolytic anemia </e2> , and usually thrombocytopenia ) after treatment with <e1> cisplatin </e1> , bleomycin , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2> thrombocytopenia </e2> ) after treatment with <e1> cisplatin </e1> , bleomycin , and a vinca alkaloid .
NO_RELATION	Five patients with <e2> carcinoma </e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1> bleomycin </e1> , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed <e2> thrombotic microangiopathy </e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1> bleomycin </e1> , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2> renal insufficiency </e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , <e1> bleomycin </e1> , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2> microangiopathic hemolytic anemia </e2> , and usually thrombocytopenia ) after treatment with cisplatin , <e1> bleomycin </e1> , and a vinca alkaloid .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2> thrombocytopenia </e2> ) after treatment with cisplatin , <e1> bleomycin </e1> , and a vinca alkaloid .
NO_RELATION	Five patients with <e2> carcinoma </e2> developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1> vinca alkaloid </e1> .
NO_RELATION	Five patients with carcinoma developed <e2> thrombotic microangiopathy </e2> ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1> vinca alkaloid </e1> .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by <e2> renal insufficiency </e2> , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1> vinca alkaloid </e1> .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , <e2> microangiopathic hemolytic anemia </e2> , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a <e1> vinca alkaloid </e1> .
NO_RELATION	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually <e2> thrombocytopenia </e2> ) after treatment with cisplatin , bleomycin , and a <e1> vinca alkaloid </e1> .
NO_RELATION	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because <e2> renal failure </e2> may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .
CID	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1> cisplatin </e1> <e2> nephrotoxicity </e2> and the anemia and thrombocytopenia to drug - induced bone marrow suppression .
NO_RELATION	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the <e2> anemia </e2> and thrombocytopenia to drug - induced bone marrow suppression .
NO_RELATION	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the anemia and <e2> thrombocytopenia </e2> to drug - induced bone marrow suppression .
NO_RELATION	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the anemia and thrombocytopenia to drug - induced <e2> bone marrow suppression </e2> .
NO_RELATION	Salvage therapy with <e1> nelarabine </e1> , etoposide , and cyclophosphamide in relapsed / refractory paediatric <e2> T - cell lymphoblastic leukaemia and lymphoma </e2> .
NO_RELATION	Salvage therapy with nelarabine , <e1> etoposide </e1> , and cyclophosphamide in relapsed / refractory paediatric <e2> T - cell lymphoblastic leukaemia and lymphoma </e2> .
NO_RELATION	Salvage therapy with nelarabine , etoposide , and <e1> cyclophosphamide </e1> in relapsed / refractory paediatric <e2> T - cell lymphoblastic leukaemia and lymphoma </e2> .
NO_RELATION	A combination of 5 d of <e1> nelarabine </e1> ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
NO_RELATION	A combination of 5 d of nelarabine ( <e1> AraG </e1> ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
NO_RELATION	A combination of 5 d of nelarabine ( AraG ) with 5 d of <e1> etoposide </e1> ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
NO_RELATION	A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( <e1> VP </e1> ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
NO_RELATION	A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and <e1> cyclophosphamide </e1> ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
NO_RELATION	A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( <e1> CPM </e1> ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T - cell leukaemia or lymphoma </e2> .
CID	The most common side effects attributable to the <e1> AraG </e1> included Grade 2 and 3 sensory and motor <e2> neuropathy </e2> and musculoskeletal pain .
CID	The most common side effects attributable to the <e1> AraG </e1> included Grade 2 and 3 sensory and motor neuropathy and <e2> musculoskeletal pain </e2> .
CID	<e2> Haematological toxicity </e2> was greater for the combination than <e1> AraG </e1> alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .
CID	Our experience supports the safety of giving <e1> AraG </e1> as salvage therapy in synchrony with etoposide and cyclophosphamide , although <e2> neurological toxicity </e2> must be closely monitored .
NO_RELATION	Our experience supports the safety of giving AraG as salvage therapy in synchrony with <e1> etoposide </e1> and cyclophosphamide , although <e2> neurological toxicity </e2> must be closely monitored .
NO_RELATION	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and <e1> cyclophosphamide </e1> , although <e2> neurological toxicity </e2> must be closely monitored .
CID	A 34 - year - old lady developed a constellation of <e2> dermatitis </e2> , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero - negative rheumatoid arthritis .
CID	A 34 - year - old lady developed a constellation of dermatitis , <e2> fever </e2> , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero - negative rheumatoid arthritis .
CID	A 34 - year - old lady developed a constellation of dermatitis , fever , <e2> lymphadenopathy </e2> and hepatitis , beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero - negative rheumatoid arthritis .
CID	A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and <e2> hepatitis </e2> , beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero - negative rheumatoid arthritis .
NO_RELATION	A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero - negative <e2> rheumatoid arthritis </e2> .
NO_RELATION	<e1> Bupropion </e1> ( Zyban ) <e2> toxicity </e2> .
NO_RELATION	Bupropion ( <e1> Zyban </e1> ) <e2> toxicity </e2> .
NO_RELATION	Recurrent <e2> seizures </e2> were treated with <e1> diazepam </e1> and broad complex tachycardia was successfully treated with adenosine .
NO_RELATION	Recurrent seizures were treated with <e1> diazepam </e1> and broad complex <e2> tachycardia </e2> was successfully treated with adenosine .
NO_RELATION	Recurrent <e2> seizures </e2> were treated with diazepam and broad complex tachycardia was successfully treated with <e1> adenosine </e1> .
NO_RELATION	Recurrent seizures were treated with diazepam and broad complex <e2> tachycardia </e2> was successfully treated with <e1> adenosine </e1> .
NO_RELATION	<e1> Zyban </e1> caused significant <e2> neurological and cardiovascular toxicity </e2> in overdose .
NO_RELATION	<e1> Zyban </e1> caused significant neurological and cardiovascular toxicity in <e2> overdose </e2> .
NO_RELATION	<e1> Bradykinin </e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model .
NO_RELATION	<e1> Bradykinin </e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model .
NO_RELATION	Bradykinin receptors antagonists and <e1> nitric oxide </e1> synthase inhibitors in vincristine and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model .
NO_RELATION	Bradykinin receptors antagonists and <e1> nitric oxide </e1> synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model .
CID	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1> vincristine </e1> and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model .
NO_RELATION	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1> vincristine </e1> and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model .
CID	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1> streptozotocin </e1> induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model .
CID	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1> streptozotocin </e1> induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive <e1> NO </e1> synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible <e1> NO </e1> synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal <e1> NO </e1> synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] <e1> bradykinin </e1> ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( <e1> HOE 140 </e1> ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or <e1> des Arg10 HOE 140 </e1> ( 70 nmol / kg ip ) respectively , in model of <e2> diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy </e2> was investigated .
NO_RELATION	RESULTS : The results of this paper confirm that inhibition of <e1> bradykinin </e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces <e2> diabetic hyperalgesia </e2> .
NO_RELATION	RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible <e1> NO </e1> synthase but not neuronal NO synthase activity reduces <e2> diabetic hyperalgesia </e2> .
NO_RELATION	RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal <e1> NO </e1> synthase activity reduces <e2> diabetic hyperalgesia </e2> .
NO_RELATION	It was also shown that both products of inducible <e1> NO </e1> synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2> hyperalgesia </e2> produced by vincristine .
NO_RELATION	It was also shown that both products of inducible NO synthase and neuronal <e1> NO </e1> synthase activation as well as bradykinin are involved in <e2> hyperalgesia </e2> produced by vincristine .
NO_RELATION	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as <e1> bradykinin </e1> are involved in <e2> hyperalgesia </e2> produced by vincristine .
CID	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2> hyperalgesia </e2> produced by <e1> vincristine </e1> .
NO_RELATION	Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of <e1> HOE 140 </e1> or des - Arg10HOE 140 in <e2> toxic neuropathy </e2> .
NO_RELATION	Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or <e1> des - Arg10HOE 140 </e1> in <e2> toxic neuropathy </e2> .
CID	In <e1> streptozotocin </e1> - induced <e2> hyperalgesia </e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
CID	In <e1> streptozotocin </e1> - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced <e2> hyperalgesia </e2> , inducible <e1> NO </e1> synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced hyperalgesia , inducible <e1> NO </e1> synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced <e2> hyperalgesia </e2> , inducible NO synthase participates in pronociceptive activity of <e1> bradykinin </e1> , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of <e1> bradykinin </e1> , whereas in vincristine - induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway .
CID	In streptozotocin - induced <e2> hyperalgesia </e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in <e1> vincristine </e1> - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
CID	In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in <e1> vincristine </e1> - induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced <e2> hyperalgesia </e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia <e1> bradykinin </e1> seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced <e2> hyperalgesia </e2> <e1> bradykinin </e1> seemed to activate neuronal NO synthase pathway .
NO_RELATION	In streptozotocin - induced <e2> hyperalgesia </e2> , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal <e1> NO </e1> synthase pathway .
NO_RELATION	In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal <e1> NO </e1> synthase pathway .
NO_RELATION	Therefore , concomitant administration of small doses of <e1> bradykinin </e1> receptor antagonists and NO synthase inhibitors can be effective in alleviation of <e2> neuropathic pain </e2> , even in hospital care .
NO_RELATION	Therefore , concomitant administration of small doses of bradykinin receptor antagonists and <e1> NO </e1> synthase inhibitors can be effective in alleviation of <e2> neuropathic pain </e2> , even in hospital care .
NO_RELATION	<e2> Cardiac toxicity </e2> observed in association with high - dose <e1> cyclophosphamide </e1> - based chemotherapy for metastatic breast cancer .
NO_RELATION	Cardiac toxicity observed in association with high - dose <e1> cyclophosphamide </e1> - based chemotherapy for metastatic <e2> breast cancer </e2> .
NO_RELATION	STUDY DESIGN : We combined <e1> paclitaxel </e1> , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic <e2> breast cancer </e2> .
NO_RELATION	STUDY DESIGN : We combined paclitaxel , <e1> melphalan </e1> and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic <e2> breast cancer </e2> .
NO_RELATION	STUDY DESIGN : We combined paclitaxel , melphalan and high - dose <e1> cyclophosphamide </e1> , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic <e2> breast cancer </e2> .
NO_RELATION	STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , <e1> thiotepa </e1> , and carboplatin in a triple sequential high - dose regimen for patients with metastatic <e2> breast cancer </e2> .
NO_RELATION	STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and <e1> carboplatin </e1> in a triple sequential high - dose regimen for patients with metastatic <e2> breast cancer </e2> .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic <e2> breast cancer </e2> receiving 96 - h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
CID	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high - dose regimen to assess association between presence of peritransplant <e2> congestive heart failure </e2> ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
CID	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( <e2> CHF </e2> ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , <e2> hypertension </e2> , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , <e2> diabetes mellitus </e2> , prior use of anthracyclines , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic <e2> breast cancer </e2> receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1> anthracyclines </e1> , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant <e2> congestive heart failure </e2> ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1> anthracyclines </e1> , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( <e2> CHF </e2> ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of <e1> anthracyclines </e1> , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , <e2> hypertension </e2> , prior cardiac history , smoking , diabetes mellitus , prior use of <e1> anthracyclines </e1> , and left - sided chest irradiation .
NO_RELATION	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , <e2> diabetes mellitus </e2> , prior use of <e1> anthracyclines </e1> , and left - sided chest irradiation .
CID	RESULTS : Six of 61 women ( 10 % ) developed clinically reversible grade 3 <e2> CHF </e2> following infusional <e1> cyclophosphamide </e1> with a median percent decline in ejection fraction of 31 % .
NO_RELATION	Incidence of transient <e1> cyclophosphamide </e1> - related <e2> cardiac toxicity </e2> ( 10 % ) is comparable to previous recorded literature .
CID	Routine EKG monitoring during infusional <e1> cyclophosphamide </e1> did not predict <e2> CHF </e2> development .
CID	Inappropriate use of <e1> carbamazepine </e1> and vigabatrin in typical <e2> absence seizures </e2> .
CID	Inappropriate use of carbamazepine and <e1> vigabatrin </e1> in typical <e2> absence seizures </e2> .
CID	<e1> Carbamazepine </e1> and vigabatrin are contraindicated in typical <e2> absence seizures </e2> .
CID	Carbamazepine and <e1> vigabatrin </e1> are contraindicated in typical <e2> absence seizures </e2> .
CID	Frequency of absences increased in four children treated with <e1> carbamazepine </e1> and two of these developed <e2> myoclonic jerks </e2> , which resolved on withdrawal of carbamazepine .
CID	Frequency of absences increased in four children treated with carbamazepine and two of these developed <e2> myoclonic jerks </e2> , which resolved on withdrawal of <e1> carbamazepine </e1> .
CID	<e2> Hemolytic anemia </e2> associated with the use of <e1> omeprazole </e1> .
CID	We report the first case of a serious short - term adverse reaction with the use of <e1> omeprazole </e1> : <e2> hemolytic anemia </e2> .
CID	The patient developed weakness , <e2> lethargy </e2> , and shortness of breath 2 days after starting therapy with <e1> omeprazole </e1> .
CID	The patient developed weakness , lethargy , and <e2> shortness of breath </e2> 2 days after starting therapy with <e1> omeprazole </e1> .
CID	The mechanism by which <e1> omeprazole </e1> caused the patient ' s <e2> hemolytic anemia </e2> is uncertain , but physicians should be alerted to this possible adverse effect .
NO_RELATION	The use and <e2> toxicity </e2> of <e1> didanosine </e1> ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of <e1> didanosine </e1> ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( <e1> ddI </e1> ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( <e1> ddI </e1> ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to <e1> zidovudine </e1> ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to <e1> zidovudine </e1> ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( <e1> AZT </e1> ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( <e1> AZT </e1> ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to <e1> zidovudine </e1> ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to <e1> zidovudine </e1> ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( <e1> AZT </e1> ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( <e1> AZT </e1> ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received <e1> didanosine </e1> ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received <e1> didanosine </e1> ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and <e2> toxicity </e2> of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( <e1> ddI </e1> ) to a maximum dose of 12 . 5 mg / kg / day .
NO_RELATION	The use and toxicity of didanosine ( ddI ) in <e2> HIV antibody - positive </e2> individuals intolerant to zidovudine ( AZT ) One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( <e1> ddI </e1> ) to a maximum dose of 12 . 5 mg / kg / day .
CID	Seven patients developed <e2> glucose tolerance curves </e2> characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing <e1> didanosine </e1> .
NO_RELATION	Seven patients developed glucose tolerance curves characteristic of <e2> diabetes </e2> but these were mild , did not require treatment and returned to normal on ceasing <e1> didanosine </e1> .
NO_RELATION	Can angiogenesis be a target of treatment for <e1> ribavirin </e1> associated <e2> hemolytic anemia </e2> ?
NO_RELATION	BACKGROUND / AIMS : Recently <e1> ribavirin </e1> has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute <e2> hemolysis </e2> .
CID	BACKGROUND / AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as <e1> sunitinib </e1> and sorafenib have been found to cause acute <e2> hemolysis </e2> .
CID	BACKGROUND / AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and <e1> sorafenib </e1> have been found to cause acute <e2> hemolysis </e2> .
NO_RELATION	METHODS : Fourteen patients <e2> chronically infected with hepatitis C virus </e2> were treated by <e1> pegylated interferon alpha 2a </e1> and ribavirin .
NO_RELATION	METHODS : Fourteen patients <e2> chronically infected with hepatitis C virus </e2> were treated by pegylated interferon alpha 2a and <e1> ribavirin </e1> .
NO_RELATION	CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1> ribavirin </e1> induced <e2> anemia </e2> in patients with hepatitis C and we could not find any relation .
NO_RELATION	CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1> ribavirin </e1> induced anemia in patients with <e2> hepatitis C </e2> and we could not find any relation .
NO_RELATION	<e1> Cocaine </e1> causes <e2> memory and learning impairments </e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .
NO_RELATION	Cocaine causes <e2> memory and learning impairments </e2> in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by <e1> topiramate </e1> .
NO_RELATION	Different mechanisms have been suggested for <e1> cocaine </e1> <e2> toxicity </e2> including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .
NO_RELATION	Different mechanisms have been suggested for cocaine <e2> toxicity </e2> including an increase in oxidative stress but the association between oxidative status in the brain and <e1> cocaine </e1> induced - behaviour is poorly understood .
NO_RELATION	Therefore NFkappaB activity , oxidative stress , neuronal <e1> nitric oxide </e1> synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for <e2> cocaine addiction </e2> , were evaluated in an experimental model of cocaine administration in rats .
NO_RELATION	Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of <e1> topiramate </e1> , a previously proposed therapy for <e2> cocaine addiction </e2> , were evaluated in an experimental model of cocaine administration in rats .
NO_RELATION	Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for <e2> cocaine addiction </e2> , were evaluated in an experimental model of <e1> cocaine </e1> administration in rats .
NO_RELATION	( + / - ) - <e1> PG - 9 </e1> ( 10 - 40 mg kg - 1 i . p . ) was able to prevent <e2> amnesia </e2> induced by scopolamine ( 1 mg kg - 1 i . p . ) and dicyclomine ( 2 mg kg - 1 i . p . ) in the mouse passive - avoidance test .
CID	( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent <e2> amnesia </e2> induced by <e1> scopolamine </e1> ( 1 mg kg - 1 i . p . ) and dicyclomine ( 2 mg kg - 1 i . p . ) in the mouse passive - avoidance test .
CID	( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent <e2> amnesia </e2> induced by scopolamine ( 1 mg kg - 1 i . p . ) and <e1> dicyclomine </e1> ( 2 mg kg - 1 i . p . ) in the mouse passive - avoidance test .
NO_RELATION	Affinity profiles of ( + / - ) - <e1> PG - 9 </e1> for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - <e2> amnesic </e2> effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .
NO_RELATION	Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - <e2> amnesic </e2> effect induced by ( + / - ) - <e1> PG - 9 </e1> through an increase in acetylcholine extracellular levels .
NO_RELATION	Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - <e2> amnesic </e2> effect induced by ( + / - ) - PG - 9 through an increase in <e1> acetylcholine </e1> extracellular levels .
NO_RELATION	Hyperbaric <e1> oxygen </e1> therapy for control of intractable cyclophosphamide - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Hyperbaric oxygen therapy for control of intractable <e1> cyclophosphamide </e1> - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	We report a case of intractable <e2> hemorrhagic cystitis </e2> due to <e1> cyclophosphamide </e1> therapy for Wegener ' s granulomatosis .
NO_RELATION	We report a case of intractable hemorrhagic cystitis due to <e1> cyclophosphamide </e1> therapy for <e2> Wegener ' s granulomatosis </e2> .
NO_RELATION	Conservative treatment , including bladder irrigation with physiological saline and instillation of <e1> prostaglandin F2 alpha </e1> , failed to totally control <e2> hemorrhage </e2> .
NO_RELATION	In future , this form of therapy can offer a safe alternative in the treatment of <e1> cyclophosphamide </e1> - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	The results have shown that the degradation product <e1> p - choloroaniline </e1> is not a significant factor in chlorhexidine - digluconate associated erosive <e2> cystitis </e2> .
CID	The results have shown that the degradation product p - choloroaniline is not a significant factor in <e1> chlorhexidine - digluconate </e1> associated erosive <e2> cystitis </e2> .
CID	A high percentage of <e1> kanamycin </e1> - colistin and povidone - iodine irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage .
CID	A high percentage of kanamycin - <e1> colistin </e1> and povidone - iodine irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage .
CID	A high percentage of kanamycin - colistin and <e1> povidone - iodine </e1> irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage .
NO_RELATION	<e1> Picloxydine </e1> irrigations appeared to have a lower incidence of erosive <e2> cystitis </e2> but further studies would have to be performed before it could be recommended for use in urological procedures .
NO_RELATION	In the double blind study with <e1> haloperidol </e1> , both substances were found to be highly effective in the treatment of <e2> psychotic syndromes belonging predominantly to the schizophrenia group </e2> .
NO_RELATION	<e1> Curcumin </e1> ameliorates <e2> cognitive dysfunction </e2> and oxidative damage in phenobarbitone and carbamazepine administered rats .
CID	Curcumin ameliorates <e2> cognitive dysfunction </e2> and oxidative damage in <e1> phenobarbitone </e1> and carbamazepine administered rats .
CID	Curcumin ameliorates <e2> cognitive dysfunction </e2> and oxidative damage in phenobarbitone and <e1> carbamazepine </e1> administered rats .
CID	The antiepileptic drugs , <e1> phenobarbitone </e1> and carbamazepine are well known to cause <e2> cognitive impairment </e2> on chronic use .
CID	The antiepileptic drugs , phenobarbitone and <e1> carbamazepine </e1> are well known to cause <e2> cognitive impairment </e2> on chronic use .
NO_RELATION	Therefore , the present study was carried out to investigate the effect of chronic <e1> curcumin </e1> administration on phenobarbitone - and carbamazepine - induced <e2> cognitive impairment </e2> and oxidative stress in rats .
CID	Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on <e1> phenobarbitone </e1> - and carbamazepine - induced <e2> cognitive impairment </e2> and oxidative stress in rats .
CID	Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and <e1> carbamazepine </e1> - induced <e2> cognitive impairment </e2> and oxidative stress in rats .
CID	The administration of <e1> phenobarbitone </e1> and carbamazepine for 21days caused a significant <e2> impairment of learning and memory </e2> as well as an increased oxidative stress .
CID	The administration of phenobarbitone and <e1> carbamazepine </e1> for 21days caused a significant <e2> impairment of learning and memory </e2> as well as an increased oxidative stress .
NO_RELATION	Concomitant <e1> curcumin </e1> administration prevented the <e2> cognitive impairment </e2> and decreased the increased oxidative stress induced by these antiepileptic drugs .
NO_RELATION	These results show that <e1> curcumin </e1> has beneficial effect in mitigating the <e2> deterioration of cognitive functions </e2> and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .
CID	These results show that curcumin has beneficial effect in mitigating the <e2> deterioration of cognitive functions </e2> and oxidative damage in rats treated with <e1> phenobarbitone </e1> and carbamazepine without significantly altering their serum concentrations .
CID	These results show that curcumin has beneficial effect in mitigating the <e2> deterioration of cognitive functions </e2> and oxidative damage in rats treated with phenobarbitone and <e1> carbamazepine </e1> without significantly altering their serum concentrations .
NO_RELATION	The findings suggest that <e1> curcumin </e1> can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing <e2> cognitive impairment </e2> associated with these drugs .
CID	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to <e1> phenobarbitone </e1> and carbamazepine therapy in preventing <e2> cognitive impairment </e2> associated with these drugs .
CID	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and <e1> carbamazepine </e1> therapy in preventing <e2> cognitive impairment </e2> associated with these drugs .
NO_RELATION	<e1> Pyrrolidine dithiocarbamate </e1> protects the piriform cortex in the pilocarpine <e2> status epilepticus </e2> model .
CID	Pyrrolidine dithiocarbamate protects the piriform cortex in the <e1> pilocarpine </e1> <e2> status epilepticus </e2> model .
NO_RELATION	Both , production of reactive <e1> oxygen </e1> species as well as activation of NF - kappaB have been implicated in severe <e2> neuronal damage </e2> in different sub - regions of the hippocampus as well as in the surrounding cortices .
NO_RELATION	The effect of <e1> PDTC </e1> on <e2> status epilepticus </e2> - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .
CID	The effect of PDTC on <e2> status epilepticus </e2> - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated <e1> pilocarpine </e1> model .
NO_RELATION	Treatment with 150 mg / kg <e1> PDTC </e1> before and following <e2> status epilepticus </e2> significantly increased the mortality rate to 100 % .
NO_RELATION	Administration of 50 mg / kg <e1> PDTC </e1> ( low - dose ) did not exert major effects on the development of a <e2> status epilepticus </e2> or the mortality rate .
NO_RELATION	A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and <e1> PDTC </e1> - treated rats following <e2> status epilepticus </e2> .
NO_RELATION	In conclusion , the NF - kappaB inhibitor and antioxidant <e1> PDTC </e1> protected the piriform cortex , whereas it did not affect hilar <e2> neuronal loss </e2> .
NO_RELATION	These data might indicate that the generation of reactive <e1> oxygen </e1> species and activation of NF - kappaB plays a more central role in <e2> seizure </e2> - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .
NO_RELATION	These data might indicate that the generation of reactive <e1> oxygen </e1> species and activation of NF - kappaB plays a more central role in seizure - associated <e2> neuronal damage </e2> in the temporal cortex as compared to the hippocampal hilus .
CID	Development of <e1> levodopa </e1> - induced <e2> dyskinesias </e2> in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .
NO_RELATION	Development of <e1> levodopa </e1> - induced dyskinesias in <e2> parkinsonian </e2> monkeys may depend upon rate of symptom onset and / or duration of symptoms .
CID	<e1> Levodopa </e1> - induced <e2> dyskinesias </e2> ( LIDs ) present a major problem for the long - term management of Parkinson ' s disease ( PD ) patients .
CID	<e1> Levodopa </e1> - induced dyskinesias ( <e2> LIDs </e2> ) present a major problem for the long - term management of Parkinson ' s disease ( PD ) patients .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesias ( LIDs ) present a major problem for the long - term management of <e2> Parkinson ' s disease </e2> ( PD ) patients .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson ' s disease ( <e2> PD </e2> ) patients .
CID	Using macaque monkeys with different types of <e1> MPTP </e1> - induced <e2> parkinsonism </e2> , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .
NO_RELATION	Using macaque monkeys with different types of <e1> MPTP </e1> - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of <e2> LIDs </e2> .
NO_RELATION	Using macaque monkeys with different types of MPTP - induced <e2> parkinsonism </e2> , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of <e1> levodopa </e1> therapy may be involved in the development of LIDs .
CID	Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of <e1> levodopa </e1> therapy may be involved in the development of <e2> LIDs </e2> .
NO_RELATION	Monkeys with acute ( short - term ) <e1> MPTP </e1> exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed <e2> dyskinesia </e2> between 11 and 24 days of daily levodopa administration .
CID	Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of <e1> levodopa </e1> therapy developed <e2> dyskinesia </e2> between 11 and 24 days of daily levodopa administration .
CID	Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed <e2> dyskinesia </e2> between 11 and 24 days of daily <e1> levodopa </e1> administration .
NO_RELATION	In contrast , monkeys with long - term <e1> MPTP </e1> exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing <e2> LIDs </e2> ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
NO_RELATION	In contrast , monkeys with long - term <e1> MPTP </e1> exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , <e2> dyskinesia </e2> developed no sooner than 146 days of chronic levodopa administration ) .
CID	In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of <e1> levodopa </e1> therapy were more resistant to developing <e2> LIDs </e2> ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
CID	In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of <e1> levodopa </e1> therapy were more resistant to developing LIDs ( e . g . , <e2> dyskinesia </e2> developed no sooner than 146 days of chronic levodopa administration ) .
CID	In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing <e2> LIDs </e2> ( e . g . , dyskinesia developed no sooner than 146 days of chronic <e1> levodopa </e1> administration ) .
CID	In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , <e2> dyskinesia </e2> developed no sooner than 146 days of chronic <e1> levodopa </e1> administration ) .
CID	These data suggest distinct differences in the propensity to develop <e2> LIDs </e2> in monkeys with different rates of symptom progression or symptom durations prior to <e1> levodopa </e1> and demonstrate the value of these models for further studying the pathophysiology of LIDs .
CID	These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to <e1> levodopa </e1> and demonstrate the value of these models for further studying the pathophysiology of <e2> LIDs </e2> .
NO_RELATION	<e1> Propylthiouracil </e1> - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive <e2> vasculitis </e2> in conjunction with pericarditis .
CID	<e1> Propylthiouracil </e1> - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with <e2> pericarditis </e2> .
NO_RELATION	OBJECTIVE : To describe a case of <e1> propylthiouracil </e1> - induced <e2> vasculitis </e2> manifesting with pericarditis .
CID	OBJECTIVE : To describe a case of <e1> propylthiouracil </e1> - induced vasculitis manifesting with <e2> pericarditis </e2> .
NO_RELATION	METHODS : We present the first case report of a woman with <e2> hyperthyroidism </e2> treated with <e1> propylthiouracil </e1> in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .
CID	METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of <e2> pericarditis </e2> , fever , and glomerulonephritis developed .
CID	METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of pericarditis , <e2> fever </e2> , and glomerulonephritis developed .
CID	METHODS : We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of pericarditis , fever , and <e2> glomerulonephritis </e2> developed .
CID	A literature review revealed no prior reports of <e2> pericarditis </e2> in anti - MPO pANCA - positive vasculitis associated with <e1> propylthio - uracil </e1> therapy .
NO_RELATION	A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive <e2> vasculitis </e2> associated with <e1> propylthio - uracil </e1> therapy .
CID	CONCLUSION : <e2> Pericarditis </e2> may be the initial manifestation of drug - induced vasculitis attributable to <e1> propylthio - uracil </e1> therapy .
NO_RELATION	CONCLUSION : Pericarditis may be the initial manifestation of drug - induced <e2> vasculitis </e2> attributable to <e1> propylthio - uracil </e1> therapy .
CID	Two mouse lines selected for differential sensitivities to <e1> beta - carboline </e1> - induced <e2> seizures </e2> are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .
NO_RELATION	Two mouse lines selected for differential sensitivities to beta - carboline - induced <e2> seizures </e2> are also differentially sensitive to various pharmacological effects of other <e1> GABA </e1> ( A ) receptor ligands .
NO_RELATION	We measured <e1> diazepam </e1> - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced <e2> seizures </e2> after i . p .
NO_RELATION	We measured diazepam - induced anxiolysis with the elevated plus - maze test , <e1> diazepam </e1> - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced <e2> seizures </e2> after i . p .
CID	We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and <e1> picrotoxin </e1> - and pentylenetetrazol - induced <e2> seizures </e2> after i . p .
CID	We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and <e1> pentylenetetrazol </e1> - induced <e2> seizures </e2> after i . p .
NO_RELATION	Analgesic effect of intravenous <e1> ketamine </e1> in <e2> cancer </e2> patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .
NO_RELATION	Analgesic effect of intravenous ketamine in <e2> cancer </e2> patients on <e1> morphine </e1> therapy : a randomized , controlled , double - blind , crossover , double - dose study .
NO_RELATION	<e2> Pain </e2> not responsive to <e1> morphine </e1> is often problematic .
NO_RELATION	Animal and clinical studies have suggested that <e1> N - methyl - D - aspartate </e1> ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult <e2> pain </e2> syndromes , such as neuropathic pain .
NO_RELATION	Animal and clinical studies have suggested that <e1> N - methyl - D - aspartate </e1> ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2> neuropathic pain </e2> .
NO_RELATION	Animal and clinical studies have suggested that N - methyl - D - aspartate ( <e1> NMDA </e1> ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult <e2> pain </e2> syndromes , such as neuropathic pain .
NO_RELATION	Animal and clinical studies have suggested that N - methyl - D - aspartate ( <e1> NMDA </e1> ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2> neuropathic pain </e2> .
NO_RELATION	Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as <e1> ketamine </e1> , may be effective in improving opioid analgesia in difficult <e2> pain </e2> syndromes , such as neuropathic pain .
NO_RELATION	Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as <e1> ketamine </e1> , may be effective in improving opioid analgesia in difficult pain syndromes , such as <e2> neuropathic pain </e2> .
NO_RELATION	A slow bolus of subhypnotic doses of <e1> ketamine </e1> ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 <e2> cancer </e2> patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .
NO_RELATION	A slow bolus of subhypnotic doses of <e1> ketamine </e1> ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose <e2> pain </e2> was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .
NO_RELATION	A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 <e2> cancer </e2> patients whose pain was unrelieved by <e1> morphine </e1> in a randomized , double - blind , crossover , double - dose study .
NO_RELATION	A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose <e2> pain </e2> was unrelieved by <e1> morphine </e1> in a randomized , double - blind , crossover , double - dose study .
NO_RELATION	<e1> Ketamine </e1> , but not saline solution , significantly reduced the <e2> pain </e2> intensity in almost all the patients at both doses .
NO_RELATION	<e1> Ketamine </e1> can improve morphine analgesia in difficult <e2> pain </e2> syndromes , such as neuropathic pain .
NO_RELATION	<e1> Ketamine </e1> can improve morphine analgesia in difficult pain syndromes , such as <e2> neuropathic pain </e2> .
NO_RELATION	Ketamine can improve <e1> morphine </e1> analgesia in difficult <e2> pain </e2> syndromes , such as neuropathic pain .
NO_RELATION	Ketamine can improve <e1> morphine </e1> analgesia in difficult pain syndromes , such as <e2> neuropathic pain </e2> .
NO_RELATION	PURPOSE : We reviewed the results of serum <e1> testosterone </e1> and prolactin determination in 1 , 022 patients referred because of <e2> erectile dysfunction </e2> and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .
CID	Every patient was screened for <e1> testosterone </e1> and 451 were screened for prolactin on the basis of <e2> low sexual desire </e2> , gynecomastia or testosterone less than 4 ng . / ml .
NO_RELATION	Every patient was screened for <e1> testosterone </e1> and 451 were screened for prolactin on the basis of low sexual desire , <e2> gynecomastia </e2> or testosterone less than 4 ng . / ml .
CID	Every patient was screened for testosterone and 451 were screened for prolactin on the basis of <e2> low sexual desire </e2> , gynecomastia or <e1> testosterone </e1> less than 4 ng . / ml .
NO_RELATION	Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , <e2> gynecomastia </e2> or <e1> testosterone </e1> less than 4 ng . / ml .
NO_RELATION	Endocrine therapy consisted of <e1> testosterone heptylate </e1> or human chorionic gonadotropin for <e2> hypogonadism </e2> and bromocriptine for hyperprolactinemia .
NO_RELATION	Endocrine therapy consisted of <e1> testosterone heptylate </e1> or human chorionic gonadotropin for hypogonadism and bromocriptine for <e2> hyperprolactinemia </e2> .
NO_RELATION	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for <e2> hypogonadism </e2> and <e1> bromocriptine </e1> for hyperprolactinemia .
NO_RELATION	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and <e1> bromocriptine </e1> for <e2> hyperprolactinemia </e2> .
NO_RELATION	Two <e2> pituitary tumors </e2> were discovered after <e1> testosterone </e1> determination .
NO_RELATION	Most of the other low <e1> testosterone </e1> levels seemed to result from nonorganic <e2> hypothalamic dysfunction </e2> because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
NO_RELATION	Most of the other low <e1> testosterone </e1> levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in <e2> erectile dysfunction </e2> ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
CID	Determining <e1> testosterone </e1> only in cases of <e2> low sexual desire </e2> or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .
CID	Determining testosterone only in cases of <e2> low sexual desire </e2> or abnormal physical examination would have missed 40 % of the cases with low <e1> testosterone </e1> , including 37 % of those subsequently improved by androgen therapy .
NO_RELATION	CONCLUSIONS : Low prevalences and effects of low <e1> testosterone </e1> and high prolactin in <e2> erectile dysfunction </e2> cannot justify their routine determination .
CID	We now advocate that before age 50 years <e1> testosterone </e1> be determined only in cases of <e2> low sexual desire </e2> and abnormal physical examination but that it be measured in all men older than 50 years .
CID	Prolactin should be determined only in cases of <e2> low sexual desire </e2> , gynecomastia and / or <e1> testosterone </e1> less than 4 ng . / ml .
NO_RELATION	Prolactin should be determined only in cases of low sexual desire , <e2> gynecomastia </e2> and / or <e1> testosterone </e1> less than 4 ng . / ml .
NO_RELATION	<e1> Thiopentone </e1> pretreatment for propofol injection <e2> pain </e2> in ambulatory patients .
CID	Thiopentone pretreatment for <e1> propofol </e1> injection <e2> pain </e2> in ambulatory patients .
CID	This study investigated <e1> propofol </e1> injection <e2> pain </e2> in patients undergoing ambulatory anaesthesia .
NO_RELATION	We conclude that <e1> lidocaine </e1> reduces the incidence and severity of propofol injection <e2> pain </e2> in ambulatory patients whereas thiopentone only reduces its severity .
CID	We conclude that lidocaine reduces the incidence and severity of <e1> propofol </e1> injection <e2> pain </e2> in ambulatory patients whereas thiopentone only reduces its severity .
NO_RELATION	We conclude that lidocaine reduces the incidence and severity of propofol injection <e2> pain </e2> in ambulatory patients whereas <e1> thiopentone </e1> only reduces its severity .
NO_RELATION	<e1> glycopyrrolate </e1> and atropine in the prevention of <e2> bradycardia </e2> and arrhythmias following repeated doses of suxamethonium in children .
NO_RELATION	<e1> glycopyrrolate </e1> and atropine in the prevention of bradycardia and <e2> arrhythmias </e2> following repeated doses of suxamethonium in children .
NO_RELATION	glycopyrrolate and <e1> atropine </e1> in the prevention of <e2> bradycardia </e2> and arrhythmias following repeated doses of suxamethonium in children .
NO_RELATION	glycopyrrolate and <e1> atropine </e1> in the prevention of bradycardia and <e2> arrhythmias </e2> following repeated doses of suxamethonium in children .
CID	glycopyrrolate and atropine in the prevention of <e2> bradycardia </e2> and arrhythmias following repeated doses of <e1> suxamethonium </e1> in children .
NO_RELATION	glycopyrrolate and atropine in the prevention of bradycardia and <e2> arrhythmias </e2> following repeated doses of <e1> suxamethonium </e1> in children .
NO_RELATION	immediately before the induction of anaesthesia , to prevent <e2> arrhythmia </e2> and bradycardia following repeated doses of <e1> suxamethonium </e1> in children , was studied .
CID	immediately before the induction of anaesthesia , to prevent arrhythmia and <e2> bradycardia </e2> following repeated doses of <e1> suxamethonium </e1> in children , was studied .
NO_RELATION	Reduction in <e1> caffeine </e1> <e2> toxicity </e2> by acetaminophen .
NO_RELATION	Reduction in caffeine <e2> toxicity </e2> by <e1> acetaminophen </e1> .
NO_RELATION	Because salicylates have been reported to augment the stimulatory effects of <e1> caffeine </e1> on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS <e2> toxicity </e2> of caffeine .
NO_RELATION	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of <e1> acetaminophen </e1> ( 52 micrograms / mL ) reduced the CNS <e2> toxicity </e2> of caffeine .
NO_RELATION	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS <e2> toxicity </e2> of <e1> caffeine </e1> .
NO_RELATION	Studies in DBA / 2J mice showed that : 1 ) pretreatment with <e1> acetaminophen </e1> ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal <e2> convulsions </e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
NO_RELATION	Studies in DBA / 2J mice showed that : 1 ) pretreatment with <e1> acetaminophen </e1> ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
CID	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of <e1> caffeine </e1> ( 300 to 450 mg / kg IP ) and the onset of fatal <e2> convulsions </e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
CID	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of <e1> caffeine </e1> ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
NO_RELATION	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal <e2> convulsions </e2> by a factor of about two ; and 2 ) pretreatment with <e1> acetaminophen </e1> ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
NO_RELATION	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with <e1> acetaminophen </e1> ( 75 mg / kg ) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
CID	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal <e2> convulsions </e2> by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of <e1> caffeine </e1> ( 12 . 5 to 75 mg / kg IP ) .
CID	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of <e1> caffeine </e1> ( 12 . 5 to 75 mg / kg IP ) .
CID	The frequency of sound - induced <e2> seizures </e2> after 12 . 5 or 25 mg / kg <e1> caffeine </e1> was reduced from 50 to 5 % by acetaminophen .
NO_RELATION	The frequency of sound - induced <e2> seizures </e2> after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by <e1> acetaminophen </e1> .
CID	In the absence of <e1> caffeine </e1> , acetaminophen ( up to 300 mg / kg ) did not modify the <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
NO_RELATION	In the absence of caffeine , <e1> acetaminophen </e1> ( up to 300 mg / kg ) did not modify the <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
CID	In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of <e1> pentylenetetrezol </e1> in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
NO_RELATION	<e1> Flestolol </e1> produced a dose - dependent attenuation of isoproterenol - induced <e2> tachycardia </e2> .
CID	Flestolol produced a dose - dependent attenuation of <e1> isoproterenol </e1> - induced <e2> tachycardia </e2> .
NO_RELATION	<e1> Flestolol </e1> effectively reduced heart rate in patients with <e2> supraventricular tachyarrhythmia </e2> .
NO_RELATION	In patients with <e2> unstable angina </e2> , <e1> flestolol </e1> infusion was found to be safe and effective in controlling chest pain .
NO_RELATION	In patients with unstable angina , <e1> flestolol </e1> infusion was found to be safe and effective in controlling <e2> chest pain </e2> .
NO_RELATION	Adverse effect of the <e1> calcium </e1> channel blocker nitrendipine on <e2> nephrosclerosis </e2> in rats with renovascular hypertension .
NO_RELATION	Adverse effect of the <e1> calcium </e1> channel blocker nitrendipine on nephrosclerosis in rats with <e2> renovascular hypertension </e2> .
CID	Adverse effect of the calcium channel blocker <e1> nitrendipine </e1> on <e2> nephrosclerosis </e2> in rats with renovascular hypertension .
NO_RELATION	Adverse effect of the calcium channel blocker <e1> nitrendipine </e1> on nephrosclerosis in rats with <e2> renovascular hypertension </e2> .
NO_RELATION	The effect of a 6 - week treatment with the <e1> calcium </e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , <e2> albuminuria </e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
NO_RELATION	The effect of a 6 - week treatment with the <e1> calcium </e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip <e2> renovascular hypertension </e2> .
CID	The effect of a 6 - week treatment with the calcium channel blocker <e1> nitrendipine </e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure , <e2> albuminuria </e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
NO_RELATION	The effect of a 6 - week treatment with the calcium channel blocker <e1> nitrendipine </e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip <e2> renovascular hypertension </e2> .
NO_RELATION	The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the <e1> angiotensin </e1> converting enzyme inhibitor enalapril on blood pressure , <e2> albuminuria </e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
NO_RELATION	The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the <e1> angiotensin </e1> converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip <e2> renovascular hypertension </e2> .
NO_RELATION	The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1> enalapril </e1> on blood pressure , <e2> albuminuria </e2> , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
NO_RELATION	The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1> enalapril </e1> on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip <e2> renovascular hypertension </e2> .
NO_RELATION	Six weeks after clipping of one renal artery , <e2> hypertensive </e2> rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , <e1> enalapril </e1> - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .
NO_RELATION	Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated <e2> hypertensive </e2> controls ( n = 8 ) , <e1> enalapril </e1> - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .
NO_RELATION	Six weeks after clipping of one renal artery , <e2> hypertensive </e2> rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or <e1> nitrendipine </e1> - treated ( n = 10 ) .
NO_RELATION	Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated <e2> hypertensive </e2> controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or <e1> nitrendipine </e1> - treated ( n = 10 ) .
NO_RELATION	Renal plasma flow increased , but albumin excretion and <e2> glomerulosclerosis </e2> did not change after <e1> enalapril </e1> treatment .
CID	In contrast , in the <e1> nitrendipine </e1> - treated group <e2> albuminuria </e2> increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / - 9 mg / 24 hr in the hypertensive controls .
NO_RELATION	In contrast , in the <e1> nitrendipine </e1> - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / - 9 mg / 24 hr in the <e2> hypertensive </e2> controls .
NO_RELATION	Furthermore , <e2> glomerulosclerosis </e2> index was significantly increased in the <e1> nitrendipine </e1> - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .
NO_RELATION	Furthermore , glomerulosclerosis index was significantly increased in the <e1> nitrendipine </e1> - treated group compared with the <e2> hypertensive </e2> controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .
NO_RELATION	In addition , glomerular size was higher in the <e1> nitrendipine </e1> - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the <e2> hypertensive </e2> controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the <e1> enalapril </e1> - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the <e2> hypertensive </e2> controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	Treatment of <e2> tinnitus </e2> by intratympanic instillation of <e1> lignocaine </e1> ( lidocaine ) 2 per cent through ventilation tubes .
NO_RELATION	Treatment of <e2> tinnitus </e2> by intratympanic instillation of lignocaine ( <e1> lidocaine </e1> ) 2 per cent through ventilation tubes .
NO_RELATION	This paper presents the results of treating <e2> IST </e2> by intratympanic instillation of <e1> lignocaine </e1> ( lidocaine ) 2 per cent through a grommet , for five weekly courses .
NO_RELATION	This paper presents the results of treating <e2> IST </e2> by intratympanic instillation of lignocaine ( <e1> lidocaine </e1> ) 2 per cent through a grommet , for five weekly courses .
CID	<e1> Perhexiline maleate </e1> and <e2> peripheral neuropathy </e2> .
CID	<e2> Peripheral neuropathy </e2> has been noted as a complication of therapy with <e1> perhexiline maleate </e1> , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .
NO_RELATION	Peripheral neuropathy has been noted as a complication of therapy with <e1> perhexiline maleate </e1> , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of <e2> angina pectoris </e2> .
CID	Effect of humoral modulators of <e1> morphine </e1> - induced <e2> increase in locomotor activity </e2> of mice .
CID	The effect of humoral modulators on the <e1> morphine </e1> - induced <e2> increase in locomotor activity </e2> of mice was studied .
CID	The subcutaneous administration of 10 mg / kg of <e1> morphine </e1> - HC1 produced a marked <e2> increase in locomotor activity </e2> in mice .
CID	The <e1> morphine </e1> - induced <e2> hyperactivity </e2> was potentiated by scopolamine and attenuated by physostigmine .
CID	The morphine - induced <e2> hyperactivity </e2> was potentiated by <e1> scopolamine </e1> and attenuated by physostigmine .
NO_RELATION	The morphine - induced <e2> hyperactivity </e2> was potentiated by scopolamine and attenuated by <e1> physostigmine </e1> .
NO_RELATION	In contrast , both <e1> methscopolamine </e1> and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the <e2> hyperactivity </e2> produced by morphine .
NO_RELATION	In contrast , both methscopolamine and <e1> neostigmine </e1> , which do not penetrate the blood - brain barrier , had no effect on the <e2> hyperactivity </e2> produced by morphine .
CID	In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the <e2> hyperactivity </e2> produced by <e1> morphine </e1> .
NO_RELATION	On the other hand , pretreatment with <e1> p - chlorophenylalamine </e1> ( 3 X 320 mg / kg i . p . , 24 hr ) , a serotonin depletor , caused no significant change in the <e2> hyperactivity </e2> .
NO_RELATION	On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p . , 24 hr ) , a <e1> serotonin </e1> depletor , caused no significant change in the <e2> hyperactivity </e2> .
CID	Mechanisms of <e1> FK 506 </e1> - induced <e2> hypertension </e2> in the rat .
CID	The clinical utility of <e1> FK 506 </e1> is complicated by substantial <e2> hypertension </e2> and nephrotoxicity .
NO_RELATION	The clinical utility of <e1> FK 506 </e1> is complicated by substantial hypertension and <e2> nephrotoxicity </e2> .
CID	To clarify the mechanisms of <e1> FK 506 </e1> - induced <e2> hypertension </e2> , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .
CID	To clarify the mechanisms of FK 506 - induced <e2> hypertension </e2> , we studied the chronic effects of <e1> FK 506 </e1> on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .
NO_RELATION	To clarify the mechanisms of FK 506 - induced <e2> hypertension </e2> , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial <e1> nitric oxide </e1> synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .
NO_RELATION	In addition , the effect of the specific endothelin type A receptor antagonist <e1> FR 139317 </e1> on FK 506 - induced <e2> hypertension </e2> in rats was studied .
CID	In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on <e1> FK 506 </e1> - induced <e2> hypertension </e2> in rats was studied .
CID	d - 1 ) prevented <e1> FK 506 </e1> - induced <e2> hypertension </e2> in rats .
CID	<e1> Suxamethonium </e1> induced prolonged <e2> apnea </e2> in a patient receiving electroconvulsive therapy .
CID	<e1> Suxamethonium </e1> causes prolonged <e2> apnea </e2> in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .
CID	Suxamethonium causes prolonged <e2> apnea </e2> in patients in whom pseudocholinesterase enzyme gets deactivated by <e1> organophosphorus ( OP ) poisons </e1> .
CID	Prolonged <e2> apnea </e2> in our case ensued because the information about suicidal attempt by <e1> OP compound </e1> was concealed from the treating team .
NO_RELATION	The effects of the adjunctive <e1> bupropion </e1> on male <e2> sexual dysfunction </e2> induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .
NO_RELATION	The effects of the adjunctive bupropion on male <e2> sexual dysfunction </e2> induced by a <e1> selective serotonin reuptake inhibitor </e1> : a double - blind placebo - controlled and randomized study .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained - release ( SR ) on male <e2> sexual dysfunction </e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained - release ( SR ) on male sexual dysfunction ( <e2> SD </e2> ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as <e2> SD </e2> is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male <e2> sexual dysfunction </e2> ( SD ) induced by a <e1> selective serotonin reuptake inhibitor </e1> ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( <e2> SD </e2> ) induced by a <e1> selective serotonin reuptake inhibitor </e1> ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a <e1> selective serotonin reuptake inhibitor </e1> ( SSRI ) , as <e2> SD </e2> is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male <e2> sexual dysfunction </e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( <e1> SSRI </e1> ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( <e2> SD </e2> ) induced by a selective serotonin reuptake inhibitor ( <e1> SSRI </e1> ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( <e1> SSRI </e1> ) , as <e2> SD </e2> is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male <e2> sexual dysfunction </e2> ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of <e1> SSRIs </e1> and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( <e2> SD </e2> ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of <e1> SSRIs </e1> and the most effective treatments have yet to be determined .
NO_RELATION	OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as <e2> SD </e2> is a common side - effect of <e1> SSRIs </e1> and the most effective treatments have yet to be determined .
NO_RELATION	In linear regression analyses the CGI - SF score was not affected significantly by the duration of <e2> SD </e2> , type of <e1> SSRI </e1> used and age .
NO_RELATION	CONCLUSIONS : <e1> Bupropion </e1> is an effective treatment for male <e2> SD </e2> induced by SSRIs .
NO_RELATION	CONCLUSIONS : Bupropion is an effective treatment for male <e2> SD </e2> induced by <e1> SSRIs </e1> .
NO_RELATION	<e1> Lamivudine </e1> for the prevention of <e2> hepatitis B </e2> virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
NO_RELATION	<e1> Lamivudine </e1> for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy .
CID	Lamivudine for the prevention of <e2> hepatitis B </e2> virus reactivation in <e1> hepatitis - B surface antigen </e1> ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
NO_RELATION	Lamivudine for the prevention of hepatitis B virus reactivation in <e1> hepatitis - B surface antigen </e1> ( HBSAG ) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy .
CID	Lamivudine for the prevention of <e2> hepatitis B </e2> virus reactivation in hepatitis - B surface antigen ( <e1> HBSAG </e1> ) seropositive cancer patients undergoing cytotoxic chemotherapy .
NO_RELATION	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( <e1> HBSAG </e1> ) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy .
NO_RELATION	In this study , <e2> cancer </e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent <e1> lamivudine </e1> prior and during CT compared with historical control group who did not receive lamivudine .
NO_RELATION	In this study , cancer patients who have solid and <e2> hematological malignancies </e2> with chronic HBV infection received the antiviral agent <e1> lamivudine </e1> prior and during CT compared with historical control group who did not receive lamivudine .
NO_RELATION	In this study , cancer patients who have solid and hematological malignancies with chronic <e2> HBV infection </e2> received the antiviral agent <e1> lamivudine </e1> prior and during CT compared with historical control group who did not receive lamivudine .
NO_RELATION	In this study , <e2> cancer </e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> .
NO_RELATION	In this study , cancer patients who have solid and <e2> hematological malignancies </e2> with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> .
NO_RELATION	In this study , cancer patients who have solid and hematological malignancies with chronic <e2> HBV infection </e2> received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> .
NO_RELATION	In the prophylactic <e1> lamivudine </e1> group severe <e2> hepatitis </e2> were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .
NO_RELATION	Our study suggests that prophylactic <e1> lamivudine </e1> significantly decreases the incidence of HBV reactivation and overall morbidity in <e2> cancer </e2> patients during and after immunosuppressive therapy .
NO_RELATION	<e1> Ginsenoside Rg1 </e1> restores the <e2> impairment of learning </e2> induced by chronic morphine administration in rats .
CID	Ginsenoside Rg1 restores the <e2> impairment of learning </e2> induced by chronic <e1> morphine </e1> administration in rats .
NO_RELATION	<e1> Rg1 </e1> , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial <e2> learning impairment </e2> .
NO_RELATION	Rg1 , as a <e1> ginsenoside </e1> extracted from Panax ginseng , could ameliorate spatial <e2> learning impairment </e2> .
NO_RELATION	The aim of this study was to investigate the effect of <e1> Rg1 </e1> on <e2> learning impairment </e2> by chronic morphine administration and the mechanism responsible for this effect .
CID	The aim of this study was to investigate the effect of Rg1 on <e2> learning impairment </e2> by chronic <e1> morphine </e1> administration and the mechanism responsible for this effect .
CID	A study on the effect of the duration of subcutaneous <e1> heparin </e1> injection on <e2> bruising </e2> and pain .
CID	A study on the effect of the duration of subcutaneous <e1> heparin </e1> injection on bruising and <e2> pain </e2> .
CID	AIM : This study was carried out to determine the effect of injection duration on <e2> bruising </e2> and pain following the administration of the subcutaneous injection of <e1> heparin </e1> .
CID	AIM : This study was carried out to determine the effect of injection duration on bruising and <e2> pain </e2> following the administration of the subcutaneous injection of <e1> heparin </e1> .
CID	BACKGROUND : Although different methods to prevent <e2> bruising </e2> and pain following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
CID	BACKGROUND : Although different methods to prevent bruising and <e2> pain </e2> following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
CID	BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described , the effect of injection duration on the occurrence of <e2> bruising </e2> and pain is little documented .
CID	BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described , the effect of injection duration on the occurrence of bruising and <e2> pain </e2> is little documented .
CID	Dimensions of the <e2> bruising </e2> on the <e1> heparin </e1> applied areas were measured using transparent millimetric measuring paper .
CID	CONCLUSIONS : It was determined that injection duration had an effect on <e2> bruising </e2> and pain following the subcutaneous administration of <e1> heparin </e1> .
CID	CONCLUSIONS : It was determined that injection duration had an effect on bruising and <e2> pain </e2> following the subcutaneous administration of <e1> heparin </e1> .
CID	Acute <e1> reserpine </e1> and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit <e2> orofacial dyskinesia </e2> in rats .
CID	Acute reserpine and subchronic <e1> haloperidol </e1> treatments change synaptosomal brain glutamate uptake and elicit <e2> orofacial dyskinesia </e2> in rats .
NO_RELATION	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain <e1> glutamate </e1> uptake and elicit <e2> orofacial dyskinesia </e2> in rats .
CID	<e1> Reserpine </e1> - and haloperidol - induced <e2> orofacial dyskinesia </e2> are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	<e1> Reserpine </e1> - and haloperidol - induced orofacial dyskinesia are putative animal models of <e2> tardive dyskinesia </e2> ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	<e1> Reserpine </e1> - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( <e2> TD </e2> ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	Reserpine - and <e1> haloperidol </e1> - induced <e2> orofacial dyskinesia </e2> are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	Reserpine - and <e1> haloperidol </e1> - induced orofacial dyskinesia are putative animal models of <e2> tardive dyskinesia </e2> ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	Reserpine - and <e1> haloperidol </e1> - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( <e2> TD </e2> ) whose pathophysiology has been related to free radical generation and oxidative stress .
CID	In the present study , the authors induced <e2> orofacial dyskinesia </e2> by acute <e1> reserpine </e1> and subchronic haloperidol administration to rats .
CID	In the present study , the authors induced <e2> orofacial dyskinesia </e2> by acute reserpine and subchronic <e1> haloperidol </e1> administration to rats .
NO_RELATION	Importantly , a decrease in <e1> glutamate </e1> uptake correlates negatively with an increase in the incidence of <e2> orofacial diskinesia </e2> .
CID	<e2> Acute psychosis </e2> due to treatment with <e1> phenytoin </e1> in a nonepileptic patient .
CID	The case of a nonepileptic patient who developed <e2> psychosis </e2> following <e1> phenytoin </e1> treatment for trigeminal neuralgia is described .
NO_RELATION	The case of a nonepileptic patient who developed psychosis following <e1> phenytoin </e1> treatment for <e2> trigeminal neuralgia </e2> is described .
CID	This case suggests that the <e2> psychotic symptoms </e2> that occur following <e1> phenytoin </e1> treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .
NO_RELATION	This case suggests that the psychotic symptoms that occur following <e1> phenytoin </e1> treatment in some <e2> epileptic </e2> patients may be the direct result of medication , unrelated to seizures .
NO_RELATION	This case suggests that the psychotic symptoms that occur following <e1> phenytoin </e1> treatment in some epileptic patients may be the direct result of medication , unrelated to <e2> seizures </e2> .
NO_RELATION	The effect of treatment with <e1> gum Arabic </e1> on gentamicin <e2> nephrotoxicity </e2> in rats : a preliminary study .
NO_RELATION	The effect of treatment with gum Arabic on <e1> gentamicin </e1> <e2> nephrotoxicity </e2> in rats : a preliminary study .
CID	In the present work we assessed the effect of treatment of rats with <e1> gum Arabic </e1> on <e2> acute renal failure </e2> induced by gentamicin ( GM ) nephrotoxicity .
NO_RELATION	In the present work we assessed the effect of treatment of rats with <e1> gum Arabic </e1> on acute renal failure induced by gentamicin ( GM ) <e2> nephrotoxicity </e2> .
CID	In the present work we assessed the effect of treatment of rats with gum Arabic on <e2> acute renal failure </e2> induced by <e1> gentamicin </e1> ( GM ) nephrotoxicity .
NO_RELATION	In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by <e1> gentamicin </e1> ( GM ) <e2> nephrotoxicity </e2> .
CID	In the present work we assessed the effect of treatment of rats with gum Arabic on <e2> acute renal failure </e2> induced by gentamicin ( <e1> GM </e1> ) nephrotoxicity .
NO_RELATION	In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( <e1> GM </e1> ) <e2> nephrotoxicity </e2> .
NO_RELATION	<e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of <e1> creatinine </e1> and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
NO_RELATION	<e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and <e1> urea </e1> in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
NO_RELATION	<e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced <e1> glutathione </e1> ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
NO_RELATION	<e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( <e1> GSH </e1> ) in the kidney cortex , and by light microscopic examination of kidney sections .
NO_RELATION	The results indicated that concomitant treatment with <e1> gum Arabic </e1> and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and <e1> GM </e1> significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased <e1> creatinine </e1> and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and <e1> urea </e1> by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and <e1> GM </e1> ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical <e1> GSH </e1> by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus <e1> GM </e1> group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The <e1> GM </e1> - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given <e1> GM </e1> together with gum Arabic than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with <e1> gum Arabic </e1> than in those given GM and cellulose .
NO_RELATION	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given <e1> GM </e1> and cellulose .
NO_RELATION	It could be inferred that <e1> gum Arabic </e1> treatment has induced a modest amelioration of some of the histological and biochemical indices of GM <e2> nephrotoxicity </e2> .
NO_RELATION	It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of <e1> GM </e1> <e2> nephrotoxicity </e2> .
CID	<e2> Visual hallucinations </e2> associated with <e1> zonisamide </e1> .
NO_RELATION	<e1> Zonisamide </e1> is a broad - spectrum antiepileptic drug used to treat various types of <e2> seizures </e2> .
CID	Although <e2> visual hallucinations </e2> have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after <e1> zonisamide </e1> treatment was begun or its dosage increased .
CID	Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex <e2> visual hallucinations </e2> and altered mental status after <e1> zonisamide </e1> treatment was begun or its dosage increased .
NO_RELATION	GLEPP1 receptor <e1> tyrosine </e1> phosphatase ( Ptpro ) in rat PAN <e2> nephrosis </e2> .
CID	GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat <e1> PAN </e1> <e2> nephrosis </e2> .
CID	<e1> Puromycin aminonucleoside </e1> <e2> nephrosis </e2> was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100g BW ) .
CID	Puromycin aminonucleoside <e2> nephrosis </e2> was induced by single intraperitoneal injection of <e1> puromycin aminonucleoside </e1> ( PAN , 20 mg / 100g BW ) .
CID	Puromycin aminonucleoside <e2> nephrosis </e2> was induced by single intraperitoneal injection of puromycin aminonucleoside ( <e1> PAN </e1> , 20 mg / 100g BW ) .
CID	Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of <e2> proteinuria </e2> associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .
CID	Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of <e2> proteinuria </e2> associated with glomerulosclerosis ( days 45 - 126 ) .
NO_RELATION	Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with <e2> glomerulosclerosis </e2> ( days 45 - 126 ) .
CID	<e1> Ticlopidine </e1> - induced <e2> aplastic anemia </e2> : report of three Chinese patients and review of the literature .
CID	In this study , three Chinese patients with <e1> ticlopidine </e1> - induced <e2> aplastic anemia </e2> were reported and another 13 patients in the English literature were reviewed .
CID	<e2> Agranulocytosis </e2> occurred 3 - 20 weeks after initiation of <e1> ticlopidine </e1> , so frequent examination of white cell count during treatment is recommended .
CID	Treatment for <e1> ticlopidine </e1> - induced <e2> aplastic anemia </e2> with colony - stimulating factors seemed to have little effect .
CID	<e2> Amnesia </e2> produced by <e1> scopolamine </e1> and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
CID	<e2> Amnesia </e2> produced by scopolamine and <e1> cycloheximide </e1> were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
NO_RELATION	<e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by <e1> morphine </e1> given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
NO_RELATION	<e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test <e1> morphine </e1> also facilitated the memory retrieval in the animals administered naloxone during the training trial .
NO_RELATION	<e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered <e1> naloxone </e1> during the training trial .
CID	Similarly , pre - test <e1> scopolamine </e1> partially reversed the scopolamine - induced <e2> amnesia </e2> , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .
CID	Similarly , pre - test <e1> scopolamine </e1> partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced <e2> amnesia </e2> .
CID	Similarly , pre - test scopolamine partially reversed the <e1> scopolamine </e1> - induced <e2> amnesia </e2> , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .
CID	Similarly , pre - test scopolamine partially reversed the <e1> scopolamine </e1> - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced <e2> amnesia </e2> .
CID	Similarly , pre - test scopolamine partially reversed the scopolamine - induced <e2> amnesia </e2> , but not significantly ; and pre - test <e1> cycloheximide </e1> failed to reverse the cycloheximide - induced amnesia .
CID	Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test <e1> cycloheximide </e1> failed to reverse the cycloheximide - induced <e2> amnesia </e2> .
CID	Similarly , pre - test scopolamine partially reversed the scopolamine - induced <e2> amnesia </e2> , but not significantly ; and pre - test cycloheximide failed to reverse the <e1> cycloheximide </e1> - induced amnesia .
CID	Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the <e1> cycloheximide </e1> - induced <e2> amnesia </e2> .
CID	<e1> Apomorphine </e1> , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce <e2> hypothermia </e2> , and to produce distinct changes to dopamine turnover in the rodent brain .
NO_RELATION	Apomorphine , a nonselective <e1> dopamine agonist </e1> , was selected due to its biphasic behavioral effects , its ability to induce <e2> hypothermia </e2> , and to produce distinct changes to dopamine turnover in the rodent brain .
NO_RELATION	Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce <e2> hypothermia </e2> , and to produce distinct changes to <e1> dopamine </e1> turnover in the rodent brain .
CID	In rats , detection of <e1> apomorphine </e1> - induced <e2> hyperactivity </e2> was facilitated by a period of acclimatization to the test conditions .
CID	Moreover , test conditions can impact upon other physiological responses to <e1> apomorphine </e1> such as drug - induced <e2> hypothermia </e2> .
